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SUMMARY 
Cystic fibrosis (CF) is an autosomal recessive genetic disease caused by mutations 
on chromosome 7 in the gene for the CFTR protein. This gene encodes for a chloride 
channel on the apical surface of certain epithelial cells. The clinical manifestations of 
CF largely arise out of the resultant defect in water and electrolyte secretions in 
exocrine glands and epithelia such as are found in the pancreas, respiratory, 
gastrointestinal and genital tracts and sweat glands. 
First delineated as a clinical entity in the mid_20th century, CF was shown to be 
identifiable through the demonstration of elevated electrolyte levels in sweat - the 
sweat test. After many false starts, the underlying genetic defect was identified in the 
1980s, culminating in the identification of the defective gene in 1989. This opened up 
possibilities of more accurate diagnosis and targeted treatments. 
Treatment of CF with pancreatic enzyme replacement therapy and antibiotics in the 
1950s proved successful in controlling some of the severe and often fatal aspects of 
the disease. Further refinements to nutritional and antimicrobial therapies in the 
1970s and 1980s produced rapid increases in longevity in many patients with CF. 
In SA, CF' has been identified since the 1950s. Clinical and research activities 
developed in the 1980s, mainly focused on the epidemiological.and genetic aspects. 
Two clinical studies described features in children in Cape Town and adults in 
Johannesburg. 
My own clinical involvement in the RCCH's CF Service in Cape Town since 1992 
led to the research activities that make up the bulk of this thesis. 
The thesis describes a number of aspects of CF as it affects patients in SA. The study 
popUlation (described in Chapter 2) for most of the projects consists of 181 CF 
patients born between October 1974 and September 2003 who were identified by a 
combination of clinical features,positive sweat or genetic tests and/or post mortem 
findings. All were resident in the Western Cape province and received at least part of 
xii 
their health care at the RCCH. One hundred and sixty (88%) were born in the 
province and 21 settled in the province from elsewhere. 
Cape Town is unique in SA for its population demographics and the CF patients 
reflect this. CF has mainly been identified in coloured and white patients. Four black 
cases have been diagnosed. Compared with the CF population as described in the 
early 1980s, the CF population in the 21st centwy is larger (100 versus 64), older and 
there is a greater proportion of coloured patients. Nearly 3 in every 4 patients live in 
CapeTown. 
The Epidemiology of CF in SA is described from a population perspective ('Classical 
Epidemiology') and a molecular genetic perspective (,Molecular Epidemiology') in 
Chapter 3. Owing to uncertainties surrounding both denominators and the numerators 
in the only study to describe the epidemiology of CF in this region, advantage was 
taken of the greater time period that has elapsed to further study this aspect of CF in 
the Western Cape. While I was cognisant of the issues surrounding 'racial' 
classification in SA, I took a scientific but pragmatic approach to studying the 
differing epidemiologiy of CF in the 'population groups' that make up the Western 
Cape province's unique demographics. From the perspective of diseasewcausing 
genetic mutations, the coloured and white populations differ. Using the CF study 
population and birth data from the 1996 census, the incidence of CF was found to be 1 
in 3 003 live births for the white population (compared with the previous figure of 1 
in 2027 live births) and I in 10273 live births for the coloured population (compared 
with the previous figure of I in 12 305 live births). The incidence figure for the white 
population approximates that for the parts of Europe that have had the most migrants 
to SA. The prevalence rates per 100000 in the population for 1996 were 53 and 28 
for the white and coloured groups respectively. There is evidence that there is still 
under-ascertainment of coloured CF cases in non-metropolitan areas of the province. 
The molecular epidemiology of CF in the white and coloured population of SA has 
been well described. Two CFTR mutations, l\F508 and 3120+1G~, are 
responsible for most of the CF disease in SA. The former makes up 75% of mutation 
in the white population and 50% in the coloured population. The latter is the second 
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most common mutation in the coloured population and is the single commonest 
mutation in the black population both in SA and in the USA. 
Advantage was taken of a greater number of tested coloured patients in the local 
population than in any studies so far published .. In fact the published figure of 50% 
AF508 remains robust. 
Combining the figures for common mutations and the new incidence figures one finds 
a changed set of figures for the reproductive risk predictions required for genetic 
counseling in the white and coloured populations. 
Despite the published frequency of the 3120+IG A mutation in healthy black 
Africans in SA, few cases of CF have been seen. Five case reports illustrating the 
changing perspective on CF in black patients are described in Chapter 3. A number of 
theories based on possible differences in phenotype, modifying genes and health 
services are raised to explain the apparent under-representation of black African CF 
cases in SA. 
Clinical aspects of CF are presented in Chapter 4. In the Western Cape province CF 
presented much as it does in the rest of the world. The only exception was a greater 
incidence of the anaemia-oedema complex in the coloured population, a possible 
consequence of socio-economic conditions in this region. Median age at diagnosis 
(no newborn screening took place) was 6 months (14,5 months if patients with MI or 
an older sibling were excluded). This was relatively late compared with Western 
norms. No improvement in age to diagnosis over the 29 years could be demonstrated. 
Complications of CF were divided into those that are caused directly by the CFTR 
mutations, those that are secondary to these changes and those induced by therapy. PI 
affected 95% of patients, a relatively high figure. A full spectrum of complications of 
CF has been seen over the 29 years. Apart from the ubiquitous PI and lung disease, 
117 of the 181 patients had at least one other complication of CF. 
Chapter 5 describes the surgical experience of the CF population over 29 years. In the 
first 20 years 154 operations were done on 57 of 111 patients, 30% of whom had an 
xiv 
operation related to CF. MI dominated the major surgery. Three lobectomies were 
done. Outcomes were generally good and surgical and anaesthetic misadventure were 
minor and few (9,2% and 11,4% respectively). An update covering recent years 
reveals changes to practice: more operations for gastro-oesophageal reflux and the 
advent of percutaneously inserted gastrostomies for nocturnal calorie 
supplementation. Case histories of three unusual surgical presentations are described. 
Attention to nutrition is a central part of CF care. Chapter 6 presents a description of 
nutritional indices in this CF population in two cross-sectional studies. Median 
percentage weight for height was 93 (interquartile range 84-101). Sixty eight percent 
of patients consumed less than the recommended daily intake of energy. There was 
an improvement in mean weight for height in the decade between 1986 and 1996. 
Lung disease was difficult to study in a small population such as this. In Chapter 7 it 
is demonstrated that the bacteriology of CF in this region has mirrored that elsewhere 
with Staphylococcus aureus infection occurring earlier (median age 118 months) than 
Pseudomonas aeruginosa infection (median age 150 months). M508 homozygosity 
but not ethnicity was associated with earlier infection with P aeruginosa. 
The Cystic Fibrosis Service is described in Chapter 8. Transition to adult-oriented 
care has been actively worked on. In our study, concerns around the move to Groote 
Schuur Hospital and the independence of young people with CF were shown to be 
significant. A letter to the editor of Pediatrics demonstrates that the management of 
end-of-life care in our service differs from that in the USA. 
Finally, the prognosis of CF in this region is the subject of Chapter 9. A 20 year study 
showed a median survival of about 18 years with coloured patients doing worse than 
white patients. A later longer study shows survival to be improving, at least for white 
children. Deaths in infancy still occur in the 2151 century but prognosis in this region 
seems to be better than in other resource-poor countries. 
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Since the delineation of its classic fonn by Fanconi I, Andersen2 and Farber3, "cystic 
fibrosis of the pancreas" or ''mucoviscidosis'' (hereinafter, "CF") has been a source of 
great clinical and scientific interest. Clinicians have been fascinated by the ever-
expanding spectrum of clinical problems associated with the disease. They have been 
heartened by their ability to extend the lives of their CF patients. Scientists, having 
conquered the molecular basis of CF, are still challenged to explain the exact mechanisms 
underlying its manifestations. Fifteen years after the identification of the cystic fibrosis 
transmembrane regulator (CFTR) and its associated gene, physiologists still cannot 
satisfactorily explain how the defect in salt and water transport caused by mutations in 
the gene for CFTR leads to viscid secretions in exocrine glands. This is especially the 
case in the lung, damage to which is the chief cause of the premature mortality associated 
withCF. 
Cystic fibrosis as a genetic disease 
CF is caused by mutations in the CFTR gene which is found on the long arm of 
chromosome 7. It is an autosomal recessive condition requiring that the patient receive 
one CFTR gene mutation from each biological parent. To date over 1000 disease-causing 
mutations of the CFTR gene have been described. Only a few are common; some are 
population-specific; most are rare, even occurring in only one family. While gene-
specific clinical traits are not found with most CFTR mutations, some mutations have 
been associated with clinical variables such as severity of disease, organ-specific 
manifestations or responsiveness to specific therapies. 
Thus although CF is a single gene disorder, exactly which CFTR gene mutations an 
individual has inherited may influence the disease's clinical fonn. 
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Cystic Fibrosis as a clinical entity 
In essence CF is a disease that affects the epithelia of exocrine glands and hollow organs. 
Owing to a defect in the balance of water and electrolyte transport, viscid secretions are 
produced. These secretions are unable to move normally through the ducts and organs. 
This has different effects in different organ systems. 
In the pancreas, the secretions carry digestive enzymes. When the enzymes are not 
satisfactorily excreted and transported to the duodenum, they digest the pancreas itself. 
In about 90% of CF cases, there is eventually insufficient residual pancreatic tissue to 
allow normal digestion of food. Untreated this leads to steatorrhoea and growth failure 
with multiple nutritional deficiencies. Eventually even the endocrine cells contained 
within the pancreas are destroyed leading to problems with glucose tolerance and overt 
diabetes mellitus. 
In the lung, thick secretions lead to poor ciliary escalator function, retention of secretions 
and reduced clearance of pathogens. There is thus a propensity to airway obstruction, 
atelectasis and infection that in time leads to the destruction of lung tissue. These lung 
manifestations are almost universal among patients with CF. 
In the upper respiratory tract, as with the lung, poor ciliary transport leads to 
inadequate clearance of secretions and increased incidence of infection, particularly 
sinusitis. Mucosal hypertrophy in the sinuses and polyp formation in the nose are 
frequent consequences. 
In the liver, bile flow is compromised by the salt and water imbalance, leading to stasis 
and bile duct obstruction. The consequence of this is focal biliary cirrhosis which leads 
to liver cirrhosis and portal hypertension in 10-15% ofCF patients. 
In the sweat glands, salt and water imbalance leads to excess salt loss. In infancy and in 
hot climates or environments this can lead to the clinical consequences of salt deficiency 
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(failure to thrive, hypochloraemic metabolic alkalosis and heat prostration). This defect 
also provides the basis for the best diagnostic test for CF, the "sweat test". 
In the male genital tract, seminal secretions are of such limited volume that the vas 
deferens does not form in 99% of male fetuses. The consequence of this is infertility. 
Females with CF are also relatively infertile owing to thick cervical mucus. 
Through mechanisms not fully understood but which include secretions from mucous 
glands, the contents of the intestine may obstruct its lumen leading to meconium ileus 
(MI) in 10-15% of CF fetuses, and, in some older CF patients, to the distal intestinal 
obstruction syndrome (DIOS). 
Thus CF is a multisystem disease. It is evident from the preceding discussion that how 
CF affects an individual patient is an amalgam of his or her genetic make-up, the range of 
organs involved and how severely those organs are affected. On top of this, it must be 
noted that the disease's course is also affected by environmental factors such as exposure 
to respiratory pathogens and pollutants, by parental coping styles and socio-economic 
factors, particularly poverty. 
Milestones in the understanding and treatment of CF 
The names of the Swiss paediatrician Guido Fanconi and American pathologist Dorothy 
Andersen are inextricably linked with the emergence of CF from the complex of 
conditions associated with steatorrhoea, severe failure to thrive and death in infancy and 
early childhood. Features of the disease such as MI and its inherited nature had been 
described early in the 20th century but, in the 1930s, these two workers delineated the 
essential features of CF and established it as a clinical entity. 
In 1935 Fanconi noted the connection between "zysticher pankreasfibromatose" (cystic 
fibrosis of the pancreas) and "bronchiektasien" (bronchiectasis).) In 1938 Andersen 
published a paper in which 22 cases of "celiac disease" in whom pancreatic changes were 
identified at post mortem were described? In her article she included another 27 cases 
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from the literature, including those of Fanconi. Her paper meticulously described the 
association of "cystic fibrosis of the pancreas" with MI and its complications, severe 
nutritional impairment and chronic respiratory disease characterised by plugging of the 
bronchial lumen by "tenaceous (sic), greenish gray (sic) mucopurulent material", 
abscesses and dilated bronchi. The familial nature of the disease was also noted in this 
classic report. 
Interestingly the common pathogenesis of the pancreatic and pulmonary lesions was not 
postulated in either the article or discussion following the paper's first presentation on 
May 5, 1938. Andersen's suggestion, repeated in a later paper in which the role of 
Staphylococcus aureus in the lung disease was noted,4 S was that Vitamin A deficiency 
might have led to the bronchiectasis. In articles in 19443 and 1945,6 Farber, who also 
remarked on the frequent association of S aureus with the lung disease, suggested that 
the feature common to both pancreas and lung was inspissation of secretions. In an 
article published a year later, Andersen was dismissive of this idea,S still believing that 
nutritional deficiencies, especially that of Vitamin A, led to the lung disease. Farber 
speculated that a problem with nervous control of mucous secretion caused the multi-
organ pathological changes.6 He coined the term "mucoviscidosis" which survives today 
as the name for CF in Romance languages such as French. A number of other authors 
confirmed this characteristic finding and CF was thus thought to be exclusively a disease 
of mucus-producing exocrine glands. 
Bodian in 1952 established unequivocally that CF was an inherited condition with a 
Mendelian autosomal recessive pattern7 (though some doubters remained right up till the 
time the gene was cloned). 
That CF was due to a more broadly-based defect than simply that of viscid secretions 
came to light in 1953 when Paul di Sant'Agnese (who had previously worked with 
Andersen) and colleagues in New York, USA demonstrated the abnormality in sweat 
electrolyte concentration now known to be a cardinal, indeed diagnostic, feature of CF.8 
It was Gibson and Cooke who, six years later and at di Sant'Agnese's suggestion, 
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described the method of measuring sweat electrolyte concentration using pilocarpine 
iontophoresis, providing the only definitive ante mortem diagnostic test for CF until the 
CFTRera.9 
By this time one of the pioneers of CF management, Dr Harry Shwachman in Boston, 
USA was leading the field in improving the lives of children with CF. IO Pancreatic 
extracts were used to overcome the effects of pancreatic insufficiency. The antibiotic 
revolution was also in full swing allowing paediatricians such as Dr Shwachman to 
modify the effects of bacterial infection in the lung. He was able to report a rapid 
improvement in survival from a norm of death before two years of age in the 1930s and 
1940s to death under two being a rarity by the mid-1970s. II He also made plain that CF 
is a disease of varying severity, introducing a score (which became known as the 
Shwachman score) by which the efficacy of new therapies might be measured. 10 
Through the 1960s and 1970s continuing efforts were made to understand the causation 
of CF with a myriad of potential explanations and clues being found and then discarded. 
"Factors" that affected ciliary function or mucus secretion, hyperpermeable mucus, 
disorders of calcium secretion - all were to be found in this melting pot of ideas. An 
advance came when Michael Knowles and colleagues demonstrated abnormal potential 
difference across respiratory epithelia. 12 In 1982-3 an unequivocal lead was found when 
Paul Quinton, himself a CF sufferer, demonstrated a defect in chloride ion resorption in 
the sweat glands (his own).13 This defect was then demonstrated in other epithelia. 
Simultaneously in the early 1980s, genetic studies of affected siblings and their parents 
showed that the CF gene was on the long arm of chromosome 7 and in a very short space 
of time (a reflection of the speed of the general increase in molecular genetic knowledge 
at that time) scientists in Toronto and Michigan had identified, cloned and named the 
causative gene and its protein product, CFTR.14 15 CFTR was found to be a chloride ion 
channel, thus linking the physiology of CF directly to the molecular biology of CF. The 
world of CF had changed - vistas of new knowledge and hopes of new therapies opened 
up. 
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On a therapeutic level from the 1960s to the 1980s progress was continuing to be made, 
though slowly. A major conceptual change occurred in the early 1980s when it was 
shown by the Toronto CF Clinic that increased fat intake, introduced there in 1970, 
improved nutritional outcomes without unpleasant symptoms. 16 Up till this time low fat 
diets that decreased the steatorrhoea were the norm. The introduction of products 
containing microspheres of enteric-coated pancreatic enzymes radically reduced fat 
malabsorption. These two developments meant a much better nutritional state could be 
expected for CF patients, with an associated improvement in prognosis. The advent of 
fibrosing colonopathy and its relationship with big doses of high lipase pancreatic 
enzyme supplements in the 1990s led physicians to use the products more carefully. 17 
Regarding lung disease, inhaled antibiotics, although introduced in the 1950s, were only 
formally evaluated in the UK in the early 1980S18 and later elsewhere. 19 20 They were 
shown to help with the control of Pseudomonas aeruginosa infections. It was also shown 
that permanent infection of the lungs by this organism could be postponed by early 
aggressive antibiotic use? 1 
The major role of the immune system in the pathophysiology of CF lung disease was 
detailed in the 1990s?2 The full benefit of this knowledge has yet to be felt at a clinical 
level with oral steroids having significant side effects23 and non-steroidal anti-
inflammatory drugs and inhaled anti-proteases being difficult to use?4 Heart lung 
transplant was introduced in 1984 and is now established practice for late-stage CF in 
many countries?5 
By the mid-1990s median survival had increased to more than 30 years in many 
countries26 and competition between centres to improve outcomes became intense. 
The advent of the third millennium finds CF scientists hard at work pushing back the 
frontiers of knowledge. As they work with CFTR at a physiological and molecular 
genetic level, their clinical colleagues find themselves somewhat marking time, 
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continuing to promote "established CF therapy" (attention to nutrition, antibiotics, 
physiotherapy, pancreatic enzyme replacement) while awaiting the fruits of this science. 
Cystic fibrosis in South Africa 
There has not been a shortage of interest in CF among clinicians and scientists in 
southern Africa. A lone report in 1958 from a clinician in Johannesburg shows that CF 
was being sought even then. Catzel, who had worked with Shwachman, investigated 230 
children, mostly 'Bantu-speakers', with Shwachman's new screening test: the agar plate 
'Finger-print sweat test'. 27 He was clearly disappointed not to find any black African CF 
patients and he thought very highly of the discriminatory power of Shwachman's test. 
Though compared to the USA and Europe, other South African authors were slow off the 
mark, by the 1980s and 1990s there was a steady flow of reports on many aspects of the 
disease as experienced in this part of the world. 
First reports of CF in South Africa (SA) were, ironically, of black African children. 
These cases represented something unusual, suggesting that CF was being seen by 
clinicians among populations of European stock - Catzel would have been an example of 
such a clinician. That CF was relatively common amongst southern Africa's European 
populations was brought to local and international attention by Super in the then South 
West Africa (S W A) who suggested that the incidence of CF in that country was 1 :622 
white newborns.28 Later, using a questionnaire survey and MI data, he revised these 
figures to 1 :635 to 1: 1192 - the highest incidence in the world, it appeared.29 In the same 
study he suggested that the minimum incidence in SA was between 1:5175 and 1:6534 
white newborns. He noted that amongst people of European stock, Afrikaners had a 
higher incidence than Britons. Botha and Beighton in SA also noted that CF was a 
significantly common condition amongst Afrikaners.3o Super also noted the presence of 
CF in a few coloured and black African South Africans?8 
Super devoted much of his thesis on CF, completed in 1978, to an exploration of putative 
reasons for the high incidence of the disease amongst SW A's Afrikaners. 3 1 These varied 
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from heterozygote immunity to malaria to increased mutation rates because of elderly 
fathers. He was unable to prove any of these theories. 
On a clinical level Super's thesis examined a small number of CF patients, illustrating the 
variety of clinical courses associated with the disease.3) Most of the children he 
described died in infancy and early childhood. In contrast, in the early 1980s clinicians 
in Johannesburg were able to describe a group of 33 adolescents and adults with CF (all 
of whom were of European origin), paralleling articles from a decade earlier in Europe. 32 
The Cape Town CF Clinic outlined their experience in an article in 1988.33 
The Cape Town paper also shed new light on the epidemiology of CF: the incidence was 
more like that of Europe than Super4 had suggested (incidence among whites was 
1 :2027), and it was not uncommon among the coloured population of the western Cape 
Province (Chapter 3 discusses epidemiology in detail).33 That CF was rare among SA's 
black African population seemed self-evident through the lack of clinical cases. Super 
described one case in his thesis but was not convinced that she really had the disease,34 
and noted a few in his 1978 paper.28 
During the 1980s, social scientists in Cape Town took an interest in the effect of CF on 
families. De Wet, working under the guidance of Prof. S Cywes, the head of Paediatric 
Surgery at the Red Cross Children's Hospital (RCCH), explored parental reaction to the 
diagnostic process in CF. 35 -37 Henley, working with Dr I Hill, produced a doctoral thesis 
and two papers which examined CF families' understanding of CF and its treatment. 3839 
In his 1975 article and 1978 thesis, Super expressed enthusiasm for bringing together 
southern African scientists, clinicians and CF families. CF associations developed in 
SA's provinces, their aims being the promotion of CF awareness and support of families 
facing CF. In 1989 the provincial groups came together and formed an umbrella body, 
the South African Cystic Fibrosis Association (SACF A). This association funded a 
Medical and Scientific Advisory Committee (MSAC) on which sat senior clinicians and 
scientists with experience in CF matters. This body, established in 1991, has overseen 
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the introduction of new tests and therapies for CF in the country and has arranged regular 
symposia, keeping workers in CF abreast of scientific and medical developments. It has 
also taken the needs of CF patients to the highest offices in the Department of Health and 
represented SA's CF scientists internationally. 
The advent of reasonably accurate prenatal diagnosis of CF for affected families in the 
early 1980s was enthusiastically greeted in SA. Nelson and colleagues from Cape Town 
reported their findings40 less than two years after the first report of the utility of 
measuring levels of a specific alkaline phosphatase in the amniotic fluid had been 
reported in a scientific letter by Brock and colleagues in Edinburgh.41 
Within three years however DNA-based prenatal diagnosis using polymorphic markers 
was introduced in Johannesburg and Cape Town for affected families. The utility of the 
two forms of prenatal testing in SA were compared in an collaborative article from the 
two centres.42 Ironically, by the time this article was published in 1991, the CFTR gene 
had been ~loned and new and even more exciting and widely applicable methods of 
prenatal diagnosis became available to South Africans in the form of CFTR mutation 
analysis. IS 
Soon after the appearance of the article from Cape Town on the epidemiology of CF, the 
CF gene was cloned in North America. With this major advance, new avenues of 
epidemiological opened to SA's scientists as carriers of common mutations could now be 
identified. The genetic basis of CF in SA could now be explored. 
Through the 1990s to the present day many articles appeared as South African scientists 
and clinicians sought to define the genetic characteristics of CF as it occurs in the 
region.43-48 Most interesting among these was the discovery that, not only were CFTR 
gene mutations and CF patients to be found among SA's black chiefdoms, they appeared 
to be a by no means rare phenomenon!49 so 
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The author's involvement in cystic fibrosis 
I joined the RCCH CF Clinic in February 1992 when I began work as a specialist at the 
hospital. I had met children with CF in the hospital wards during my paediatric training. 
I had not realised how complex and wide was the range of problems associated with the 
disease. This soon dawned on my callow consciousness as I met the children and their 
families in the Clinic. 
In an attempt to understand the disease better I studied its surgical complications under 
the guidance of the senior consultants at the Clinic (Prof. M Bowie and Dr J Ireland). 
This work, published later in the South African Journal of Surgery,S I also resulted in an 
updated database of patients who had been diagnosed as having CF at the hospital or who 
received follow-up at the Clinic. This database I have maintained to the present. 
The surgical study had covered 20 years of experience with CF at the hospital. By 
mining further into the data I was able to explore the prognosis of CF in the Western 
Cape province and the factors affecting outcome. The paper arising from this study was 
published in 1996.52 The circumstances of these CF deaths were examined in response 
to an article published in Pediatrics by a CF Clinic in the USA. 53 I responded in letter 
form giving contrasting data from Cape Town.54 
By now the bit was firmly between my teeth and, while preparing and publishing a book 
of nutrition in CF for South African patients and their families to use, I initiated studies 
of nutritional aspects of CF. This led to a B. Sc. (Hons) dissertation for my co-worker, 
Romy Saitowitz who studied calcium intake and metabolism, and two papers published 
in 1999 and 2000.55 56 
The psychosocial aspects of chronic illness have always interested me and, in 1996, with 
the help of Dr Lesley Henley, a study of the process of transition between RCCH CF 
Clinic and Groote Schuur Hospital's (GSH) Respiratory Clinic was conducted. The paper 
this work produced was published in 1999.57 
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In 1993, for the first time in Cape Town (apparently - see p67), a Xhosa child was found 
to have CF. We had also noted an increase in the proportion of coloured CF patients seen 
at the Clinic. These two changes led to a collaboration with Prof. M Ramsay and her 
workers in the Department of Genetics at the South African Institute for Medical 
Research at the University of the Witwatersrand in Johannesburg.48 This resulted in our 
database containing the genotype details of a 'racial' mix that is unique internationally 
and in SA. The large numbers of new coloured CF patients identified in the 1990s also 
led us to re-examine the epidemiology of CF in the Western Cape province: Hill and 
colleagues' paper of 1988 needed review and updating (see Chapter 3). 
The late 1990s and the start of this century have brought an increase in therapeutic 
options for lung infections in CF. This has prompted a review of the bacteriology of the 
lung disease in CF, particularly the time to first infection with the common pathogens, S 
aureus and P aeruginosa (see Chapter 7). 
This ~hesis takes in all these studies. Other studies conducted through the clinic in which 
the initiation and the bulk of the work have been done by colleagues (lung function by Dr 
H Zar; adolescent body image by Dr L Carew), though referred to, do not form part of 
this work. 
The scope and aim of the thesis 
The thesis brings together in one document all my studies over the past 10 years. In some 
the data are given as previously published. Others have been updated and some contain 
data that has not been published before. The aim is to give as comprehensive a view as 
possible of how CF has affected children, adolescents and young adults in the Western 
Cape province over the past 30 years. 
The structure of the thesis 
Each chapter explores one aspect of CF and may encompass one or more studies. The 
study popUlation and database are described in Chapter 2. Thereafter each chapter 
contains its own Literature review, Methods, Results and Discussion sections. 
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CHAPTER 2 
THE STUDY POPULATION 
All the studies reported in this thesis were undertaken on children and adolescents 
who had been diagnosed as having CF. What constitutes clinical CF has become a 
matter of debate in clinical and research circles since the identification of the 
molecular basis of the disease in 1989. 14 15 Thus, before the criteria for inclusion of 
patients in the study populations are described, current issues and recommendations 
surrounding the diagnosis of CF will be presented. 
What is cystic fibrosis? 
Before the molecular basis of CF was elucidated, it was relatively simple to define CF 
by its clinical features and positive sweat tests. Although it required fussy attention to 
detail, the Gibson-Cooke method of perfonning a sweat test using pilocarpine 
electrophoresis proved very useful in identifying typical CF.9 True, there was a list of 
conditions that produced false positive results but few of these had more than one 
clinical feature in common with CF.58 It was also possible to enhance the utility of 
the test in cases with borderline sweat electrolyte levels by testing the response to 
fludrocortisone, a potent mineralocorticoid. 59 Unchanged electrolyte levels after two 
doses was characteristic ofCF; a decline made the diagnosis ofCF much less likely. 
The identification of CFTR has made it possible to find gene mutations in persons 
with very mild symptoms (e.g. sinusitis, absent vas deferens) and no pancreatic or 
lung disease. Often the sweat test is nonnal in such cases.60 Do these persons have 
CF? Conversely, patients have been described with many clinical features of CF who 
have no CFTR mutation.61 Do these persons have CF? The S 1455X mutation causes 
elevated sweat electrolyte levels mediated through CFTR but no other manifestations 
of CF?62 Do persons with this mutation have CF? 
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To attempt to bring unifonnity to nomenclature in clinical CF, international 
organisations have, in recent years, attempted to define what constitutes a diagnosis of 
CF. The Cystic Fibrosis Foundation Consensus Panel (CFFCP) in the United States 
of America published their statement in 1998.63 Their recommendations required 
A) i) At least one of 4 phenotypic features, or 
ii) a history of CF in a sibling, or 
iii) a positive newborn screening test. 
And 
B) evidence of CFTR abnonnality (i.e. abnonnal sweat tests; CFTR mutations on 
both 7th chromosomes; or in vivo demonstration of characteristic abnonnalities 
in ion transport across nasal epithelium [This latter test is not available in 
South Africa].) 
Full details of the interpretation of these tests were given in the CFFCP statement. 
The report emphasises the priority of the sweat test in making a diagnosis of CF 
especially where mutation analysis is uninfonnative. The continuing priority of the 
sweat test was reinforced by Wallis (incidentally, a fonner member of the RCCH CF 
team) in an annotation from the United Kingdom (UK).64 
The CFFCP classification was challenged by Bush and Wallis who were concerned at 
the potential labelling of genetic abnonnality or subclinical organ damage as CF 
"disease". For example, the fulfilling of condition A through having a sibling with 
CF would label a child as having CF if he or she had CF mutations even if the child 
was asymptomatic and had no evidence of airway or pancreatic disease. They 
suggested categories of pre-clinical and sub-clinical CF be created. Children in such 
categories could be monitored for the development of clinical disease but not treated 
as having it. 65 
In response to debates such as these, the World Health Organisation (WHO) convened 
a panel of experts in 2000 to classify the disease for epidemiological purposes. The 
classification which uses the overall tenn "Cystic Fibrosis and Related Disorders" and 
which depends on a mixture of phenotypic and genotypic features appears in Table 
2.1.66 
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TABLE 2.1 
CYSTIC FIBROSIS AND RELATED DISORDERS 
Classical CF pancreatic-insufficient (PI) 
Classical CF pancreatic-sufficient (PS) 
Atypical CF 
CF other specified 
CF not otherwise specified 
Isolated obstructive azoospermia* 
Chronic pancreatitis* 
Allergic bronchopulmonary aspergillosis (ABPA)* 




'" At least one CFTR mutation identified 
That this classification will need revision as knowledge and understanding of these 
conditions expands is acknowledged in the WHO report. 
Identification of cystic fibrosis in Cape Town 
The studies to be described in this thesis cover years before and after the advent of 
CFTR mutation analysis. Prior to 1989 the sweat test, performed according to the 
Gibson-Cooke method and repeated if positive, was used to confirm a diagnosis of 
CF. Both the sweat test and mutation analysis have been used as diagnostic tests 
since 1989. The CF Clinic at the RCCH has always carried a few children in whom 
the diagnosis of CF is not clear owing to atypical or mild clinical features and/or 
equivocal or variable sweat electrolyte results. 
The compilation of the Study Population 
There have been two phases in this process. The first was retrospective: 
In 1993, when I began my first CF-related research, I compiled a database of patients 
through exploring the RCCH CF Clinic records. All outpatient notes had been 
recorded in duplicate and the notes of patients who had died or been transferred had 
been kept in the same filing cabinet as current patients' records. From this source a 
list of past and current patients was compiled. 
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Further patients were identified from copies of surgicaL summaries arranged by 
diagnosis in the Department of Paediatric Surgery. Summaries under the headings 
Meconium ileus, Mucoviscidosis and Cystic Fibrosis were examined and patients 
entered into the database if they fitted the criteria for CF. 
Another source of data was the raw data sheets from Hill and colleagues' 
epidemiological and clinical study published in 1988. Hospital folders of patients not 
already entered into my database were studied for proof of the diagnosis of CF. This 
source yielded a few patients who had ~ied in hospital before being seen in the CF 
outpatient clinic. Two or three more patients were identified through examining 
ward-based summaries of admissions in the early 1990s. 
This process identified 130 CF patients for whom 128 folders could be accessed. 
The second phase of the compilation was prospective: 
Since the compilation of the retrospective database, all new CF patients who have 
been seen at the hospital and were resident in the Western Cape province before 
September 2003 have been added to the database that forms the basis of this work. 
As with the first phase this includes patients referred to the CF Clinic, patients 
identified in hospital and patients identified post mortem. 
Every attempt has been made to identify all children and adolescents diagnosed as 
having CF in the Western Cape region up to September 2003. This has been both to 
offer such young people the benefits of receiving care at a specialised CF centre and 
in order to arrive at accurate epidemiological and prognostic figures for the region. 
This second phase has added 80 more patients to the list all of whose folders have 
been available for scrutiny. The total of potential CF patients for study was thus 208 
(i.e. 128 retrospective and 80 prospective). 
Almost all studies reported in this thesis aimed to describe patterns of CF-related 
disease and its health care for children and adolescents who live or lived in the 
Western Cape province region. The aims of all the clinical studies required that the 
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subjects had received at least some of their health care at the RCCH. They also 
required that sufficient clinical detail be available. Thus, given the thrust of this 
thesis, criteria that included diagnostic, geographical and health care stipulations were 
needed to define the study population for almost all studies (for the exceptions to this 
p 18). These criteria are shown in Box 2.1. 
Within this definition, individual studies had other specific inclusion and exclusion 
criteria depending on their objectives. These are detailed in the individual reports in 
later chapters. 
By this definition, the Study Population of children and adolescents with CF who 
were resident in the Western Cape province and had received some 0 f their CF care at 
the RCCH consisted of 181 subjects. The full anonymised patient set with diagnostic 
and demographic details is given in Appendix A. 
BOX2.1 
DEFINITION OF CASES OF CYSTIC FIBROSIS FOR STUDY 
Inclusion criteria: 
A) Proven cystic fibrosis 
One or more of the following criteria: 
1) Two positive sweat tests carried out by pilocarpine iontophoresis at a reputable 
centre (mostly RCCH); and/or 
2) Two CFfR mutations known to cause CF; ~ 
3) Post mortem features for which CF was the most likely diagnosis 
AND 
clinical features compatible with a diagnosis ofCF. 
B) Resident in the regions of the former Cape Province incorporated into the Western 
Cape province and receiving health care for CF in the province 
C) Unless diagnosed post mortem, seen at least once at the RCCH for CF-related disease. 
D) Born after September 1974* 
* For the purposes of all studies except one (Study 5.1 which used patients seen at the 
hospital from January 1972), clinical details were often not complete for patients born before 
this date. 
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There are three studies reported in this thesis that, for reasons related to their scientific 
objectives, use patients beyond the date of birth, geographical and RCCH care 
stipulations in the definition. 
1) Surgical complications ofCF (Study 5.1 Chapter 5) 
patients are included from 1972 
2) Epidemiology ofCF (Study 3.1 Chapter 3) 
all known CF patients in the Western Cape province 
3) Transition to adult-oriented care in CF (Study 8.1 Chapter 8) 
patients attending GSH at the time of the study were included 
These study popUlations are defmed in more detail in these chapters. 
How successful is this attempt to identify all children and adolescents with proven CF 
likely to have been? The RCCH has been and remains a referral centre for children 
for the Western Cape province and, for certain highly specialised services, the rest of 
SA. A specialised CF Clinic was set up at the hospital in the early 1970s under the 
auspices of the Gastroenterology Service. Until the late 1980s this Clinic was the 
only specialised CF service in the western part of the then Cape Province and remains 
the only such service for children and young adolescents. Until 1989 all CF patients 
were seen at this Clinic; since then adolescents have been transferred to GSH at about 
18 years of age. Physicians throughout the region (including other academic centres) 
were encouraged to refer patients to the RCCH for confirmation of the diagnosis and 
for ongoing care. The Clinic co-operated with the Genetic Department at Tygerberg 
Hospital (TBH) in managing the genetic aspects of the disease including antenatal 
testing for CF. 
There has also been a close working relationship between the CF Service at the 
RCCH, the Cape CF Association (a lay organisation promoting the welfare of persons 
with CF) and the Departments of Molecular Genetics at the Universities of 
Stellenbosch and the Witwatersrand. This co-operation and the RCCH's reputation as 
a centre of excellence for CF have ensured that almost all children with CF are known 
to the CF Service and almost all of these have received the majority of their care at 
the hospital. 
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Within the RCCH there is close liaison between surgical departments and the medical 
division that includes the CF Service. Likewise laboratory staff inform the CF Clinic 
staff of any positive sweat test result. 
For all these reasons it is very likely that the 181 patients in this CF population 
represent almost all children recognised as having CF in the Western Cape province 
in the 29 years since October 1974. 
Characteristics of the Study Population 
Of the 181 patients, 96 (53%) were male. One hundred and sixty (88%) were born in 
the province and 21 settled in the province from elsewhere. Seven left to settle 
elsewhere with one returning after a number of years. Contact was lost with 4 
patients. Sixty one (33,7%) patients are known to have died. (The prognosis ofCF in 
this population is discussed in detail in Chapter 9.) 
The popUlation includes one family with three siblings with CF and 14 sibling pairs 
with CF. One sibling pair had a mother who had CF. Two extended families 
included first cousins with CF (6 children in all). 
Cape Town is unique in SA for its population demographics and the CF patients 
reflect this. That CF was not uncommon in the coloured community was shown by 
Hill and colleagues who reported that 30% of patients came from this community.33 
The breakdown of the current Study Population according to ethnic group is shown in 
Table 2.2. (For a full discussion of the use or the terms 'coloured', 'white' and 'black 
African', see Chapter 3 p25.) 
TABLE 2.2 Cystic fibrosis population by 'ethnic group' 
GROUP NUMBER PERCENTAGE 
White 101 55,8 
Coloured 76 42,0 
Black African ~ 1,6 Asian 0,6 
As will be shown in Chapter 3, the genetic basis of CF is different in each of these 
groups. Because of the 'race'-based policies in the country for much of the study 
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period, there was also a significant difference in socio-economic status between the 
groups. Because of these differences (and possibly also because of cultural 
differences) the effect of 'ethnic group' on clinical and prognostic features of CF in 
the Western Cape province will be explored in Chapters 3 and 9. The opportunity to 
update knowledge of the epidemiology of CF using this larger population than the one 
on which current incidence, prevalence and carrier rates in white and coloured 
populations are based is followed through in Chapter 3. 
It is interesting to compare this population with that described in the mid-1980s from 
the RCCH.33 Up till then (and although it is not stated, patients may have attended the 
hospital from as early as 1956, the year the hospital opened) 86 CF patients resident in 
the western Cape Province had been seen at the hospital (20 other patients described 
did not reside in the province). There are now more than twice as many CF patients 
to learn from. At that time 30% of patients (32 patients) were from the coloured 
population; from 1974 onwards, 42% (76 patients) have been. Black African CF 
patients had not been identified at the hospital then; now three attend (five have been 
diagnosed but one was resident in the Eastern Cape province - see Chapter 3 p67). 
It is difficult to compare the mortality of21% by the mid 1980s and 33,7% between 
1974 and the present. Length of follow up is not given by Hill and colleagues and all 
deaths had taken place before 10 years of age.33 In more recent times, as shown in 
Chapter 9, death (at least among white patients) was unusual before that age. It is 
likely therefore that the higher mortality reflects longer follow up rather than worse 
prognosis. 
The study population at the end of the compilation period (September 2003) 
One hundred patients from this popUlation of 181 were known to be alive and 
receiving health care in the province in September 2003. Eighty three, with an age 
range of 5 months to 19 years, attended the RCCH and 17 attended GSH, TBH or 
private practice. The oldest patient was born in 1975 (28 years old). 
Of the 83 patients at RCCH, 12 were not born in the Western Cape province. Forty 
seven patients are white, 32 coloured, 3 black African and one Asian. Their ages are 
shown in Table 2.3. 
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Table 2.3 Ages of patients at Red Cross Children's Hospital Cystic Fibrosis Clinic 
Age Number (%) 
< I year 5 (6) 
1- 5 years 16 (19) 
5 - 10 years 25 (30) 
> 10 years 37 (46) 
In comparing these characteristics with the state 0 f the clinic in the 1980s as reported 
by Hill and colleagues, 33 three changes stand out. Firstly the clinic has become 30% 
larger (83 patients versus 64 patients) despite the adults having moved to GSH from 
1989. Secondly there are more older patients. Hill and colleagues reported that 67% 
of their clinic was under the age of 10 years. The equivalent figure in 2003 was 55% 
meaning that nearly half of all patients exceed this age. Both these factors have 
implications for how the clinic is run and what it costs to do so. If one combines this 
figure for patients over 10 years of age with that for adult patients attending the GSH 
CF service (including the 17 older survivors from this population), it is clear that there 
has been a sea change in the experience with CF in the Western Cape province in just 
under 20 years. 
The third point is the changed 'ethnic' make up of the clinic. Forty three percent of 
patients were non-Caucasoids in 2003. Of the 71 patients used by Hill and colleagues 
to calculate the prevalence ofCF, 21 (29,6%) were coloured and the rest were white.33 
This change has occurred despite the higher mortality of coloured CF patients which 
was shown in my 1996 paper on the prognosis ofCF in the Western Cape province.52 
The lower socio-economic and educational status of many coloured families 
compared to white patients means that this change is likely to influence the amount of 
support the clinic needs to give to patients. It also has implications for the complexity 
of genetic counselling as AF508 homozygosity is less common in non-Caucasoid 
patients. 
The geographic location of patients at the CF Clinic in 2003 was as follows. A large 
majority of patients, 61 in all (73,5%), resided in the Cape Metropole region i.e. 
within 40 kilometres of the RCCH. Twelve resided in the BolandiOverberg region, 7 
in the West CoastlWinelands region and 5 in the Southern Cape/Karoo region. 




OUTLINE OF CHAPTER 
This chapter details both the classic and molecular epidemiology of CF in the 
Western Cape province. After a discussion of 'race' in South African medical 
literature, new epidemiological data, presented in two studies, is compared 
with previous Western Cape and South African literature on these subjects. 
Experience with CF in black patients is then presented. 
Introduction 
The epidemiology of a Mendelian genetic condition such as CF can be described in 
two linked ways. Firstly, it can be described in the classic way (Classic 
Epidemiology) with incidences and prevalences being given based on clinically 
identified cases of the condition. The condition's Mendelian inheritance minimises 
analysis of risk factors in its epidemiology and focuses interest on carrier rates and 
reproductive risk in popUlations with differing genetic histories. 
Secondly, the major advances in molecular genetics of the last two decades make it 
possible to describe conditions such as CF in terms of individual mutations in the 
human genome (Molecular Epidemiology). Tracing the pattern of these mutations in 
different populations casts further light on the history of individual disease-causing 
genes and populations. It also informs the clinical and diagnostic aspects of the 
condition, leading to greater understanding of the condition's place in the health of 
human populations. 




THE DEMOGRAPIDCS OF SOUTH AFRICA AND THE WESTERN CAPE 
PROVINCE 
South Africa (SA), the 'Rainbow Nation', is mainly populated by immigrants. Most 
current populations are made up of persons whose ancestors arrived in the region in 
the last 500 to 1000 years. South African European Caucasoids ('white') largely hail 
from Western Europe as a result of migration through the 17th to 20th centuries. First 
came the Dutch, followed soon by French and German immigrants. Later the British 
arrived and, in the last 100 years, immigrants from most European countries have 
settled in SA. While by no means mutually exclusive in their origins, the white 
population can largely be divided into two groups: English-speaking and Afrikaans-
speaking. The 'mixed race' ('coloured') population contains a variable admixture of 
the inhabitants of the Cape of Good Hope at the time of European settlement 
(KhoiKhoi and San), European, East Asian and black African populations. The 
Negroid ('black African') population results from the southward extension of the 
Bantu expansion. The white and coloured populations contain almost all clinically 
identified cases ofCF in SA. 
The Western Cape province has three main population groups: coloured 
(approximately 54% of the total), Xhosa-speaking black Africans (21%) and white 
(20%) (Census 1996). Given the diverse origins of these three groups, a Mendelian 
genetic condition such as CF is likely to have a different epidemiology in each group. 
The issue of 'race' in medical research in South Africa 
The foregoing section has used many terms to describe the groups who live in SA and 
the Western Cape province. These terms have arisen in anthropological science, 
common custom and, more sinisterly, the social, political and legal history of SA. It 
is necessary in a work of medical science such as this to ensure that any terms used 
are appropriate to the scientific questions being asked and are non-pejorative in their 
usage. 
'Race', in anthropology, is not a valid concept. As Cavalli-Sforza and colleagues in 
their comprehensive work on human population genetics point out, 
23 
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..... the concept of race has failed to obtain any consensus; 
none is likely, given the gradual variation in existence.57 
Superficially recognisable features such as hair colour and facial structure do not 
reflect significant differences at a genetic level. Partition into groups on the basis of 
genetic analysis is by its very nature arbitrary and uncertain. 
The validity of 'race' as a point of departure in medical research is also disputed. This 
is a corrective to a situation in which 'race' was used unthinkingly as a variable, 
regardless of any biological pertinence to the scientific question being pursued. This 
was raised in the 1980s in SA's dentalliterature68 and in the 1990s in the country's 
medical literature. 69-7 I The authors of these articles maintained that assumptions had 
been made regarding groups and their make up that had led to erroneous (and 
sometimes degrading) conclusions. As pointed out by Ellison and colleagues who had 
initiated a heated discussion in the pages of the South African Medical Journal in 1996 
and 1997,69 'race' or 'ethnicity' in medical research have to be used with great 
circumspection, particularly in SA, as many of their apparent effects on health may be 
related more to social than biological factors. They showed that in SA, 'race' and its 
surrogate terms had been used indiscriminately in medical writing leading to false or 
inadequate conclusions regarding the effect of 'race' on medical outcomes. In 
response to a letter from ARP Walker (a doyen of SA's medical research) and 
colleagues in which, among other issues, the use of 'race' in research on single gene 
disorders such as Tay-Sachs disease which have high incidences in certain groups was 
defended,70 Ellison and colleagues wrote 
While interethnic differences in some genetic disorders, 
such as sickle-cell anaemia and Tay-Sachs disease, are 
known to be due to ethnic differences in the frequency of 
those genes responsible, few genetic disorders are linked 
to traditional 'racial' characteristics, .... ,71 
Following Ramphele who raised the pernicious use of 'race' in South African medical 
research in 1992,72 Ellison and colleagues stated that, in order to avoid the potential 
misleading use of 'racial' terms, "[u]nambiguous and detailed definitions" of 




On the Genetics of being called Coloured (,Race' in medical research in South Africa) 
This section, with its intentionally confused title, heralds this necessary discussion on 
'ethnic' classification in SA and in this thesis. It discusses two important questions 
that have to be answered before what follows can be evaluated for its validity: 
1) Are the white and coloured populations described in this work genetically 
distinct? 
2) How was each subject classified? 
Embedded in these two questions is the issue of the use of the terms 'white' and 
'coloured'. This will be dealt with when Question 2 is discussed (p28). 
In the South African context, these two questions have troublesome resonances. The 
first is a valid scientific question whose answer caused much furore when Apartheid 
held sway. Every attempt was made to give the second question an anthropologically 
scientific and legal validity under the terms of the 1950 Population Registration Act in 
SA. This Apartheid-inspired Act together with the Group Areas Act of 1950 (and 
subsequent amendments to both) required a rigid separation of 'White' and 
'Coloured' persons. When classification of persons into groups proved unworkable 
for the 'Coloured' group, an amendment to the Population Registration Act 
subdivided 'Coloureds' into seven 'distinct' groups. The pain and disruption of this 
classification system and its consequences have been felt and are still felt in the 
Western Cape province. Those classified as 'Coloured' were subject to the 
discriminatory laws that went with the system whose aim was to separate the 'races' 
from each other. Those classified as 'White' entered into a system designed, by and 
large, to their benefit despite Apartheid's slogan, "Separate but equal". 
The present work explores a condition (CF) whose basis is entirely biological. As a 
single gene disorder (like Tay-Sachs disease), its presence in human populations 
relates to their genetic and evolutionary histories. To explore its epidemiology 
through the description of its appearance in different populations is, on the face of it, 
valid but needs clarification in the SA context where 'racial' terms have been widely 
used for different purposes and with different meanings. 
In modem anthropological terms, the 'distance' between populations is the 'distance' 
between their genes. The greater the 'distance', the greater the differences in their 
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genetic diversity and phenotypic expression will be (and the further back in time will 
their common evolution be). The point at which populations are considered to be 
different may depend on the problem being studied.67 
QUESTION ONE 
Are the white and coloured populations of the Western Cape Province genetically 
distinct? 
From the point of view of the study of a genetic condition such as CF, the white and 
coloured populations of the Western Cape Province are different. Their histories 
overlap, their genes overlap, but there are sufficient differences genetically for their 
classification into two groups when genetic disease is to be discussed. The evidence 
comes from studies of allotypes and of genetic disorders. 
While he was not the first person to explore allotypes in SA's populations, Botha, in 
his 1972 study of blood groups in the Western Cape undertook by far the largest 
investigation into population genetics in the area up to that time.73 Using data from 
blood specimens from blood donors and scholars from around the Cape Peninsula, he 
explored similarities and differences of a number of red blood cell antigen systems 
between 'White Afrikaans speakers', 'White English-speakers' and 'Cape Coloured' 
persons. In placing his results in the context of the histories of the groups, he 
attempted to calculate the size of differences and similarities in the genetic structures 
of the populations groups. That the differences in histories led to genetic differences 
between the 'White' groups and the 'Cape Coloured' group was incontrovertible, but 
that the immigrant groups had evidence of significant admixture of southern African 
, 
and, in the case of 'Afrikaans-speaking White' group, Asian genes was also certain. 
Despite a declaration by the Afrikaner Studentebond in the year before Botha's 
publication of these results that the ancestry of the Coloured people of SA did not 
include 'White' genes,14 'race' was not an all-or-none phenomenon. The 'Cape 
Coloured' genetic base was KhoiKhoi (Botha used the term 'Hottentot'), European, 
Negroid and South and South East Asian. Botha's findings landed him in political hot 
water at the time with denunciations from high levels in Afrikanerdom (ibid p136). 
His findings were firmly supported by Jenkins from the University of the 
Witwatersrand whose parallel investigation in Johannesburg had not yet been 
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published.75 The 'Coloured' population of the Reef had a greater Negroid 
contribution, but Jenkins' results otherwise reproduced what Botha had found. 
Writing later, Nurse and Jenkins from Johannesburg stated, on the basis of their 
researches, that 
In South Africa a 'Coloured' (sic) is not simply someone of 
mixed ancestry, but someone into whose ancestry a 
Caucasoid element has entered. 76 
They then pointed to the unique ancestry of 'Coloured' people at the Cape where 
Caucasoid, KhoiKhoi, East and South Asian and, to a lesser extent, Negroid (mainly 
from slave imports from West and East Africa) had made genetic contributions in the 
last three centuries. 
That the 'Cape Coloured' population is genetically distinct has had more recent 
confirmation from a study of GMlKM allotypes in populations from all over Africa. 
This study (performed by researchers not one of whom came from Africa) showed the 
'Cape Coloured' to be genetically distant from Negroid, Khoisanid and Caucasoid 
populations while containing significant affinities with the latter two groupS.77 These 
results together with those from Botha and Nurse and Jenkins indicate that, in genetic 
terms (and answering the questioned posed above), white and coloured populations 
differ. [The Negroid affinities of the coloured population will be discussed when the 
molecular genetics of CF in this group (P58).] 
Studies of monogenic disorders other than CF also give insight into the genetic 
distinctiveness and affinities of the coloured population. Haemoglobinopathies such 
as haemoglobins S and C and beta thalassaemia that are not found or are rare in white 
immigrant communities are not infrequently found in this population (F Desai -
personal communication). Familial hypercholesterolaemia (FH), a condition whose 
presence in SA's Afrikaners, Jews and Indians is ascribed largely to genetic drift 
(,founder effect'), has been genetically investigated in coloured persons with the 
disease. 78 "Afrikaner" mutations in the low density lipoprotein receptor genes were 
found and haplotypes were identical indicating a common genetic origin. Lithuanian 
Jewish and Gujerati mutations were also present in coloured patients. Six of seven 
mutations known to be prevalent in SA accounted for 22% of FH in coloured patients. 
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Mirroring the situation with CF, there was a lower incidence in the coloured 
population than the populations from whom the mutations came, but a higher 
incidence than in SA black African in whom FH is rare. In another genetic example, 
the 677C-+ T mutation of the methylenetetrahydrofolate reductase gene that can lead 
to hyperhomocysteinaemia, a cardiovascular disease risk factor, was found in 
frequencies in the coloured population between those for white and black African 
subjects.79 
Studies of SA's Caucasoid populations, whether English- or Afrikaans-speaking, 
suggest strong similarity to each other and to their north-west European forebears76 
p204-206. Botha, exploring blood groups found the differences in admixture mentioned 
above, but the Caucasoids of the Cape were otherwise very similar. Indeed, the 
difference in admixture was questioned by Nurse and Jenkins who felt that it might 
reflect assimilation of coloured persons 'passing for white,.73 p20S 
QUESTION 2 
How was each CF subject classified? 
Though coloured and white populations may differ genetically, classification of the 
individual on the basis of genetic testing is not practical or adequately predictive. 
Not all the above studies state how subjects whose genotypes and phenotypes were 
examined were defmed. Botha, working in the time of mandatory 'racial' 
classification used forms that blood donors completed.73 Nurse and Jenkins used 
motphology.76 Others do not state how classification took place. All methods were 
undoubtedly to some degree subjective or influenced by socio-political orthodoxy. 
In the studies that follow, 'black African' subjects were those whose home language 
was Xhosa. Except in one case (a child of South Asian descent, see below), non-
Xhosa-speaking subjects were dichotomised into 'white' or 'coloured'. Lower case 
initial letters are used to avoid suggesting that the categories have any basis beyond 
that which I have given them in this work. 
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Until very recently it was the practice in South African hospitals to register patients' 
gender and 'race' by one of eight digits on the hospital sticker, based on a fonn filled 
in by the patient or parent. '1' and '2' indicated 'White' males and females 
respectively; '3' and '4' indicated 'Coloured' males and females respectively. In this 
work, the first two categories have been called white and the latter two, coloured. The 
few patients diagnosed since classification at registration ceased have been classified 
based on a combination of features such as skin, iris and hair pigmentation and suburb 
of residence. The outcome of these methods of classification is that the white group 
will include English- and Afrikaans-speaking European and Jewish subjects. The 
coloured group could include Cape Malay and Khoi subjects and does include three 
children whose fathers were white and mothers coloured (2 families). No cases with 
only one black African parent have been seen. 
The child of one family of South Asian descent who arrived in SA from the United 
Kingdom in 1998 was classified as Asian. This group would also include any South 
African subjects who were classified as Indian (categories '5' and '6') on hospital 
stickers. 
All subjects were classified prior to the results of genotype testing being known. 
If, as discussed above, 'races' are not genetically exclusive, yet, for certain purposes, 
Cape Town's non-Negroid 'persons of colour' are genetically distinct from Caucasoid 
populations, this method of classification, despite its dependence on a pre-existing 
'race' -based system, seems the most practical in the circumstances and is likely to be 
sufficiently discriminating (in the scientific sense of a word that has a difficult history 
in SA). 
The Classic Epidemiology of CF in the Western Cape Province 
In the 1980s, medical staff working in the CF Clinic at the RCCH were the first to 
attempt to put figures to the epidemiology of CF in the then western Cape Province 
region.33 The incidence rate that Hill and colleagues calculated was based on figures 
for CF in the population of metropolitan Cape Town. The prevalence of CF was 
based on all CF cases seen at the hospital and known about up to 1984. Breaking new 
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ground, they showed that CF was not uncommon in the coloured community. (Their 
definitions of these two groups were not stated but are likely to be similar to the ones I 
have adopted.) There was nevertheless a considerable difference in the incidence of 
CF between the white and coloured populations in Cape Town (1:2 027 versus 1: 12 
305 live births). These figures were based on the 12 white and 8 coloured children, 
born in 1980 to 1983, who had been diagnosed as having CF. 
Prevalence figures reflected this difference. There were four times as many white as 
coloured cases (8,3 versus 2,1) per 100000 of the population in urban Cape Town. A 
lower prevalence in rural parts of the region was ascribed to under-recognition of CF 
outside metropolitan Cape Town. This was noted for both groups but was especially 
significant in the coloured population, showing an apparent 3,5 times lower 
prevalence in the rural western Cape Province region compared with Cape Town. For 
the authors this highlighted the relative under-recognition of CF in coloured children. 
Only in the 1990s was CF identified in a Xhosa-speaking black African in the 
Western Cape and to date only 4 such children are known to have lived in the 
province (see p89 below for a full description of these cases). 
Motivation for the current study 
II CF birth data in Hill and colleagues' study was on a narrow base 
The incidence figures for CF in the white and coloured populations in this paper 
were based on 12 and 8 births respectively. While the aggregation over four years 
would have smoothed out some variation in annual CF births, confidence intervals 
(CI) (not reported in the paper) were wide. For example, the incidence of 1 in 
2027 (carrier rate 1 in 23) for the white population has 95% CIs of 1 in 1297 
(carrier rate 1 in 18) to 1 in 4672 (carrier rate 1 in 34). For the coloured group the 
CIs make incidence rates even less certain: anywhere from 1 in 7246 to 1 in 38759 
live births. Notably, though, the two sets of 95% CIs do not overlap suggesting a 
real difference in incidences despite the uncertainty of each rate. 
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.f1 The proportion ofCF patients in each 'population group' has changed over 
time 
As demonstrated in Chapter 2, the proportion of CF patients who belong to the 
coloured group has risen over time. This could be related to demographic change, 
greater relative survival or better case ascertainment in this group (in part as a 
result of Hill and colleagues' paper). Reviewing the incidence of CF would 
indicate if the latter cause explains this change. 
Although they did not test their assertion statistically, Hill and colleagues' paper 
demonstrated that there was under-ascertainment of coloured patients in rural 
Western Cape areas compared with white patients. In fact their figures did not 
show under-ascertainment for white rural patients compared to urban patients (the 
95%Cls for the difference spanned zero) but their statement regarding coloured 
rural patients was statistically true (see below p78). Whether this remains the case 
in an era of increased CF awareness needs to be tested. 
n There are uncertainties regarding the numerators and denominators in Hill and 
colleagues' study of incidence 
It is uncertain where the live birth data for 'the Cape Town area' used in the 
paper was obtained from. They cannot be census-based as the years 1980-1983 
were used and only the 1980 census mentioned as fonning the basis of other 
calculations. If Municipal Department of Health data were used, they are 
unreliable. These data are reported in the Medical Officer of Health (MOR) 
Annual Reports and come largely from public sector facilities. They thus 
undercount the white group in particular. Birth registration by the Department of 
Home Affairs, another possible source, often lags behind the time of birth and is 
unreliable among poorer communities, even in urban areas. 
The data on CF births I have collected cast doubt on the numerator used in the 
paper. The 'Cape Town area', if the fonner 'City of Cape Town' was meant, 
had 17 CF births in 1980-1983 (one of whom was not diagnosed at the time of 
Hill and colleagues' study), rather than the 20 they reported. If the whole ofwban 
Cape Town was meant, the number ofCF births was 26. 
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With Hill and colleagues' figures being the only ones available in SA, it will be 
important either to confirm or refute them, if it is possible to do so. Decisions 
about the availability of diagnostic and clinical services as well as the feasibility 
and utility of screening for CF have and will be made on the basis of incidence 
and prevalence figures. Educational strategies for health care workers are also 
influenced by how common a condition such as CF is. For example, if CF is 
really more common in the coloured population than Hill and colleagues' study 
suggests, efforts to change health care workers' perceptions of the likelihood of 
CF in certain clinical scenarios (e.g. persistent chest symptoms) will need to 
change. 
Study 3.1 THE CLASSIC EPIDEMIOLOGY OF CYSTIC FIBROSIS IN THE 
WESTERN CAPE PROVINCE 
Aim 
To establish the incidence and prevalence of CF in the white and coloured populations 
of the Western Cape province of SA. 
Objectives 
1) To determine the incidence of CF in the coloured and white populations 
2) To determine carrier rates for CFTR mutations in the coloured and white 
populations 
3) To determine the prevalence ofCF in the coloured and white populations 
4) To compare these rates with those determined in the previous study from 
this region 
5) To determine whether apparent under-recognition of CF in areas beyond 
the Cape Metropole and between the 'population groups' still pertains 
Methods 
Incidence 
The number of children born with CF in Cape Town in each of the years from 1984 to 
1995 was determined using data on year and place of birth from the database. As late 
32 
Chapter 3 
diagnosis is still not uncommon for CF, figures for CF births after 1995 were not used 
in this analysis. 
The following data sets were explored in an attempt to find accurate birth data for this 
period: Municipal MOH Reports, Birth registration data and the 1996 population 
census. The municipal data for the City of Cape Town was readily available but, as 
discussed above, undercounted white births. It was therefore discarded and the data 
for Bellville and other metropolitan municipalities not sought. Birth registration has 
been found to be significantly low among SA's poorer and more rural populations 
making it a poor source for accurate birth data. 80 It was decided to use population 
data from the 1996 census, which, while acknowledged to have some inaccuracies for 
black African groups where enumerating proved to be logistically difficult, was 
reasonably accurate for the two popUlations under investigation here. 8! 
The number of children between the ages of 0 and 9 years were tabulated in two 5 
year groups (0-4 and 5-9 years) directly from the 1996 population census data using 
the CD ROMs supplied by Statistics SA.8! These figures were equated with the 
number of live births in those 5 year periods and the overall 10 year period. For ease 
of reporting, these periods were converted into calendar years i.e. 1992-1996 = 0-4 
years, 1987-1991 = 5-9 years, 1987-1996 = 0-9 years. The census was carried out in 
October 1996. It was assumed that numbers would not be significantly altered by this 
conversion. The assumption was also made that under five mortality would not have 
significantly altered the figures as childhood mortality was relatively low in these two 
groups. The 1998 Demographic and Health survey gave an overall figure of under 5 
mortality for the Western Cape province of 39 and an infant mortality of 30.82 These 
figures included the black African population in which higher child mortality rates 
than the average were found. Thus at most there would be a 0,03 - 0,04% cumulative 
inaccuracy (about 3-4110000 live births), a difference of no significance even over 10 
years given the very low expected numerator in any incidence calculation for CF. The 
other assumption was that migration would not have significantly altered the. child 
population figures for these two groups in the census. 
The Western Cape was divided into two parts, Cape Metropole (Western Cape 
province Census areas 1-7 i.e. Bellville, Cape, Goodwood, Kuilsriver, Mitchell's 
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Plain, Simonstown, Wynberg) and non-Cape Metropole (all other areas) using the 
Census areas. Both CF birth and population birth data were classified according to 
these areas. 
Incidence rates for CF (with 95%CIs) in the two parts of the province and the 
province as a whole were computed by dividing the number of CF births in the area 
by the number of live births derived from the census data and converting the fraction 
to a ratio. The two periods were examined separately to determine if there was 
consistency in the incidence rates. 
Carrier rates 
Carrier rates were calculated for the coloured and white populations by the formula: 
-J(I/Incidence) /2. 
Prevalence rates 
Prevalence rates were determined for 1996. This was a Census year, allowing 
accurate determination of the coloured and white populations of the Cape Metropole 
and other areas of the Western Cape Province divided as for the determination of 
incidence (the denominators).81 1996 was also the year in which the study of 
Transition in CF reported in Chapter 8 was undertaken. This study required the 
names of all adults and older adolescents with CF attending the CF Clinics at GSH 
that, together with the RCCH database, allowed the ascertainment of nearly all 
patients with CF in the province and their addresses. As with the previous study of 
prevalence, a few cases who did not receive their care at RCCH or GSH were 
included (the numerators). Prevalence is reported as the number of CF cases per 100 
000 of the popUlation. 
Results 
The incidence and carrier rates for CF for the two periods and the two census areas 
together with the totals are given in Table 3.1. The proportion of CF births that were 
in non-Cape Metropole areas were the same for the two groups (8/31 coloured; 4/23 
white, chi-square for difference = 0,54, P = 0,46). 
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Table 3.1 Incidence and carriers rates for cystic fibrosis in the Western Cape province 
Non-Cape Metropo\e areas 






Cape Metropo\e areas 






Western Cape province 






CI- confidence mterval 









I: 12750 1:2725 




1 :58 1:30 
Periods 
1987-1991 1987-1996 
coloured white Total coloured Total white 
113989 21839 228078 39112 
0 2 8 4 
I: 10920 1:28510 1:9778 
I: 16835 - 1:92593 1:4950'" 
1:52 1:84 1:49 
1:65-1:152 1:35'" 
121524 29815 236278 57066 
14 9 23 19 
1:8680 1:3313 I: 10273 1:3003 
1:7299 - 1: 17361 1 :2070 - 1: 5464 
1 :47 1:29 1 :51 1 :27 
1 :43-1 :66 1:23-1 :37 
235513 51654 464356 96178 
14 II 31 23 
1: 16822 1:4695 1:14979 1:4181 
1: 110742 - 1:23094 1:2967 - 1 :7092 
1:65 1:34 1 :61 1:32 
1:53-1:76 1 :27-1 :42 
There was a significant difference in the overall incidence of CF between the white 
and coloured groups (p = 0.000000) in the province. If the Cape Metropole figures 
were taken as representing the true incidences of CF as suggested by Hill and 
colleagues, the difference between the groups remained (p = 0.000000). 
A comparison of the incidence and carrier rates in this study and those of Hill and 
colleagues is given in Table 3.2. 
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Table 3.2 Comparison of incidence and carrier rates for cystic fibrosis in Hill and 
colleagues' study and this study. 
1980 -1983 (Hill et aI., 198833) 1987 -1996 (Westwood 2004) 
Cape Metropole areas Coloured White Coloured White 
Number of births 98443 24324 236278 57066 
CF births 8 12 23 19 
Incidence 12305 2027 10273 3003 
95% CI 1:7246 -1:40000 1:1295 -1:4673 1 :7299 - 1: 17361 1 :2070 - 1 :5464 
Carrier Rate 1:55 1:23 1 :51 1 :27 
95%CI 1:43-1: 100 1:18-1:34 1 :43-1 :66 1 :23-1:37 
Data in italics were not given in the original study 
CI confidence interval 
A total of 108 CF patients were known to be living in the Western Cape province in 
1996. Only one of these was a black African. Forty were coloured and 67 white. The 
prevalence rates for CF in the coloured and white populations for the Cape Metropole 
and the non-Cape Metropole areas of the Western Cape province are given in Table 
3.3. 
Table 3.3 Prevalence of cystic fibrosis in the Western Cape province in 1996 
Population group 
White Total population 
Non-Cape Metropole areas 
Population 1016443 331247 1 347690 
CF patients 12 14 26 
Prevalence rate I 100000 1,2 ~1,9 
Cape Metropole areas 
Population 1 129668 490303 1619971 
CF patients 28 53 81 
Prevalence rate /100000 2,5 10,8 5,0 
Table 3.4 compares these 1996 prevalence figures with those derived by Hill and 
colleagues from 1980 census data.33 The differences in prevalence rates between 
1980 and 1996 for each population group and in each area were not statistically 
significant. Table 3.4 shows that prevalence of CF in the two population groups was 
significantly lower in the non-Cape Metropole areas in both studies with the exception 
of the white group in 1980. 
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Table 3.4. Comparison of prevalence of cystic fibrosis in 1980 and 1996. 
Coloured White 
Non-Cape Metropole 1996 (Westwood) 1980 (Ref33) 1996 1980 
areas 
Population 1 016443 634720 331247 219980 
CF patients 12 4 14 10 
Prevalence rate / 100 000 1,2 0,6 4,2 4,5 
Cape Metropole areas 
Population 1 129668 793020 490303 482240 
CF patients 28 17 53 40 
Prevalence rate /100000 2,5 2,1 10,8 8,3 
Difference in prevalence 1,3 1,5 6,6 3,8 
between areas (95%CI) (0,16 -2,43) (0,32 - 2,7) (2,9 - 10,2) (Not significant) 
Discussion 
This study aimed to have a second look at CF epidemiology in the Western Cape 
province. There was an opportunity to review the picture given by Hill and 
colleagues in the 1980s,33 both because of doubts over some of the data in the paper 
and because of an apparent change in the demography of CF cases. Having a 10 year 
period available has allowed a consistency in incidence over time to be demonstrated. 
These figures are based on a database of cases that goes up to 2003. The vast 
majority of CF cases have been diagnosed by the age of 7 years increasing the validity 
of the incidence (and prevalence) figures for a period that ended in 1996. Hill and 
colleagues' figures were calculated at most 4 years after the years during which births 
were counted. The figures given here must therefore be considered to be more robust 
than those in the first study of CF epidemiology in this region. 
Birth incidence figures may be influenced by a number of factors. This study uses 
clinical identification rather than any form of screening to arrive at the figures. Birth 
screening and screening of married couples (except where there is a family history of 
CF) does not occur in this area. Any systematic under-ascertainment of clinical cases 
would have distorted the figures. This is particularly possible in the coloured group 
where infant death even in diagnosed cases has been a problem. In both groups cases 
of CF diagnosed in adults would also not be reflected in the incidence figures in this 
study. To my knowledge this is not a common phenomenon in the Western Cape 
province (I know of one case. He was born before 1974). In recent years accurate 
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prenatal diagnosis has become possible. When incidence rates are converted to carrier 
rates the formula does not take account of cases in which affected pregnancies are 
terminated. Based on cases known to me, about one pregnancy every second year has 
been terminated for CF since the early 1990s. 
This study confirms the difference in the incidence of CF between the coloured and 
white population groups that was first shown by Hill and colleagues.33 In no part of 
the province and in none of the time periods were the incidences close to being the 
same. 
The study also shows an apparently lower incidence of CF in non-Cape Metropole 
areas. Hill and colleagues related a lower prevalence rate in rural areas to under-
ascertainment. There is no biological explanation for the difference in incidence as 
the urban and rural populations in these two groups come from the same stock so 
under-ascertainment is the most reasonable explanation for this phenomenon. In 
support of this is the apparent absence of CF births in the non-Cape Metropole 
coloured popUlation in 1987-1991 compared to the 8 cases born in the next 5 year 
period by which time the data from Hill and colleagues study had been published and 
discussed. Thus the true incidences of CF were likely to approximate to those found 
in the Cape Metropole. 
The incidence figures were similar to but not the same as those from the early 1980s. 
The incidence in the coloured population was lower by a factor of about 16%. More 
confidence can be placed in the figure of 1 in 10273 live births as the greatly reduced 
95%CI indicates. For the white population, CF would appear to have been slightly 
less common that the 1980-1983 figures suggested. The lower 95%CI for the 1987-
1996 incidence was the almost same as the incidence of 1 :2027 given by Hill and 
colleagues.33 
If the same incidences are applied to the non-Cape Metropole areas as were found in 
the Cape Metropole areas and if full case ascertainment in the Cape Metropole is 
assumed, 4-5 coloured and 3-4 white babies with CF (7-9 babies in all) were born 
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CF were not being diagnosed each year. (It should be noted that about one CF 
pregnancy every two years is terminated in a family with an index case) 
The study shows that carrier rates for CF were higher for the coloured group and 
lower for the white group than the figures used since the publication of Hill and 
colleagues' paper. This has implications for counselling for CF risk in these groups. 
(This is discussed further with the Molecular Epidemiology of CF p42.) 
As presented in the Introduction to this chapter, the white population of SA, though 
having some admixture from other groups is largely descended from European 
Caucasoids. Most of these antecedents were from the northern countries of Europe. 
Dodge and colleagues in a thorough multicentre attempt to count every CF patient in 
the United Kingdom found an incidence of 1 in 2415 live births. 83 This figure is 
encompassed by the 95%CI for white CF births in Cape Town. Across the English 
channel in Brittany, recent research using neonatal screening data has suggested a 
similar incidence of 1 in 2838.84 A retrospective study back to 1960 shows a similar 
incidence: 1 in 2640.85 This incidence among a population with strong Celtic roots is 
probably not representative of the whole of France. An incidence of 1 in 3200 has 
been proposed for France based on three sites of neonatal screening.86 SA's white 
Afrikaner population, particularly in the Western Cape province, is partly made up of 
descendants of French Huguenots who migrated to SA in the 17th century. This 
incidence is also compatible with that among SA whites. The Netherlands is the 
origin of a significant proportion of the Afrikaner population of SA. Recent data 
using the L\F508 mutation in 11 654 blood donors has suggested that the CF carrier 
frequency there is 1 in 32 (95%CI 1 in 28 to 1 in 36), less than the European average 
of 1 in 25.87 The South African incidence found in the Cape Town study lies between 
the two and the 95%CI spans both. It thus would seem that the South African 
incidence and carrier rates for CF for the white population correlate with those of the 
countries from which this population is largely derived and are not as high as Hill and 
colleagues suggested in 1988. There is therefore no sign of genetic drift or 
heterozygote advantage or disadvantage for this disease in SA. 
The coloured families in this study would appear to be representative of the 
population they carne from. Only two families had a 'pure' Caucasoid parent (one 
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from England; one an Afrikaner); none had a 'pure' black African parent. The 
significantly lower incidence in this group compared to the white group suggests that 
CF genes were less common in the KhoiKhoi, West and East African and East Asian 
antecedents of this group. Cases of CF and CFTR mutations are known to be rare in 
the latter two groups. Of the 'original' inhabitants of the Cape, the San have not been 
shown to have CFTR mutations. Padoa and colleagues, in their study of CFTR 
mutations in Africa, did not find any mutations in 208 healthy San subjects.sO 
Populations with dominant KhoiKhoi antecedents such as the Griqua and the Nama 
have not been studied in this respect.so It is likely therefore that the difference 
demonstrated in this study, though probably smaller than that suggested by the 
original study of Hill and colleagues, was real and was not a product of under-
ascertainment. (Further light on the origins of CF in this group is shed by the study of 
the Molecular Epidemiology of CF reported on p42.) 
Prevalence rates for CF depend on the number of cases diagnosed and their survival. 
As Table 3.1 shows, there was a 3,4 fold difference in the incidence of CF between 
the white and coloured groups. The prevalence of CF in the Cape Metropole, 
however, was over 4 fold higher in the white group compared to the coloured group. 
Greater early mortality in the coloured group, as demonstrated in my 1999 study of 
the prognosis of CF in the Western Cape province (reproduced in Chapter 9 p250), is 
likely to explain this greater difference. 
For both groups CF prevalence was about 2,5 times lower in rural than urban areas. 
For the white group in 1996, unlike in 1980, this was statistically significant. This 
urban/rural difference in prevalence rates probably reflects the under-ascertainment 
demonstrated by the incidence data, but a greater rural mortality may also be a factor 
given problems with access to specialised health care experienced by poor South 
Africans. 
The study was unable to demonstrate a change in the prevalence of CF in 16 years 
even in the Cape Metropole. If there is a trend to increased prevalence as the figures 
suggest, increased longevity is likely to have been responsible as incidence will not 
have increased over the two decades. 
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These prevalence data make it possible to estimate the number of CF patients from the 
coloured and white groups in SA. Using data on the national population from the 
2001 National Census,88 there would have been 100 coloured and 464 white persons 
with CF in the country in 2001; a total of 564 (Table 3.5). Thirty nine of the expected 
100 coloured persons in SA were known in the Western Cape in 2003. According to 
the 2001 Census, 61% of SA's coloured population live in the Western Cape 
province. Table 3.5 shows that 61 (95%CI 46-76) coloured CF patients would be 
expected in the province. The apparent absence of over a third of them suggests that, 
even in 2003, CF is being missed in this group, presumably largely in non-Cape 
Metropole areas. Chapter 2 showed the increasing proportion of coloured patients at 
the RCCH CF Clinic (P19). The CIs in Table 3.5 suggest that the number of white 
and coloured CF persons in the province may even be about equal. 
Table 3.5 Expected numbers of coloured and white persons with cystic fibrosis in 
South Africa in 2001 
Coloured White Total 
Population Persons with CF Population Persons with CF Persons with CF 
(95%CI) (95%CI) (95%CI) 
Eastern Cape 478807 12 304506 33 45 
Free State 83193 2 238791 26 28 
Gauteng 337974 8 1758398 190 198 
KwaZulu Natal 141887 4 483448 52 56 
Limpopo 10163 0 126276 14 14 
Mpumalanga 22158 1 203244 22 23 
Northern Cape 424389 11 102043 11 22 
North West 56969 1 244035 26 28 
Western Cape 2438976 61 832901 90 151 
(95%CI:46-76) (95%CI:71-108) (95%CI:127-175) 
Total 3994516 100 4293642 464 564 
(95%CI:80-119) (95%CI:421-507) (95%CI:517-611) 
Table 3.5 shows the number of coloured and white persons with CF expected in each 
of SA's provinces in 2001. Gauteng would expect the largest number of persons with 
CF, almost all of whom would be white. The figures in this table assume that 
prognosis of CF in all the provinces was about equal and therefore may reflect higher 
numbers than the actual number of persons with CF in provinces in which the 
condition has a poorer prognosis than in the Western Cape province. There is no data 
on which to take this issue further. 
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This study has only taken account of coloured and white persons with CF. CF is rare 
in Asians and only one such patient has ever attended the Cape Town CF Clinics. CF 
among black Africans is the subject of much conjecture and debate since Padoa and 
colleagues suggested that carrier rates were possibly as high as in other populations 
groups in SA.sO Only one black CF patient was known in the Western Cape in 1996. 
The Classic Epidemiology model is unable to give incidence and prevalence data in 
this group. It can only ask the Molecular Epidemiology model that was used by 
Padoa and colleagues where all the expected black African CF patients were. This the 
Molecular Epidemiology model will attempt to answer (P5I). 
In conclusion, this study has established new incidence figures for CF in SA in the 
coloured and white groups. It has confirmed that there is a difference in the incidence 
and prevalence between the groups and that rural under-ascertainment of CF cases 
was occurring in both groups in 1996. The prevalence of CF in the Western Cape 
province may be rising. 
The Molecular Epidemiology of cystic fibrosis in the Western Cape 
province 
Soon after the identification of CFTR it became clear that, at a molecular level, CF 
was a heterogeneous disease.89 Although one mutation, 6F508, dominated in the first 
CF popUlations investigated with the new molecular tool, many CF-causing mutations 
were soon found, confounding hopes that molecular methods would provide a simple 
diagnostic tool and that a genetic cure might lie within reach. 
This expanding evidence of the genetic heterogeneity of CF led to the discovery that 
populations of differing genetic histories carried different patterns of CF mutations. 
The earliest evidence of this was found in Europe.90 There was a decreasing 
proportion of CF patients with 6F508 the further South they lived.91 For those in 
northern Europe e.g. in Denmark, the frequency of 6F508 was 88% whereas in the 
southern Europe, e.g. Albania, it was 52% with other CF-causing mutations making 
up the remainder. Certain mutations were found to be specific to certain populations 
e.g. 394delTT in Nordic countries and Q359K1f360K among Jews in Georgia.92 
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The molecular basis of cystic fibrosis in South Africa 
The molecular basis of CF in South African populations has now been well studied. 
The first studies following the identification of CFTR pursued haplotype analysis and 
AF508. Initial work by the South African Institute for Medical Research (SAIMR) at 
the University of the Witwatersrand was reported in a letter to the American Journal 
of Human Genetics published in 1990.93 This letter was written by the Cystic Fibrosis 
Genetic Analysis Consortium and contained the results of a worldwide survey of 
AF508. Thirty six CF chromosomes from Caucasoids had been screened in 
Johannesburg and 27 (75%) had AF508. 
In the same year a study of DNA from South West African Afrikaners with CF was 
presented.94 These six patients had been studied by Super in the 1970s, before the 
country's name was changed to Namibia. Eight (67%) of the 12 chromosomes had 
AF508 showing the mutation to be common among Afrikaners. 
Groups from within SA reported their experience with the molecular genetics of CF in 
an edition of the South African Medical Journal in 1992. A study from the 
Department of Human Genetics at Tygerberg Hospital in Cape Town described 
patients from the RCCH CF Clinic.4S DNA from 71 white and coloured patients was 
studied. Tables 3.6 and 3.7, reproduced from this study, show the frequencies of 
AF508 and of genotypes in the two populations. 
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Table 3.6 Number and proportion of the LlF508 mutation in 142 mutant cystic fibrosis 
genes from 71 cystic fibrosis patients (after Herbert and Retief 199245) 
Frequency of No. of 
mutations in CF genes CF 
Ethnic group LlF508 Other genes 
White 0,82 (94) 0,18 (20) 114 
Coloured 0,53 (15) 0,47 (13) 28 
Total 0,77 (109) 0,23 (33) 142 
Other refers to mutations in CF genes other than M508 
mutation. The number of CF genes is indicated in parentheses 
Table 3.7 Genotypes of71 cystic fibrosis subjects (after Herbert and Retief 199245) 
No. ofCF subjects per genotype 
Ethnic LlF5081 LlF5081 Other*1 
group LlF508 other" 
White 68 
iColoured 
Total 42 (59) 25 (35) 4 (6) 
-Other refers to mutations in CF genes other than 6FS08 mutation. 






The high frequency for LlF508 in CF chromosomes from white patients was also 
shown in the other studies reported in that SAMJ edition. Geneticists from 
Johannesburg reported on 81 families and found an 82% prevalence of LlF508.43 44 
This study also shed light on the origin of most white CF families. Haplotype 
analysis of the CFfR region coincided with those found in chromosomes from 
northern European persons. 
The relatively low rate of 53% for LlF508 in CF chromosomes in coloured patients 
indicates a different genetic background. Only one third of coloured patients were 
homozygous for LlF508 compared with two thirds for whites. It should be noted that 
frequencies for the coloured group were based on 28 chromosomes (14 patients). CIs 
reveal that the difference between white and coloured patients in terms of LlF508 
frequency may not have been as great as given unanalysed in Herbert and Retiefs 
Tygerberg paper (Tables 3.6 and 3.7),45 The 53% figure for the coloured group has a 
wide 95%CI at 34 to 72,5%. The 95%CI for the 82% of CF chromosomes from white 
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patients is 75,5 to 89%. Likewise the difference between the rates of homozygosity 
for ~F508 (21 %) and compound heterozygosity (64%) in the coloured group, i.e. 43, 
could be as little as 9 or as much as 76. It would be important to have frequencies on 
a larger number of CF chromosomes from coloured patients before these figures could 
be taken as representing the situation precisely. 
The place of genetic testing for CF and the counselling implications were discussed in 
detail in these articles.43-5 ~F508 testing was noted as a great advance that would 
replace much of the restriction fragment length polymorphism (RFLP) analysis that 
had guided most genetic counselling regarding carrier status and prenatal counselling 
up till then. It was noted that, owing to its lower prevalence in the coloured 
population, ~F508 testing was going to be less informative in this group. Screening 
for CF in the SA context was thought to be impractical on the basis of the data from 
these studies. 
As Denter and colleagues put it in the conclusion of their paper: 
"It is highly desirable to determine which mutations occur 
in southern Africa, and at what frequency in order to 
improve carrier detection and the accuracy of risk 
calculation.,,44 
World wide through the 1 990s, dozens of new disease-causing CFTR mutations were 
identified. Which ones would be informative in SA? In particular, which ones would 
help in identifying the genetic basis for CF in coloured patients and so fulfil the hopes 
expressed in 1992? 
Rather unexpectedly, a big step forward was made through the study of a number of 
black African patients with CF who were diagnosed in the 1990s.49 This research is 
described in detail on p62 in the section of this chapter discussing CF in black 
Africans in the Western Cape Province. The important outcome for the understanding 
of the Molecular Epidemiology of CF in the coloured population was the 
identification of one common mutation in black African patients: 3120+ 1 G~. 
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The next phase in the understanding of the Molecular Epidemiology of CF in SA 
came through the application of panels of the more common CFTR mutations 
(including 3120+1G""'A) to local CF chromosomes. 
This analysis was largely performed in Johannesburg by the SAIMR at the University 
of the Witwatersrand in collaboration with CF workers in SA and laboratories in 
France and Germany. These studies, which have given cumulative insight into the 
Molecular Epidemiology of CF in SA, were published in 1994, 2001 and 2003.46-8 
They are summarised in Table 3.8 and show a progressive refining of knowledge in 
this area. 
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Table 3.8 CFTR gene mutation analysis in chromosomes from South African cystic 
fibrosis patients: 1994, 2001, 2003 
• Goldman et a11994 Goldman et al 2001 Goldman et al 2003 
(Reference 46) (Reference 47) (Reference 48) 
White Coloured White Coloured Black White Coloured 
(N* = 250) (N = 2) (N = 384) (N = 28) (N = 24) (N = 402) (N = 86) 
Frequency of mutations 
Mutation 
80,4 50 76 42,9 7 
3272·26A>G 4 4 
394de1TI 3,6 3,7 
G542X 1,2 1,3 3,6 1,7 
R553X 0,4 1 1 
W1282X 1 1 
N1303K 0,4 1 0,8 
G551D 0,8 3,6 0.25 2,3 
~0+1G>A 0,5 28,6 45.8 0.5 17,4 
R117H 0,3 0,25 
Q493X 0,3 0.25 
S549N 0,4 0,3 0.25 
621+1G>T 0,4 0.3 0,25 
1717·1G>A 0,3 0,25 
2789+5G>A 0.3 0.25 
3659deiC 





Unknown 16,8 50 9,1 17.9 37,5 ~ 25.6 
Total detected 90,9 82,1 42,5 4,4 
• N IS the number of chromosomes tested 
dF508 is the dominant mutation in the white population of SA with a frequency of 
76% in CF patients.48 This is less than the frequency of 81 or 82% reported on fewer 
patients in 1992. Sixteen mutations account for 91 % of CFTR mutation in the white 
population. In the coloured population dF508 is the commonest mutation (50%) with 
the 3120+ 1 G -?'A mutation being significantly common at 17,4%. Six mutations 
account for 74,4% of CFTR mutations in this population. 
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AFRICA'S BIG TWO: A Description of the two commonest CFTR gene mutations 
in southern Africa 
Delta F 508 
With the identification of the CF gene in 1989 came the discovery of the 
common mutation that had been predicted by haplotype analysis. 14 15 This was 
a three base pair deletion in exon 10 of the CF gene that led to the absence of 
phenylalanine at position 508 in the as yet unnamed protein product, later 
CFTR. The shorthand for this is L\F508 and it accounted for 70% of mutant 
genes in the initial study. L\F508 was common in Caucasoids, particularly 
those living in north west Europe and North America. Haplotype analysis had 
already suggested that this mutation had been a once-off phenomenon. Study 
of L\F508 among European populations indicated that it probably originated in 
older European populations as demonstrated by the prevalence of 87% in 
people of pure Basque descent and spread to the new immigrants from the 
South East.95 
The clinical correlate of L\F508-associated CF had been anticipated by 
haplotype studies in 1989.96 These showed that the dominant haplotype-
associated mutation was associated with pancreatic insufficiency (PI) whereas 
with many other CF-associated chromosomes pancreatic sufficient (PS) forms 
of CF were more common. This was confirmed by the Canadian group in 
Toronto (who must have been working feverishly hard at this exciting time). 
In a paper published in the New England Journal of Medicine in 1990, L\F508 
homozygosity was shown to be almost always (99%) associated with PI 
whereas PS occurred in 72% and 36% of L\F508 compound heterozygotes and 
patients with no identified mutation respectively.97 Further correlations 
between the L\F508 homozygous genotype and clinical features of CF were 
found: meconium ileus (MI), high sweat chloride concentrations, earlier 
diagnosis. As PI itself was associated with worse lung disease and nutritional 
status, L\F508 was characterised as a 'severe' mutation i.e. homozygosity for 
L\F508 meant severe disease in almost all cases, compound heterozygosity of 
the mutation leading to mitigation of its 'severe' nature in some cases. 
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This hopeful prediction (i.e. better outlook for D.F508 compound 
heterozygotes) was disproven in a large study comparing D.F508 homozygotes 
with compound heterozygotes for D.F508 and 7 non-D.F508 mutations.98 No 
differences were found between the two groups except for the D.F508/Rl17H 
genotype in which PS was the rule. Notably pulmonary function, even 
between D.F508 homo zygotes, was very variable. These findings have been 
established as correct across other Caucasoid populations. 
D.F508 has not been found in populations amongst whom CF is rare: American 
Indians, black Africans, Asians. 
In summary D.F508 is the commonest CFTR mutation in most European 
Caucasoid populations. It is associated with PI and other gastrointestinal 
conditions in homozygotes. Most homozygotes will have significant 
pulmonary disease. 
3120+ 1 G--+A 
The 3120+ 1 G--+ A mutation, though much less common worldwide than 
D.F508, assumes a greater role in non-Caucasoid populations.99 It is a splicing 
defect in intron 16 owing to a change from guanine (G) to adenosine (A) at 
position 3120+1. That it was a mutation rather than a polymorphism was 
indicated by its absence in a large number of normals and CF carriers. It is 
very rarely found in Caucasoids but is present in 12,2% of African American 
CF chromosomes.99 Macek and colleagues who have conducted the largest 
study of African American CF mutations showed that, if 'Caucasoid' alleles 
were excluded, 3l20+1G--+A would be responsible for 53% of African 
American alleles.99 Even more significantly, it has comprised 5 out of 8 CF 
mutations in 4 black African children with CF.49 
The mutation is also found in Brazi1. 100 In Rio de Janeiro it was the second 
most common mutation after D.F508 (D.F508 25,7%, 3l20+1G--+A 4%), 
reflecting the priority of this mutation as found in African Americans. 
Negroid admixture in the city was 52% suggesting an African origin for the 
mutation in this population. 
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3120+1G-A was first identified in three African Americans with CF and was 
the first of a number of mutations that were initially found in Negroid 
populations.99 However it is not exclusive to them. It was identified in Arabs 
in Saudi Arabia in 1997. 101 It constitutes 10% of known CFTR mutations in 
that country but, of the 7 families with the 3120+ 1 G-A mutation, only 3 (all 
homozygotes for the mutation) were Saudi. The nationalities of the other 
families were not given. The mutation has also been found in a Bahraini Arab 
family.l02 In Europe the mutation has only been found in Greece where it 
constituted 3 out of 500 CF chromosomes from Greek patients. 103 
Figure 3.1 Sites in which the 3120+ 1 G-A mutation has been found (adapted 
from Reference 104. 
That this mutation appeared so common in Negroid populations yet was also 
found in southern Europe and Saudi Arabia (see map Fig 3.1) led to a study of 
haplotypes to test whether the mutation had a common origin or was the result 
of multiple mutational events. 104 Strong correlations between the Arab, 
African and African American haplotype patterns were found suggesting a 
common origin. The Greek haplotype, while it differed in a minor way from 
the others, was not thought to be different enough to be explained by a second 
mutational event. "Gene flow" across the Sahara is known to have brought 
spread of other genetic disease and CF seems to have been no exception and 
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3120+ 1 G-+ A is the evidence. Its presence in Brazil is likely to relate to the 
slave trade from West Africa in the 17th and 18th centuries. 
Analogous to the relationship between the ilF508 and 3120+ 1 G-+ A mutations 
amongst African Americans, though for different historical reasons, the two 
mutations dominate the molecular biology of CF in the coloured population of 
SA. Between the two, they accounted for 67% of mutations in the coloured 
population in the most recent study of CF in SA.48 The origin of the 
3120+1G-+A mutation in this population is thought to be Negroid. 
The 3120+1G-+A mutation has now been found in black African 
heterozygotes. Carrier rates of 1 in 91 have been found in southern Africa 
leading to questions regarding the apparent rarity of clinical CF amongst black 
Africans in the area. 50 This is discussed in detail with Study 3.3. 
In summary the 3120+1G-+A mutation has earned the epithet of the 'African 
mutation' and it is appropriate. Its identification may have opened the way to 
a change in our understanding of the epidemiology ofCF in Africa. 
Study 3.2 THE MOLECULAR EPIDEMIOLOGY OF CYSTIC FIBROSIS IN 
THE WESTERN CAPE PROVINCE 
Aim 
To describe the Molecular Epidemiology of CF in a Western Cape CF population. 
Objectives 
1) To determine the prevalence of ilF508 in the white and coloured patients in 
this Western Cape CF population 
2) To determine the frequency of other CFTR mutations in the white and 
coloured patients in this CF population 
3) To determine the prevalence of homozygosity and compound heterozygosity 
for the two common mutations (ilF508 and 3120+1G-+A) and undetermined 





The CF population described in Chapter 2. 
Data 
Genotype information from the CF database. Patients' genotypes had been 
determined using a number of laboratories: 
The RCCH which tested for ~F508 and, when kits were available, other 
CFTR mutations 105; 
The SAIMR in Johannesburg who undertook testing in both the course of 
clinical work and in studies of the Molecular Epidemiology of CF 
coloured patients in SA; 
A private laboratory associated with the University of Stellenbosch at 
Tygerberg Hospital, Cape Town. 
The mutation analysis of patients who settled in the Western Cape Province 
from elsewhere was taken from referral letters where available. 
Where mutation analysis was done beyond simply testing for ~F508, it usually 
consisted of a panel of mutations found to be significantly common in South 
African populations. Formal testing of every patient could not be undertaken. 
Analysis 
Data was analysed in the format used in Goldman and colleagues' 2003 paper48 
and Herbert and Retief s 1992 papel5 i.e. mutation frequency by population 
group and genotype frequency according to the presence or absence of ~F508. 
Proportions and differences in proportions between the white and coloured 
groups were subjected to confidence interval analysis (Confidence Interval 
Analyser Version 1.0, Gardner GM, BMJ Publishers 1989) 
Results 
Of the 181 patients in the CF population, 176 were in the white (101) and coloured 
(75) groups. Fourteen siblings (5 white and 9 coloured) were excluded from this 
genetic analysis as they were presumed to have identical mutations. Twenty four 
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(14,8%) of the remaining 162 patients (16 white and 8 coloured) did not have any 
mutation analysis. Nineteen of these had died or moved elsewhere before testing 
became possible; in five cases, genetic testing had not been indicated by reproductive 
or diagnostic questions. Of the 138 (80 white, 58 coloured) who had some form of 
mutation analysis, 107 (77,5%) were only tested for ~F508. Thirty one (22,5%) (21 
coloured) patients who were not ~F508 homozygous had had more extensive 
mutation analysis. 
Mutation analysis 
In all therefore, 276 chromosomes were tested, 160 from white patients and 116 from 
coloured patients. Table 3.9 shows the number and frequency of CFTR mutations in 
these two groups. 
Table 3.9 Frequency of CFTR mutations in white and coloured cystic fibrosis patients 
in the Western Cape province 
White Coloured 
Number Frequency Number Frequency 
(N = 160) (95%CI) (N = 116) (95%CI) 
Mutation 
~F508 126 0,79 (0,72-0,85) 55 0,47 (0,38-0,57) 
3120+1G>A 12 0,10 (0,05-0,16) 
G551D 2 0,012 2 0,015 
G542X 1 0,0075 
A455E 2 0,012 
W1282X 1 0,006 
N1303K 1 0,006 
394deiTI 1 0,006 
3272-26A>G 1 0,0075 
Unknown 27 0,17 45 0,39 
Total 133 0,83 (0,77-0,89) 71 0,61 (0,52-0,70) 
detected 
The frequency of ~F508 versus all other mutations for the two groups is shown in 
Table 3.10. Ninety two percent (95%CI 84-97) of white patients had at least one copy 




Table 3.10 Frequency of the ilF508 mutation versus other mutations in the white and 
coloured cystic fibrosis patients 
I Frequency of I No. of 
mutations in CF genes CF 
Ethnic group! ilF508 Other genes 
White 0,79 (126) 0,21 (34) 160 
[95%CI] 0,72 - 0,85 0,15 - 0,28 
Coloured 0,47 (55) 0,53 (61) 116 
[95%CI] 0,38 - 0,57 0,44 - 0,62 
Total 0,66 (181) 0,34 (95) 276 
Other refers to mutations in CF genes other than t.F508 
mutation. The number of CF genes is indicated in parentheses 
Genotypes 
The genotypes of the two groups according to ilF508 status are shown in Table 3.11. 
The difference between the percentage of coloured patients who were homozygous for 
ilF508 (24) and those who were heterozygous for the mutation (47) was 23 (95% CI 
6-39). Ten coloured patients had the 3120+1G-+A mutation: 6 patients (10,3% 
95%CI 3,7-21,2%) had the ilF508/3120+1G-+A genotype; 2 had the 3120+1G-+A 
mutation in combination with another mutation; 2 were homozygous for this 
mutation. 
Table 3.11 Frequency of genotypes in coloured and white cystic fibrosis patients 
No. of CF subjects per genotype 
Ethnic ilF508! ilF508! Other*! No. of 
group ilF508 other* other* subjects 
White 52 (65) 22 (27,5) 6 (7,5) 80 
Coloured 14 (24) 27 (47) 17 (29) 58 
I 
Total 70 (46) 58 (38) 24 (16) 138 
·Other refers to mutations in CF genes other than ~F508 mutation. 
.. . . 
. Percentages are indicated In parentheSIS 
A full genotype was available for 59 (74%) white and 26 (45%) coloured patients i.e. 
851138 (62%) CF patients. If siblings were included, the number of patients with full 




Molecular genetic studies of CF in SA in the CFTR era started with explorations of 
the role of the ~F508 mutation in SA.43-5 These studies were published in 1992 and 
showed "European" levels (>80% of chromosomes) of the ~F508 mutation in white 
CF subjects. The mutation was significantly less common in SA's coloured 
population (53%). By 2003 it was possible on a national scale to identify full 
genotypes for 83% of white CF patients and 55% of coloured patients if the mutation 
panels developed by the SAIMR in Johannesburg were used.48 
The present study reproduces the regional work on ~F508 of Herbert and Retief that 
was published in 199245 but with a much larger patient base from the Western Cape 
province. The study aimed to describe the pattern of CFTR mutations in the region 
using patient related data. It was therefore not a systematic study in the form of the 
SAIMR studies discussed in the Introduction to this section. However the 
demographics of the Western Cape are such that the data for coloured patients is 
unique. Herbert and Retiefs study had 14 coloured patients. The latest SAIMR 
report had 43 patients.48 The present one has 58. Apart from ~F508, CFTR 
mutations that have been found in white CF patients in the Western Cape have not 
previously been described (except in one familylo5) although some are embedded in 
the SAIMR data. 
For white CF patients, the rate of the ~F508 mutation among CF chromosomes and 
the rate of ~F508 homozygosity coincide with those given by the SAIMR and a 
decade ago by Herbert and Retief (but now with tighter 95%CIs).45 The SAIMR's 
study with the largest number of chromosomes (384), published in 1994, showed a 
~F508 frequency of 0,76,46 well within the 95%CI presented here. Likewise the 
~F508 homozygosity rate in the SAIMR study published in 2001 was coincident with 
that presented here at 64,5%.47 These rates mirror those of northern Europe as the 
authors of the 1992 reports noted. 
Very few white patients had been tested for other mutations. The mutations found are 
all in the SAIMR panel.48 The 3120+1 G--A mutation was not found in a white 
subject. One such patient was found in Johannesburg. There is no reason to suspect 
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that the mutation detection rate of 0,91 that the SAIMR has achieved in white subjects 
could not be achieved in the Western Cape province. However with access to 
excellent sweat testing and with a 6F508 homozygosity rate of 65%, it seems 
unnecessary in diagnostic terms to extend the range of mutations routinely tested for 
in this population in this region. For genetic counselling and antenatal testing in 
affected families, the figures given by the SAIMR in 2003 are the best available and 
allow much more precise estimates of risk than 6F508 alone can achieve. Further 
testing would be dictated by the circumstances of the individual family. 
This study allows a more precise value for the frequency of the 6F508 mutation in the 
coloured group to be given than previous work allowed. The frequency of 0,52 
shown by Herbert and Retiet5 is encompassed by the 95%CI given here but the 
95%CI is much narrower. The 0,5 frequency for the 6F508 mutation given in 2003 
by the SAIMR (and which included a number of patients from the Western Cape 
province) has a 95%CI of 0,39-0,61,48 a little wider than in this report. In practical 
terms the latter difference is insignificant and a frequency of about or just under 0,5 
can be accepted. 
The new figures prove that there are more coloured compound heterozygotes for 
6F508 than homo zygotes though the difference may not be large. There were too few 
patients in Herbert and RetiePs study to prove this. At 24% homozygosity, testing for 
the 6F508 mutation to diagnose CF must be considered inadequate in this group. 
Even with the new figures, one cannot be certain that there is a difference between the 
proportion of those who were heterozygous for the 6F508 mutation (47% 95%CI 33-
60) and those who did not have a copy of the mutation (29% 95%CI 18-43). 
Importantly, at 29%, the absence of the 6F508 mutation is more common in a true 
coloured CF patient than the unanalysed figure of 15% given in 1992 had suggested. 
The practice of • screening' patients with symptoms of CF with a 6F508 test cannot be 
supported. 
With 6F508 being a poor indicator of CF in the coloured population, what is the value 
of the other CFTR mutations in diagnosing CF? The 3120+1G-A mutation has 
proven itself to be an important player in CF in this group. Ten of the 58 coloured 
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patients, only 21 of whom had been tested, had at least one copy. Of the 86 
chromosomes from coloured CF patients tested by the SAIMR, 15 (frequency 0,174 
95%CI 0,1-0,27) had the mutation.48 Combining the SAIMR frequency for the 
3120+ IG---+A mutation with the frequency of LiF508 from this study, 64% of 
chromosomes would be identified as abnormal with an upper confidence limit of 84%. 
Only 38% of coloured subjects had their full genotype delineated by testing for these 
two mutations. These frequencies are not enough to make testing for the two 
mutations diagnostically useful. In the 2003 SAIMR study in which all except 5 of 
the 43 coloured subjects were examined using the full South African mutation panel, 
55% had both mutations identified.48 There is a need to explore the role of this 
mutation in the coloured population further as frequencies are not yet precise enough. 
No other mutation yet identified has proved significantly common in this group. In 
the meantime, the sweat test must remain the gold standard for CF testing in coloured 
patients. Mutation analysis should be reserved for informing reproductive choices in 
affected families. 
The 3120+ IG-7A mutation has convincingly been shown to be of African origin. 104 
Its presence at a significant frequency in the coloured population therefore speaks of a 
significant frequency of African genes in this group. All other mutations identified in 
this group have been well described in European Caucasoids with CF. It is difficult to 
be sure whether the mutation entered the Cape through West Africa (slaves brought to 
the Cape) or via the southern extension of the Bantu expansion. A third possibility 
exists that might explain its presence in this group. It is not impossible that the 
mutation already existed in the Cape at the time of European colonisation though 
there is no evidence of this. The mutation was not found in 208 San subjects.5o It was 
not found in 52 Xhosa subjects, a group in whom there is significant Khoisanid 
admixture.5o However some anthropological theories have the KhoiKhoi migrating as 
far as West Africa where the mutation is hypothesised to have originated.76 Could it 
in fact have originated in the Cape and could the mutation frequency of 0,174, which 
translates to a carrier rate of 1 in 291 (51x(1I0,174)) among healthy 20th century 
coloured subjects, be a reflection of a diluted background significant carrier rate 
among the KhoiKhoi of the 17th century? Padoa and colleagues found a frequency for 
this mutation among southern African healthy black subjects of 1 in 91 (95%CI 1 in 
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46 to 196).50 The meaning of these figures for the Western Cape province is 
discussed in terms of the Cape's black African population on p71. Suffice it to say 
here that the uncertainty of these figures for individual chiefdoms means that they 
cannot prove that the 3120+ 1 G-A mutation came into the coloured population of the 
Cape via the most southward extension of the Bantu expansion. 
In their 1992 papers on CF in SA in the light of new knowledge of the i1F508 
mutation, the geneticists from Johannesburg and Cape Town explored the 
implications of their work (which incorporated the epidemiological work of Hill and 
colleagues33) for genetic counselling.43-5 Risk estimates for an individual being a 
carrier of a mutation for CF or having a child with CF were given in various clinical 
settings were calculated. The revisions to the classic and molecular epidemiology of 
CF in SA over the last decade presented in this chapter mean that these figures have 
changed. 
An example will illustrate this change. In Family B in Denter and colleagues' second 
1992 paper,44 the sibling of a deceased CF child was 8 weeks pregnant. She and her 
husband did not carry the i1F508 mutation. Their risk of having a child with CF was 
2/3(the chance that the mother was a carrier)x3/10(the chance that she had a non-
i1F508 mutation [this figure was more conservative than the 2/10 risk their study had 
shownDx 1 123(the probability that her husband was a carrier)x3/10(the probability that 
he had a non-i1F508 mutation)xl/4(the probability that two CF carriers would have a 
child with CF) i.e. 1: 1534. U sing the latest figures, this fonnula would read: 
2/3x2411 OOx 1I27x24/100x 114 i.e. 1 :2812, a considerably smaller risk. If the panel of 
SA CFTR mutations was tested for in both spouses, the risk would fall to 
2/3x1l10x1l27x1l10x1l4 i.e. 1:16200. Similarly for a coloured family, if both parents 
were i1F508 negative, the risk would be 2/3x5110x1l51x5/10x1l4 i.e. 1: 1224. If the 
3120+ 1 G-A mutation was added to the screen in this coloured family, the risk would 
halve to 2/3x33/100xl/51x33/100xl/4 i.e.l:2810 - almost identical with the risk in a 
white family tested for i1F508 alone! 
For a known CF carrier in the coloured population, the exclusion of the i1F508 and 
3120+ 1 G-A mutations in the prospective spouse with no family history of CF would 
give a risk of having a child with CF of lh(the chance of carrier passing on their 
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mutation)x 1 /51 (the chance of the spouse being a carrier)x3311 OO( carrier risk for 
another mutation in that spouse)xY2(the chance of the spouse passing on their 
mutation) for each pregnancy i.e. 1 :612. The risk if only L\F508 was excluded would 
be 1 :408. The equivalent figure in Herbert and Retiefs 1992 paper was 1 :468.45 The 
addition of the 3120+ 1 G-+ A test and the new carrier figure for the coloured 
population therefore make it possible to give a considerably reduced risk to 
prospective parents. Use of the full panel of mutations reduces the risk to 1: 816. In 
individual settings the costs of these various options would have to be taken into 
account. 
In essence, then, knowledge of the classic and molecular epidemiology of CF among 
the white and coloured populations of the Western Cape province has revised one's 
view of the disease in this region. Almost as many coloured as white patients would 
be expected. Affected children (and probably adults) are being missed in areas 
beyond metropolitan Cape Town. Informative molecular genetic testing has moved 
beyond testing for L\F508 alone. All decisions around counselling and testing need to 
take account of this new knowledge. 
But what of the epidemiology of CF in the other major population group in the 
Western Cape, blacks of African origin? Four cases from this group were seen among 
the 181 CF patients. Is CF as rare as has always been thought in this group? The 
following section explores these questions. 
Cystic fibrosis among Negroid populations 
That CF was much less common in Negroid peoples than among Caucasoids was 
noted early in the understanding of CF as a genetic and clinical entity.89 In fact as 
senior a figure as Steinberg, the editor of the American Journal of Human Genetics in 
the 1950s, stated in an article on the epidemiology of CF that it was most likely that 
CF did not occur in black Americans. 106 However it was soon to be shown that it did 
occur in this population. Di Sant' Agnese noted in 1961 that only 4% of CF patients 
in his New York clinic were black despite the community served by the hospital being 
30% black. 107 Kulczycki and colleagues described 9 patients in Washington in 1964, 
noting early mortality.108 After an active search for cases, enough black CF patients 
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had been identified in this area by 1974 for Kulczycki and Schauf in Washington DC 
to estimate an incidence of 1: 17 000, considerably less than the 1: 1 000 to 1:3 500 for 
Caucasoids. 109 However this figure was based on only eight births. Stern from 
Cleveland reported 17 patients over nearly 20 years. I 10 This apparently low incidence 
was further refined to 1:15 000 using data from the CF Foundation National CF 
Patients Registry. I I I This registry carried data on 601 African American CF patients 
in 1994. Up to this time reports on CF in other Negroid populations only came in the 
form of case reports (See p62). 
CF in the African American population 
The African American population is considered to have a significant Caucasoid 
admixture. Reed estimates this to be about 20%.112 This makes this population a poor 
basis for prediction of the incidence of CF in other Negroid populations. This 
Caucasoid admixture was confirmed when African American CF patient's 7th 
chromosomes were compared with those from Caucasoids.89 Haplotype analysis 
showed that there was to some extent a different haplotype frequency in black 
chromosomes compared to that pertaining to chromosomes from Caucasoids. 
Notably, though, the overlap was significant enough for them to calculate that 
.... one might predict that Caucasian genes account for 
50% or more of the CF genes in American blacks.89 
This prescient statement took place before the identification of CFTR. Once the new 
molecular methodologies became available in 1989, Macek and colleagues 
investigated the CFTR mutations in 82 chromosomes from black CF patients, all 
except one of whom (a Cameroonian) were African Americans.99 Remarkably, they 
confirmed the earlier estimate: 52% of mutations were Caucasoid mutations. A 
further 23% were specific to Negroids and 25% could not be identified, suggesting 
extreme rarity. Dominant among the Negroid mutations was 3120+10 A (12,2%) 
which has already been discussed for its role in CF causation in coloured CF patients 
in the Western Cape province. Thus it is confirmed for those working with other 
Negroid populations that the African American experience with CF epidemiology 
cannot be expected to parallel that found elsewhere. 
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Could the same be said for the clinical manifestations of CF in Negroid populations 
elsewhere? Are they distinguishable from the features of CF in Caucasoids? From an 
early stage the clinical features of CF in African Americans were compared with their 
Caucasoid counterparts in an attempt to answer this question. Until recently the 
answers were equivocal or contradictory, owing to limited case numbers. 
Kulczycki and Schauf, in Washington, reported in 1974 that gastrointestinal 
manifestations of CF dominated the presentation of CF in African Americans.109 
Stem and colleagues in Cleveland also noted significant amounts of MI (6/17 
patients) in 1976 and all their African American patients were PI. lIO Lung disease 
was though to be mild when compared with that in white Americans. 
In 1991 McColley and colleagues reported the Baltimore experience with African 
American CF patients. l13 They compared 24 of them with 48 matched white CF 
patients. They found few differences. Only hyponatraemic dehydration and peptic 
ulcer disease differed, being higher among the African Americans. They noted a 
predominance of respiratory presentations rather than the gastrointestinal ones noted 
in the earlier reports. Genetic heterogeneity was postulated as the reason for the 
differences because at that time 
... a number of mutations were found and only a relatively 
small number of subjects had gene analYSiS, [they] were 
unable to correlate specific mutations with disease 
severity .113 
It took the large Registry-based study reported in 1997 to bring a steadying hand to 
this confusion arising from small series. III Out of 60 1 African American CF patients, 
47 were homozygous for AF508. These patients were each matched with 4 white 
homozygotes. Notably, the nutrition measures of the African Americans were worse. 
Lung function was equivalent as were the presence of PI (95,7%), P aeruginosa and 
Afumigatus colonisation, MI and the distal intestinal obstruction syndrome. 
When all 60 I African American patients were compared with white patients in the 
Registry, they were found to be younger, to survive as long, to have less MI and more 
of the distal intestinal obstruction syndrome. A worrying difference in health service 
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utilisation was noted. The gastro-intestinal differences were thought to relate to the 
higher number of compound heterozygotes in the African American group. 
Nutritional lag was not dependent on CF genotype. This together with the health 
service data suggested that non-biological factors were impacting detrimentally on the 
course of CF in African Americans. This was reinforced by a paper in the same 
edition of the Journal of Pediatrics that showed that there was an over-representation 
of African American CF patients on Medicaid (a proxy for poorer socio-economic 
conditions).114 
Of particular relevance to the understanding of CF in SA was the comparison between 
African American patients homozygous for AF508 and those with the 
AF508/3120+ I G -+A genotype of whom there were II: 
There were no statistically significant differences between 
the groups in sex ratio. current age, age at diagnosis, 
sweat chloride concentration, pulmonary function, 
percentage of colonisation with P aeruginosa and S 
aureus organisms, PS, MI, rate of hospitalization, or 
frequency of outpatient visits.111 
Thus, CF in African Americans is not very different from that experienced in 
Caucasoid populations. Only the higher incidence of some gastrointestinal features 
could be considered biological (i.e. genetic) in nature. What about CF in non-
American Africans? Does the lack of AF508 mean a phenotype significantly at 
variance with that experienced in America may be found in Africa? 
Cystic fibrosis in non-American Africans 
Cystic fibrosis in non-American Africans has only been described in case reports. 
Occasional papers have appeared since the 1950s giving clinical details of infants and 
young children with manifestations suggesting CF. Almost all these children died in 
infancy. 
Two infants were described in the French literature in 1954. 115 These two West 
African children presented with a syndrome mimicking kwashiokor, a fact of 
considerable interest to South African CF workers for whom this has a familiar ring. 
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In a letter to The Lancet in 1962, Lorna MacDougall from Toronto in Canada 
described two Kikuyu children she had seen in Kenya. 116 The frrst child failed to 
thrive to the point of emaciation. Pneumonia developed and there was no tryptic 
activity in duodenal juice. There was some improvement on tetracycline and cow's 
milk. Mantoux was negative. Stools were pale and bulky. She died during a 
diarrhoeal illness at 8 months of age. Post mortem showed staphylococcal abscesses 
in the lungs and "typical histological changes of fibrocystic disease" in the 
pancreas. This was the parents' (both Kikuyu) first child. 
The second child described by MacDougall was two years old at presentation. The 
family background was unknown. He was severely underweight and had 
bronchiectasis. Mantoux was negative, there was no tryptic activity in duodenal juice 
even after refeeding, and a Shwachman sweat plate (a screening test of the time) was 
"strongly positive". Steatorrhoea was present. Follow up was brief. 
These two cases are very compatible with CF. As MacDougall pointed out, duodenal 
enzyme activity is low in malnourished infants but should return with refeeding. 
CF was first identified in a South African black child in 1957 and reported by SS 
Grove, a surgeon in Durban, in 1959.117 A "Bantu" baby who died within half an 
hour of birth was found to have intra-abdominal changes suggestive of meconium 
peritonitis. No mention of the characteristic microcolon ofMI was made; indeed, the 
colon was dilated. However, on histology, glands swollen with mucus were found in 
the lungs, pancreas and intestines. Reflecting a concern that is to be found in SA 
writing in the present day Grove wrote, 
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Pancreatic fibrocystic disease in the older Bantu child has 
very likely escaped diagnosis largely because of the fact 
that many Bantu children suffering from this disease die of 
an acute respiratory illness either before medical advice is 
sought or very shortly after, and before clinical 
investigations have started. Malnutrition, gastrointestinal 
infections and pulmonary diseases are frequently 
associated .... 
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Grove hoped that his paper would encourage the identification of CF in "Bantu 
children". In an addendum, he reported that he had seen another newborn case ofCF. 
Working in SA at the same time, Catzel had been unable to find a case using 
Shwachman's finger print sweat test on 118 black children.27 It was to be another 10 
years until the next case ofCF in a black African from SA was reported. 
In 1967 Levin and colleagues at Baragwanath Hospital in Johannesburg described 
twins born to a Sotho mother and a Zulu father. 118 The first twin presented with 
intestinal obstruction soon after birth. The X-ray had typical features of MI. At 
laparotomy there was a perforation of the ileum. The state of the colon was not 
described. The neonate died not long after surgery. Histology of the bowel showed 
the typical mucin accumulation of CF in the intestinal glands, appendix and pancreas. 
Hirschsprung's disease (a more common cause of intestinal obstruction in Africa) was 
excluded as a cause for the obstruction by the presence of ganglion cells in the colon. 
The other twin had loose stools with no tryptic activity from the third day of life. 
Sweat test using the agar imprinting method of Shwachman was "3+ positive". The 
child went on to develop oedema, anaemia with reticulocytosis, hypoalbuminaemia 
and hypopigmentation on the skin. There was an improvement in the child's 
condition after a blood transfusion and a change to cow's milk formula. Respiratory 
symptoms developed at 10 weeks of age. Soon chest X-ray changes of consolidation 
supervened. Further treatment was refused by the family and follow up was lost. 
These two cases appear typical of CF - the oedema/anaemia presentation of the 
second twin being a consistent though uncommon feature of CF - and are compatible 
with a familial disease. Levin and colleagues noted that a search for other CF patients 
at Baragwanath Hospital had been fruitless. 
Further cases from Francophone Africa were reported in 1981 and 1984. Three 
children presented with malnutrition in Senegal, being diagnosed post mortem. 119 A 
case report of a Cameroonian child (the same one whose DNA appears in later genetic 
literature) who travelled to France to have the diagnosis made appeared in 1984. 120 
This child called Diana presented with classic CF: severe failure to thrive, 
steatorrhoea and chest infections. Four sweat tests showed chloride levels above 
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80mmol/l. Full therapy for CF produced an excellent response and Diana "regagne 
Ie Cameroun". The authors claimed this child as the first African child to have CF 
confirmed with the sweat test. 
In his questionnaire-based survey of CF in southern Africa, Super knew of 8 black 
patients: 5 cases were the ones in the published literature?8 
The way things stood for CF in South African black populations was summarised by 
Beighton and Botha in one of the articles they published in 1986, reviewing genetic 
conditions in SA. In noting its rarity they invoked 'unknown genetic mechanisms" 
and stated rather oddly that "... knowledge of the rarity of the disorder is 
important in differential diagnosis and in planning for the provision of health 
services.,,121 
It was not long before molecular genetics was able to bring the final proof that CF 
was found in Africa. As will be discussed now, molecular genetics was soon claiming 
that CF among black Africans was by no means as rare as the paucity of case reports 
over the past 50 years suggested. 
A collaborative study of three cases of CF in black South Africans published in 1996 
included clinical data and the results of a systematic investigation of the gene for 
CFTR in each case.48 All three appeared to have impeccable credentials for no 
Caucasoid admixture although one father was dead by the time his son was diagnosed 
with CF. Clinical details were convincing for CF. All three children had repeatedly 
positive sweat tests. To complete the diagnostic certainty, all 6 chromosomes had 
CFTR gene mutations on them. Four of them carried the 3120+ 1 G~ A mutation that 
had significant prevalence in African Americans and had not been found in 
Caucasoids. Another carried a different mutation (G 1249E) and the last carried a 
previously unidentified 54 base pair deletion in exon 17a. Thus there was now 
unequivocal genetic proof that CF as seen rarely in Africa was a CFTR mutation-
based disease. Furthermore the 3120+ 1 G~A mutation was a significant contributor 
to this (4/6 mutations in this small study) and was likely to contribute significantly to 
CF in Africa. This finding meant that carriers of this mutation could now be 
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identified, presenting science with the first opportunity to investigate the incidence of 
CF in black Africans. 
Pursuing the lead given by the prevalence of the 3120+IG-+A mutation in African 
Americans and the new black African cases of CF, Padoa and colleagues from the 
SAIMR in Johannesburg searched for it and three other mutations that had been found 
in African Americans (A559T, S1255X, 444delT) in 208 San and 1152 unrelated 
healthy African black persons from southern, western and central Africa. Their work 
was published in 1999.50 Nine heterozygotes, all black Africans and all with 
3120+ 1 G-+ A were found. Statistically it could not be determined if carrier 
frequencies differed between the chiefdoms studied. Overall, in southern African 
black groups, eight 3120+ 1 G-+ A heterozygotes were found out of 728 subjects giving 
a carrier frequency for this mutations of 1 in 91 (1,1 % 95%CI 0,51 - 2,17%). 
O'Jote should be made that one other mutation, D1270N, was found in two 
symptomatic patients who did not fulfil the criteria for CF. This mutation is rare and 
usually associated with mild or monosymptomatic CF, usually with normal sweat 
electrolytes. Its possible role in mitigating the effects of other CF mutations in SA is 
discussed on p73.) 
In the same study the mutations of five new black African CF cases were described. 
Two chromosomes showed the 3120+ 1 G-+ A mutation. Combining these five CF 
cases with the three from the earlier study, 6 out of 16 CF chromosomes (37,5% 
95%CI 15,2 - 64,5%) carried this mutation. This meant that the 1 in 91 southern 
African carriers of the mutation were only 37,5% of the total carrier population. 
Clearly the wide CIs made estimation of actual carrier frequency very uncertain: 
anywhere from 1 in 14 to 1 in 59. However what was most important about these 
carrier frequencies was that they encompassed the rates for both the South African 
white and coloured populations. This study suggested that CF among South African 
blacks should be seen as often as in the known CF-carrying populations of the 
country! Using 1994/5 birth figures, Padoa and colleagues estimated that between 57 
and 1015 black African babies are born with CF every year in SA, or an incidence of 
between 1 in 796 and 1 in 13 964. 
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South African clinicians and scientists are faced with a challenge: to find the missing 
black CF cases or to explain why they are not being diagnosed. The following section 
uses case reports from the RCCH to pursue this issue. 
STUDY 3.3 WESTERN CAPE EXPERIENCE WITH CYSTIC FIBROSIS IN 
BLACK PATIENTS 
Five black African cases of CF have been diagnosed at the RCCH since 1984. They 
each illustrate the evolution of our understanding of the disease in this' group'. 
CASE 1 "Cystic fibrosis unlikely because of race." 1984 
This child of a Xhosa-speaking mother was born prematurely in 1983. She presented 
at two months of age with a macrocytic anaemia and was failing to gain weight. She 
was hypoproteinaernic and had a lower respiratory tract infection with lower airways 
obstruction. She was investigated for the anaemia with genetic haematological causes 
being ruled out. A blood transfusion was given. Weight gain in the ward was very 
poor and the respiratory infection persisted. Haemophilus injluenzae was grown from 
sputum. Gastro-oesophageal reflux (GOR) was demonstrated. After discharge she 
was readmitted a month later with another chest infection and dehydration. The 
diagnosis of 'early kwashiorkor' was also made. GOR was thought to be a significant 
factor in her chest disease although a pH study was negative. In view of persistent 
poor weight gain and chest signs a sweat test was performed (Table 3.12). As it was 
abnormal it was repeated. Tests for malabsorption were undertaken: fat globules were 
seen, tryptic activity was normal, faecal fat testing was unsuccessful. The 
gastroenterology team was called in who felt that the child's 'race' made CF unlikely. 
Endocrine testing was then undertaken and proved to be normal. The child stayed in 
hospital for six months, gaining some weight on an elemental formula. By the time of 
discharge, five positive sweat tests had been obtained. After a 6th positive test, the CF 
Clinic followed the child but felt unwilling to attach a definitive CF diagnosis to the 
child. A 7th and an 8th sweat test were positive. The child, now aged two and a half 
years, presented with a severe lower respiratory chest infection soon after this and 
rapidly succumbed. Post mortem demonstrated a severe Pseudomonas pneumonia 
with air trapping. There were typical changes of CF in the pancreas. 
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Table 3.12 Sweat tests results for Case 1 




83 122 157 
68 101 
73 96 280 
73 102 386 
78 110 427 
95 131 206 
This child never received a positive diagnosis of CF and thus could not benefit from 
definitive treatment. The diagnosis was proven by post mortem but never taken 
further either by way of family studies or by way of education for SA's child health 
practitioners. Case 2 could not benefit from the experience with Case 1. 
CASE 2. "Do a sweat test." 1993 
This child presented in 1993 at three months of age to TBH with pneumonia and 
failure to gain weight. His mother was Xhosa-speaking and he was her fourth child. 
His father, said to be from the same group but not the father of the other three 
children, had been murdered. TB was suspected and, after investigation, follow up 
was arranged. The child was soon ill again and presented to the RCCH with a 
collapsed right middle and left lower lobes and severe air trapping. There was some 
response to broad spectrum antibiotics but severe lower airways obstruction persisted. 
A pulmonologist was called in who, amongst other tests, requested a sweat test. The 
ward staff viewed this suggestion with incredulity but went ahead. The result was 
positive (Test 1: mass 77mg Sodium 78mmolll, Chloride 114mmolll) as was a second 
test (Test 2: mass 153mg Sodium 94mmolll, Chloride 104mmol/l). Because he was a 
black African child a third test, which also proved positive (Test 3: mass 299mg 
Sodium 83mmolll, Chloride 103mmolll), was performed. By now molecular testing 
was available and being pursued vigorously by the Department of Genetics at the 
University of the Witwatersrand. With the help of colleagues in France, they were 
able to demonstrate two CF mutations. One was the 'African mutation', 
3120+ 1 G--+ A, and the other was a unique mutation, 3196de154.49 This child has 
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shown a typical course of CF with PI, and S aureus and mucoid P aeruginosa in the 
chest. He is 11 years old at the time of writing. 
Experience with this case coincided with new knowledge about CF mutations in black 
South Africans. Case 3 now benefited from the RCCH's experience with CF in the 
Xhosa-speaking population and the new diagnostic modality. 
CASE 3. Not HIV, so what is cause of the problem? 1995 
This infant was born in Kingwilliamstown to Xhosa-speaking parents who were both 
professionals. He had not grown since birth and was severely wasted. He had 
persistent changes on his chest X-ray with marked air trapping. He had a firm 
hepatomegaly. He had been admitted to Livingstone Hospital in Port Elizabeth where 
he had been investigated for TB and HIV infection repeatedly with negative results. 
He was transferred to RCCH for further testing. CF seemed likely despite the child's 
'race' and was proven within a few days: 2 sweat tests were positive (Test 1: mass 
371mg Sodium 80mmolll, Chloride 107mmolll: Test 2: mass 356mg Sodium 
82mmol/l, Chloride 99mmolll), there was a high faecal fat level and mucoid P 
aeruginosa and S aureus were grown from the sputum. Full treatment for CF was 
commenced and, once the child was stable, he was transferred home to have 
paediatric follow up in Kingwilliamstown by a paediatrician from Cecilia Makiwane 
Hospital in East London. Unfortunately, despite this plan, the child was lost to follow 
up. 
This case, following hard on the heels of Case 2, was rapidly diagnosed at the RCCH. 
His diagnosis brought the message of CF occurring in black African children to 
paediatricians in the Eastern Cape province. 
CASE 4. Atypical case in atypical race. 2001 
This male child of Xhosa-speaking parents presented at two years of age with 
repeated pneumonia and failure to thrive from the age of 9 months. Investigations for 
TB had been negative and the family were not poor. He had had diarrhoea 
intermittently from infancy. There was no family history suggestive of CF. On 
admission he had lung hyperinflation and respiratory distress. Chest X-ray confirmed 
air trapping and there were changes in the right upper lobe and perihilar regions. 
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53mmolll, Chloride 45mmolll). Tests for fat malabsorption were unsuccessful. 
Mutation analysis covering common South African mutations including 3120+ 1 G-9A 
was negative. CF was thought probable but not proven. With a respiratory infection 
two months later mucoid P aeruginosa was grown from his sputum, increasing the 
likelihood of CF. He was treated with PERT, nutritional advice and support and 
physiotherapy. Follow up was fitful despite appointments being given. A year later, 
during which time he had had a few mild respiratory infections and had gained 
weight, a fourth sweat test was again equivocal (Test 4: Mass 265mg, Sodium 
56mmolll, Chloride 55mmolll). His X-ray showed persistent air trapping and 
perihilar infiltrates. He is now 4 years old and stable on his therapy. His 
asymptomatic seven year old sister also had an equivocal sweat test result (Mass 
186mg, Sodium 7Ommolll, Chloride 54mmolll). 
With this patient CF among black Africans had joined the mainstream at the RCCH: 
recurrent chest infections leading to an investigation of CF and a complex of 
suggestive symptoms and test results but no absolute proof. 'Race' was no longer a 
factor against the diagnosis. The case also illustrated the need for greater 
investigation of CFTR mutations and variations among black Africans. Is CF perhaps 
phenotypically different in Africa? 
CASE 5. Typical presentation in infancy; instant diagnosis. 2003 
This male infant of Xhosa-speaking parents presented at the age of two months with 
dehydration and diarrhoea. There were no chest signs or symptoms and no significant 
family history. Investigation revealed a hypochloraemic metabolic alkalosis. Sweat 
tests were ordered by junior doctors in the Rehydration Unit and the diagnosis of CF 
confinned. Mutation analysis showed the child to be a compound heterozygote with 
one copy of the 3120+IG~A mutation. 
This encouraging case illustrates that CF is part of the differential diagnosis of 
children presenting with suggestive features in contemporary Cape Town. The 
challenge presented 20 years ago when Case 1 was born has now largely been met: 
CF occurs in black Africans and is being considered in clinical situations by non-
experts. 
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Dr George du Toit and I described a case in whom the diagnosis of CF was strongly 
entertained but never proven in the South African Respiratory Journal in 2001.122 
This black African child had short stature, intermittently positive sweat tests and 
severe resistant peripheral airways obstruction early in life with no typical CF 
pathogens but no pancreatic disease and no identifiable mutation. We aimed to 
illustrate issues around diagnosing CF and to discuss the apparent discrepancy 
between the paucity of proven cases of CF in black South Africans and the expected 
incidence based on the carrier rate calculated by Padoa and colleagues. 50 As 
illustrated by the case reports above, awareness has risen greatly at the RCCH and its 
associated services. Many other children with suggestive presentations including the 
anaemia/oedema complex have had sweat tests. Despite this, only three cases in black 
Africans in the Western Cape have been proven since then. One of those (Case 4) 
was atypical. 
Where have all the black cystic fibrosis patients gone? 
Padoa and colleagues predicted that at least 57 black African babies with CF would be 
born each year in SA.50 The number diagnosed in recent years countrywide does not 
reach double figures (personal communication - members of the MSAC to the South 
African CF Association). There are three potential explanations for this discrepancy 
between actual and predicted cases of CF among black Africans in SA. 
Firstly the data presented by Padoa and colleagues50 may not represent the truth i.e. 
there was a sampling bias or too much statistical uncertainty. Healthy unrelated 
subjects were drawn from specimens in the Johannesburg -laboratory. Such 
population based samples are unlikely to contain biases that select for CF carriers. It 
is noticeable that no carriers of the 3120+1G~A mutation were found in the Nguni 
language groups. While this was not statistically different from other groups, the 
sample size may mask a difference that a larger sample base might have revealed. For 
example, only 52 healthy Xhosa subjects were tested for the 3120+1G~A mutation; 
no carriers were found (95% CI 0 to 1 in 16). A sample size of 200 in which no 
carriers of the 3120+ 1 G~ A mutation were found would still have an upper CI equal 
to the carrier rate for all mutations in the coloured group (1 in 55). Thus, to prove that 
CF is not significantly common in this group would take a large and laborious study. 
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carriers of the 3120+ I G~ A mutation were found would still have an upper CI equal 
to the carrier rate for all mutations in the coloured group (1 in 55). Thus, to prove that 
CF is not significantly common in this group would take a large and laborious study. 
Is it possible therefore that the Sotho chiefdoms (not including the Tswanas in whom 
no carriers were found) are the only group to have significant CF carrier rates (1 in 42 
95% CI I in 20 to I in I 14)? Much of this group lives in poorer areas of SA such as 
the Free State, Mpumalanga and Limpopo provinces where infant mortalities are high 
and health services may not recognise the disease. In the Western Cape province the 
Xhosa chiefdom is the dominant black African group. Does this explain the paucity 
of CF patients in this area? Perhaps the lack of CF cases in a medically sophisticated 
and aware region such as the Cape Metropole indicates the true state of things and 
warns us against searching beyond phenotypically suspicious cases for CF in black 
Africans in this region. Likewise KwaZulu Natal province, dominated by the Zulu 
group might have a very low carrier rate. Indeed according to 200 I Census data, 
isiXhosa and isiZulu speakers account for over half of all African language speakers 
in SA. 123 The province of Gauteng with its mixed popUlation and good health 
services may be only part of the country where the black CF patients are likely to be 
found in significant numbers. The number of new patients there seems to be rising. 124 
Perhaps there is less reason for assiduous searching for 'missing' cases in areas where 
Sotho groups are a small minority? 
A second reason for the discrepancy between predicted and diagnosed black African 
CF patients was discussed in Padoa and colleagues' paperso: high infant mortality, low 
awareness of CF and poor health service infrastructure in much of SA. If one 
assumes that the overall carrier frequency calculated by Padoa and colleagues applies 
equally across all chiefdoms, then about 4 black African children with CF should be 
born in the Western Cape province every year. In fact fewer than one is diagnosed 
per year-in the Western Cape province which has relatively sophisticated health 
services. Most children with severe ongoing health problems reach the health 
services. (Many patients arrive from other provinces because of this fact.) Severe 
failure to thriv~, chronic and progressive lung disease, neonatal intestinal obstruction: 
all these manifestations of CF, if found in a child in the Western Cape province, are 
very likely to reach an expert in children's health. As demonstrated above, CF is 
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being considered in black African children with symptoms of the disease in the 
Western Cape province making such large scale under-diagnosis in this area unlikely. 
Thirdly it is possible that CF is a milder or phenotypically different disease in South 
African black persons. If one allowed the hypothesis that health services were 
missing most cases of CF owing to ignorance and the poverty of many patients, those 
neonatal CF patients with MI should still get through the system to a paediatrician or 
surgeon. They are not being seen. Is this because the MI phenotype occurs less 
frequently that the 15% reported elsewhere? Of the 12 non-black African CF patients 
who had at least one copy of the 3120+ 1 G~ A mutation, 2 had MI: a normal ratio for 
a 'severe' mutation. 
The two atypical cases described above may lend support to the possibility that CF is 
different phenotypically. However, the common 3120+ 1 G~ A mutation, when seen 
in African American black patients and in the few homozygotes (both coloured and 
black African patients) we have treated, has been associated with typical and severe 
CF. It is possible that there is a high incidence of genes that mitigate the effects of 
this mutation in SA's black patients. Alternatively the significant proportion of 
unknown CF mutations in this population may be associated with milder disease in 
some cases. There is as yet no proof of this hypothesis, but there is one tantalising 
scrap of evidence. In their mutation analysis of the nine patients with symptoms 
suggestive of CF, Padoa and colleagues' describe two patients who were 
heterozygous for the D1270N mutation. 50 One of these had a negative sweat test and 
the other had not been tested. The first of these patients, a male child, was seen at the 
RCCH at the age of 9 years with bronchiectasis and lower airways obstruction of 
unknown aetiology and which appeared not to be progressive or to be very slow in 
progression. No pathogens were grown from his sputum. He was well grown and had 
no features that suggested PI. Two sweat tests were negative. The D1270N mutation 
is associated with very mild CF, particularly congenital bilateral absence of the vas 
deferens. 125 Sweat tests are often normal. Padoa and colleagues did not screen their 
healthy subjects for this mutation yet 2 of 9 symptomatic subjects had one copy of it. 
Is it possible that this mutation is playing a role in modifying CF in black African 
subjects, lowering sweat electrolyte levels and mitigating PI and the progression of 
CF lung disease? [It should be noted that in the Discussion section of their paper, 
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Padoa and colleagues muddy the water somewhat by stating that, contrary to what is 
presented in the Results section, the two patients also had the 3120+ 1 G~ A mutation 
and positive sweat tests. As our Cape Town patient did not have either, this is 
presumably a mistake.] 
Presently there is not enough firm evidence to give credence to anyone of these three 
possible explanations of the lack of black African CF patients in SA. Certainly it 
would be unfortunate if there were significant numbers of children with typical CF 
who were not receiving therapy that would allow them to live productive and 
relatively healthy lives. Efforts to raise CF awareness amongst health workers should 
continue. It may also be useful to apply sweat testing and mutation analysis to black 
African patients (both adults and children) with chronic respiratory and GIT 
symptoms for which no cause has been found. Testing such patients for the 
3120+ 1 G~ A and the D 1270N mutations could be undertaken to explore the place of 
these mutations in lung and gastrointestinal disease. A larger screening for carriers in 
the healthy persons from the Xhosa and Zulu chiefdoms is probably not justified. The 
aim must be to identify and treat symptomatic patients who have classic CF or a 




GENERAL CLINICAL ASPECTS 
OUTLINE OF CHAPTER 
This chapter details the clinical aspects of CF as seen in this CF population in two 
ways: the presenting symptoms including time to diagnosis, and the clinical 
features. Both aspects are put into the context of CF as seen in other countries. 
BACKGROUND AND LITERATURE REVIEW 
As discussed in Chapter 1, the basis of CF as a cl inical entity is, in large part, due to the 
effect of mutations in the gene coding for a CFTR-linked chloride channel. This channel 
is found at the apex of certain cells of exocrine glands. Many organs have exocrine 
functions and thus CF is a multisystem disease. The bulk of typical symptoms and signs 
relates to the pancreas and lung but, as described in the introduction to this work (Chapter 
1), the genital tract, intestine, liver, upper respiratory tract and skin may all be directly 
affected by abnormalities of CFTR function. On top of these direct effects, secondary 
effects on skin, bones and joints, blood and the endocrine system are not uncommon. If 
complications of the management of these organ-based effects of CFTR dysfunction are 
added to the clinical spectrum of disease, the range of disease associated with CF is vast 
and complex. 
This chapter will discuss two related clinical aspects of the pattern of CF seen in the 
Western Cape province: clinical features at the time of diagnosis ("presentation"), and 
clinical features encountered during the lives of the patients cared for at the RCCH. 
Other clinical aspects of the disease are explored in Chapters 5 (Surgery), 6 (Nutrition 
and Growth) and 7 (Lung disease). 
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Despite its single gene origins, the clinical course of CF is highly variable. The disease 
may vary from single organ involvement to a constellation of organ disease developing at 
any time through a life with CF. Whether and when a particular manifestation of the 
disease will occur and how rapidly it will worsen is in large part highly unpredictable. 
Even one of the commonest features of CF such as pancreatic insufficiency (PI) may 
develop any time in a patient's life. 
Factors known to influence the manifestations of the disease in the individual include 
CFTR genotype, other genes, delay in diagnosis, environmental and health service 
factors. Exactly how these and other unknown factors influence the course of the disease 
in an individual patient is often not known. Siblings can have different manifestations 
and severity of disease. 
PART ONE: PRESENTING FEATURES OF CYSTIC FIBROSIS 
The classical picture of untreated CF is of an infant who fails to gain weight despite 
possessing a voracious appetite, passes voluminous malodorous stools and coughs 
continuously. This is the type of patient described in the 1930s by Fanconi. 1 An infant 
with this triad of symptoms almost certainly has CF. Singly each of these three typical 
symptoms, which in organ terms relate to the pancreas and lung, may also be the initial 
manifestation of the disease. The lower respiratory CF disease, which is the commonest 
marker of CF disease, can manifest with symptoms such as the persistent pertussis-like 
cough seen in infancy, recurrent chest infections (often with atypical organisms such as 
Pseudomonas aeruginosa if microbiological tests are done) and persistent chest 
problems. An acute severe bronchiolitis-like illness is also a well recognised initial 
manifestation of CF. 126 In time the signs of chronic obstructive and suppurative 
pulmonary disease will be evident on examination. The pancreatic disease usually 
manifests as poor growth and chronic steatorrhoea or non-dehydrating diarrhoea. In 
combination with these lower respiratory and pancreatic manifestations or singly, other 
organ disease may produce symptoms or signs that point to the presence of CF. 
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The earliest of all the manifestations of CF is meconium ileus (MI) which is due to CF-
related intestinal disease. This may be suspected antenatally (or recognised if there is 
family history of CF) by ultrasound when bowel obstruction with or without meconium 
peritonitis is seen.127 Soon after birth, a child with MI will show signs of intestinal 
obstruction. Rectal prolapse is another not uncommon presenting feature of CF. The 
presence of rectal prolapse in a child should lead to serious consideration of CF as the 
cause. 128 It results from chronic steatorrhoea and loss of anal tone and muscle bulk as a 
result of the nutritional deficits associated with untreated CF. Also owing to intestinal 
disease, but much less common than MI and rectal prolapse, are intestinal symptoms later 
in life. Occasionally appendiceal disease develops owing to inspissated secretions that 
block the orifice of the appendix, leading to an appendix mass or appendicitis. 129 
Appendiceal histology shows the accumulation of mucus, leading to the diagnosis ofCF. 
The characteristic high electrolyte levels in sweat results from an inability of eccrine 
sweat glands to resorb chloride ions. This excessive loss of chloride and sodium can lead 
to another of the presenting features ofCF, a hypochloraemic metabolic alkalosis.1 3o The 
saltiness of the sweat has alerted some parents to the presence of CF in their offspring. 
The upper respiratory tract features associated with CF are nasal polyposis and 
obstructive upper respiratory tract symptoms and these may be presenting features of the 
disease. Hepatobiliary manifestations of CF may be the clue to its presence. In early life 
liver involvement may show itself as a neonatal hepatitis-like syndrome with 
choiestasisYI Later in life, and less commonly, hepatic cirrhosis may occur but this is 
very seldom the only feature of CF when the disease is recognised. A secondary effect of 
pancreatic and intestinal malabsorption early in the life of a child with CF is 
hypoproteinaemia associated with multiple nutritional deficiencies.132 This manifests as a 
variable combination of growth failure (due to fat malabsorption), oedema (due to 
hypoproteinaemia secondary to protein malabsorption), skin rash (due to vitamin and 
mineral deficiencies) and anaemia (due to protein and vitamin E deficiencies) - the 
'anaemia/oedema complex' presentation. 
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Later in life male infertility due to involution of the vas deferens may be what alerts 
clinicians to the diagnosis.133 Recurrent pancreatitis is now recognised as another' late' 
presentation of CF. 134 
Two non-symptomatic reasons for the diagnosis of CF being made result from screening 
for the disease either as part of a neonatal screening programme or because of a family 
history of CF ('cascade screening'). Another means of making a non-symptomatic 
diagnosis is by antenatal genotyping through amniocentesis or chorionic villus sampling. 
An analysis of the mode of presentation of CF in a particular population can be helpful in 
giving pointers to improving the early diagnosis of the disease in a population or 
geographical area. The frequency of typical versus less typical presentations can inform 
educational goals for health workers. Atypical presentations may have particular 
relevance for certain populations. In Saudi Arabia, for example, neonatal cholestasis as a 
presenting feature of CF is unusually common.135 Clinical features of CF and patients' 
age at diagnosis can indicate whether diagnostic delay is a problem and in what way. 
Delays in attention to nutrition and management of respiratory disease have the potential 
to worsen the prognosis in an individual with CF so the aim must be, in the absence of 
population screening, to have CF diagnosed clinically as early as possible. Gender has 
been found to influence prognosis in CF. Delay in the diagnosis of CF in girls may be a 
factor in thi s 'gender gap' .136 137 
The frequencies of the various modes of presentation in the USA have been reported 
from the Cystic Fibrosis Foundation (CFF) National Patient Registry and give a clear 
picture of the typical pattern in a Western country. These are shown for 20 096 CF 
patients in August 1997 in Table 4.1.60 
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Table 4.1 Presenting features of 20 096 patients reported to the Cystic Fibrosis 
Foundation (USA) National Patient Registry (adapted from Ref. 60) 
Acute or persistent respiratory symptoms 
Failure to thrive/malnutrition 
Steatorrhoea/abnormal stools 



























As discussed in Chapter 3, patients with CF in the Western Cape province are uniquely 
genetically diverse. Is this reflected in their presentation? We suggested in a letter to the 
SAM] in 1996 that the anaemia/oedema complex presentation of CF presented particular 
diagnostic challenges in SA. 138 How common is this presentation in SA context? SA is 
also historically unique. Does ethnic group both in its 'racial' implications and in its 
capacity as surrogate for socio-economic status in SA under apartheid and beyond 
influence the age of recognition of CF? These considerations will also impinge on the 
analysis of the prognosis of CF in SA (Chapter 9). 
As the recognised clinical spectrum of CF has expanded more atypical cases have been 
identified later in Ii fe. Is this the case in SA? 
Apart from our SAM! letter,138 the presentation of CF in SA has been discussed in two 
papers. Hill and colleagues' from Cape Town in 1988 outlined the presentation in 106 
patients.33 Respiratory symptoms dominated. Poor growth was the second most common 
feature. The classic triad of recurrent chest disease, diarrhoea or steatorrhoea and failure 
to thrive was very unusual, being seen in only two cases. A 1984 report on adolescent 
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and adult patients from Johannesburg only reported respiratory and gastrointestinal 
(which included 'weight loss') presentations or a combination of the twO.32 Respiratory 
presentations dominated (50%). 
In Hill and colleagues' study all 106 patients had been diagnosed by 12 years of age.33 
The mean age at diagnosis was 20,6 months. Nearly three quarters of the patients had 
been identified by five years of age. This study came from a children's hospital though it 
included adults with CF. In the 1984 Johannesburg study, only 6% of adolescent and 
adult patients had been diagnosed in the teenage years or beyond indicating that almost 
all diagnoses in the 1960s and 1970s had taken place during the childhood years.32 In a 
similar figure to that in Cape Town (which covered a similar period but extended further 
in to the 1980s), almost 70% had been identified by five years of age. That there was a 
need for improvement at age of diagnosis of CF in the 1980s was indicated by Hill and 
colleagues' finding that the mean age of onset of symptoms was 16 months before the 
mean age at which the diagnosis was made (4,2 months versus 20,6 months). 
Furthermore, whereas 95% of patients had been symptomatic by one year of age, only 
63% had been diagnosed as having CF during infancy. 
In order to answer some of the questions posed above and to describe the situation 
regarding the presentation of CF in SA in recent decades, a study of this issue in the 
Western Cape province was undertaken. 
Chapter 4 80 
STUDY 4.1 Presenting features of cystic fibrosis in the Western Cape 
province 
Study objectives 
1) To determine the presenting features of CF in the Western Cape province 
2) To determine the age at diagnosis ofCF in the Western Cape province 
3) To determine whether gender, ethnic group or year of birth influence the 
time to diagnosis of CF 
Study population 
The 181 CF patients described in Chapter 2. 
Study Methods 
Data 
The following data were extracted from the patients' hospital folders: 
1) Demographic features 
2) Age at diagnosis 
3) Year of birth. 
4) Clinical features at diagnosis. These features were recorded in two forms: 
individually and in groups. Features were assessed through the record of 
symptoms ('history'), signs of organ involvement (,clinical examination') 
and results of clinical tests at presentation ('investigations'). Routine 
screening tests for organ involvement were not part of clinical assessment 
of new cases. The groups of features were classified as: Gastrointestinal 
tract (GIT) only (excluding MI), MI only, Chest only, Other single 
feature, Classic triad (steatorrhoea, recurrent or persistent chest symptoms 
and growth failure/malnutrition), Other combination. 
Data analysis 
Basic statistical analysis of the data included absolute numbers and frequencies. 
Gender and ethnic group data were compared using Chi2 statistics with Yates' 
correction where groups had fewer than 5 cases. For analysis of potential changes 
in time to diagnosis over the period under study, children born in two decades 
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were compared (1975 - 1984 [Period 1] and 1985 - 1994 [Period 2]). Since there 
are only 9 years from the end of Period 2 to the end of the study period, only 
children diagnosed by the age of 9 years were included in this analysis. Age-
related data for groups were compared using non-parametric statistics. 
Results 
Presenting features of CF were recorded in the notes in all but 7 (3,9%) cases. These 7 
cases had been referred with established CF from other centres. The number of patients 
with each of 15 individual presenting features of CF in the remaining 174 patients are 
shown in Table 4.2. Lower respiratory tract features were present at diagnosis in 121 
patients, 69,5% of the total. The presence of P aeruginosa in acute pneumonia led to a 
diagnosis of CF in 4 cases. Four other patients were diagnosed as having CF while on 
ventilatory support for acute lower respiratory tract infections. 
In 15 of the 18 patients with a family history, a sibling was affected with or had died of 
CF. One younger sibling of a known CF case had had MI diagnosed through antenatal 
ultrasound screening. Three families who had had a child (one family had had two) who 
had died of a condition that was probably CF before the index case was diagnosed were 
not included under Family History in Table 4.2. 
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Table 4.2 Individual presenting features of cystic fibrosis 
Presenting Feature Number 
Percentage of 
patients with feature· 
Failure to thrive/malnutrition 49 28.2 
Recurrent chest infections 40 23.0 
Steatorrhoea/abnormal stools 35 20.1 
Meconium ileus$ 28 16.1 
Acute or atypical pneumonia 23 13.2 
Family history 18 10.3 
Persistent chest symptoms 16 9.2 
Rectal prolapse 11 6.3 
Anaemia/oedema complex 10 5.7 
Chronic obstructive airways disease 7 4.0 
Electrolyte imbalance 6 3.4 
Hepatobiliary disease 3 1.7 
Nasal/sinus disease 3 1.7 
Salty taste 2 1.1 
Appendix histology 0.6 
·r otal patients = 174 
$ One patient had the meconium plug syndrome 
No patients were diagnosed through newborn screening. Likewise, although prenatal 
genetic diagnosis has been made in Cape Town, this has always been in the context of 
abortion of the affected fetus. 
None of the 3 cases in which there was hepatobiliary disease at presentation had infantile 
cholestasis and in none of them was the liver disease the principal reason for suspecting 
CF. 
Analysis of presentation by groups of features of CF at the time of diagnosis is shown in 
Table 4.3. The 'Other single feature' group was made up of family history (12), 
anaemia/oedema complex (6), failure to thrive (4), electrolyte imbalance (3), and nasal 
polyposis (1). 
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Table 4.3 Groups of features of CF in patients at the time of diagnosis 
Group 
Chest only 
Meconium ileus only 
Gastrointestinal only 
Other single feature 
Classic triad' 
Other combination 








'Steatorrhoea, recurrent or persistent chest symptoms, growth failure/malnutrition 
In terms of groups of features of CF, no statistical differences in presentation between 
two main ethnic groups could be identified except in the case of pure gastrointestinal 
presentations (excluding MI) (Table 4.4). There was no difference between coloured and 
white patients in terms of having malnutrition at the time of presentation (Chi2 = 1,27, P = 
0,25). Of the 28 children who presented with MI, 18 were white and 10 were coloured 
(no statistical difference p = 0,33). However the anaemia/oedema complex was present at 
diagnosis in 8 coloured children versus only one white child (the 10th child was black 
African - Case 1 p67). This difference was statistically significant (p = 0,005). The 
single white child was 12 months of age when the diagnosis was made whereas all the 
other children had the diagnosis made by 6 months of age. 
Table 4.4 Groups of features of cystic fibrosis in patients at the time of diagnosis: ethnic 
group 
Group Number· (%) Chil2 
Coloured (N = 51) White (N = 71) 
Chest only 21 (41,2) 23(32.4) O,99(p = 0,32) 
Gastrointestinal only 3 (5,9) 15 (21,1) 5,48 (p = 0,02) 
Classic Triad' 5 (9,8) 3 (4,2) 0,73 (p = 0,39) 
Other combination 22 (43,1) 30 (42,3) 0,01 Cp = 0,92) 
*Total = 122 (Patients with meconium ileus alone were excluded from this analysis) 
'Steatorrhoea, recurrent or persistent chest symptoms, growth failure/malnutrition 
The overall mean age at diagnosis was 22 months. The median age was 6 months (range 
o - 169 months, interquartile range 3 30 months). The ages at diagnosis did not differ 
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for the white and coloured groups (p;:; 0,67, Mann-Whitney U test). The proportion of 
patients diagnosed in infancy was 58,9%. 
The median age at diagnosis of those without MI was 12 months. If those diagnosed in 
infancy who, at birth, had an older sibling known to have or to have had CF are also 
excluded from the analysis (where the family history, as with MI, led to an early 
diagnosis), the median age at diagnosis of this CF population (N= 148) was 14,5 months. 
The median age at diagnosis for females in this group was 9,5 months and for males 19 
months. This difference just achieved statistical significance (p = 0,05, Mann-Whitney U 
test). The median ages at diagnosis for the two largest ethnic groups (again excluding 
cases with MI and/or older siblings with CF) were: white 15 months (range 1 - 137 
months), coloured 9 months (range 2 - 169 months). There was no statistical difference 
between these groups (p = 0, 186, Mann-Whitney U test). 
The presenting complaints of the 21 (11,6%) patients who had not been diagnosed by 
their 5th birthdays are given in Table 4.5. The three patients with a family history 
(Patients 80, 63 and 86 Appendix A) were diagnosed when a younger sibling was shown 
to have CF. Eight of the 21 patients were PS at diagnosis (including the three siblings). 
Only one of the 9 children diagnosed after the age of7 years was female. 
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Table 4.5 Presenting features of patients diagnosed after their 5th birthdays 
Age at diagnosis 






















see Appendix A 
M = Male, F = Female 
C = coloured, W = white 

































Persistent chest, symptoms, hepatomegaly 
Steatorrhoea 
Ghronic IlJllgdiliease 
Recurrentchest infections, steatorrhoea 
Recurrent chest infections 
.9hrcmicchestsymptoms, FTT, steatorrhoea 
Persistent chest symptoms, underweight 
,Sibling 
W .Pse,udomonas pneumonia, bronchiectasis 
C Bronchiectasis 
W Steatorrhoea 
, .... ·1 .... 
W .Recurrent chest infections 
W ;Pneumonia 
C ",Sibling 
W .Recurrent bronchitis 
W iSibling" 
W Recurrent chest infections 
W Steatorrhoea, persistent chest symptoms 
W;Recljrrel1t chest infections 
W Nasal polyposis 
C ;Chronic IUn disease, liver cirrhosis 
Sixty seven patients were born in Period 1 and 59 in Period 2. The median (mean) ages 
at diagnosis for the two periods were 8 (21) months and 10 (19,5) months respectively. 
There was no statistical difference between the periods (p = 0.63 Mann-Whitney U test). 
Omitting cases with MI and an older sibling with CF, the figures for the two periods 
(Period 1 51 patients, Period 2 = 52 patients) changed to 18 (27) and 11,5 (22) months 
but were still not significantly different (p 0,44 Mann-Whitney U test). 
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Discussion 
The diagnosis ofCF depends on the recognition by a child's family and health workers of 
symptoms and signs that suggest the disease. Most South African families will not have 
heard of CF since it does not have the public profile it has in countries with 
predominantly Caucasoid populations. Family history of the disease is unusual as CF is 
an autosomal recessive condition, and, even where there is a family history, except in the 
case of siblings, that history is only thought of after the diagnosis is made. One in ten 
children had a family history of CF in this study. In nearly all cases it was a sibling. A 
more distant relative with CF was rare, confirming that the absence of a family history of 
CF is the norm in Cape Town as it is elsewhere. 
As shown by Hi II and colleagues33 and confirmed here, the classic triad of presenting 
features of CF is unusual in Cape Town. Indeed only one third of our cases had 
recognised malnutrition at diagnosis (failure to thrive 49, anaemia/oedema complex 10 = 
59/181). Malnutrition gains greater status as a presenting feature of CF if the cases who 
presented with MI or had an older sibling with CF (and thus had a very early diagnosis) 
are excluded but, even so, fewer than half the cases (59/148) were recognised as 
malnourished at diagnosis. 
That malnutrition is significant at diagnosis of CF has been demonstrated by the 
Wisconsin controlled study of screening for CF.139 Length, weight and head 
circumference were all significantly lower in the unscreened population when the 
diagnosis was made. It is likely that the same nutritional deficits pertain in SA. The 
North American Registry study which was less rigorous as it depended on clinical 
assessment by staff at CF Centres throughout the USA, gave a figure for the prevalence 
of malnutrition at diagnosis of 35,6%,140 in keeping with that reported here. In this study 
the presence of malnutrition was not gauged by detailed anthropometries or blood 
investigations; it depended on clinician's notes and their assessment of basic data such as 
weight and, less often, length or height. It has been our experience that many newly 
diagnosed children with CF rapidly gain weight after the initiation of pancreatic enzyme 
replacement therapy (PERT) and dietary therapy even when their weights fall within the 
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'normal' range at diagnosis. This early catch up growth was also demonstrated in the 
Wisconsin trial.!39 Importantly, the finding that fewer than half of the children had 
features of malnutrition on straightforward clinical assessment means that South African 
clinicians who expect this to be present in order to suspect CF are going to miss the 
diagnosis. 
Lung disease affected two thirds of patients, making it more important than malnutrition 
as a clue to the presence ofCF. Indeed chest disease alone was the presenting feature in a 
quarter of the cases. This study demonstrates that, in SA, a wide variety of respiratory 
presentations can be presenting features of CF. While 'recurrent chest infections' are 
well known as a reason to think of CF, 'persistent chest symptoms', meaning that the 
child is not particularly sick but always coughing or productive of sputum, is also a 
significant respiratory presentation. Asthma is a much more common cause of this 
symptom complex but CF should be considered if there is an inadequate response to 
asthma therapy or if there is associated malnutrition. Likewise the association of severe 
acute lower respiratory tract disease and early presentation of CF is less known than it 
should be given that 4 children were on ventilators before CF was thought of. As shown 
as long ago as 1974, CF may need to be considered in any infant with an acute life-
threatening lower respiratory tract infection characterised by marked lower airways 
obstruction. 126 
While abnormal stools must have been present in those with malnutrition (as lung disease 
of sufficient severity to cause growth disturbance is unlikely in CF without PI), they had 
often not been recognised as abnormal by the family. Thus health workers need to think 
of CF in children with unexplained malnutrition and persistent chest disease alone as well 
as in combination, even if there are no apparent GIT symptoms. 
The anaemia/oedema complex presentation affected about one in 20 children. Two of the 
10 cases were diagnosed post mortem. All those diagnosed while alive had been 
diagnosed since 1988 suggesting that there was lack of awareness of this presentation in 
the earlier years. The first child to be diagnosed with this presentation ante mortem spent 
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two months in hospital being investigated for anaemia before CF was considered. He 
died soon after the diagnosis was made. A similar case dominated by anaemia in which 
vitamin E deficiency played a major part has been reported from Detroit in the USA. 141 
The younger sibling of our patient presented similarly four years later and the diagnosis 
of CF was rapidly proved. Based on this study, at least one child with CF presents in this 
fashion every 18 months or so in Cape Town. As we noted in 1996, children with this 
form of CF may even now be dying labelled as having kwashiorkor. 138 Phillips and 
colleagues presented two cases in the UK who had features that mimicked 
kwashiorkor,132 so how much more will confusion occur in SA where the malnutrition 
syndrome remains prevalent? Interestingly, this presentation and its pitfalls in poor 
societies has been recognised in South Asia. 142 Is this lack of recognition of this 
presentation of CF the reason that some of the black African children with CF are 
'missing'? Of note is the early age at which features of anaemia/oedema develop (less 
than 6 months in all but one case). This is consistent with the literature on CF but is 
earlier than the age that nutritional kwashiorkor develops which is typically in the second 
year of life. The late diagnosis of the one white child to have this syndrome, the daughter 
of parents from the professional classes, demonstrates the lack of recognition of this 
syndrome in SA. 
The first study to estimate the proportion of patients with CF who present with oedema 
was published in 1978.143 This paper noted the case reports of this presentation that 
stretch back to the 1940s though only those from the 1960s forward were reviewed in the 
paper. Writing from Montreal, Canada, the authors reported 6 cases (2,6%) out of the 
229 identified as having CF over a 10 year period. This is just over half the Cape Town 
incidence reported here. Reporting three years later, Danish authors described 7 out of 
130 infants (5,4%, 95% CI 2,17-10,84%) who had presented under the age of6 months 
and who turned out to have CF.144 While this seems to be a higher incidence than the 
Montreal study, the denominator was different as it only contained infants. It is not 
possible to compare these data with Cape Town's since the age of diagnosis of some 
children in the Danish series does not coincide with their presentation with 
anaemia/oedema. Abman and colleagues from Denver in the USA reported that 13% 
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(9/66, 95%CI 6,4-23,3%) of CF patients diagnosed in infancy had this presentation. 145 
The equivalent figure in Cape Town was lower (9,5%, 101105, 95%CI 4,7-16,8%). 
However if only those born in the second half of the study period (when awareness had 
risen) are included, the incidence was 16,4% (9/55, 95%CI 7,8-28,8%). Prospectively 
this presentation was found in 2 out of 49 (4%, 95%CI 1-14%) patients screened for CF 
in Wisconsin trial. 139 In this trial few patients had had sweat test before 6 weeks of age. 
Most reports show that the signs and symptoms of this complex are present as early as 
this, suggesting that this incidence for this presentation (albeit with wide CIs) represents 
as accurate a figure as is possible at the moment in developed countries. It cannot 
therefore be shown conclusively that the presentation is more common in Cape Town but 
the suspicion that it is remains. This suspicion is intensified by the ethnic distribution of 
our cases. This is unlikely to relate to CFTR genotype as, by definition, this presentation 
is a severe one and more white CF patients have ~F508 homozygosity (a severe CFTR 
genotype) than coloured patients do. Delay in diagnosis cannot be blamed either. It must 
therefore be considered that socio-economic differences between the groups are playing a 
role in this phenomenon, presumably through nutritional mechanisms. 
Further complicating the diagnosis of CF in this presentation is the unreliability of the 
sweat test in the presence of oedema. Some studies have shown that sweat chloride 
levels are often low in the oedematous phase, rising to typical CF levels as the oedema 
clears. 143 CF cannot be excluded as the cause of the syndrome until the oedema is gone. 
The main problem experienced with the sweat test in this situation in our hands has been 
difficulty collecting enough sweat from oedematous infants. From the early 1990s, when 
faced with this situation, we have sought a molecular diagnosis while starting PERT and 
vigorous nutritional rehabilitation. With the advent of the human faecal pancreatic 
elastase 1 test, testing for PI and/or starting PERT early can lead to a diagnosis and rapid 
amelioration of this potentially lethal nutritional state. The mortality associated with the 
anaemia/oedema complex is discussed in Chapter 9. 
Initially recognised as a complication in known CF cases in heat wave conditions such as 
those in New York in 1948;46 electrolyte derangements as a presentation of CF have 
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been recognised since the 1950s. Their relative frequency was initially put at 46% (5 out 
of 11 patients diagnosed in infancy) in Tucson, Arizona. 147 This high frequency has not 
been reproduced elsewhere and may relate to the hot, dry Arizona climate. In Cape 
Town, which is very hot in mid-summer, only 3,4% of presentations were due to this 
complication. Among those who presented in infancy, its frequency was 5,7% (6/105). 
More recently a study from Eastern Europe showed 16,5% of infants to have had this 
complication. 148 It is conceivable that cases are missed in Cape Town. The annual 
summer diarrhoea epidemic takes its toll and among these deaths there may be children 
who have CF and die from the severe metabolic derangement associated with the excess 
salt loss before the tell-tale metabolic alkalosis, never a biochemical feature of 
dehydrating diarrhoeal disease, can be identified. 
Rectal prolapse was never the only pointer to CF in this series. This is consistent with the 
findings of Zempsky and Rosenstein who reviewed 54 children presenting with rectal 
prolapse. 149 Six of them proved to have CF and all 6 had other features of CF present 
when the rectal prolapse developed. 
Fitzsimmons, in the largest study to appear up till then, presented the data from 17,857 
patients in the US National CF Patient Registry as it stood in 1990.140 Seventy percent of 
patient had been identified in infancy, 80% by 4 years of age and 90% by age 12 with a 
median of 7 months. Our figures compare well with these with medians and means being 
slightly lower. The absence of adult-age diagnoses in our cohort means that our figures 
cannot be taken as better than the USA ones, but nonetheless they are encouraging. 
However, a lower proportion of CF patients were diagnosed in infancy in the Western 
Cape province compared to the USA, indicating that late diagnosis is still a problem here. 
This is further emphasised when patients without MI are compared with those from the 
control group (which also excluded patients with MI) from the Wisconsin CF Neonatal 
Screening Study (12 months in Cape Town, 28 weeks in Wisconsin).ISO 
In Latin America where adverse social circumstances are not unlike those in SA, mean 
age at diagnosis of CF varied from 3,3 (SD 4,2) years in Argentina to 4,3 (SD 5,5) years 
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in Mexico in an epidemiological study published in 1991.151 These are well above the 
figures for Cape Town and, while they do include persons diagnosed in adulthood, the 
standard deviations show that they are in the main young populations such as ours. In our 
region, coloured patients are generally poorer that white patients but this did not lead to 
later median age at diagnosis. It is likely therefore that another reason explains the 
significantly later age at diagnosis in Latin America e.g. greater lack of awareness of CF 
in the lay and medical communities. Indeed Macri and colleagues suggest that this is the 
case. 151 
Antenatal diagnosis was only made on one of these children and this was through the use 
of ultrasonography. This picked up the features of MI through the pregnancy. As 
Corteville and colleagues have shown, bowel wall hyperechogenicity and bowel 
dilatation continuing into the 3rd trimester are highly suggestive of CF.127 This young girl 
proved to have MI postnatally and did well after surgery. Antenatal genetic diagnosis has 
not been made on any child in Cape Town. Antenatal genetic testing by amniocentesis or 
chorionic villus sampling has only been taken up by families planning further children 
after the birth of child with CF in the context of abortion of the affected fetus. 
Girls were diagnosed earlier than boys in this study. This is counter to the largest study 
to address this issue, the North American CFF Registry study published in 2002,137 and 
probably relates to the preponderance of males among those with a later diagnosis of CF 
(Table 4.5). If these patients are excluded, the difference ceases to be statistically 
significant. Using a very large cohort (11 275 subjects) the Registry study showed that 
girls were diagnosed a mean of 4 months later than boys, the difference being greater (18 
months) if there was a respiratory presentation.137 The reasons for this and its 
significance with respect to poorer life expectancies for girls remain conjecturaL In this 
Cape Town study it is likely to have been a matter of chance that more boys than girls 
had later diagnoses. As shown above, many late diagnoses were due to atypical disease 
(e.g. PS) or identification of mildly affects older siblings - reasons that are not gender-
specific. 
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This study covered 20 years during which changes have taken place in diagnostic 
techniques and the understanding of the range of ways in which CF can present. Median 
ages in this analysis were higher than the overall figures for the study owing to the 
omission of children born in the last nine years. No clear improvement in the age at 
which children were diagnosed with CF could be demonstrated. Given the low median 
ages at diagnosis, this is not surprising, although omitting the children with MI and older 
siblings with CF produced a larger rise in median age at diagnosis for the 1 st Period (8 to 
18 months) than for the 2nd Period (10 to 11,5 months). Farrell reported that in the USA 
from 1970 age at diagnosis fell sharply but has not fallen during the 1980s and 1990s.152 
He quotes median age at diagnosis in the USA to have been 0,5 years among the 900 
patients diagnosed in 1996, but the inclusion of screened patients make this figure 
difficult to compare with the median age of 10 months in the 2nd Period in this Cape 
Town study. Hill and colleagues in the 1980s studied CF in an earlier generation of 
South Africans many of whom had been born in the 1960s and 1970s.33 Mean age at 
diagnosis was 20,6 months, much like that presented here. Unfortunately median age at 
diagnosis was not given, however would have been less than 1 year overall as 63% of 
patients had been diagnosed by that age. In the present study 88,4% of patients were 
diagnosed by the age of five years compared with 74% in Hill and colleagues' study. All 
in all these trends suggest that a modest reduction in age at diagnosis has occurred in the 
last three decades in this region. 
Recent evidence from the CFF Registry has suggested that mode of and age at 
presentation of CF can influence survival. 153 These aspects will be discussed further in 
the chapter on the prognosis of CF (Chapter 9). 
CONCLUSION 
In the Western Cape province CF presents much as it does in other parts of the world. 
Overt malnutrition and the typical diagnostic triad are often not present requiring 
clinicians to think of CF in other clinical situations e.g. patients with persistent, recurrent 
or severe respiratory symptoms without overt nutritional depletion. The anaemia/oedema 
complex is particularly common in this region among coloured patients, perhaps 
Chapter 4 93 
mediated through socio-economic factors. Age at diagnosis compares favourably with 
better resourced countries and may have improved over the period covered by the study. 
There is room for further reductions in age to diagnosis. There are demonstrable benefits 
to early diagnosis but, since population screening is not yet justifiable in this context for 
reasons of prevalence, cost and logistics,43 this will only be brought about if greater 
awareness of CF is created amongst the public and in the health services of this region. 
PART TWO: CLINICAL FEATURES OF CYSTIC FIBROSIS 
For the purposes of the chapters that cover clinical aspects of CF, the manifestations and 
patterns of CF disease seen in the Cape Town population will be divided into the three 
groups described in the introduction to this chapter: 
1) Those clinical features directly due to CF. These features are the result of 
dysfunction of organs and consequent damage to the same organ. PI would be 
an example in this group. 
2) Clinical features resulting from secondary effects of CF-related organ 
dysfunction and damage. These may be features affecting the whole person 
(e.g. malnutrition) or other organ systems (e.g. the bones). 
3) Clinical features resulting from therapy for clinical CF disease. 
Classification of certain complications of CF into one of these groups is not always a 
simple matter given the complexity or the uncertainty of their pathogenesis. The 
following section that explores current understanding of the development and 
characteristics of the clinical features of CF will discuss these difficulties. 
GROUP 1: Clinical features directly due to CF 
IHE .. ~UNQ~ 
In view of frequency, complexity and threat to survival, the lung disease ofCF is its most 
important feature. Almost all persons with CF have significant lung disease. The lung 
disease is responsible for most illness and therapy and it kills almost all CF patients. 
While the exact pathogenesis remains unknown, CF lung disease is characterised by 
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endobronchial inflammation and infection that leads to chronic obstructive and 
suppurative lung disease.1s4 Respiratory failure is the end result of this progressive 
process. 
Because of its importance, the lung disease of CF merits a chapter on its own. The 
studies in the present chapter aim to present the pattern of manifestations of CF in Cape 
Town. Thus, with respect to the'lung disease, its presence or absence in the patients will 
be noted and specific major complications of CF lung disease in this population will be 
dealt with in this chapter. Details of infections and pulmonary function are the focus of 
Chapter 7. The progressive lung disease of CF can lead directly to four major 
complications: IS4 
Empyema 
Rare in the antibiotic era, the development of empyemata with lower respiratory tract 
infections in CF patients was not uncommon before then. Shwachman and colleagues 
described two cases in 130 patients whose CF had been diagnosed before the age of 3 
years. 128 Taussig and colleagues described four cases all of whom had empyema in 
infancy before the diagnosis of CF was made. ISS The most common causative organism 
was S aureus. Since that time and with the introduction of powerful anti-staphylococcal 
antibiotics, this complication has been reported even less frequently. 
Massive Haemoptysis 
This serious complication of CF lung disease has been defined as the coughing up of 
>24OmI of blood per 24 hours or the recurrent bleeding of substantial volumes of blood 
(> 1 OOmI) regularly.lS4 This complication is very uncommon in the childhood years. 
After the age of 16 years it occurs in about 1 % of patients each year. The bleeding comes 
from bronchial arteries that have become greatly enlarged and tortuous. Management 
consists of the reduction of risk factors for bleeding (Vitamin K deficiency, the use of 
non-steroidal anti-inflammatory drugs) and pro-coagulant drugs such as tranexamic acid. 
If these measures fail to stem the flow, the bleeding bronchial artery will need to be 
occluded through embolisation using interventional radiological techniques.1S4 
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Pneumothorax 
This complication occurs in the presence of significantly damaged lungs. It is thought to 
occur when a cystic cavity or bleb on the surface of the lung bursts into the pleural cavity. 
It tends to occur in older patients and, while treatable, is a sign of a poor prognosis. 156 
Pneumothoraces may recur and, when this happens, often require pleurodesis. 154 
Cor pulmonale 
Pulmonary hypertension in CF is a consequence of the chronic lung disease. It is difficult 
to diagnose in the absence of clinical signs of right heart failure such as an elevated 
jugular venous pressure and peripheral oedema. Electrocardiography and 
echocardiography are not sensitive tests of the cardiac effects of pulmonary hypertension 
in the context of CF. Cor pulmonale is a very late manifestation in CF. 
ItlE __ f.ANC_R,gA~ 
Pancreatic insufficiency 
PI occurs as a result of blockage of pancreatic ducts by inspissated secretions as a result 
of low water and electrolyte efflux from ductal cells. These digestive enzyme-rich 
secretions cause autodigestion of the pancreas. Pathologically there is fibrosis and cystic 
change with loss of glandular acinar tissue. (These macroscopic features led to the 
soubriquet Fibrocystic Disease of the Pancreas, an early name for CF.7) In the majority 
of cases this process is well advanced by the time of birth. 157 The resultant PI leads to 
nutrient malabsorption from the initiation of feeding. In a minority of patients, PI 
develops later in life. In a screened population, about a third of babies do not have PI at 
birth:57 Between 10 and 15 % ofCF patients never develop pI. 158 159 
The main clinical manifestation of PI is steatorrhoea which impacts on the child's growth 
unless there is a proportionate increase in calorie intake through increased appetite. l60 
Malabsorption of fat soluble vitamins also occurs as a result of PI. 
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Fat malabsorption can be suspected on stool inspection when free fat may be seen and 
proven using a 3-day stool fat measurement. The origin of this malabsorption can be 
shown to be pancreatic by the absence of proteases of pancreatic origin in the stool 
(chymotrypsin or faecal-I-human pancreatic elastase). These tests, while desirable, are 
not essential to the diagnosis in the presence of obvious steatorrhoea and growth failure. 
Diabetes mellitus 
The pancreatic destruction and fibrosis caused by abnormal ductal function as a result of 
the CFTR abnormality in the ducts leads to damage of pancreatic tissues that do not 
express CFTR. The Islets of Langerhans have insulin producing cells. These cells (p 
cells) are reduced in number in CF. The exact pathogenesis of CF-related diabetes 
mellitus (CFRD) is not fully understood as p cell numbers do not differ between those 
with and those without the complication.161 The complication is at the severe end of a 
continuum of abnormalities of glucose tolerance in CF, being defined as fasting 
hyperglycaemia with a 2-hour peak glucose level > 11,1 mmol/l on the oral glucose 
tolerance test (OGIT) or through typical symptoms of diabetes mellitus: polydipsia and 
polyuria in association with hyperglycaemia. 162 
CFRD is unusual before the second decade of life. The proportion of CF patients with 
diabetes mellitus rises with age. CFRD is an indication of a relatively poor prognosis. 163 
CFRD differs from both Type 1 and Type 2 diabetes mellitus. Unlike the former, 
ketoacidosis is unusual and auto-antibodies are not present. Secretion of the 
gluconeogenic hormone glucagon is also decreased in CFRD. Insulin resistance, the 
cardinal feature of Type 2 diabetes mellitus, may be found in CFRD (most commonly in 
association with acute pulmonary exacerbations) but not to the same degree and not in 
association with obesity, the other cardinal feature of Type 2 diabetes mellitus. 161 
There is growing evidence that the glucose intolerance that precedes full blown CFRD is 
detrimental to the health of CF patients. l64 Lung function deteriorates in this phase 
despite the absence of symptoms of diabetes mellitus. There is a strong move towards 
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screening for CF -related glucose intolerance using glucose tolerance tests In older 
children and adolescents with CF. Currently this is not the policy at the RCCH. 
Pancreatitis 
Acute or relapsing pancreatitis is an unusual complication of CF. It usually occurs 
beyond the early childhood years and used to be thought to be exclusive to who have 
PS.134 This has been shown not to be so with significant numbers of CF patients with PI 
developing pancreatitis. 16s It typically presents with recurrent abdominal pain and should 
be considered when a CF patient has this symptom. 
IHI; __ G_A$.TRQlliI~$.TINAL_IMQr. 
Meconium ileus 
Since MI causes severe clinical disease early in the neonatal period, it is a presenting 
feature of CF as has been discussed above (p 109). It occurs in about 18% of CF 
patients. IS3 It may be complicated by meconium peritonitis or intestinal atresia. Because 
MI usually requires the services of surgeons, it will be discussed in detail in the next 
chapter (Surgical Aspects of CF). The meconium plug syndrome in which there is 
delayed passage of meconium after birth until a meconium plug is passed is an occasional 
variation on the early intestinal obstruction group of CF presentations. 
Distal intestinal obstruction syndrome 
A cause of intestinal obstruction after the neonatal period, the distal intestinal obstruction 
syndrome (DIOS) used to be called the meconium ileus equivalent following a 1962 
paper by Jensen. l66 It is not an equivalent to MI, so that name has dropped from usage. 
The term DIOS was introduced by Park and Grand in 1981.167 DIOS results from 
maldigestion and CF-induced changes in intestinal motility. It might be considered to be 
secondary to PI as it is unusual in patients with PS,168 but the consequences of CFTR 
dysfunction in the gastrointestinal tract also contribute to the syndrome, hence its 
inclusion in this section. 
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In DIOS there is an accumulation of the products of mal digestion mainly in the ileum and 
the right side of the large colon. It is likely that decreased intestinal motility and other 
gastrointestinal factors such as abnormal mucus contribute to this accumulation. The 
clinical effect is to produce colicky abdominal pain associated in many but not all cases 
with symptoms (vomiting, constipation) and signs (abdominal distension) of intestinal 
obstruction. Anorexia may also be a consequence. Often a right lower quadrant 
abdominal mass is felt. Faecal masses may also be felt elsewhere in the abdomen. 
DIOS can occur at any age, is often recurrent and may be associated with inadequate 
PERT. It may present acutely or less severely over many weeks and months. This latter 
presentation of DIOS can contribute to anorexia and poor growth. There is an overlap in 
the clinical features and pathogenesis of DIOS and 'functional' faecal loading in CF. 
Both have recurrent abdominal pain and a build up of faecal material in the colon. The 
mode of treatment (purging and attention to optimising PERT and diet) is also similar. 
An exact definition of DIOS is hard to come by. The triad of intestinal obstruction, 
severe abdominal pain and a right lower quadrant abdominal mass equated to meconium 
ileus equivalent and is what Park and Grand meant by DIOS, though they say that a 
chronic form may occur:67 In their review, Rosenstein and colleagues do not define 
DIOS.169 They list a series of symptoms and signs and report a 41,3% incidence ofDIOS 
among 68 patients. Rubinstein and colleagues studying a larger cohort (168 patients) 
coupled constipation and DIOS. 170 The former required there to be a reduction in stool 
frequency. This is not a necessary feature for the diagnosis of functional faecal loading 
meaning that cases of functional faecal loading were not included in this group. 
'Meconium ileus equivalent' required 'severe' abdominal pain in this study meaning that 
only the acute form was studied. This approach leaves out many cases with recurrent 
abdominal pain and faecal loading who may have had DIOS. Thus this study's incidence 
for DIOS of 9% is an underestimation. 170 
In practical terms, abdominal pain (acute or recurrent) and clinical and/or radiological 
evidence of retention of faecal matter in the right colon and beyond tend to lead to the 
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diagnosis ofDIOS in a CF patient. For the purposes of this review, abdominal pain with 
faecal retention with or without other symptoms of intestinal obstruction is considered to 
be evidence ofDIOS unless another cause was found. 
Rectal prolapse 
Rectal prolapse, as was discussed with the presenting features ofCF (P126), is associated 
with untreated or poorly controlled steatorrhoea. Kulczycki and Shwachman noted that, 
untreated, 22,6% of patient had prolapse but only 2 out of 106 on treatment had it.17l 
Once the diagnosis of CF has been made and PERT established, its appearance strongly 
suggests poor adherence to therapy. Thus rectal prolapse tends to be a presenting feature 
ofCF and is unusual after that. 
Intussusception 
This complication of CF occurs in about 1 % of cases. 172 Unlike in non~CF patients in 
whom intussusception occurs in early infancy, it occurs later in childhood and can even 
happen in adulthood. It is thought that the sticky, maldigested intestinal contents of CF 
form a lead point for the intussusception. Bloody stools, a cardinal feature of 
intussusception in infants, are unusual in the form that occurs in CF patients. 
Crohn 's disease 
Inflammatory bowel disease can occur in the context of CF and, according to an active 
case finding study by Lloyd~Still, 173 is more common in CF that in the general 
population. It is likely to be an immune response to the abnormal contents of the CF 
bowel. The diagnostic criteria are the same as in non~CF patients. 
Iij~ .. U~r.AIQ~JL.lARY.~Y.S.1J~·~M 
Focal biliary cirrhosis 
As with other water~based secretions in CF, bile is abnormal. As a result of CFTR 
dysfunction in cholangiocytes,174 hydration of bile is inadequate. 175 The exact 
pathophysiology beyond this point is not yet clear. There is sludging of bile in the 
canaliculi of the liver causing obstruction. Consequent on this are focal areas of necrosis. 
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Gradually over many years this may lead to multilobular biliary cirrhosis. Toxicity of 
taurine-poor bile is another putative factor leading to liver damage. Abnormal function 
of stellate cells, perhaps secondary to the abnormal bile, has also been implicated in the 
. fib' th 17S promment rOSlS at occurs. 
This process is usually clinically silent. To palpate a liver in CF is often normal, 
particularly where there is significant lung overinflation. An enlarged liver may be due to 
steatosis, an association with severe malnutrition. The palpation of aflrm hepatomegaly 
should lead to consideration of developing biliary cirrhosis. Signs of portal hypertension 
such as splenomegaly develop in a proportion of cases, leading in some to complications 
such as bleeding oesophageal varices. Hepatic encephalopathy is unusual in CF owing to 
the relative sparing of hepatocyte function. 
With the advent of a therapy that can potentially delay progression to biliary cirrhosis, 
ursodeoxycholic acid (UDCA), an effort is being made to diagnose CF-related liver 
disease earlier in its course using regular abdominal ultrasound and serum liver enzyme 
estimations. Whether this will have a effect of the incidence of serious complication is 
not yet proven. 176 
The onset of CF-related liver disease seems to be almost exclusively in childhood and 
adolescence. 177 How common CF-related liver disease is is a matter of some debate 
owing to the use of varying diagnostic criteria in the studies (anything from 1,4 - 43%). 
It appears invariably to be associated with PI.177 
Cholestasis in infancy 
The biliary obstruction associated with CF can produce a neonatal hepatitis-like 
syndrome in early infancy. 131 Clinically this can be indistinguishable from other causes 
of the syndrome such as congenital infection. Sweat testing should be a routine part of 
the work-up for this presentation. A child with CF who presents like this will not 
necessarily continue to have significant liver disease. It is reported to occur in about 2% 
of cases. PI is an invariable correlate. 
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Gallstones 
Cholelithiasis in CF usually occurs in adulthood and is not common. 178 
Rhinosinusitis 
As with the lower respiratory tract, the upper respiratory tract is dysfunctional when 
CFTR is abnonnaL Airway clearance is compromised leading to more infections which 
take longer to clear and become chronic. Nearly all children with CF develop 
hypertrophy of the nasal sinus mucosa leading to complete filling of the cavity seen 
radiologically as opacification. 179 However, significant symptoms occur in fewer 
children. Acute sinusitis with its typical symptoms of fever, congestion and facial pain is 
unusual in CF. Rather there may be chronic ill health, anosmia, intermittent fever, 
persistent nasal obstruction with or without continuous purulent nasal discharge and 
headaches. 179 The bacterial causes of this are the usual upper respiratory tract pathogens 
such as Streptococcus pneumoniae as well as typical CF-associated bacteria such as P 
aeruginosa. The contribution of the paranasal sinus disease to the poor health of children 
with CF is often underestimated making prevalence figures difficult to establish. 
Compounding this difficulty is the overlap with allergic upper respiratory tract symptoms 
and signs. 
Nasal polyposis 
The nasal polyps of CF are a direct result of the mucosal hypertrophy just discussed. 
They are common in CF, occurring in 10-32% of cases in most series. 179 Asymptomatic 
polyps may be seen if rhinoscopy is a routine procedure at follow up visits. Symptoms 
are usually those of nasal obstruction. Some patients are troubled by repeated bouts of 
obstruction despite surgical removal of the polyps. Surgical management of polyps is 
discussed in Chapter 5. 
Nasal polyposis may be the presenting feature of CF. Testing for CF is recommended 
when a child has nasal polyps. 
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IH~ .. O.ENJIAL .. IRA~I. 
Male and female infertility are mentioned here for completeness' sake. They are unlikely 
to be complained of in childhood or adolescence. Almost all males with CF have no vas 
deferens and this may be noted clinically in childhood when no spermatic cord is 
palpable. 
GROUP 2: Clinical features secondary to CF-related organ dysfunction 
N.lJtrj,~nt.Q.<!.fi~i~n~Y 
This is by far the most important secondary feature of CF. Chapter 6 is devoted to a 
discussion of growth and nutrition and its correlates in CF and covers five studies 
undertaken in Cape Town. It will not be discussed further in this chapter. 
A.I).~.<!m.i.?!.9.~4~m~.~9.mp.!~~ 
This manifestation of CF was first described in the 1940s. It is usually seen in the 
context of exclusive breast feeding or soya formula feeding. Its cardinal feature is 
oedema resulting from hypoproteinaemia which relates to the lower protein content of 
breast and soya milk. Variably associated with the oedema is a haemolytic anaemia 
secondary to vitamin E deficiency, itself due to fat malabsorption, and a rash caused by 
vitamin and mineral deficiency. Alban and colleagues have suggested that children with 
this feature of CF do worse than others, possibly because of a delay in diagnosis. ISO Five 
of the 9 infant deaths reported from the RCCH in 1994138 were associated with this 
complex. 
Q.~.~lr.9.:Q~~.9.p.h~.g<!.~1.x~tll:l.'.\ 
Incompetence of the gastro-oesophageal junction has been described commonly in 
association with CF. It occurs with increased frequency in both young and old with CF, 
leading to worsening of lung disease, and gastrointestinal symptoms from oesophageal 
dysmotility and oesophagitis. It is thought to be caused by changes in acidity in the 
proximal small bowel and to changes in diaphragmatic tone and shape secondary to lung 
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overinflation. 181 It can be demonstrated with contrast radiography, ultrasound, 
scintigraphy or pH studies . 
. -P.~p.ti~.!-!J ~~r. g.i.~~~~.~ 
The pathogenesis of peptic ulcer disease in CF may relate to stress (as suggested by 
Littlewoodl81 ) or the altered gut microenvironinent associated with poor alkalinisation of 
the duodenum . 
.o.~~.t!gP.W9.~.l~ 
The pathogenesis of bone disease in CF is complex involving calcium and protein 
metabolism, nutrient malabsorption, vitamin D, high levels of inflammatory cytokines, 
reduced activity levels and pubertal delay.182 What is clear is that, at least during 
childhood, it can be prevented. Salamoni and colleagues in Switzerland saw no evidence 
of bone mineral density disorder in normally nourished CF patients. 183 Silent in the 
childhood years, osteoporosis is becoming a significant source of symptoms as CF 
populations age. This is particularly evident in the vertebral column where 
microfractures and collapse of vertebral bodies lead to back pain. Fractures of limb 
bones are also seen. 
Saitowitz studied the calcium and vitamin D status of children in Cape Town in the late 
1990s. 184 Half took in insufficient calcium but almost all had normal levels of 25-
hydroxy vitamin D, calcium, phosphate and alkaline phosphatase. Bone mineral density 
was not studied. All children have received supplemental calcium since then . 
. A.xthr.i.ti~ 
This takes two forms. One is hypertrophic pulmonary osteoarthropathy, the same entity 
that can occur with any chronic suppurative lung disease. The other form is rheumatoid 
in nature, affecting mainly large joints. It is sero-negative and is not usually 
destructive. 18s It occurs in the context of high circulating levels of immunoglobulins as a 
result of the chronic inflammation in the lungs. 
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R.~~tiY~.4~p.!:~.~~.i.Qn 
Depression is included in this group because, although it is not an organ-based entity, it is 
a serious concomitant ofCF. It has direct effects on the physical health of those with CF. 
Its cause is multifactorial, involving reactions to physical disease, perceived and actual 
problems and family/social circumstances. Clinicians need to be alert to its appearance, 
often subtle, in their CF patients. 
A.I.l~(gi~.br.Qrw.u9.p.lA!m9.I}.J1IY..~$p..~rgi!!~mi~'(Aap.A} 
Aspergillus fumigatus can colonise the airways of CF patients. In some it is a 
commensal, but in others it induces an immune response. This response has elements of 
Types I and III hypersensitivity reactions producing IgE and IgG antibodies. These in 
turn react with the organism's antigens at the airway surface inducing inflammation. The 
dominant clinical effect of this is airway obstruction manifesting as wheezing. 
Radiologically, lung infiltration may be seen. ABPA should be thought of if a 
deterioration of lung function occurs in a CF patient and there is a poor response to 
antibiotics or if the wheezing is persistent or dominates. I 86 
Because A jumigatus and the antibodies may be present without clinical disease and 
because ABPA in CF differs from that associated with asthma, diagnostic criteria as set 
out in Box 4. I have been recommended. 187 
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Box 4.1. Diagnostic criteria for acute bronchopulmonary aspergillus in cystic fibrosis 
patients (Reference 187) 
All immunologic parameters required 
• SPT positive to Af and 19E-Af (RAST) 
• IgE elevation >500 iulme 
• IgG antibodies to Af or precipitins 
• Hypereosinophilia! >400/ml 
• Reduction by >50% in 19E after 2 weeks of daily systemic corticosteroid therapy 
Supportive (at least 3 required) 
• Airway obstruction/wheezing 
• Bronchiectasis on chest CT 
• Pulmonary infiltrates on chest radiograph 
• Af in sputum culture 
• Decrease in pulmonary function (>19% decrease in FEY!) 
! Hypereosinophilia not required when on systemic steroids 
21 iu = 2.4ng 
Af - Aspergillus fumigatus 
CT - computed tomography 
FEY! - forced expiratory volume in 1 second 
SPT - skin prick test 
RAST - radioallergosorbent test 
Treatment is with glucocorticoids. The role of anti-fungal drugs such as intraconazole is 
not yet established. 188 
Hyp.Qn~tn!~mj.c;.g~h'ig.~~tjQn!m.~~.~J?QJ.i9._~tK~!9.~_i_~ 
As discussed in the section on the presentation of CF (p76), excessive electrolyte loss in 
the sweat can lead to electrolyte depletion. 148 When this happens over time, it may 
manifest with anorexia, weakness and poor growth. Metabolic alkalosis with 
hypochloraemia, hypokalaemia and hyponatraemia is typical (pseudo-Bartter's 
syndrome). More acutely (for example, after exercising in hot conditions), CF patients 
may present with heat prostration. Hyponatraemia is found on electrolyte testing. It was 
this manifestation of CF during a heat wave in New York in 1948 that led to the 
development of the sweat test in the 1950s. 146 
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QJb.~x.~~mgj~.i.9.n$ 
The literature names a few other conditions that have been associated with CF: volvulus 
of the bowel beyond infancy,l89 coeliac diseasel8l . 
GROUP 3: Clinical features secondary to CF treatment 
Given the large number of therapeutic interventions associated with the treatment of CF, 
patients are put at risk of side effects and complications. Some misadventures may be 
associated with the drugs, others with hospitalisation, others with procedures. Some risks 
are known e.g. fibrosing colonopathy associated with high doses of certain forms of 
PERT;l7 increased risk of antibiotic allergy with time and exposure.l 90 Others are 
idiosyncratic. It may not always be easy to attribute a symptom to an intervention 
leading to underdiagnosis of its side effects. Conversely patients and their parents may 
attribute symptoms to certain therapies erroneously. Formal monitoring for some known 
side effects may be undertaken e.g. audiometry to check for amino glycoside toxicity. 
Making measurement of side effects and complications of therapy difficult can be the 
length of time between the initiation of the intervention and the development of harmful 
consequences. It is important that therapeutic teams are aware of the potential for their 
interventions to do harm. Audit of new and tried therapies can go some way to 
measuring any harm that may be occurring. 
Study 4.2 was undertaken to attempt to quantify the spectrum of clinical features of CF 
seen in the CF population cared for at the RCCH. 
Study 4.2 Clinical features and complications of cystic fibrosis in the 
Western Cape province 
Objectives 
1) To determine the range and rates of clinical features and complications of CF 
seen in the Western Cape province. 
2) To determine the age at which individual clinical features of CF appear in the 
Western Cape province 
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3) To determine whether 'ethnic group' influences the frequency or appearance 
of the clinical features and complications of CF in the Western Cape province 
4) To determine whether CFTR genotype influences the frequency or appearance 
of the clinical features and complications ofCF in the Western Cape province 
Methods 
Study population 
The 181 CF patients described in Chapter 2. 
Data collection 
The following data were extracted from the patients' hospital folders in a chart 
review: 
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1) Demographic features 
2) CFTR genotype: Homozygous for l1F508, heterozygous for l1F508, no 
l1F508, not tested. 
3) Clinical features: The presence of the clinical features and complications 
of CF and the child's age at their recognition were recorded. Following 
the structure used in the Introduction to this study, Table 4.6 lists and 
defines the features sought in the clinical record and classifies them 
according to organ system. Group 1 contains features and complications 
directly caused by CFTR dysfunction. Group 2 contains features and 
complications that occur secondary to primary CF-related organ 
dysfunction. In addition, complications of therapy (Group 3) were 
recorded where identified as such by a clinician. [Complications 
associated with surgery and anaesthesia are recorded in Chapter 5.] 
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Table 4.6 Clinical features and complications of cystic fibrosis 
Organ system Feature or Complication Definition 
GROUP 1 
GIT Pancreatic insufficiency I Ongoing abnormal stools or steatorrhoea when 




(Proven high faecal fat estimation not needed) 
GIT Meconium ileus (MI) Clinician report in notes 
GIT Complicated MI MI with peritonitis or intestinal atresia 
GIT Rectal prolapse Clinician report in notes 
GIT Distal intestinal obstruction Recurrent abdominal pain associated with 
syndrome radiological evidence of intestinal obstruction 
and/or faecal loading in the right colon or 
Intestinal obstruction with no other cause 
identified. 
GIT Intussusception Clinician report in notes 
GIT I1eitislCrohn's disease Clinical, radiological and histological features 
consistent with the diagnosis. 
GIT Liver disease Persistently abnormal liver (size, shape or 
consistency) on palpation and/or 
Two or more raised transaminase levels separated 
by an interval of more than 3 months and/or 
Abnormal ultrasound liver features 
GIT Complication of portal Clinician report in notes 
hypertension 
GIT Infantile cholestasis Cholestatic jaundice in an infant, no other cause 
found 
GIT Liver failure Clinician report in notes 
Respiratory Massive haemoptysis Coughing up of>240ml of blood per 24 hours or 
the recurrent bleeding of substantial volumes of 
blood (> 100m!) regularly 
Respiratory Pneumothorax Clinician report in notes 
Respiratory Empyema Clinician report in notes 
Respiratory Cor pulmonale Clinical features of heart failure in the presence of 
severe lung disease 
Respiratory Nasal polyposis Nasal polyps seen on inspection on more than one 
occasion 
Respiratory Rhinosinusitis Persistent nasal obstruction not responsive to anti-
allergic therapies and/or 
Clinician report in notes 
Other Diabetes mellitus Symptomatic glycosuria and hyperglycaemia 
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Table 4.6 continued 
GROUP 2 
GIT Anaemia/oedema complex Oedema due to hypoproteinaemia with or without 
anaemia, failure to thrive and a nutritional skin 
rash 
I 
GIT Gastro-oesophageal reflux disease Symptoms consistent with GORD and positive 
(GORD) investigation for gastro-oesophageal reflux. 
i Other Bone and joint disease Arthritis in a child with significant chest disease 
Back pain or fractures in a child with osteoporosis 
Other Reactive depression Clinician report in notes 
Respiratory Allergic bronchopulmonary Immunological evidence of infection with 
aspergillosis Aspergillus species associated with persistent 
respiratory symptoms not responsive to antibiotic 
therapy 
i GIT Peptic ulcer disease opic report in notes 
Other Hyponatraemic dehydration! Blood results consistent with this complication 
• metabolic alkalosis 
Results 
Table 4.7 shows the incidence of the features of CF from Group 1 in this population. 
Ninety five percent (95% CI 90,8-97,7%) had PI. MI affected 15% (95%CI 9,7-20,1%) 
of cases (white 16,8% [17/101], coloured 13,3% [10175]). 
intussusception had three episodes of bowel obstruction. 
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The patient with 
Table 4.7 Direct clinical features of cystic fibrosis in 181 patients 
Median age at onset 
Group Clinical feature or Complication Number (%) (months) Range 
GIT Pancreatic insufficiency 172 (95) Not recorded 
DIOS 41 (22,7) 98 5 - 169 
Meconium ileus 22 (12,2) Birth 
Complicated meconium ileus 5 (2,8) Birth 
Rectal prolapse 15 (8,3) 18 5 to 43 
Crohn's disease 1 (0,6) 
Intussusception 1 (0,6) 
Liver disease 17(19,4) 108" 7 -152* 
Complications of portal hypertension 5 (2,8) 110* 74 -189" 
Infantile cholestasis 1 (0,6) 
Respiratory Lung disease 180 (99,4) Not recorded 
Pneumothorax 3 (1,8) 164 116 - 207 
Massive haemoptysis 1 (0,6) 194 
Cor pulmonale 11 (6,1) 118 75 - 248 
Empyema 1 (0,6) 67 
Nasal polyposis 19 (10,5) 97 4 - 200 
Rhinosinusitis 6 (3,3) 60 19 - 95 
Other Diabetes mellitus 8 (4,4) 192 109 - 242 
GIT - Gastrointestinal tract 
mos Distal intestinal obstruction syndrome 
'" Age at onset unclear in 2 patients (one <5 years [liver disease only], one <9 years [liver disease and portal 
hypertensi on]) 
Only 9 patients (6 coloured, 3 white) remained pancreatic sufficient. None of those with 
PS was 6F508 homozygous; 3 had a single copy of the mutation. Median age at 
diagnosis had been 71 months (range 0 - 169 months) compared to 6 months for the 
whole population. All except three had mainly lower respiratory tract symptoms when 
diagnosed. One of the three only had nasal polyposis and was diagnosed at II years of 
age, one had MI, and the other was the asymptomatic sibling of a girl with CF who had 
PI. 
The 17 patients with CF-related liver disease and their modes of diagnosis are shown in 
Table 4.8. There was no difference in incidence between gender, ethnic or genotype 
groups. All patients with CF-related liver disease also had PI. Five of the 17 patients had 
had MI. Two other patients had severe liver disease whose connection with CF was not 
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clear. One of these, a boy, presented with hepatomegaly at four years of age. Liver 
biopsy showed typical features of chronic active hepatitis. He did not have 
immunological features of the disease. Chest disease became significant late in this life 
and CF was diagnosed when he was 14 years old. Review of liver histology confirmed 
the chronic active hepatitis; no features suggestive of CF were seen. He did not have fat 
malabsorption on 3-day stool fat estimation. He developed portal hypertension with 
bleeding oesophageal varices and died in liver failure at the age of 17 years. The second 
child, diagnosed with CF owing to meconium peritonitis and malnutrition, had not had 
evidence of liver disease until the sudden development of a Reye-like syndrome with 
hepatomegaly in his second year of life. He died during this episode. A post mortem 
showed cerebral oedema. 
The complications of portal hypertension in Table 4.8 were bleeding oesophageal varices 
(3), bleeding diathesis (1) and severe abdominal pain from splenic infarction (1). 
Table 4.8 Cases with liver disease and its complications 
Ethnic Symptomatic PHT Number'" Age (years) Gender group Mode of diagnosis (Age at onset in years) 
170 <1 M W Hepatosplenomegaly No 
136 <1 M W Hepatosplenomegaly Yes (7) 
27 3 M C Firm hepatomegaly Yes (14) 
3 M C Firm hepatomegaly No 
73 4 M W Hepatosplenomegaly No 
34 <5 M C Hepatosplenomegaly No 
133 7 F C Hepatomegaly I raised liver enzymes No 
105 8 F W Raised enzymes I coarse echogenicity No 
5 <9 F W Hepatosplenomegaly Yes «9) 
84 9 M W Firm hepatomegaly I inhomogeneous liver Yes (13) 
83 9 F W Hepatosplenomegaly No 
4 9 M W Hepatosplenomegaly No 
15 10 F W Firm hepatomegaly No 
49 11 M W Hepatosplenomegaly Yes (15) 
72 12 M W Firm hepatomegaly No 
95 12 M C Firm hepatomegaly No 
55 14 M W Firm he atome al No 
* see Appendix A 
PHT - Portal hypertension 
M = Male, F = Female 
C = coloured, W = white 
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The infant with cholestasis had had complicated MI with atresia following an intrauterine 
volvulus. He did well peri-operatively and had no jaundice. Icterus developed at the age 
of 6 months in association with severe crying. Examination showed hepatosplenomegaly 
and mild jaundice. Both alanine transferase and alkaline phosphatase levels were over 
three times the upper limit of normal. Ultrasound of the liver showed increased 
echogenicity of the liver with dilated extra- and intra-hepatic main bile ducts that were 
filled with echogenic material. Treatment with UDCA to promote choleresis was 
commenced. The jaundice cleared within a week. Liver function and ultrasound features 
had returned to normal a month later but the hepatosplenomegaly persisted. 
Of the conditions in Group 2, 10 had the oedema/anaemia complex, 9 had ABPA, 8 had 
hyponatraemic dehydration/metabolic alkalosis, 5 had reactive depression, one had 
arthritis and one had recurrent back pain as a result of osteoporosis. Peptic ulcer disease 
manifested as a gastric ulcer in one child (who eventually required surgery to cure it - see 
Chapter 5 p209) and duodenitis in another two. The former presented with recurrent 
abdominal pain and the latter with GIT bleeding. Three other significant abdominal 
emergencies that probably relate to the effects of CF on the GIT were an episode of 
appendicitis with perforation in one child, a volvulus in a teenager and a lethal acute 
colitis in an infant. This latter case may have been a pseudomembranous colitis (the child 
died in another hospital). 
Three complications were induced by therapy. One child had pseudomembranous colitis 
following antibiotic therapy and one suffered a perforation of the nasal septum associated 
with continuous oxygen therapy. One teenager developed an erythematous rash with his 
first dose of meropenem. 
Apart from CF lung disease and PI of which all except one child had one or both, 64,6% 
(1171181) had at least one additional feature or complication of CF. Sixty one had one 
additional feature, 33 had two, 12 had 3 and 5 had 4. Four patients had 5 or more 
additional features or complications of CF. 
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Discussion 
This study has demonstrated the wide range of clinical features of CF and their variability 
as found in a South African population. CF lung disease and PI affected nearly all the 
children (only one, the child with nasal polyposis, had neither) but nearly two in every 
three of them (64,6%) had additional features of CF during their association with the 
RCCH. Some features, like MI, occurred early in life while others occurred later, for 
example CFRD which was only seen under the age of 10 years in one patient. 
The 95% (95% CI 90,8-97,7%) prevalence of PI is higher than that reported in CF 
populations from Western countries. Using the definition of a patient being on PERT, the 
National Cystic Fibrosis Registry in the USA as analysed by Fitzsimmons showed that 
92,5% of CF patients had pI. 140 As she pointed out, this is an overestimation of the 
prevalence of PI as the Registry under-represents those with mild disease who are more 
likely to have PS. Other cross sectional studies of large numbers of CF patients suggest 
that 10-15% have PS.191 Studies in screened populations have shown that PS at birth is 
more common than this. Waters and colleagues in New South Wales, Australia found 
that 37% (29178) of patients had 'substantial preservation of pancreatic function' at 
birth. 157 A further 6 of the 29 children developed PI by 3 years of age. In Colorado, 
USA, the incidence of PI in 49 screened infants was 79% and 92% at 6 and 12 months 
respectively.159 Couper and colleagues described 20 patients who had PS at diagnosis 
(mean age 3,5 years) and developed PI after an average of 5,6 years, demonstrating that 
PI can develop later in childhood. 16o They also showed that the longer a patient with CF 
remains pancreatic sufficient, the less likely it is that he or she will develop PI. Few 
patients develop PI in adulthood. 
There is a number of potential reasons for the higher than expected incidence of PI in our 
non-screened population. Firstly the diagnosis of PI was made based on symptoms and 
growth with tests for malabsorption not being routine. As shown in Study 4.1, 24% of 
patients presented with respiratory symptoms alone. However almost all of these were on 
PERT at the time of this study. It is likely that poor weight gain and/or the recognition of 
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GIT symptoms by the family once the diagnosis had been made and CF discussed with 
them led to the assumption of PI and the introduction of PERT. A second reason is the 
relatively young age of the population. Some patients with PS would not yet have been 
diagnosed (particularly in SA where CF awareness among practitioners and the public is 
low - especially of the pancreatic sufficient forms) while those who have PI are likely to 
be diagnosed at ages covered in this study. Of those said not to have PI, only two had 
formal tests for fat malabsorption of pancreatic function. One had had MI and had been 
started on PERT. Later, when very overweight in her teenage years, she stopped her 
PERT with no change in her bowel habit! Given that PERT is not without potential 
severe side effects and is expensive, consideration should be given to testing all children 
with CF who have respiratory symptoms alone for pancreatic disease. The faecal human 
pancreatic elastase 1 test has been shown to be very useful in this regard 192 and is now 
available in SA. 
DIOS was the second most common gastrointestinal manifestation of CF in this 
population. As discussed in the Introduction (p98) and defined in the Methods, a 
conscious decision was made to widen the clinical definition of DIOS to include all 
patients with symptomatic faecal loading but excluding simple constipation i.e. the 
passage of hard stools infrequently. This in part reflects the practical difficulty in a 
retrospective survey: one is dependent on what is recorded in the notes. X-rays were not 
reviewed, merely the report and/or the clinician's paraphrase of it were available. It also 
reflects a suspicion on my part that there is a large overlap in the pathophysiologies of the 
ill-defined entity of DIOS and faecal loading in the CF context. The DIOS of the CF 
literature is thought to be precipitated by the products of maldigestion, abnormal mucus, 
delayed intestinal transit time and unknown changes in intestinal function in the context 
of pI. 181 Delayed transit time and abnormal effluent from the small bowel are also 
implicated in 'functional' faecal loading. Build up of faeces in 'functional' faecal 
loading, while mainly distal, also occurs significantly in the caecum and ascending colon. 
The radiological scoring system for faecal loading devised by Verrier-Jones and 
colleagues includes this feature. 193 Littlewood attributes faecal retention of this sort in 
CF to poor management of PERT, supporting an origin analogous with DIOS.181 
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Since the presentation (abdominal pain, retained faeces) and management (purging, 
attention to diet, laxatives) are similar, all patients with symptomatic retention of faeces 
were considered to have DIOS in this study. The advantage of this approach is that it 
gives a picture of the extent to which non-surgical lower abdominal symptoms affect our 
CF population. It does not however distinguish between acute and less severe episodes of 
DIOS. However this drawback is partly overcome by an unpublished review of 
admissions for CF in this population in which DIOS is one of the causes for urgent 
admission (most cases of the acute form) or elective (the 'chronic' form). 
Just under one in four of the children and adolescents suffered at least one episode of 
DIOS. It is difficult to compare this with reports in the literature for definitional reasons. 
However Rosenstein and Langbaum using a retrospective design and entry criteria based 
on symptoms (including 'severe' abdominal pain) found that 26/63 (41,3%) had DIOS 
(one had recurrent intussusception).169 No other studies have come near this incidence. 
The authors felt that this is because of their method of recording gastrointestinal 
symptoms. The 95% CI for the 40,3% (41,3% minus the case of intussusception) are 28 
- 53,5%, still well above other studies. The upper CI for our prevalence was 28,8%, just 
overlapping with theirs. 
Using a more rigid definition than ours that required 'postneonatal partial or total 
bowel obstruction unresponsive to standard laxatives', Rubinstein and colleagues 
found an incidence of DIOS of 9% of 168 patients with more adults than children 
affected. 170 
Littlewood claimed that DIOS is rare where PERT is carefully monitored (e.g. in the 
Leeds CF Clinic).181 Rosenstein and Langbaum, however, noted that adjustments made 
to PERT when their clinic was changing from non-enteric coated to the newer forms of 
PERT did not influence the symptoms of their patients. 169 They suggested that the direct 
gastrointestinal effects of CF may dominate in the pathogenesis of severe DIOS. It 
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should be noted that fat restriction was still part of the dietary regime of their patients at 
that time. 
Rubinstein and colleagues also studied 'constipation' (Le. reduction in stool frequency) in 
CF. 170 An incidence of 32% was found. This, if taken with the 9% for DIOS in the same 
population, may equate with our findings of 22,7% given that our definition encompasses 
all his DIOS cases and some of the 'constipation' cases. 
Fitzsimmons' North American Registry study showed an incidence of about 2,3% of 
'intestinal obstruction' as a complication of CF in 1990.140 If infants (they presumably 
had MI) and those older than 20 years are excluded, the figure that would be comparable 
with our population would be 2% per annum. Given that our data is not annualised, it 
cannot be directly compared but, with about 60 patients being cared for every year at the 
RCCH, many more than the one patient per year predicted by the USA figure suffers an 
episode of DIOS. 
DIOS and its potential to confuse the diagnosis of other causes of abdominal pain in CF 
will be discussed in the chapter on Surgery in CF (Chapter 5). Of the directly CF-related 
causes of abdominal pain, there were three cases: one of Crohn's disease, one 
intussusception and one volvulus. The child with Crohn's disease is discussed in detail in 
Chapter 5 (p 150). The volvulus occurred in a teenage survivor of MI but at laparotomy 
there was no evidence of an adhesive lead point. She had been managed for DIOS 
including N-acetyl cysteine before it became clear that a surgical cause for intestinal 
obstruction was present. 
MI, the third most common gastrointestinal manifestation of CF, occurred with a 
frequency equivalent to reports in the literature. Although there were fewer cases in the 
second half of the period (11 cases) versus the first half (16), this is probably the product 
of chance. No cases of MI in black African cases have yet been seen in recent years in 
SA, leaving only the historical cases 1 18 to show that this manifestation of CF occurs in 
this group. In the Western Cape province a neonate with intestinal obstruction would 
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almost always get through the health system to a paediatric surgeon. This suggests that, 
if CF among black Africans is as common as the work from the University of the 
Witwatersrand research suggests50 and if MI even in a black African neonate makes a 
surgeon think of CF, MI must account for fewer than the 10-20% of cases seen in the 
other SA groups. There are plans in process systematically to investigate this question 
nationally CA. Goldman - personal communication). The management of MI in our 
experience, largely surgical, is discussed in Chapter 5. 
Of the 15 children who manifested rectal prolapse, only 4 developed this complication 
after the diagnosis ofCF. In all it was associated with ongoing nutritional problems and 
inadequate PERT in the months following diagnosis. Consistent with the literature, it 
never appeared once PERT was optimised. 
Intussusception and Crohn's disease, with one case each, occurred much as might have 
been expected in a population of this size. The girl with Crohn's disease had no relapses 
which would be unusual, even on treatment, for inflammatory bowel disease unassociated 
with CF. Her case is discussed in detail in Chapter 5 (p150). This child was also the only 
child to develop a large joint arthritis, another manifestation of heightened auto-
immunity. 
Liver disease is often silent in CF. The extent of liver disease in our population is thus 
underestimated by the figures given here. The presence of liver disease in this study 
required findings on clinical examination and/or on investigation. In practice, ultrasound 
examination of the liver usually followed the finding of a firm hepatomegaly. For the 
early years of the study the modality was not available and it was never a routine 
investigation during the study period. The measurement of liver enzyme levels has only 
recently become part of an annual review of our patients as the evidence that UDCA may 
be able to alter the course of CF -related liver disease has mounted. (The youngest, 
healthiest patients do not have routine blood tests as part of the annual review, but they 
are the least likely to have significant liver disease.) Abnormally high liver enzyme 
levels would lead to a second test being done about three months later. Prior to this 
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practice being instituted, CF-related liver disease was never diagnosed solely on the basis 
of biochemical tests. In essence thus, liver disease in CF in Cape Town has been 
diagnosed on clinical findings and that is what the figures reported here reflect. Only 
Case 120 (Appendix A) was diagnosed on the basis of investigations alone. 
As outlined in the introduction to this study, defining CF-related liver disease is 
problematic. In a prospective study in children, Ling and colleagues showed that 92% of 
124 chi Idren had an abnormality on clinical examination, biochemistry or ultrasound 
during 4 years of follow Up.194 Furthermore features on any of these modalities of 
identification of liver disease in CF might not be present at subsequent evaluations. 
However this study did establish that biochemical abnormalities tend to precede 
ultrasonographic and clinical evidence of liver disease, but this is not invariable. Thus 
the prevalence of liver disease is highly dependent on the methodology used to identify it. 
A prospective cross-sectional study by Carla Colombo and colleagues used clinical, 
biochemical and echographic assessments.195 Clinical assessment required a firm 
hepatomegaly; biochemical assessment required at least two specimens to have raised 
serum liver enzymes levels; ultrasound features included hyperechogenic parenchyma, 
heterogeneity and nodules or features of portal hypertension. These accord well with our 
study in that identified patients required clinical evidence of liver disease but, unlike ours, 
data were collected prospectively i.e. investigations were performed systematically on all 
patients. This difference proves crucial: 34/189 (18%) patients had liver disease. All 189 
patients were, by study design, 3 years of age and over (median age 14,4 years). Using 
similar criteria but a retrospective methodology, our study showed a 10,9% prevalence 
(16/147) patients who have survived to 3 years of age. 
The North American CF registry study was unable to give prevalence figures for liver 
disease beyond raised liver enzyme levels (2,4%) and cirrhosis (1 %).140 How 
systematically these abnormalities were looked for is not specified in Fitzsimmons' 
report. The figures quoted for 1999 from this Registry were 6,4% for elevated serum 
liver enzymes levels and 2,3% for cirrhosis.1 76 
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The largest study specifically to examine liver disease in CF comes from the Midlands of 
England. The records of 1 100 patients were reviewed. 196 The patients' status as regards 
CF-related liver disease was taken as it stood in 1988. Diagnostic criteria were looser 
than ours or Colombo's were in that a single abnormal serum liver enzyme levels result 
was taken as evidence of liver disease (12,5% prevalence). Using clinical criteria only, 
4,2% of patients had liver disease. This figure is much lower even than ours, despite 
having a retrospective design and an emphasis on clinical criteria in common. 
An alternative method of defining CF-related liver disease was used in an assessment 
from Israel. Here two consecutive (at least 6 months apart) one and halftimes elevation 
in serum liver enzyme levels was all that defined non-cirrhotic liver disease. 197 Histology 
and ultrasonographic findings defined cirrhosis. A prevalence of 28% was found. What 
this high figure means in terms of clinical disease is uncertain as no clinical correlates 
were measured. It may be that our figures will rise towards this level as we have begun 
to follow a trend in taking persistently elevated serum liver enzyme levels as an 
indication to do ultrasound investigation of the liver and consider commencing UDCA 
therapy. 
In a review of CF-related liver disease, Tanner maintained that, in the light of these 
studies, clinical criteria should be the way to diagnose this complication until an 
investigation such as scintigraphy is shown to be more sensitive, specific and stable. 19s 
The recommendations from the CFF Hepatobiliary Disease Consensus Group were 
broader but still based mainly on clinical criteria: CF-related liver disease can be 
diagnosed when 'persistent hepatomegaly (increased span of liver) or 
splenomegaly, a firm or hard consistency of the liver on palpation, persistently 
abnormal liver blood test results, complications of portal hypertension. or 
abnormal liver histology' are present. 176 Our results are based on a methodology 
compatible with these recommendations. 
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The Consensus group recommended that CF-related liver disease be screened for. 176 
Abdominal palpation at every visit and annual liver function tests form the basis of this 
screening. The former of these methods has always been routine in CF care in Cape 
Town. Now, with the introduction of regular serum liver enzyme estimations followed, 
in cases with persistently elevated levels, by ultrasound investigation, the prevalence 
figures for this population will rise and the age at diagnosis fall. The hope is that 
progression to cirrhosis and its complications will be halted in at least some of the CF-
related liver disease so identified with UDCA therapy. 199 
It is important to note that the retrospective and observational nature of our study 
precludes accurate assessment of the onset of a disease process like CF-related liver 
disease. Despite this drawback, in finding more cases of liver disease in older children 
than those under 5 years of age, our study is consistent with the literature. Also 
consistent with the literature is the universal presence of PI with CF-related liver disease. 
The apparent association of liver disease with MI and DIOS in the literature is not fully 
accepted and requires verification in larger, prospective studies. Our numbers are too 
small to contribute to this debate. For the same reason, CFTR genotype and gender, other 
factors that have been explored to explain why some children with CF develop CF-related 
liver disease and others do not, could not be explored in our small population. The role 
of mannose binding lectin genotypes, part of the innate immune system, in predisposing 
to liver disease in CF has recently raised its intriguing head.2oo Such non-CFTR genetic 
predispositions may lead to differences in populations with different genetic backgrounds 
but no such difference in incidence in CF-related liver disease was found in this 
genetically diverse Cape Town population. 
Cirrhosis with symptomatic portal hypertension affected five patients. Their ages are 
consistent with the literature which shows that, in the main, older CF patients suffer the 
consequences of portal hypertension. 199 The number with portal hypertension was higher 
if asymptomatic patients are taken into account. The high prevalence of enlarged spleens 
at presentation gives some idea of its frequency amongst our patients. Oesophageal 
varices were not sought in asymptomatic patients with portal hypertension; the figures 
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therefore represent only those who suffered gastrointestinal bleeding and had the varices 
seen at endoscopy. General guidelines on health care related to portal hypertension such 
as the possibility of oesophageal bleeding and the need to avoid non-steroidal anti-
inflammatory drugs are given in every case. Those with complications all required 
specialised surgical interventions which are described and discussed in detail in the 
following chapter. 
The single child with cholestatic liver disease does not fit the typical picture of the 
neonatal hepatitis-like presentation of CF. Rather he seems to have had an episode of 
biliary colic associated with thick bile in the evolution of typical CF liver disease. This 
being the case, no cases of cholestatic liver disease were seen in CF. This is not 
surprising given that fewer than 2% of CF patients have this form of liver disease. 131 One 
child was referred from Pretoria with this complication during my tenure at the RCCH. 
This infant had had MI, a common association; those referring wondered if the child 
warranted a liver transplant since a portoenterostomy had failed to relieve biliary 
obstruction. After nutritional rehabilitation, the infant did well and returned to Pretoria. 
Three other children developed jaundice during follow up: two had hepatitis A; one 
developed jaundice in the late phase of liver disease, perhaps aggravated by a reaction to 
fusidic acid therapy. In our experience therefore, jaundice in a child with CF is more 
likely to be due to Hepatitis A than to the CF! 
Nasal obstruction can be a prominent feature of CF either through continuous or recurrent 
rhinosinusitis or through nasal polyposis. Either can reduce quality of life and are 
therefore significant complications of CF. The definition for rhinosinusitis used in this 
study is somewhat arbitrary. Allergic nasal symptoms overlap with CF ones and a lack of 
response to unit-allergy remedies does not exclude an allergic aetiology. CF-related 
symptoms may improve on anti-inflammatory therapy. Notable though was the young 
age of the children affected. Persistent nasal symptoms do not seem to have been a 
problem in older children in the absence of polyposis or allergic rhinitis. It is possible 
that too much was blamed on allergy in older children whereas it was thought to be less 
likely in the young children. Nasal polyposis was actively sought through regular 
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rhinoscopy (at least in recent years), the figure therefore representing symptomatic and 
non-symptomatic polyps. 
CFRD is only the most symptomatic of a spectrum of disorders of glucose metabolism. 
There is good evidence that abnormal metabolism of glucose affects health in CF before 
overt CFRD develops.l64 Four levels of glucose intolerance in CF are recognised, based 
on the OOTT. With normal glucose metabolism, the 2-hour blood glucose level does not 
rise beyond normal; with impaired glucose intolerance (lOT) there is no FH. CFRD 
without FH is the stage before CFRD with FH, which would be recognised as the most 
severe form of CFRD and would normally be treated. That lOT and CFRD without FH 
are detrimental to health in CF has been shown most convincingly by Antoinette Moran 
and colleagues in Minnesota, USA. FEV I and FVC deteriorated faster over a 4-year 
prospective follow up period in patients with abnormal glucose tolerance than in those in 
whom it was normal. 164 Moreover, the rate of decline correlated with the degree of 
impairment of glucose metabolism. Other studies have shown that nutritional status also 
declines in the pre-diabetic state; this can be reversed with insulin therapy.201 
This knowledge has led to more active case finding using OOTT in order to prevent this 
decline in health. In many centres OOTTs are done annually from early adolescence. 
Some centres are now investigating the merit of introducing insulin therapy when there is 
any impaired glucose i.e. before over CFRD develops. (Case reports have presented the 
intriguing possibility that insulin's anabolic effects can help those whose health status is 
declining even when the OOTT is normal.202) 
CFRD in patients in our study was diagnosed through typical symptoms of diabetes 
mellitus. No formal OOTT screening has taken place. Thus the figures presented 
represent those with overt CFRD. As CFRD is a complication in older persons with CF, 
it is not surprising that the numbers with CFRD in this study were small. Mortality has 
been high in the first two decades of life and, in recent years, most young persons over 
the age of 18 years have moved to OSH. The development of CFRD after transfer to 
OSH was not studied. 
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Small numbers precluded meaningful genetic analysis. Apart from an association with 
more severe genotype classes,203 no CFTR mutations have been consistently associated 
with this complication. 
Consistent with the literature, all patients with CFRD had PI. The prevalence in this 
population is consistent in that seen in Toronto, Canada in children between 1 and 18 
years of age204 (Toronto 2,7%, Cape Town 4,5%). In Minnesota, USA 16 out of 200 
(8%) children between the ages of 5 and 19 years had CFRD.20S The equivalent 
proportion in Cape Town was 6,2% (9/145). 
Half of the 8 patients with CFRD developed the complication in their 17th year, the 
median age of onset for the group. This age cannot be compared with the Toronto or 
Minnesota experiences which are reported cross-sectionally with a cut off at 18 and 19 
years of age respectively. No patients presented in coma and all had their 
hyperglycaemia easily controlled with insulin and nutritional advice specific to CFRD. 
Three patients were in the final phase of CF lung disease when CFRD developed. In 
summary, it appears that CFRD in Cape Town was no different from that seen elsewhere. 
The current screening approach at the RCCH is testing for glycosuria at each visit for 
teenagers and random blood glucose measurement in the annual review. Random blood 
sugar levels are the entry point for testing for CFRD in the CFF Consensus Committee 
Guidelines.206 Blood sugar testing during pulmonary exacerbations when abnormal 
glucose tolerance may be unmasked was also recommended by the Committee. This is 
not practised in Cape Town. OGTT can identify children at risk of CFRD. Whether 
earlier diagnosis should be sought through the introduction of OGTT screening in older 
children in Cape Town depends on logistical considerations. The evidence is that, for the 
individual CF patient, the search is worth the effort and discomfort as the early 
introduction of insulin therapy reverses the decline in health status associated with insulin 
hyposecretion. In the light of our experience, a targeted approach would seem 
appropriate: annual OGTTs for those with PI who reach 16 years of age. Younger 
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patients (but over 10 years of age) with unexplained declines in nutritional or lung 
function measures may merit an OGTI. 
As described in the introduction to this study, pneumothorax as a complication of CF is 
associated with advanced lung disease. That being the case one might have expected 
more than three cases in a population one third of whom have died in the period under 
review. Although its pathogenesis is not entirely clear - is it due to destruction alone (the 
high incidence of cysts in the lungs of CF patients supports this) or is it high intrathoracic 
pressures related to lower airways obstruction as suggested by Flume? 156 - pneumothorax 
has not been described before 4 years of age. Given that many very young children had 
advanced lung disease early in life in past decades, the association of pneumothorax with 
patients who have survived these initial years suggests that the inflammation and fibrosis 
after many years of CF lung disease sets the stage for the development of pneumothorax. 
However Flume has shown that the median age at pneumothorax has not paralleled the 
increased longevity of CF patients. 156 In two of our patients pneumothorax occurred 
when they were already considered to be in a terminal state (ages almost 10 and almost 
16 years). The other heralded a rapid decline in the lung function of a 17 year old boy. 
At the time of his first pneumothorax his FEV 1 was 65% of expected. He died in 
respiratory failure in his 22nd year. This pattern is consistent with the literature which 
associates the arrival of pneumothorax with a grim prognosis. Analysing all reports to 
2002, Flume calculated an overall incidence of 6,4% for pneumothorax in CF. 156 The 
low incidence of pneumothorax in this population is probably related to limited numbers 
who have survived or been followed to late adolescence, after which half of all 
pneumothoraces occur. 
Massive haemoptysis has only been seen in one teenager who was 16 years old at its 
onset. His course is described in the Surgery in CF chapter as he required repeated 
bronchial artery embolisation. 
The single case of empyema is unusual. It occurred at an age well beyond infancy, when 
CF-associated empyema used to occur. It was sterile, perhaps related to prior antibiotic 
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therapy. This right-sided empyema and the underlying lung disease led to surgery that is 
described in the next chapter on Surgery in CF. 
In all, 42 patients have died beyond the age of 5 years yet only 11 have had signs of cor 
pulmonale. Six of the deaths occurred after the patients had been referred to aSH. 
Details of their terminal disease was not available for study. Right heart failure is 
notoriously difficult to diagnose in CF. The marked hyperinflation of the lungs and 
distortion of intrathoracic anatomy owing to fibrosis and atelectasis make ECa and 
echocardiography very difficult to interpret. Invasive cardiac procedures are rarely 
indicated in CF therefore clinical signs are needed to make a confident diagnosis of right 
heart failure. In our experience management of cor pulmonale in CF has been relatively 
simple with the use of domiciliary oxygen therapy and diuretics. Right heart failure can 
be postponed by the prevention of nocturnal hypoxaemia with oxygen therapy during 
sleep. In recent years, staff at the CF clinic have become alert to the need to consider 
oxygen therapy before heart disease is suspected clinically. Pulse oximetry has become 
routine in patients with severe lung disease. 
The oedema/anaemia complex has been discussed in the section on the presentation of 
CF. No cases appeared after the diagnosis of CF was made, illustrating that nutritional 
therapy and PERT resolve this manifestation of CF. One other child from very adverse 
social circumstances developed nutritional oedema at the age of 4 years. The negative 
protein balance of poorly managed CF will have played a part in this presentation but it is 
not strictly an example of the oedema/anaemia complex. The oedema resolved rapidly 
when he was placed in institutional care for a few months. 
ABPA in CF has been defined using immunological criteria.\87 In CF the presence of A 
fumigatus in sputum is common in the absence of symptoms referable to the 
microorganism. Likewise radiological and clinical criteria that characterise ABPA in 
asthma overlap with CF lung disease in the absence of Afumigatus. In practice in Cape 
Town the CF-associated ABPA criteria are too strict to be of clinical use leading to the 
use of a combination of immunological criteria (including specific antibodies to A 
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filll1igafUS) and clinical criteria. The clinical setting has usually been of a child with 
persistent of progressive respiratory disease with prominent wheezing which, over a few 
weeks, does not respond to aggressive therapy including intravenous antibiotics, 
bronchodilators and physiotherapy. If, in this setting, immunological evidence of 
hypersensitivity to A fumigatus is found, a course of high dose corticosteroid therapy is 
commenced. Response is judged clinically, on pulmonary function testing and by a 
reduction in antibody levels. Thus the 9 cases reported here over 29 years represent those 
cases in which these steps took place. All cases except one were diagnosed in the second 
half of the period under study, suggesting increased awareness of the complication. It 
remains unusual, however. 
Two cases merit particular mention. One girl developed ABPA under the age of 5 years. 
Severe lower airways obstruction was a persistent feature. While she responded well 
immunologically to corticosteroid therapy, reductions in dosage led to recrudescences in 
antibody levels and symptoms. She died in her 6th year, ABPA and possibly steroid side 
effects, being significant in her deterioration. The second case did not fit our criteria for 
ABPA yet A fumigatus seemed to playa significant part in his declining lung function. 
Marked progressive lower airways obstruction developed in the presence of A fumigatus. 
No other organism was consistently grown from his sputum though he was colonised by 
P aeruginosa. He had normal antibody levels to Afumigatus. Total IgE levels were also 
normal. Corticosteroid therapy produced a limited response. Treatment with the 
antifungal drug, itraconazole, produced some amelioration that was not sustained when 
the drug was withdrawn. Concerns about toxicity of the drug limited its use. He died in 
his 9th year with marked peripheral airways obstruction but limited radiological evidence 
of destructive lung disease. 
Summer in the Western Cape province is hot and dry. Persons at risk of heat prostration 
such as those with CF need to take extra salt to prevent this complication. Such advice is 
a routine part of the care of children with CF in Cape Town. Of the 8 patients with 
hyponatraemic dehydration in this CF population, only 2 developed the complication 
after the diagnosis of CF had been made. The other 6 are those identified in Study 4.1. 
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One of the two patients had recurrent bouts of salt depletion in her early years; the other, 
who lived in Wellington, one of the hottest parts of the Western Cape province, had one 
episode at the age of 4 years which required admission but was able to prevent any 
recurrences. 
A 11 long term health conditions may produce severe psychological morbidity and CF is 
no exception. Care must include anticipatory guidance and an awareness of this 
predisposition. Depression is a severe condition in which lack of interest in life, low 
mood, disrupted sleeping patterns and negative and possibly suicidal ideation occur. In 
the context of CF, this can have severe repercussions on the child's health status. Eating 
is often poor and attention to self care declines. While there are specific psychiatric 
criteria for the diagnosis of depression, the criteria used here could not make use of them 
because of the retrospective study design. Involvement of mental health specialists was 
used as a proxy for the diagnosis, meaning that at least the most severe cases were 
counted. All were adolescents. This is not surprising given that psychological morbidity 
is more likely in this age group generally. Specifically in CF this is the period when the 
prognostic and social implications of the disease begin to be fully recognised by the 
young person. However this does not mean that depression did not occur in younger 
children. It may not have been recognised or may have been managed within the 
confines of the family and/or the school. The 5 cases out of 181 reported here should be 
seen as the minimum incidence of this complication. Given the severe implications for 
the child's health, psychiatric morbidity in our CF population needs more active 
investigation. A social worker is a key team member in this endeavour. 
It is important to note that, although only three non-surgical, non-anaesthetic-associated 
complications of therapy were recorded in this study, other may have been missed. 
Repeated courses of aminoglycoside antibiotics are a risk factor for auditory nerve 
damage. Only one child had formal testing for this. No cases of fibrosing colonopathy as 
described as a consequence of PERT have occurred. Of the high-lipase forms of PERT, 
only Creon High Lipase has been used in this service. Since the first cases of fibrosing 
colonopathy were reported in 1994, every attempt has been made to keep lipase doses 
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below 10 000 IU/kg. Most children with CF spent many days in hospital and thus were at 
risk for nosocomial infections. It is likely that these (and relatively minor complications 
such as drip-site sepsis) may have been overlooked or not recorded in the notes. 
Antibiotic sensitivity was apparently only seen once. Other significant episodes are 
unlikely to have been missed. In adult CF care, it represents a significant factor in the 
complexity of the management of pulmonary exacerbations. 
One male adolescent suffered severe back pain related to kyphosis and microfractures 
secondary to osteoporosis. He required frequent admissions and the pain made chest 
physiotherapy difficult. Intensive vitamin and calcium therapy was given but is unlikely 
to have made a significant difference to his bone mineral density (BMD). Formal study 
of BMD in our population has been contemplated but not undertaken. One child had 
BMD measured in private practice and it was low but there were concerns regarding the 
calibration of equipment usually used for adults. Treatment of osteoporosis with 
hormonal therapies is difficult and so far untested in children with CF, so prevention 
remains the key to reducing morbidity in older patients with CF. We demonstrated a low 
average calcium intake in our popUlation enabling us to intervene in one factor that 
contributes to osteoporosis in CF. 184 While 25-0H-cholcalciferol and alkaline 
phosphatase levels were normal in our population, recent evidence suggests that this does 
not adequately exclude vitamin D .deficiency in CF?07 It is known that winter at the 
latitude of Cape Town leads to potentially inadequate ultraviolet radiation208 so it is 
possible that our patients are mildly deficient in Vitamin D during this season. Further 
data on vitamin D metabolism in CF from the northern hemisphere are awaited. 
Optimising nutritional status is the other key to achieving maximum BMD. A more 
aggressive approach to this has been introduced at the RCCH as the frequent use of 
gastrostomy feeding attests to (See Chapter 5). 
Three children showed features of peptic ulcer disease. Only one had a persistent 
problem, eventually leading to vagotomy and antrectomy in the era before the role of 
Helicobacter pylori in the pathogenesis of ulcers had been shown (see Chapter 5 pI55). 
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In conclusion, then, it appears that CF as a clinical entity as seen in children and 
adolescents in the Western Cape province is comparable with other centres in the world. 
For reasons that require investigation, only the anaemia/oedema complex appears to be 
more common than elsewhere and only in coloured children. This chapter has illustrated 
the complexity of CF and its many complications. Only one in three children is destined 
to have disease that confines itself to PI and lung disease and those problems are 
burdensome enough. Most children will suffer additional complications of their disease 
at some time in their formative years. As this chapter and the following clinical chapters 
illustrate, a broad range of expert services is required to deal with the myriad facets of 
this disease. 
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CHAPTER 5 
SURGERY IN CYSTIC FIBROSIS 
OUTLINE OF CHAPTER 
The previous chapter described the clinical manifestations of CF encountered in 
this population of children and young people with the disease from the Western 
Cape province. As described there, a number of the features and complications of 
the disease require surgical interventions. This chapter details the surgical 
histories of these patients from 1972 to the present day and presents the overall 
contribution of surgical expertise to the total management over many years of 
children and adolescents who have CF. After an introduction, a published study 
covering the 20 years from 1972 is presented. This followed by an update 
including a recently published letter on the subject of splenectomy in CF. 
INTRODUCTION 
Exploration of the surgical histories of our patients constituted the means by which I 
rapidly enlarged my knowledge and understanding of CF. The folder reviews and 
literature search that were required for this study served as an invaluable boost to my 
understanding of CF, its true complexities and its range of challenges that, 10 years later, 
are being presented in this thesis. 
The full multisystem nature of the disease is represented in the range of surgical 
procedures undergone by a significant proportion of CF patients. The gastrointestinal 
tract COlT) is the focus of much of the major surgery associated with CF with meconium 
ileus CMI) and its complications being responsible for the bulk of this.209 Intestinal 
obstruction is often a feature of life with CF beyond the neonatal period. Surgery may be 
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required to relieve thiS.172 Pathological gastro-oesophageal reflux (GOR) may necessitate 
anti-reflux procedures in certain cases.2lO The lung, though the focus of much of the 
morbidity associated with CF, less commonly demands surgical intervention. However, 
lobectomies for localised bronchiectasis, intercostal drain insertion and pleural 
procedures for pneumothoraces, interventional radiology for massive haemoptysis and 
bronchoscopy for diagnostic and therapeutic purposes are not uncommon. 154 In some 
countries lung transplantation is a major surgical intervention in patients with CF.25 
Liver disease also has its surgical consequences. Procedures for the management of 
portal hypertension such as injection sclerotherapy, band ligation of oesophageal varices 
or porto-systemic shunts may be required?l1 Biliary surgery may be needed for 
obstructive and infective complications. Liver transplant is also now an established mode 
of therapy for intractable liver disease in CF.211 For the Ear, Nose and Throat (ENT) 
surgeon, there are the problematic nasal polyps and persistent nasal sinus symptoms to be 
dealt with using procedures such as polypectomy and ethmoidectomy.212 Enteral feeding 
with gastrostomy tube placement was introduced in the late 1980s to optimise nutritional 
status in selected patients with CF.213 Likewise placement of central and peripheral 
venous catheters has been regularly performed to reduce the recurrent discomfort 
associated with the regular intravenous antibiotic therapy that a more vigorous approach 
to pulmonary infections requires.214 
The stimulus to the first study reported in this chapter was the management of a young 
girl who had persistent right iliac fossa pain associated with a mass. Senior doctors in the 
clinic decided she had to have an exploratory laparotomy. (Her case, being somewhat 
unusual, is written up fully on p 150.) My feeling of great ignorance as to the reasoning 
and pathology that had led to this decision encouraged me to explore the indications for 
surgery in patients with CF. My co-workers, Dr J Ireland and Prof M Bowie, helped me 
with the task of protocol development and collating and distilling the vast range of 
disease and interventions I uncovered in this retrospective study of 20 years-worth of 
surgery in CF patients at the RCCH. 
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The study was published (after getting lost in the editorial offices for some considerable 
time) by the South African Journal of Surgery in 1997.51 It was accompanied by an 
editorial by Prof Sam Moore of TBR's Department of Paediatric Surgery on the subject 
of 'Surgery and Cystic Fibrosis,.21s This paper in reproduced here as Study 5.1. 
References are included at the end of the paper. 
Following the presentation of this article, the surgical experience in the decade following 
the end of that study period is presented and the full 30 years commented upon in the 
light of international experience with surgery in CF patients. 
STUDY 5.1 
ABSTRACT 
Surgery in cystic fibrosis - a 20-year review 
Anthony T R Westwood 
John D Ireland 
Malcolm D Bowie 
South African Journal a/Surgery 1997,'35:181-184 
The surgical histories of 111 patients with cystic fibrosis (CF) seen between 1972 
and 1991 were examined. Fifty seven of these children underwent 154 
operations and in 34 the surgery was directly related to CF accounting for 84 
operations. Meconium ileus and its complications were responsible for 26 of the 
32 major abdominal CF-related procedures and there were 3 major CF-related 
thoracic operations. Only 1 child died within a month of operation. Complications 
occurred in 11,9% of general anaesthetics and post-operative complications in 
9,2% of operations. Patients with CF are likely to need operative intervention and 
when indicated surgery should have a low morbidity and mortality. 
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Cystic fibrosis (CF) is a multisystem disorder resulting from a genetic abnormality of the 
transport of chloride ions across apical membranes of epithelial cells. The brunt of the 
complications of this defect is borne by the respiratory and gastrointestinal systems. 
Therapy is largely medical with prevention and treatment of pulmonary infections and 
pancreatic enzyme replacement being the mainstay. The disease process may demand 
surgical intervention for diagnostic or therapeutic reasons. 1 This can begin in the 
neonatal period with meconium ileus (MI)2 and, at an advanced stage of the disease, 
heart-lung transplantation is now a possibility.3 The effects of respiratory compl ications 
such as bronchiectasis and pneumothorax in some instances can be ameliorated with 
surgical techniques.4,5 Laparotomy is often indicated when abdominal complications 
such as intussusception occur.6 Exploratory laparotomy may be indicated when 
abdominal pain or masses cause diagnostic uncertainty.2 The associated lung disease 
increases the anaesthetic risk especially in the later stages of the disease.7 
As surgery is likely to playa significant role in the overall management of CF we 
reviewed the surgical histories of our patients to document 1) the number and types of 
surgical procedures undertaken, 2) the indications and outcomes and 3) the risks of 
surgery. 
PATIENTS AND METHODS 
The hospital records of all CF patients who had been seen at the Red Cross War 
Memorial Children's Hospital were examined. CF had been diagnosed on clinical 
features or family history and confirmed by a positive sweat test. Details recorded 
included gender, ethnic group, presenting symptoms and, where known, genetic status. 
Children who had only been seen for confirmation of the diagnosis and those in whom 
the diagnosis was made post-mortem were excluded. 
All diagnostic and therapeutic procedures requiring anaesthesia or sedation performed on 
this group of children in the 20 year period from January 1972 to December 1991 were 





Major procedures related to CF 
Minor procedures related to CF 
Procedures unrelated to CF 
For Group 1, indications were defined based on experience and a literature review prior 
to retrieval of the data and were recorded as in the preoperative assessment regardless of 
the surgical findings (see Box 5.1). Outcomes were defined as good, ineffective or bad 
using criteria related to the indication. For Groups 2 and 3 the type of procedure alone 
was recorded. 






Persistent abdominal pain 
with focal RLQ tenderness 
not responsive to medical therapy 
Persistent abdominal pain 
suggestive ofDIOS inadequately 
responsive to bowel 
clearing procedures and 
other medical therapy with 
demonstrable i1eocaecal faecal 
retention 
C) Caecal or other bowel-related 
mass unresponsive to bowel 
clearing procedures and symp-
tomatic 
D) Bowel obstruction, except 
demonstrable intussusception, 
not responding to 
conservative measures 
E) Intussusception not responsive 
to enema therapy 
F) Meconium ileus unresponsive 
to enema therapy 
G) Complicated meconium ileus 
H) Persistent abdominal pain 
due to disease ofthe biliary tree 
I) Uncontrolled bleeding oesophageal varices 
J) Persistent symptomatic GOR 
K) Acute abdomen, peritonitis 



























M) Severe localised chest pathology Fewer chest As many See 
with no improvement or infections infections above 
shortlived improvement in re- than in the 
spiratory symptoms after year before 
vigorous medical therapy 
N) Progressive scoliosis due to Reduction in Unchanged 
localised lung or pleural scoliosis 
fibrosis 
0) Recurrent and/or persistent No pneumo- Recurrence 
pneumothorax thorax 
P) Empyema not completely reo Clearing of Not cleared 
sponsive to thoracocentesis empyema 
and medical measures 
Q) Life threatening or severe reo No further Ongoing 
current haemoptysis haemoptysis haemoptysis 
R) Rapidly declining respiratory Improvement No arrest.or 
function and severe focal in clinical slowing 
chest pathology respiratory of decline 
state 
For all groups anaesthetic complications (see Box 5.2) were described as being related or 
unrelated to CF as defined by Lamberty and Rubin.? Complications due to the surgery 
were recorded separately. Only complications related to operations carried out at our 
hospital were recorded. 
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BOX 5.2 
ANAESTHETIC COMPLICA nONS 
COMPLICATIONS RELATED TO CF 
A) Difficult induction 
B) Excessive coughing and secretions 
C) Difficult intubation because of secretions 
D) Difficulty with ventilation 
E) Difficulty maintaining anaesthesia 
F) Secretions causing airway obstruction 
G) Unstable blood sugar 
H) Haemoptysis 
RESULTS 
One hundred and thirteen patients with CF fulfilled the criteria for inclusion in the study. 
The records of 2 were missing. Fifty seven of the remaining III patients had undergone 
at least one procedure. There was no difference between those who had had surgery and 
those who had not with respect to gender, ethnic group, delta F508 mutation status or 
symptoms at initial presentation analysed by organ system. 
One hundred and fifty four procedures were carried out on the 57 patients in the 20 year 
period (Table I). The maximum number of operations per child was 14. Twenty three 
patients had 1 operation, 12 had 2, 7 had 3 and 10 had 4. Five patients underwent 5 or 





TABLE I: TYPES OF OPERATION 
I--____ ..,--__ ---,-G.:..R---"-O_UP ----i 
2 3 
r---------~------+-----
Ab 34 18 
Chest 8 
ENT 6 30 
Other o 21 
Total(N=154) 35 49 70 
36 (23,3%) operations were done elsewhere (Group] ·10, Group 2 - 4, Group 3·22). 
Operations related to CF 
Thirty four (30,6%) of the III patients underwent an operation related to CF. Eighty 
four (54,5%) operations were related to CF (Table I). Indications and outcomes for major 
surgery are shown in Table II. Ten operations done at other hospitals are not included in 
the Table as indications for surgery were not available to us. These were all laparotomies 
and 8 were related to MI. 
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TABLE II: MAJOR OPERATIONS RELATED TO CYSTIC FIBROSIS 
INDICATION 
Abdominal mass6, 15 
Bowel obstruction 
obstruction. 




MI, failed enema( s) 
Complicated MI 
Persistent symptom-
atic GOR· 2 









































Incision and drainage of abdominal wall 
abscess 
Previous MI surgery. Adhesive bowel 
segment of bowel resected 
Jejunal atresia. Microcolon with 
meconium plugs. Santulli procedure 
Previous MI surgery and laparotomy for 
adhesions. 
Severe adhesions. Pseudo-membranous 
colitis. 
Ileostomy. Wound sepsis. Died after 
re-exploration of the wound. 
Previous MI surgery. Adhesive bowel 
obstruction. Adhesions divided. 
Closure of colostomy followed by 
torsion at site due to adhesions. 
Previous complicated MI. Bowel 
resection. 
Perforated appendicitis with peritonitis. 
Appendicectomy 
Terminal ileitis with haemorrhagic 
lymph nodes. Free peritoneal fluid 
grew a-haemolytic streptococcus. 
Appendix showed chronic inflammatory 
cells. Responded to peritoneal lavage 
and antibiotics. 
Various. See Ref21. 
Perforation of splenic flexure with 
meconium peritonitis. Colostomy. 
Proximal volvulus with atresia, 
meconium peritonitis and pseudocyst. 
Ileostomy. 
Mid ileal volvulus with peritonitis. 
Resection and ileostomy. 
Nissen Fundoplication. 
Right upper lobectomy. 
Right pneumonectomy. 
Right decortication following empyema 
and pneumonia. 
Minor procedures undertaken are shown in Table III. 
TABLE III 
MINOR OPERATIONS RELATED TO CYSTIC FIBROSIS 
Operation 
Abdominal 
Chest Insertion ICD 
Bronchosco 
ENT 
Examination under anaesthetic 
Other Ex loration of suture line 
I CD Intercostal drain 












Seventy operations fell into this category (Table I). The majority of this surgery was 
minor. ENT operations predominate. Thirteen of the 18 abdominal procedures were 
endoscopies performed on one patient for a chronic duodenal ulcer. (These endoscopies 
were classified as unrelated to CF owing to the uncertainty about the relationship between 
peptic ulcer disease and CF.8) 
Complications 
One hundred and nine general anaesthetics (GA) were carried out at our hospital. There 
were 13 (11,9%) complications. Eight related to CF were bronchospasm(3), 
laryngospasm(2), a difficult induction owing to secretions, a small haemoptysis and one 
child was difficult to keep anaesthetised. There were 2 minor epistaxes, one brief apnoea, 
an urticarial reaction to alcuronium and one child became dehydrated when a drip 
disconnected. None of these complications produced more than shortlived morbidity. 
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Seven procedures were perfonned with local anaesthesia and 2 under sedation. No 
complications were encountered. 
Post-operative complications occurred with 11 (9,2%) operations. Infections accounted 
for 7 of these (chest infection 3, wound sepsis 3, nosocomial enteritis 1). Torsion of 
bowel at the ileostomy site was the only early non-infective complication of MI surgery 
(but one child developed bowel obstruction due to adhesions and meconium plugs 3 days 
after closure of ileostomy (Patient 7 Table II) and surgical emphysema affected one of the 
thoracotomy cases. One child developed a stricture following repeated injection 
sclerotherapy for oesophageal varices. 
DISCUSSION 
Since the first delineation of the variable course of CF by Shwachman and Kulczycki,9 
the need for surgical intervention to relieve some of its symptoms and complications has 
been recognised. 1 ° 11 In subsequent decades this has been amply attested to with heart-
lung transplant being the latest regularly perfonned procedure.3 Despite the multiplicity 
of operations demanded by the complications of CF there are few reports of the extent of 
surgical intervention and morbidity in CF populations. Most reports relate to a single 
system or disease process. Olsen et alI2 report a 15 year experience at one hospital but 
operations before diagnosis and those perfonned at other hospitals are not included. 
Three studies over 3 decades describe surgical experience in CF from the anaesthetist's 
perspective.? 13 14 Gastrointestinal surgery over a 10 year period is presented by Gross 
et al,2 appendix surgery over 24 years by Coughlin et ailS and there is a number of series 
covering pulmonary resection.4 16 17 Ear, nose and throat (ENT) surgery over 2 decades 
is presented by Reilly et al. I8 
In this study the total surgical burden experienced by a CF population over 2 decades is 
presented. Half of our CF population underwent at least one surgical procedure. The 
majority (54,5%) of surgery was related to the disease and was carried out on 30,6% of 
the patients. 
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The extent of surgery due to the disease is higher than this as some procedures were 
undertaken before the diagnosis of CF was established (a liver arteriogram and a small 
bowel biopsy) and another was the result of complications of CF therapy (eg. 
oesophageal stenosis after sclerotherapy). Although classified as 'unrelated' many of the 
adenotonsillectomies, grommet insertions and sinus washouts were done prior to 
diagnosis presumably for chronic respiratory tract symptoms. Maw19 states that such 
operations for CF-related symptoms are of questionable benefit. In our study they 
represent 14,6% of the total. Early diagnosis could significantly decrease the amount of 
surgery CF patients undergo. 
Abdominal sUrgery dominates the CF-related interventions. Sixty six of the 81 related 
operations were abdominal and of the major procedures in this group those related to MI 
fonn the bulk (27/32). 
Intestinal obstruction, abdominal pain and right lower quadrant masses frequently cause 
diagnostic difficulty in CF patients. The distal intestinal obstruction syndrome (DIOS) is 
the commonest entity responsible but intussusception, appendiceal pathology, Crohn's 
disease or biliary tract disease may occur with overlapping symptoms, signs and results 
on investigation. In all, 4,5% of our cohort had surgery for these indications. In a 10 year 
period Gross et a(2 operated on 61189 patients (cholecystectomy 3, DIOS 2, 
intussusception 1). Olsen et al12 reports 36 such operations in 210 patients in 15 years. 
This higher rate reflects an older CF population. 
The small number of pulmonary resections (2,7%) accords with recent experience in 
larger centres. Steinkamp et al16 report 3 out of 160 patients undergoing lobectomies for 
localised bronchiectasis. It is well established that with careful selection pulmonary 
resection in CF can have an excellent effect on a patient's well-being4 and both our 
children have enjoyed much better health following surgery. Empyema is an uncommon 
problem in CF. No organism was isolated in the child reported and he did well 
postoperatively and remains so 4 years on. 
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Postoperative complications were for the most part minor and transitory. The most 
serious (bowel torsion, adhesive intestinal obstruction) related to MI surgery but the 
introduction ofT-tube ileostomy has prevented these in recent years.20 Only 3 patients 
had a chest infection within a week of surgery. Atelectasis and respiratory failure, both 
features of earlier series,13 14 did not occur probably reflecting the improved pulmonary 
status of children with CF in recent years as well as advances in management) 
Morbidity was higher than that reported by Olsen et al12 (9,2% vs 3%) but nasal 
polypectomies and central intravenous line insertions, both procedures with low 
morbidities, constituted almost half of their operations. 
The nutritional and respiratory effects of CF potentially make administration of GAs 
problematic) Ventilationlperfusion mismatch, airway reactivity and secretions demand 
careful management in the peri operative period. The anaesthetic complications seen here 
(11,9%) compare well with those reported from a centre in which much more CF surgery 
is performed (13,4%).7 In a young population such as ours, morbidity will be lower 
because lung disease is less advanced but the use of GA is high as sedation or regional 
anaesthesia present problems in young children. Concerns expressed about the long term 
effect of GA on lung function patients with CF21 have not been addressed by this study 
but we have not noted a difference in disease status between those who had surgery and 
those who did not. 
CONCLUSIONS 
In this study, the total surgical burden experienced by a CF population is reported. It is 
important to note that this is a relatively young popUlation and that some surgically 
important complications of the disease appear mainly in late adolescence and adulthood. 
Yet the experience shows that half of our patients had surgery. The disease itself is 
responsible for over half of the procedures with MI-related operations forming a 
significant proportion. Given the right indications a good outcome with limited 
morbidity can be expected. The number of operations and thus morbidity could be 
reduced by early recognition of CF and will probably continue to diminish with advances 
in medical and surgical management. 
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UPDATE AND COMMENTARY 
Apart from teaching me a great deal about CF, this study remains unique in its 
comprehensive view of surgery in CF. However, as shown in the discussion in the 
article, the proportion of surgical procedures in CF varies between centres e.g. the virtual 
absence of central venous line placement in Cape Town and its high usage in North 
American studies. Access to lung transplantation would constitute another difference. 
Over time practice changes: advances are made; fads are shown to be just that. The use 
of Intralipid and other forms of parenteral nutrition was all the rage in the 1970S216 but 
their use passed once effective PERT and high fat diets reversed much of the malnutrition 
seen in CF. Even within the two decades of our small study the complication rate of MI 
surgery diminished. This fact was noted by Moore in the editorial that accompanied our 
article.215 
It is now 12 years since the procedures entered into this study were performed. Have 
changes in clinical practice in Cape Town changed the frequency or the pattern of surgery 
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in this population? We predicted a diminution of the surgical burden with the earlier 
diagnosis of CF and advances in treatment. Has this taken place? 
Using the same methodology as the study reported in the SAJS, experience from January 
1992 to August 2003 (the end of the study period for the population described in Chapters 
2 and 3) was reviewed. The number and range of procedures are shown in Tables 5.1 and 
5.2. In all, 59 patients underwent 128 surgical procedures, 21 patients having had earlier 
procedures that were included in the first study. Sixty eight of the 128 procedures (53%) 
were performed at the RCCH. 
Table 5.1 Operations performed from January 1992 to August 2003 
Group 
1 2 13 
Abdominal 27 37 4 
Chest 3 6 0 
ENT 0 10 17 
Other 0 6 8 
TOTAL (N = 128) 30 69 29 
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Table 5.2 Operations related to cystic fibrosis perfonned between January 1992 and 
August 2003 
Operations related to Cystic Fibrosis 















Other Venous lines 
PEG percutaneous endoscopIc gastrostomy 
ENT - ear, nose and throat 
Abdominal Surgery 
11 
7 See text & Table 5.3 for 
details 
1 See text & Table 5.3 for 
details 
8 3 with gastrostomy 
See text & Table 5.3 for 
details 
1 See text for details 










Of the 9 MI-related operations since 1992 only two took place at the RCCH. Five were 
perfonned in private hospitals and two at TBH. Only one child born in the last 11 years 
developed a complication related to MI surgery (adhesive bowel obstruction at 6 months 
of age in 2003. See Table 5.3). There has been no mortality from MI. The excellent 
outlook for MI in Cape Town continues. The surgery that took place in private hospitals 
was all perfonned by paediatric surgeons affiliated to Cape Town's two tertiary public 
paediatric centres. 
In the period covered by the first study, MI-related surgery made up the bulk of major 
abdominal surgery in CF (26/34 procedures). Things have changed: between 1992 and 
2003 only 12 of the 27 major abdominal operations were related to MI. Changes in 
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operative technique have removed stoma closure from the list of procedures. Two of the 
major operations were for volvuli in two girls whose initial MI surgery took place years 
before in the period covered by the first study. These and the other major abdominal 
surgery and its indications and outcomes are shown in Table 5.3. 




Bowel obstruction not 
responding to 
conservative measures 
Persistent peptic ulcer 
disease 
Persistent GOR with 
symptoms (see text) 
Bleeding after Boix-
Achoa procedure 
MI - mecomum deus 




















Removal of mucocoele of the appendix Good 
(see text) 
Splenectomy (see text) Good 
Adhesive bowel obstruction following MI Good 
surgerY. Division of adhesions 
Volvulus in child with previous MI surgerY Good 
Volvulus in adolescent with previous MI Good 
surgery. 
Vagotomy and antrectomy Good 
Nissan soon after CF diagnosis Good 
Nissan soon after CF diagnosis Fair (see 
line below) 
Re-do with repair of paraoesophageal Good 
hernia 
Nissan & gastrostomy after CF diagnosis Good 
Nissan before CF diagnosis Good 
Abdominal pain with anorexia. Nissan and Good 
gastrostomy 
Heart burn and anorexia. Nissan and Good 
gastrostomy 
Boix-Achoa procedure performed before Bad (see 
r<r • line below) 
Laparotomy to tie off bleeding artery Good 
Surgery for GOR in CF has changed considerably between the two periods under review. 
In the first period only one operation for GOR was performed. In the last 11 years, 8 
such operations have been carried out (Tables 5.2 and 5.3). Two of the 8 procedures 
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were done for persistent chest symptoms before the diagnosis of CF was made but the 
other 6 were done after the diagnosis. The potentially lethal combination of the tendency 
of CF to produce severe chest disease in some infants and severe GOR which has a 
higher prevalence in CF led to early anti-reflux procedures in three infants. In all three 
there was considerable consequent reduction in the respiratory symptomatology. All 
three are now healthy young children with minimal pulmonary disease. One of these 
infants presented with dysphagia a year after the anti-reflux procedure having developed 
a paraoesophageal hernia. Surgery to repair this and to re-do the wrap was successful. 
In contrast to the respiratory indication for GOR surgery in infants, two older boys 
required procedures for GOR because of severe gastrointestinal symptoms: abdominal 
pain and heart burn. In both patients GOR was worsening nutritional status, and the 
opportunity to insert a gastrostomy button during surgery was taken to allow 
supplemental feeding. Both boys responded well to these interventions. 
Three patients who underwent three other major abdominal procedures warrant special 
mention. 
Case 1: Right lower quadrant mass 
This female CF patient had presented in infancy with failure to thrive and recurrent chest 
infections. She had PI and had been placed on PERT. She had had an uncomplicated 
course until the age of 5 and a half years apart from a single episode of painless rectal 
bleeding. She was then noted to have a right iliac fossa (RIF) mass which was thought to 
be due to faeces. This persisted and enlarged. Clearance was attempted with balanced 
polyethylene glycol/electrolyte solution to no effect. Ultrasound confinned the presence 
of the mass but did not help characterise it. Abdominal CT scan suggested an ileocolic 
intussusception but was not diagnostic. A laparotomy was undertaken. Inspissated 
faeces were found in the appendix and caecum. Appendicectomy was perfonned with 
evacuation of faeces through a caecostomy. Histology showed an appendix distended 
with mucin with focal cryptitis and increased numbers of polymorphs in the lamina 
propria. 
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In the months following the operation she remained well but there was still a vague mass 
palpable in the RIF. There was occasional pain localised to this area. With time the mass 
became more prominent and further oral attempts at bowel clearance were made with 
partial success. 
Nine months after the operation she began to lose her appetite, complained of satiety and 
over two months she lost 3 kg in weight. She had intermittent cramping abdominal pain 
and episodes of fever. Chest X-ray and sputum culture were clear. Urine microscopy 
and culture were normal. She had a white cell count of 13,5x109/l with a neutrophil 
predominance. Electrolytes, urea and creatinine were normal but her serum albumin 
level was 30 gldl. ESR was 121 mmIhr. 
Abdominal X-ray suggested a mass in the RIF and a few small air/fluid levels in the 
small bowel. Ultrasound showed marked thickening of the terminal ileum and ascending 
colon walls and mucosa. There were several enlarged mesenteric lymph nodes in the RIF 
and paracaval regions with a small amount of fluid in the Pouch of Douglas. Contrast CT 
of the abdomen with Gastrografin® showed delayed bowel transit with an irregular 
narrow track of contrast passing through thickened terminal ileum, caecum and ascending 
colon. 
Colonoscopy was performed. This showed ulceration and granulomatous inflammation 
in the ascending colon. There were thick adherent secretions in the lumen of the bowel. 
The rest of the colon appeared to be normal. Radioisotope scanning with Gallium67 
showed a large irregular area of increased uptake extending across the abdomen from the 
RIF towards the left costal margin suggesting diffuse small bowel inflammation. 
Yersinia antibodies and culture of tissue from the caecum were negative. Tests for TB 
were also negative. 
She was treated with broad spectrum antibiotics, initially for two weeks. However over 
the following three months symptoms recurred frequently, only settling (and often 
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incompletely) when further antibiotic courses were given. During this time she 
developed swollen painful ankles. Intennittent abdominal pain continued, often 
associated with fever and raised ESR level; the RIF mass remained palpable. It was 
decided to treat her as if she had Crohn's disease. Prednisone therapy brought about an 
immediate cessation of pain and reduction in the size of the mass. Sulphasalazine was 
added enabling the steroid dose to the reduced and then stopped. The symptoms did not 
return. The anti-inflammatory medication was continued until she was 16 years old. 
Symptoms had not recurred by the end of the study period when she was 17 years and 
nine months old. 
Lloyd Still from Chicago has taken a special interest in Crohn's Disease in the context of 
CF. He reviewed the literature in 1994, identifying 12 reported cases, 33% of whom had 
arthritiS. I?3 Seventy five percent had fistulae, a complication our patient was spared. His 
survey of CF centres revealed 28 cases of inflammatory bowel disease, 25 of which were 
Crohn's disease. One out of every 404 CF cases had inflammatory bowel disease; it is 
not a common complication of CF but is more common in CF than in the general 
population. Most cases were associated, as in our case, with DIOS. The diagnosis of 
Crohn's disease depends on clinical, radiographic and histologic features. These this 
patient had and, together with the gratifying response to anti-inflammatory therapy, they 
make a convincing case for Crohn's disease. 
Case 2: Massive splenomegaly 
This case was described in a letter we wrote to the Archives of Diseases in Childhood 
that was published in November 2004.217 In 2003 the journal had published a paper by 
Thalhammer and colleagues describing three CF patients who had undergone partial 
splenectomy.218 The first patients had his spleen partially removed for hypersplenism and 
abdominal discomfort; the second for severe abdominal pain; and the third for pain and 
increasing dyspnoea. The authors discussed the risks of this procedure. Increased 
suspectibility to infection was the main concern. One of their patients required re-
laparotomy for intra-abdominal bleeding and they quoted a previous paper that described 
problematic post operative complications of splenectomy in 3 out of 6 patients. These 
152 
risks led to a Commentary that accompanied Thalhammer and colleagues' paper. Kelly 
and de Ville de Goyet were 
..... doubtful that this operation [could] be justified in 
patients with cystic fibrosis in view of modern methods 
for controlling portal hypertension ...... 219 
This commentary drew two letters to the Archives, one from the authors of the original 
report and another from the group whose work they had quoted defending 
splenectomy.220 22' It was into this ferment that we made our contribution, based on our 
experience. 
Arch Dis Child 2004;89: 1 078 
Dear Sir 
Re: Splenectomy in cystic fibrosis patients 
A recent article', a comrnenta.x-Y and two letters3 4 in the Archives of Disease in 
Childhood have revealed controversy over the place of partial splenectomy in portal 
hypertension in cystic fibrosis (CF). We wish to contribute to the debate with a case 
report: 
Our male patient was homozygous for the ~F508 mutation. He was pancreatic 
insufficient, his lungs were colonised with Pseudomonas aeruginosa from an early age 
and he had two episodes of allergic bronchopulmonary aspergillosis. When he was 8 
years old abdominal ultrasound showed variable echogenicity of the liver compatible 
with cirrhosis with thick bile in the biliary tree. Treatment with ursodeoxycholic acid 
was commenced. Recurrent abdominal pain associated with severe gastro-oesophageal 
reflux led to an anti-reflux procedure being performed when he was 9 years old. A 
gastrostomy button was placed at the same time for night time supplementary feeding. 
Cirrhosis of the liver was confirmed intraoperatively. Over the next few years a massive 
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splenomegaly developed. Full blood count showed features of hypersplenism but he 
remained asymptomatic with respect to the haematological abnormality. At the age of 13 
years he developed severe abdominal pain in the area over the spleen. Oral analgesia was 
not sufficient to deal with this ongoing pain and he was unable to attend school, exercise 
or do chest physiotherapy over a number of months. He had 2 episodes of probable 
melaena. He developed severe, intercurrent shoulder tip pain secondary to diaphragmatic 
irritation from splenic infarcts. Computerised tomography of the abdomen showed the 
spleen's span to be 30 cm, with 2 infarcts. Opiates were given to control pain but it 
proved to be intractable in an otherwise stoical patient. Eventually, because of the risk to 
his lungs, his poor quality of life and the risk posed to his gastrostomy by the massive 
spleen, partial splenectomy and possible splenorenal shunting were planned. 
Pneumococcal vaccine was prescribed. His white cell count (WCC) was 1,5x109/l, his 
platelet count was 58x 1 0911 and his INR was 1,6. At laparotomy, perisplenitis in the 
diaphragmatic area necessitated a total splenectomy. Shunting was not undertaken. The 
spleen weighed 1 834g and there were numerous infarcts. Post operatively he did well, 
patient-controlled analgesia being used to encourage early mobilisation. Eight days later 
elective banding of oesophageal varices took place. Follow up endoscopy showed that 
this had ablated all the vessels. Two years later he no longer has abdominal pain, has not 
had severe infections, has a normal full blood count (WCC 12.3x1091l, haemoglobin 
14.1 gldl, platelets 486x 1 09/1) and has stable lung function. 
The debate on the justification for removing all or part of the spleen in patients with CF 
and portal hypertension hinges on two considerations: indications and risks In their 
commentary, Kelly and de Ville de Goyer emphasised the risks: infection, compromising 
future transplantation, while questioning the indications in the cases presented by 
Thalhammer et al: hypersplenism and discomfort!. In their rebuttal, Thalhammer et ae 
emphasise the hypersplenism and not the pain and discomfort described in their case 
reports. In their accompanying letter, Chazalette and colleagues4 do not mention pain as 
an indication. We would agree with Kelly and de Ville de Goyet2 that hypersplenism in 
the absence of significant consequences is not on its own an indication for this major 
procedure (we note the number of re-laparotomies required in these small series) but 
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would emphasise that quality of life and local effects of the size of the spleen may justify 
the surgical and immunological risks. 
Dr ATR Westwood, Prof AJW Millar, Prof JD Ireland. 
Divisions of Paediatric Medicine and Paediatric Surgery, Red Cross War Memorial 
Children's Hospital, Klipfontein Rd, Cape Town, South Africa 
Dr A Swart, George, South Africa 
Correspondence to Dr Westwood: westwood@ich.uct.ac.za 
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Case 3: Persistent peptic ulcer disease 
The vagotomy and antrectomy indicated in Table 5.3 was perfonned on a young man 
with a recurrent and persistent duodenal ulcer. During the period described in our first 
paper he had had 13 endoscopies related to this ulcer. The 'curative' procedure predated 
the advent of triple therapy for Helicobacter pylori and is unlikely to be perfonned ever 
again in a patient with CF! His ulcer was indeed cured by the operation. 
The idea of gastrostomy insertion to enhance nutrition in CF was introduced to the RCCH 
CF team by Dr J Littlewood in 1988. PEG insertion was first used at the hospital in the 
early 1990s and CF patients were among the first to have the procedure perfonned. The 
experience took the fonn of an accelerated version of international experience. The first 
two patients to have the procedure were sisters with advanced lung disease. The older 
sister gained 2 kg in the 11 months before she died; the younger sister gained no weight 
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in the 8 months before she died. As Levy and colleagues had shown in 1986, such 
patients are unlikely to receive optimal benefit from enhanced enteral feeding,z13 In their 
study the patients who died all had severe malnutrition and lung disease, most dying 
within 0,2 years of the nutritional intervention. Weight gain was not achieved in nearly 
all of them. Such feeding, in the opinion of the authors, 'is likely to be most beneficial 
when it is begun early in the development of malnutrition.' Since this lesson has 
been learnt, 11 patients have had gastrostomies inserted: 3 at the time of anti-reflux: 
surgery and 8 with the PEG technique. Four of the 8 PEG cases were included in an 
article about PEG experience at RCCH by van der Merwe and colleagues in the South 
African Medical Journal,z22 Interestingly two teenage boys not included in the SAMJ 
report determinedly put on weight by oral means in order to have their gastrostomies 
removed 5 and 15 months after insertion. The longest period any child had a gastrostomy 
was 73 months. Apart from the sisters, five other patients have died with their PEGs in 
situ, 16, 22, 28, 55 and 42 months after insertion. All in all 21 procedures involving 
PEGs (insertion, replacement, removal) were undertaken in the latter period where none 
were done in the first period. Peri-operative complications were few: two older boys 
complained of considerable pain in the immediate post-operative period when their PEGS 
were first inserted. Most children were discharged within two days of the procedure. 
The PEG has thus proved simple and effective in CF in recent our experience; an advance 
in the nutritional care of children and adolescents with CF. 
Only in the 1990s did a more aggressive approach to the presence of P aeruginosa take 
root in the Clinic, but routine intravenous therapy has never been practised. As shown in 
Chapter 7, the organism was identified relatively late in this population. This may 
explain the very low use of implantable devices. The lack of experienced nurses and 
almost no home care support also led to avoidance of this means of venous access. 
Percutaneous indwelling catheters have been preferred. This contrasts with practice in 
well-resourced countries. 2 14 
Transplantation surgery is undertaken in SA but has not so far been performed on patients 
from Cape Town. No patient from our service has been offered lung transplantation. The 
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procedure and the ongoing immunomodulatory management have not been offered by 
public services in Cape Town. The history in the private sector has not so far been 
positive. The RCCH CF team has not been recommending that parents follow possible 
options elsewhere unless they plan to emigrate. Lung transplantation is being practised 
with increasing success in highly specialised centres in Western countries but requires 
high levels of staffing and expertise as well as easy access to this expertise for patients?)) 
Without these resources, outcomes are dismal. Warner has pointed out the dangers of 
false expectations being given to families?24 He noted that good palliative care options 
may be denied a child because of a perceived chance of rescue by transplantation. The 
scales in Western countries may be balanced differently now, but, for SA, Warner's 
words are wisdom itself. Liver transplantation has a much happier pedigree in SA.22S 
With most operations performed for biliary atresia and acute liver failure, survival in 
recent years has exceeded 82%. However no child with CF has had liver disease severe 
enough to consider transplant assessment. 
CONCLUSION 
This review has highlighted the need for a multidisciplinary approach to the management 
ofCF. General paediatric surgical expertise as well as that provided by a number of sub-
disciplines is required for a significant proportion of CF patients. Together with this, 
anaesthetic and intensive care expertise needs to be available for optimal treatment of CF 
patients. Experience at the RCCH has been that good outcomes can be expected with few 
complications even when major surgery such as lobectomy is performed. 
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CHAPTER 6 
NUTRITIONAL AND GROWTH ASPECTS 
OUTLINE OF CHAPTER 
This chapter on Nutrition and Growth in CF reports two cross-sectional studies. 
After a discussion on the development of modem nutritional management of CF 
and current understanding of energy balance in CF (which is critical to auxology), 
the first study (Study 6.1) that I undertook is presented. This is a cross-sectional 
study of nutritional status and energy balance. This is followed by Study 6.2. By 
comparing the growth of children attending the CF Clinic at the time of Study 6.1 
with those who attended 10 years previously, I attempted to put the nutritional 
status of the children in Study 6.1 into an historical context. These two studies 
are followed by a commentary that examines the value of the studies, the changes 
in nutritional care at the RCCH CF Clinic introduced as a result of these studies 
and recent developments in the CF nutrition literature that impact on the 
assessment of nutrition and growth in CF in South Africa. Proposals around 
future areas of study in this field and their methodological considerations 
complete the chapter. 
INTRODUCTION 
The development of nutritional treatments in cystic fibrosis 
While the malabsorptive aspects of CF led to its delineation as a clinical entity, t 2 in terms 
of management and assessment, attention soon turned to its respiratory aspects. The 
advent of early forms of PERT ameliorated some of the nutritional effects of 
steatorrhoea. The prognostic significance of nutritional status was recognised by 
Shwachman in Boston who included an assessment of nutrition in his scoring system. to 
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However it is clear from the following quotation from the paper that proposed this 
method of assessment that malabsorption was far from being overcome: 
NUTRITION. Moderate grade: ....... poorly formed, bulky, fatty 
offensive stools; ...... . 
Patients reported in this study were "practically all" on pancreatin. In fact to reduce the 
persistent symptoms of fat malabsorption, low fat diets were advocated: 
The treatment aimed at improving nutrition consisted of a liberal diet 
in which a relatively high protein intake was emphasized (sic), and 
an effort was made to reduce the total fat intake. 
Improvement in nutritional status and prognosis in CF at this time related largely to 
earlier diagnosis, the advent of better antibiotics and their liberal use and the greater 
experience of clinic staff. 
That attention to improved energy balance by using liberal amounts of fat in the diet 
would yield better overall outcomes in CF was the thesis that led the Toronto CF Clinic 
in Canada to adopt this approach to nutrition?26 In advocating this approach in 1974, 
Crozier227 wrote, 
To deprive the child with cystic fibrosis who usually has very little 
subcutaneous fat of this important nutrient seems ridiculous. 
High doses of pancreatic enzyme supplementation were given to maximise fat absorption. 
Five years later the Toronto group was able to show improved growth to the point of near 
normal heights and weights of CF patients as a result ofthis approach. A seminal paperl6 
that this group produced comparing patient outcomes between their 'high fat' and 
Boston's 'low fat' regimes strongly suggested both that high fat diets worked and that 
careful attention to good nutrition in CF could prolong survival. Patients in Boston were 
shorter than those in Toronto and from the age of 10 years the survival curves separated 
with median survival being 21 years in Boston versus 30 years in Toronto. This high fat 
approach to nutrition in CF took a while to be accepted and even in the mid-l 980s some 
still advocated the low fat approach (Charlotte Anderson, Birmingham CF Clinic, UK in 
slide-tape presentation 1984, ICH Library, UCT - now deleted). 
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That the key to optimal growth and thus optimal survival was an adequate (and usually 
very high [see below]) energy intake led to new standards of care in the nutritional 
management of CF patients.228 Energy intake was the watchword. New methods of 
boosting energy intake, including night time gastrostomy feeding, became the norm in the 
1990s. 
Current understanding of the pathogenesis of growth and nutritional problems in 
cystic fibrosis 
It is a fundamental precept of auxology that the growth of a developing organism can 
only occur if energy intake exceeds energy expenditure. Genetic growth potential will 
only be realised ifthere is a sufficiently positive energy balance to allow optimal growth. 
In healthy children energy is expended on 
1) Resting energy expenditure (REE): energy used in metabolic (e.g. protein 
synthesis, ion pumps) and resting mechanical activities (e.g. heart beat and 
breathing) that are needed to maintain body integrity. This makes up 50-60% of 
total energy expenditure (TEE); 
2) Diet induced thermogenesis (5-8% of TEE). 
3) Activities of daily living (30-40% of TEE) 
4) Faecal energy losses (vary with dietary energy intake) 
Where there is adequate access to food, the healthy child eats enough to account for 
energy expenditure and what is needed to grow. This energy balance is shown in Figure 
6.1. 
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Figure 6.l: ENERGY BALANCE 




The child with CF has a more complex energy balance equation?29 Figure 6.2 shows the 
balance in a child with CF. In the majority of such children the balance will tend to the 
negative leading to poor growth unless remedial measures are taken. 
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Energy expenditure in the child with CF (Figure 6.2): 
Increased faecal losses 
Pancreatic exocrine gland insufficiency eventually occurs in about 90% of CF 
cases. This leads to malabsorption and steatorrhoea. Even with modem PERT an 
average of 11 % of dietary fat intake may be lost in the stool. Increased 
carbohydrate losses in the stool may also occur owing to inadequate colonic salvage 
secondary to antibiotic effects on colonic flora. 230 
Acute and chronic inflammation 
Inflammation consumes energy. In acute exacerbations of pulmonary infections in 
CF, an vigorous inflammatory response is nonnal. That this may increase REE has 
been demonstrated by Steinkamp and colleagues.231 When assessing 29 patients 
with an acute pulmonary exacerbation due to P aeruginosa they found an average 
REE of 119% of expected. Twelve patients had no increase in REE. Treatment of 
the exacerbation with anti-pseudomonal antibiotics decreased measures of 
inflammation such as white blood cell count and C-reactive protein. The elevated 
REEs decreased simultaneously. Naon and colleagues were also able to show a 
decrease in REE during treatment for acute infection in CF.232 This group were 
able to show that the magnitude of the decrease in REE exceeded that for measures 
of lung function, suggesting that the explanation for the decrease does not relate 
only to a possible decrease in the work of breathing. Stallings and colleagues have 
suggested that this increase is statistical rather than actual as REE's were not 
nonnalised for fat free mass in these studies so the jury may still be out on this 
aspect of energy utilisation in CF.233 
Chronic inflammation is a cardinal feature of lung disease in CF. It is thought to 
precede airway infection. The degree of the inflammatory response increases 
markedly once chronic infection with P aeruginosa develops. How inflammation 
increases metabolic demands is not understood. Exploration of cytokine activity, 
hugely elevated in the CF lung, has not shown direct correlations with REE.234 
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Increased work of breathing 
With airway obstruction being a cardinal feature of CF lung disease, increased 
biomechanical work of breathing is inevitable. However its contribution to REE is 
unclear. That it significantly contributes to difficulty maintaining weight when 
there is severe pulmonary disease seems clear from studies in diseases such as 
emphysema,235 but its contribution to REE in milder disease is probably not 
significant. As indicated in the discussion of inflammation above, acute changes in 
lung function do not make a large contribution to changes in REE. Indeed, Naon 
and colleagues present evidence that the pulmonary function improvement on 
antibiotics largely relates to improved matching of ventilation with perfusion.232 
Possible increased REE 
Studies in the late 1980s suggested that CF cells had a supranormal energy 
requirement. With the identification of CFTR, a theoretical base for this possibility 
appeared since ATP use is central to CFTR activity. However such a 
'hypermetabolism' is now thought not to exist as it has not been consistently shown 
in vitro or in vivo. 229236 
Repeated infections 
Although probably mediated through inflammatory demands including pyrogenesis, 
repeated infections deserve mention as a factor inducing increased REE. 
Pulmonary infections occur frequently in most children and adolescents with CF. 
The negative consequences of these for energy balance must be understood so that 
prevention and early treatment of such exacerbations are prioritised in CF 
management. 
Complications of CF 
Certain of the common complications are likely to tip the energy balance further in 
the extra expenditure direction. Liver disease may lead to further fat malabsorption 
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as a result of decreased bile acid secretion. Excess carbohydrate losses may occur 
with CF-related diabetes mellitus. 
Energy intake in the child with CF (Figure 6.2): 
Gastrointestinal problems (anorexia, vomiting, abdominal pain) 
A number of mechanisms may lead to reduced intake as a result of gastrointestinal 
problems. Inadequate control of steatorrhoea is associated with recurrent 
abdominal pain often aggravated by eating. Reduction in intake of food is often the 
result. Full blown distal intestinal obstruction syndrome affects many children with 
CF. This results in repeated episodes of poor intake. 
Gastro-oesophageal reflux is common in CF. If this is complicated by oesophagitis, 
anorexia is a likely accompaniment. 
Respiratory infections 
While a decrease in intake during respiratory exacerbations associated with CF 
would seem likely, this has not been proven scientifically. Reilly and colleagues 
examined 14 CF patients during treatment for a pulmonary exacerbation using a 
food intake diary and found a mean reduction of 47kJ per kg of body weight per 
day.237 However McCloskey and colleagues using similar dietary methodology 
were unable to show a difference in intake between patients when well or during a 
pulmonary exacerbation.238 Similarly Stallings and colleagues showed no decrease 
in intake but the population they studied were taking in nearly twice the 
recommended energy for CF! 233 All three found little change in energy balance. 
Eating patterns 
There is good evidence for altered eating patterns in CF. These are sufficient to 
threaten adequate nutrient intakes. The most comprehensive studies have been 
undertaken in the USA by a group led by Lori Stark. Both toddlers and school age 
children have longer meal times than controls, parents use more coaxing techniques 
and are more concerned about their children's eating patterns.239-40 While energy 
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intakes differed little from controls they mostly did not reach those recommended 
for CF patients. 
International trends in growth of children with cystic fibrosis in the 1980s and 1990s 
The ground work for study of nutritional status and growth in CF was set by Shwachman 
in the 1950s. The inclusion of growth and nutrition in his scoring system emphasised its 
role in clinical well being in CF.10 Corey and colleagues' study comparing growth and 
nutritional status of CF patients in Toronto and Boston brought the critical prognostic role 
of nutrition to international attention. 16 This study examined patients up to 1982 and 
therefore can be said to reflect the effects of care in the 1970s and before. After the age 
of 8 years, the mean height of Toronto patients approximated the normal curves, while 
those of Boston were significantly below (42nd percentile for males, 33rd percentile for 
females). Weight percentiles for both populations were significantly below the age 
norms from early childhood; again Boston patients fared worse than those in Toronto. 
This study precipitated further attempts to maximise nutrition and growth in CF patients. 
Many centres and countries published their data in the following two decades. 
In the USA, the CFF Registry has led to a number of papers on nutrition and growth. 
Reflecting CF care in the 1980s, FitzSimmons charted the 'changing epidemiology of 
cystic fibrosis' in 1993.140 Her cross-sectional data from 1990 showed that 50% of 
patients were below the 10th percentile for height or weight. About 15% were above the 
50th percentile for these parameters. The most comprehensive study from the Registry 
examined the nutritional status of 13 116 patients in 1993 from a number of 
anthropometric angles?41 Percentile charts were constructed using height and weight for 
age; these were compared with NCHS percentiles. Beyond the very earliest ages these 
percentiles deviated greatly from the norm. By teenage the 50th percentile for male 
height for CF patients approximated the 5th percentile for normal subjects. The effect 
was much the same for weight but with a much larger downward deviation of the CF 5th 
percentile. The curves for females deviated even further for weight than those for males 
but the height percentiles, though lower than for normal subjects, did not deviate as 
much. The same effect was seen when z-scores were used. 
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The CF working group in the UK has also published percentile charts covering 
aggregated data for CF centres in the whole country.242 These measurements were 
perfonned in 1994/5 on 3 056 subjects. Z-scores for height and weight, and body mass 
index (BMI) were all below 1990 UK nonns for persons less than 23 years of age with 
height being the best preserved index. The authors noted that there had been an 
improvement of 0,5 in this standard deviation score compared to USA data from 1975. 
When their measurements were presented as percentiles, British children approximated 
population nonns for growth indices for longer than their counterparts in the USA (in 
most cases to 10 years of age). By adulthood the percentile deviation reflected the 
pattern seen in the USA. It should be noted that USA data included patients not attending 
specialised CF centres; the UK data did not. 
A Danish study of 223 subjects reflected growth in patients attending the Copenhagen CF 
Clinic over many years.243 In 1989, height was nonnal though adult height was achieved 
later than the nonn. Weights were nonnal for males below 15 years of age and females 
below 10 years of age. Ten percent of male and females were below the 10th percentile 
for height and 9% for weight. BMI also approximated the nonn in younger patients but 
deviated significantly after 20 years of age. These data represent the best growth so far 
shown in a population of CF patients. 
In an attempt to chart change within these two decades workers in Queensland, Australia, 
compared the growth of children under 18 years of age in 1986 and 1996244 (rather as we 
did see below Study 6.2). In their cross-sectional study they found worse growth in the 
latter year, especially among boys! However the patients in 1996 were older on average 
than in those in 1986 and may therefore have been sicker (indeed their lung function was 
worse). It was a pity that stratifying by age group was not carried out (as we did) as 
trends in the growth in younger children may have given a more detailed view of growth 
trends over time. 
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One of the putative motivations for neonatal screening in CF has been that early 
intervention will prevent the growth deficits seen in early years and may prevent later 
growth deficits, too. Data such as that presented by the UK growth study242 (in which 
screening was not the norm) shows rapid 'catch up' growth after the diagnosis of CF but 
normal growth is not necessarily achieved. Screening aims to bypass this potentially 
deleterious phase 0 f CF. 
Newborn screening has been undertaken in Australia since the early 1980s. In their 
assessment of 15 years of experience Waters and colleagues in New South Wales 
compared children identified in the four earliest years of screening with those born in the 
four years preceding the introduction of the programme.24S They were at pains to point 
out that the two groups were likely to have received the same care but this cannot be 
known with certainty. As predicted the screened group had a greater proportion of 
children who had PS, but allowing for this, screened children still grew better than non-
screened children. Height and weight standard deviation scores were greater at diagnosis 
and longitudinally to age 10 years. At 10 years screened children were an average of 
2,7cm taller than the non-screened historical controls. Notably measures of lung function 
were also better in the screened group. 
The Wisconsin randomised controlled study of neonatal screening in the USA has now 
demonstrated that better growth is achievable through screening. ISO At diagnosis 
screened infants were significantly longer and heavier than the control children. For 
example, the median weight z-score of the screened group was -0,5 while that for the 
control groups was half a standard deviation lower at -1,0. The screened children also 
had better head circumferences; a demonstration of how significant nutritional deficits 
have been in early life with CF. Height z-scores were consistently lower in the control 
group right through to the age of 13 years (the maximum follow up time). The screened 
group had a normal height for age z-score through childhood, a demonstration that height 
deficits are not intrinsic to CF. Notably energy intake in the two groups was the same 
suggesting that early deficits in growth due to CF have long term effects on stature and 
head circumference. 
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A review of screening programmes (only available to me in abstract form) summarises 
these as follows: 
The literature consistently shows evidence of benefits and lack of 
harm from newborn screening for CF.246 
Improved growth outcomes have now been demonstrated in centres of excellence for CF 
care. The Danish study cited above is one example.243 The same was noted in 
Cambridge, UK?47 In Newcastle in New South Wales, nutritional expertise offered to 
children from birth in a CF centre has been shown, even in a short period (1993 to 1997) 
to improve growth in a CF population.248 The cohort who had had specialised centre care 
had normal z-scores for height up to the age of 15 years; those in the earlier cohort who 
had fewer years of such care deviated from the norm by 10 years of age. This was in a 
largely screened population, showing that screening alone is not a guarantee of improved 
growth. 
It should be noted that, despite the achievement of normal growth in early childhood and 
adolescence in CF in many parts of the world, an Australian analysis of total body 
potassium levels, a proxy for body cell mass, showed significant deficits in children 
whose growth indices are norma1.249 In their population only 7,5% of subjects were 
malnourished according to weight and height z-scores yet 29,9% of males and 22% of 
females had total body potassium levels of less than the cut off level for abnormality of 
80% expected indicating much greater levels of actual under-nutrition. 
In summary, improvements in the growth of CF populations have occurred through recent 
decades. Deficits still occur in many patients with the proportion rising to high levels 
among older patients. Approximations to genetic potential for growth are more likely in 
the presence of neonatal screening and access to a specialised CF centre. 
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Literature review of South African experience of nutrition and growth in cystic 
fibrosis 
There is very limited South African literature on this subject. In his thesis on CF, Super 
gives a number of case reports but nutritional details are sketchy.3l A picture of slow 
growth and delayed puberty emerges in those patients who survived infancy. Parenteral 
treatment with Intralipid, fashionable at the time,2l6 was tried on a few occasions. High 
protein, low fat diets were the norm. 
In their report on 33 adolescents and adults with CF (94% of whom had had the diagnosis 
of CF made during childhood) in Johannesburg, Lewis and colleagues noted that 70% of 
the patients had 'normal height,.32 Ninety percent of patients were below normal weight 
for height (WFH). The authors suggested that this related to the severity of ~heir lung 
disease (92,5% were hypoxaemic in room air) rather than to pancreatic insufficiency (PI). 
No description of nutritional management protocols at the adult CF clinic was given. 
Up to the time the studies reported in detail in this chapter were published, the only report 
on the clinical status of South African children with CF also came from the Red Cross 
Children's Hospital. Hill and colleagues' report includes nutritional parameters in a 
comprehensive description of CF in Cape Town in the mid 1980s.33 The nutritional 
status of the 64 patients alive at that time is given. Thirty six percent were under the 3rd 
percentile for weight and 24% for height indicating a significant prevalence of 
malnutrition. The report does not give further details except to suggest that coloured 
patients were more malnourished than their white counterparts. 
"Strenuous efforts to improve their nutrition .. "II 
are recommended in the Discussion, showing appreciation of the importance of good 
nutrition in CF. 
Simultaneous with the gathering of data for this study, Henley conducted a detailed study 
of patients', parents' and siblings' understanding of CF and their information needs. 
With respect to understanding of the nutritional aspects ofCF, she reported that the 
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.. main constituents of familiar foodstuffs were well-known but practical 
application of this knowledge was often poor. 38 
Of great significance for potentially restricting growth was the fact that 90% of patients 
believed that fats should be totally excluded from the diet. Parents' understanding was 
not much better at 50%. In mitigation was a 44% need expressed by patients for 'a great 
deal more information' on 'what kinds of food to eat to increase your weight'. A 
quarter of mothers claimed not to have received any nutritional advice and two in three 
wished for 'a great deal more information' on healthy meals for their CF-affected 
child. 
The fairly dismal figures for growth presented in Hill and colleagues' report were a spur 
to Study 6.1 which will now be reported. What was the situation in the 1990s and were 
the children taking in sufficient energy to sustain good growth? Should the emphasis be 
on enzymes or energy? 
This study undertaken with Ms Romy Saitowitz, a newly graduated B.Sc Hons (Dietetics) 
from U CT whose Honours thesis had reported on the calcium status of the children with 
CF at the RCCH CF Clinic,184 was published in the South African Medical Journal in 
1999 and is reproduced here as it appeared then. 55 References are given at the end of 
the report. 
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STUDY 6.1 
GROWTH AND NUTRITION IN SOUTH AFRICAN CHILDREN 
WITH CYSTIC FIBROSIS 
ATR Westwood 
R Saitowitz 
Department of Paediatrics and Child Health, 
Red Cross Children's Hospital, University of 
Cape Town, Rondebosch 7700, South Africa 
Cystic fibrosis (CF) is the most common life threatening genetic disease -amongst 
Caucasoid groups. It is characterised by chronic lung disease and nutrient malabsorption 
both of which significantly compromise growth. l The life span of individuals with CF 
improves with nutritional status2 probably as a result of a reduction in the rate of 
progression of the lung disease in better nourished patients.3 Nutritional management is 
one of the central tenets of CF care. 
In the past 4 decades major strides have been made in the nutritional management of CF. 
It has been recognised that high dietary energy intakes may be required to achieve 
optimal growth and nutrition. An average energy intake exceeding 120% of the 
recommended daily intake (RDI) of non-CF patients is advised.4 Fat should constitute 
35% of dietary energy intake.4 The development of efficient and effective pancreatic 
enzyme replacement fOlmulations has made it possible to minimise malabsorption. 
Coinciding with better survival rates amongst CF patients are recent reports from 
Western countries that indicate that, in the first decade of life at least, normal growth 
indices can be achieved in almost all young CF patients.s 6 
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Survival of CF patients in South Africa lags a decade behind Western countries.? In a 
clinical and epidemiological study of CF conducted at the Red Cross War Memorial 
Children's Hospital, Cape Town in 1986,36% of patients were below the 3rd percentile 
for weight and 24% below this level for height.8 Henley and Hill's report at around the 
same time showed that there was widespread ignorance of the nutritional principles of CF 
care amongst families dealing with the disease.9 If the survival of CF patients in South 
Africa is to improve, careful attention will need to be given to their nutritional care. 
The present study was undertaken to provide up-to-date and detailed data on nutritional 
status and its dietary correlates in our CF Clinic population. Such data will equip CF 
management teams to intervene more effectively at the individual and clinic levels to 
improve the nutritional status and thus the prognosis of CF patients in South Africa. 
METHODS 
The study population consisted of children and adolescents who received regular care 
from the CF Clinic at the Red Cross War Memorial Children's Hospital in Cape Town. 
This Clinic is attended by almost all children and adolescents with CF in the Western 
Cape. Patients under 2 years, those on continuous home oxygen therapy and, for 
logistical reasons, those living more than 60km from Cape Town were excluded. 
Weight was measured using a scale accurate to O,lkg. Height was measured with a 
stadiometer (Seca, Germany) accurate to 0,5cm. Mid-arm circumference (MAC) and 
triceps skin fold thickness (TST) were measured using a plastic tape measure and a 
Harpenden calliper respectively. The weight and height measurements were transformed 
to percentage of ideal weight for age (WF A), height for age (HF A) and weight for height 
(WFH) using National Center for Health Statistics percentile charts. 1O WFH of less than 
90% of expected was taken to indicate malnutrition.4 Percentiles for the upper arm 
indices were obtained from Frisancho. 11 
Each family was supplied with an electronic scale to weigh all the food and drink the 
patient consumed over 3 consecutive days (2 week days and 1 weekend day). From this 
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3-day weighed food record each patient's daily dietary intake of energy, protein, fat and 
carbohydrate was calculated using the F oodfinder computer program (Version 1.10, 
National Research Programme for Nutritional Intervention, 1992). Stool was collected 
over the same 3 day period for stool fat estimation. 12 A coefficient of fat absorption less 
than 93% defined steatorrhoea.4 
Statistical analysis was undertaken using the Statistica computer package (Version 5.1 
Tulsa, USA 1997). 
RESULTS 
Of the 45 eligible patients, 38 (ages 2-18 years, median 10 years) completed the 3 day 
weighed food record. The Table shows their anthropometric indices. TST and MAC 
measurements were taken on 21 of the 38 patients. Classification of nutritional status is 
in accordance with the recommendations of the Consensus Committee of the CF 
Foundation.4 One patient did not have pancreatic insufficiency. Median WFH was 93% 
(interquartile range 84-101%). Forty seven percent (8/17) of patients 10 years and older 
had WFH below 90% expected. In contrast, 14,3% (3/21) of those under 10 years of age 
had WFH below 90% expected. The difference was significant (X: :;:: 4,33, P = 0,037). 
Mean HFA was 96% (SD 4,7%). 
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Table 1: Anthropometric indices in CF patients 
Frequency (%) 
WFH > 110% (overweight) 5,4 
WFH 90-110% (normal) 62,2 
WFH 85-89% (underweight) 5,4 
WFH 80-84% (mild malnutrition) 13,5 
WFH 75-79% (moderate malnutrition) 5,4 
WFH <75% (severe malnutrition) 8,1 
HF A <5th percentile 16,2 
MAC <5th percentile* 38,1 
TST <5th percentile* 28,6 
I *N=21 
Daily energy intake exceeded 120% of the RDI in 8,1% of cases while 68,6% of patients 
consumed less than 100% of the RDI. There was no correlation between WFH and daily 
energy intake (r = 0,034, p = 0,84). Fat intake represented 29,6% (interquartile range 
27,5-33%) of daily energy intake. Protein and carbohydrate constituted a median of 16% 
(interquartile range 13,9-18,2%) and 51,7% (interquartile range 49,9-56,8%) of daily 
energy intake respectively. 
Nineteen pancreatic insufficient patients (51,4%) completed the 3 day stool collection. 
The median coefficient of fat absorption was 89,09% (interquartile range 81,7-96%) with 
7 patients (36,8%) achieving absorption coefficients above 93%. 
DISCUSSION 
Nutritional management is a cornerstone of CF care. The Consensus Committee of the 
CF Foundation advises regular monitoring of growth and energy intake as well as regular 
expert dietary guidance for CF patients.4 WFH is the recommended growth index for the 
assessment of nutrition in CF.4 
One third of patients 18 years or younger in this study had low WFH. That this deficit 
was nutritional in origin is supported by the similar proportion of patients with upper arm 
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indices below the 5th percentile. In 16% of patients malnutrition had led to stunting of 
growth although the mean height of 96% of expected was almost that of the normal 
population. The majority of malnutrition was found in patients 10 years of age and older. 
Only 3 of the 20 patients aged between 2 and 10 years (all of whom came from poor 
social circumstances) had WFH less than 90% (81%,89%, 73%). It is important to note 
that infants and patients with very severe lung disease in whom nutritional deficits are 
common were absent from this analysis. 
The nutritional status in CF patients reported here is surprisingly similar to reports from 
better resourced centres. Using Body Mass Index (BMI) as a measure of nutritional 
status, the most recent report from the UK CF SurveyS shows that, after the first two 
years of life, mean BMI remains in the normal range until the age of 10 years and then 
declines. Likewise North American 5 to 10 year olds with CF have WFHs in the normal 
range.6 Reports from other centres published in the 1990s show a similar proportion of 
stunted patients to our cohort (Morison et al.: 14%13, Wootton et al.: 17%14). However, 
in common with comparable studiesS 6, we have shown that, for the majority of young 
patients with CF, stature in the normal range can be expected. 
In our study, nutritional status after the first decade of life deteriorated to the point where 
47% of patients were malnourished. In contrast, similar patients in the UK have a BMI 
less than one standard deviation below population normss. Declining adherence to 
therapeutic and dietary regimes amongst adolescents is common. Compared with the 
UK, South African CF Clinics have fewer clinic and community resources to counteract 
this tendency. Given the poorer prognosis of CF in South Africa7, adolescents are likely 
to have more severe lung disease than their UK counterparts. This will also make it more 
difficult to achieve adequate nutrition and growth. 
Intuitively it would seem probable that those with the lowest relative energy intake would 
have the greatest degree of malnutrition. We were unable to show this. This may reflect 
the small sample although two studies with similar numbers of patients were able to show 
some correlation between energy intake and measures of nutritional status. 13 14 This lack 
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of correlation may also throw doubt on the accuracy of the weighed food records. 
However other results based on these records were in accord with previous studies in CF 
patients. For example, the finding that most patients did not reach the normal RDI for 
energy or fat, let alone the higher intakes recommended in CF, is not unique to Cape 
Town. 1415 
Despite the relatively low dietary energy and fat intakes, 67,6% of our patients had 
achieved WFH above 90%. This apparent paradox may be because CF patients, on 
average, weigh less than their peers.13 As Wootton et al 14 point out, since RDI is 
calculated on an individual's age rather than weight, energy needs in CF will be 
overestimated. 
Our results indicate that dietetic advice needs to be individualised, with specific attention 
being targeted at those with declining WF A, HF A or WFH and those approaching their 
teenage years. The emphasis will need to be on increasing fat intake as patients with 
higher fat intakes absorb higher amounts of energy. 13 
Only half the patients completed the 3 day stool collection. Despite pancreatic enzyme 
replacement therapy and in common with their counterparts in developed countries,6 13 14 
the majority of patients tested were malabsorbing fat. This will have contributed to 
energy deficits and consequent malnutrition. Further education and closer attention to the 
detail of enzyme use will be necessary to improve fat absorption. 
The gains made in the prognosis of CF in recent decades have largely been due to the 
greater attention given to the details of conventional care i.e. dietary management, 
pancreatic enzyme replacement therapy, physiotherapy and treatment of respiratory 
infections. Our study has shown that, with respect to nutrition, the majority of our young 
CF patients compare well with patients from better resourced countries. However, it is 
also plain that for some patients and especially for adolescents 1 greater attention to 
nutritional care and enzyme use is needed both of which require ongoing expert medical 
and dietetic care. The data in this study were collected in part to assist in tailoring advice 
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to the individual and family. The recognition of persisting dietary energy and fat deficits 
and the need to maintain gains made in the first decade of life has led to the publication 
of a South African book of nutritional advice for families dealing with CF.16 
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At the same time as this study was being undertaken and analysed I had been examining 
the prognosis of CF in the Cape Town popUlation since 1974. I was unable to show an 
improvement in the outlook of the disease despite the clinical impression of such progress 
(see Chapter 9 for the fuJi study).52 I decided to explore what had happened to the 
nutritional status of patients attending the clinic over time. Any improvement 
demonstrated might stand to bolster a sense that we were on the right path in our 
management of the disease. The idea was a simple cross-sectional comparison of 
anthropometric measures over time. The paper arising from this study appeared in the 
Journal of Tropical Pediatrics (whose editor did not hold Cape Town's latitude against 
information of the health of its paediatric population).56 Once more the references appear 
at the end of the article. 
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STUDY 6.2 
CHILDREN WITH CYSTIC FIBROSIS IN SOUTH AFRICA: AN IMPROVING 
NUTRITIONAL PICTURE. 
Westwood A TR, Ireland JD. 
J Trop Pediatr 2000; 46:119-121 
SUMMARY 
Nutritional status and growth play an important part in determining prognosis in 
cystic fibrosis (CF). In South Africa, the median survival of patients with CF is 18 
years. Using chart review, we studied the pattern of growth over time of a South 
African CF population. Percentage of expected weight for age, height for age and 
weight for height were determined for each patient in 1986 (N = 49) and 1996 (N = 
63). Mean indices were the same in the two years. In 1996, mean weight for age of 
children aged 5-10 years was 94,2% (SD 20,4), 14,3% higher (p <0,05, 95% 
confidence intervals 3-25%) than children of the same age in 1986. Improved 
growth of young children with CF has been achieved in a resource poor country 
setting the scene for improved prognosis. 
Cystic fibrosis (CF) is associated with progressive obstructive pulmonary disease. The 
majority of persons with CF also have pancreatic insufficiency. These two conditions 
together with decreased appetite, recurrent chest infections and a high resting energy 
expenditure make it difficult for persons with CF to maintain adequate growth. l 
Since the identification of the disease in 1938, its prognosis has steadily improved in 
most countries2 with the enhanced growth of persons with CF being an important 
contributory factor. 3 In South Africa, cystic fibrosis occurs in 1 in 2000 births amongst 
Caucasoids and 1 in 12000 births amongst persons of mixed ancestry. A recent study of 
the prognosis of CF in the Western Cape region of South Africa showed median survival 
to be about 18 years.4 This study was not able to demonstrate a difference in survival 
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between persons with CF born in the decades 1975-1984 and 1985-1994. This was 
probably due to a preponderance of infant deaths (some infants were mistakenly thought 
to have kwashiorkor5) and the size of the cohort To establish whether progress has been 
made in setting the scene for improved survival in this region, we compared the growth 
of patients with CF in 1986 and 1996. 
PATIENTS AND METHODS 
The charts of all patients with CF regularly attending the CF Clinic at the Red Cross War 
Memorial Children's Hospital, Cape Town in the first 6 months of 1986 (Group I) and 
1996 (Group 2) were reviewed. Patients diagnosed less than a year prior to these periods 
were excluded as their weights might not have stabilised following the institution of 
therapy. Each patient's maximum weight (kg) in the 6 month period, the associated 
height (cm) and age (years and months) were recorded. These were converted to 
percentage of ideal weight for age (WF A), height for age (HF A) and weight for height 
(WFH) using National Center for Health Statistics growth charts.6 The groups were 
compared in toto, by sex, by ethnic group and in 5-year age groups. 
RESULTS 
Group I had 49 patients (24 male) and Group 2 had 63 (35 male). WFA, HFA and WFH 
data are shown in Table I. There was no difference in mean WFA. Insufficient height 
measurements were available for 1986 for comparisons ofHFA and WFH to be made. 
There were no significant differences between the two groups when compared by sex and 
ethnic group (data not shown). 
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Table I 
Nutritional Indices: 1986 vs 1996 
WFA HFA WFH 
Number %(SO) Number %(SO) Number %(SO) 
Group 1 53 83,4(14,6) 12 95,7(4,6) 12 89,1(15,7) 
(1986) 
Group 2 63 83,6(22) 60 95(5,5) 60 87,9(20,5) 
(1996) 
.. so "" Standard deViation 
Table II 
Weight-for-age by S-year age group 
< 5 years 5-10 years 10-15 years > IS years I 
Number %(SO) Number %(SO) Number %(SO) Number %(SO) 
Group 1 16 93,1(14,1) 20 79,9(13,2)* 10 74,9(13,5) 7 83,2(12,9) 
(1986) I 
Group 2 14 91,4(9,1) 18 94,2(20,4)* 21 79,1(25,9) 10 62,9(11,6) I 
(1996) 
*Oifference = 14,3% (p <0,05 95%CI 3-25%) 
Table II, showing the groups analysed in 5-year age groups, demonstrates a significant 
improvement in WF A for those aged 5-10 years. 
DISCUSSION 
While WFH is a better measure of the nutritional contribution to growth in CF, low WFA 
does reflect the effects of the disease on growth.7 There was a significant improvement 
in the growth of patients with CF in the Western Cape in the decade under review. The 
14,3% improvement in mean WFA for 5-10 year old children translates into a shift from 
the 10th percentile to just below the 50th or an increase in Z score of 0,5. Thus, in 1996, 
CF was having a minor influence on the growth of most children in this age group. 
For the 10-15 year old patients, the number of whom have doubled between 1986 and 
1996, the large standard deviation in 1996 suggests that a subpopulation of patients is 
doing particularly badly while most may be better off than their peers of a decade before. 
The raw data support this: 3 patients in this age group had WF A below 55% in 1996 
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compared with none below 60% in 1986. With a mean WFA of 79,1 %, patients aged lO-
15 years in 1996 are of equivalent WF A to a group 5 years their junior in 1986. This is 
further evidence of improved growth in the 1996 group. These improvements in the 
growth of patients under 15 years of age should result in improved survival. 
The apparent decline in the status of patients over 15 years of age is misleading because 
an adult-oriented clinic was established in 1989 at a separate site. In 1996 only the most 
debilitated patients over 18 years of age remained at the Children's Hospital Clinic. 
What has brought about these improvements? Effective enteric-coated pancreatic 
enzyme supplementation was available before 1986 although its improved control of 
steatorrhoea may not have reversed the nutritional effects of prior malabsorption. The 
recognition of the value of high fat diets in preventing malnutrition in CF became general 
before the years under scrutiny but had not been fully implemented in 1986. Subsequent 
interventions which may have contributed to the near normalisation of WF A in young 
children with CF are greater dietetic involvement, greater use of nutritional 
supplementation including gastrostomy feeding and the more aggressive use of a greater 
range of anti-pseudomonal antibiotics. The improved recording of height data in 1996 is 
testimony to better growth monitoring which is leading to earlier recognition of faltering 
growth. Appropriate intervention can then take place. 
In the mid-1980s a study of patient and parent understanding of CF in Cape Town 
showed poor insight into the nutritional aspects of care.8 Whether this has been reversed 
in the intervening years is unknown. Recently a South African book of nutritional advice 
for families dealing with CF has been produced.9 Earlier identification of children with 
CF is probably not a factor in the improvement in growth as delayed diagnosis remains 
the norm. Only 3 patients in this study were pancreatic sufficient, a status which usually 
results in better nutrition. 
These positive trends have been achieved despite reductions in services and support for 
those with uncommon diseases which require specialised health care in South Africa. 10 11 
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They give cause for encouragement for South Africans with CF and their carers. 
Improved growth and nutrition can lead to improved health and thus enhanced quality 
and length of life. The gains made over the last decade will need to be maintained by 
careful attention to all aspects of CF care. Services geared to achieving this need to be 
sustained. 
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CRITIQUE & COMMENTARY ON CAPE TOWN STUDIES 
These two cross-sectional studies added significantly to the South African literature on 
nutrition in CF. They demonstrated that many children were growing well. The studies 
were not designed to test whether those children were growing optimally but they 
presented an encouraging view given the challenging circumstances in which health care 
was being delivered. That progress was being made over time (albeit only measured by 
weight for age (WFA)) was also encouraging, given the importance of good nutrition in 
improving the prognosis of CF. The studies demonstrated the danger adolescents were in 
from a nutritional standpoint. Although our discussion expressed the view that this might 
reflect the effect of poor lung function, it equally could have been that the poor nutrition 
was setting the scene for rapidly progressive lung disease. The care of adolescents 
became a focus of our CF care in part as a result of this study (see Chapter 8). 
Although there was a considerable amount of useful, infonnation contained in these two 
studies, there were significant gaps. Infants and those with advanced lung disease were 
missing. Rural patients had not been assessed in detail. There was no longitudinal 
information. In only 38 patients had height been studied so the 16,2% prevalence ofHFA 
less than the 5th percentile must be regarded as preliminary. The majority of patients 
(67,6%) had good WFHs, but were these masking less than adequate linear growth, a 
marker of poor early nutrition? The effect of gender, ethnicity or socio-economic status 
were not covered. Given the deleterious effect of female gender on CF 136 and the fact 
that coloured patients have a worse outlook than white patients,52 such detail might be 
illuminating in our context. There has also been no correlation of nutrition with lung 
function. Ms Saitowitz and I analysed nutrient intake beyond the macronutrients 
described in Study 6.1 using the 3 day food record but a wide scatter of results with no 
correlation to anthropometric or macronutrient intake made interpretation impossible. 
Further targeted studies such as Saitowitz' calcium studies184 might be a better approach. 
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As discussed in the introduction to this chapter, good nutrition has established itself as 
central to the quest for better survival outcomes in CF. From Hill and colleagues' studl3 
that outlined overall nutritional status through Henley's thesis exploring nutritional 
knowledge among patient and family members38-9 to our studies, there has been a 
progressive desire for nutrition to take this central role in Cape Town. The sub-optimal 
energy and fat intake of a considerable proportion of the children studied acted as a spur 
to improved dietetic management at the Clinic. Since the mid 1990s a dietician has 
attended all clinics and measured height and weight and calculated WFH at each patient 
visit, as recommended by the CFF Consensus Committee in 1992.228 This information 
has then been available to the medical staff at the time of their consultation with patient 
and parent. The clinical record was designed to make reference to previous 
anthropometry easy (see Appendix B). A graphical representation of WFH was available 
on the inside cover of the CF folder, the aim being to allow early recognition of growth 
faltering. Growth faltering has been the signal for further anthropometry such as upper 
arm measurements as well as more detailed dietetic assessment. Nutritional 
supplementation in the form of proprietary nutritional products has been available under 
the guidance of the CF Clinic's dietician. Gastrostomy feeding using the PEG method 
was introduced for patients who failed to grow despite maximal optimisation of PERT 
and full dietetic intervention including caloric supplementation. Fourteen patients have 
had supplemental feeding by this route between 1994 and 2002. (Further details are 
given in Chapter 5 (p 155). Regular faecal fat measurement as recommended by 
Littlewood!8! and others was not introduced as, even under study conditions, few families 
completed this unpleasant study. A project to produce a nutritional advice booklet for 
South Africans with CF was funded with an award from Solvay Pharmaceuticals in 1995. 
A 100 page book entitled 'Eating, Enzymes and Exercise,250 that contained advice about 
all aspects of nutrition in CF (compiled and written by this author) and dozens of recipes 
(devised by Ms Saitowitz and CF patients and their parents) was published and 
distributed in 1997 with a revised second edition appearing in 2003. 
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The deficiencies in our studies and the changes wrought in the management of patients 
over recent years should encourage further evaluation of the nutritional status of patients 
in this region (and in the whole country). 
Internationally, a number of changes in the approach to nutritional evaluation and 
management have taken place that could influence how this evaluation might be done. 
Proportional hazards statistical techniques have been applied to longitudinal data in CF, 
even in relatively small CF populations. For example, Oliviera and colleagues, in a 
Brazilian CF population of 127 subjects, were able to show that HF A at diagnosis could 
influence prognosis?SI A HFA z-score of more than -1,29 was associated with the 97% 
(95% CI 93-100) estimated survival; less than -1,29 and the survival estimate dropped to 
66% (95% CI 52-80). This effect remained on multivariate analysis: relative risk 4,06 
95% CI 0,92-17,8). 
Further thought has been given to which nutritional measurements give the best 
assessment of growth in CF. A 1998 paper published by a group studying the CFF 
Registry sought to compare a range of anthropometric indices in CF.241 These included 
comparisons with normal percentiles (HFA, WFA etc.), percent expected WFA and WFH 
medians, z-scores, and measures of adiposity such as BMI and percent ideal HFA. Using 
four criteria for malnutrition based on the literature, they demonstrated that these 
measures produce different and sometimes conflicting assessments of malnutrition in CF. 
For example, while the proportion below the 5th percentile and those with a percent of 
median WF A <80% and HF A <90% identified a similar proportion to be malnourished, 
they did not agree on whether the children were stunted, wasted or both. Of note, the 
criterion that identified the least number of children to be wasted and stunted (3,9% 
compared with 11-17% by other criteria) included measures recommended in the 1992 
Consensus statement228 (HFA <5th percentile, percent ideal WFH <85%). The 
researchers noted that, in practical terms, HFA and WFA percentiles are the easiest to 
compute. The meaning of more detailed definition of 'malnutrition' in terms of wasting 
and stunting has yet to validated in CF, they felt: ' ... longitudinal growth data is 
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necessary to address these questions.' Anthony and colleagues in Melbourne, 
Australia cast further doubt on the value of percent ideal WFH as a measure of growth in 
CF in their study of CF subjects and their siblings.252 CF subjects were distinguishable 
from their siblings by height and weight z-scores and BMI (their scores were significantly 
lower) but not by percent ideal WFH. 
Since our studies were conceived and published, the 1992 Consensus document on 
nutrition in CF has been superceded by another, published in the Journal of Pediatric 
Gastroenterology and Nutrition in 2002.253 This document related growth measures to 
the new NCHS/CDC charts of 2000254 (see next paragraph for a discussion of these charts 
in relation to SA). HF A and percent ideal WFH remain the recommended routine 
assessments of growth. The latter, updated with recent methodology, remains a 
calculated parameter. BMI percentile has been added as the NCHS/CDC charts include 
this measure. In assessing whether a patient is nutritionally compromised, height is 
related to predicted height (on the basis of parental heights). Percent ideal WFH should 
be 2:90% expected with no weight loss or plateau for 'acceptable' nutrition to be 
pronounced by the CF team. It is surprising that WFH is retained in the assessment of 
nutritional status on CF given the doubts cast on its usefulness by some the Consensus 
Statement's own authors! McNaughton and colleagues in their study of total body 
potassium levels in CF also showed WFH to be the least sensitive measure of true 
nutritional status.249 
The two Cape Town studies reported in this chapter used the older NCHS percentile 
charts that have been accepted in SA. In 2000, the CDC in the USA published new 
growth charts. These charts, also cross sectional and based on an American population, 
aimed to correct some of the demographic imbalances of the 1977 charts.254 They also 
aimed to smooth out the 'disjunction' between length and height charts. For the first time 
BMI charts were given. Overall, ranges of normal were somewhat extended as a result of 
the new anthropometric data. Whether the NCHS/CDC charts of 2000 would alter 
nutritional classification of South African children has not yet been tested. Our studies 
reflect the growth of children with CF relative to norms that have been applied (as the 
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best available) to South African children. Study 6.2, with its comparative cross-sectional 
design, compared groups across time using identical growth norms. Should future studies 
of the effectiveness of the strategies to improve nutritional and growth in CF patients in 
the Western Cape province outlined above continue to use NCHS percentiles for 
retrospective comparisons to be valid, or should we be comparing our CF patients with 
those in other centres that now base their norms of the NCHS/CDC charts (USA) or MRC 
charts (UK)? Given the socio-economic determinants of growth in childhood in SA, I 
believe that we should continue to compare our CF children with current South African 
norms and previous generations of CF children in SA i.e. use the 1977 NCHS charts with 
all their imperfections. In view of the significant levels of nutritional compromise 
demonstrated in our CF population, the caveats surrounding WFH are less pressing in 
SA. WFH estimations, especially when followed over time, are likely to add value to 
clinical anthropometry in our context. It would be interesting to see how our children 
fare on the new BMI chart. 
There is good evidence that nutritional interventions such as those we have used in Cape 
Town work. A meta-analysis of nutritional interventions published in 1997 showed 
behavioural interventions to be most effective in producing weight gain in patients with 
CF. Oral, enteral and parenteral supplementation were also found to be effective when 
studies were combined.2ss It would be important to monitor their effect in our context. 
Future studies of nutrition and growth in cystic fibrosis in South Africa: 
Recommendations 
As argued above there are good reasons to continue to monitor and study the nutrition 
and growth of patients with CF in SA. In addition, existing data from the time from when 
height has routinely been measured in Cape Town should be mined for further analysis 
(e.g. gender, ethnic group, the larger number of adolescents who have been seen since 
1996). The following practical approach is recommended in the light of experience and 
study: 
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Measures 
1. Continue routine, accurate measuring and recording of weight and height In 
specialised centres. 
2. Percent ideal WFH should be calculated as recommended by the CFF Consensus 
report. 
3. BMI percentile to 20 years of age. 
4. Head circumference through infancy. 
These measures should be part of the national CF database that is in evolution. 
Analysis 
1. Based on NCHS percentiles (except for BM!) 
2. Cross sectional comparisons over time (age groups or specific ages) 
3. Longitudinal charting of individual children in age cohorts 
4. Gender-matched comparisons for cross-sectional and longitudinal data 
5. In Cape Town, ethnic differences in prognosis mandate comparisons between 
coloured and white children. 
These measures and analyses will allow audit of expensive services, optimisation of 
interventions and use of the data in studies of other aspects of CF in SA such as prognosis 
and lung disease. 
Chapter 6 189 
CHAPTER 7 
LUNG DISEASE ASPECTS 
OUTLINE OF CHAPTER 
The present chapter reviews what is known about CF lung function and 
microbiology in South Africa and reports a new study of the microbiology of CF 
lung disease in our population. The limitations of longitudinal data on measures 
of lung disease so far in this population are demonstrated. The chapter then 
explores how routine data might be used to yield useful infonnation for clinical 
audit and patient care in South Africa. 
INTRODUCTION 
A large proportion of the morbidity and nearly all of the mortality associated with CF is 
related to lung disease. Yet despite this central role the range of patterns of lung disease 
is very wide. While the pathogenesis follows a unifonn sequence (early inflammation, 
infection with respiratory viruses and typical bacteria, increasing endobronchial disease, 
progressive destruction of lung parenchyma and airways leading to bronchiectasis and 
cystic change, the development of respiratory failure), the speed at which this occurs is 
detennined by genetic, environmental and health service factors. 256 
Many of these factors are known but their influence on and interaction in a particular 
individual are hard to predict. At a CF population level this wide variation and 
multiplicity of influences on lung disease limits the value of cross-sectional measures of 
lung disease such as lung volumes and chest X-ray scores. As Corey in Toronto has 
clearly argued, longitudinal analysis of these parameters, while more helpful in 
describing the progression of CF lung disease in a population, is also fraught with 
complexities.257 This will be especially the case for a small population spread over many 
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years such as the one under study here. In longitudinal tenns the factor that will have 
most influenced lung disease in the last 30 years will have been advances in medical 
therapy. These advances are likely to have outweighed genetic influences on lung 
disease such as M508 status and immunological phenotype. Other environmental 
changes such as reduced exposure to cigarette smoke or pathogens will also not have 
been as significant as the influence of new antibiotic regimens and better nutrition. So 
how is lung disease to be studied in a CF population such as that in the Western Cape 
province and what is the value of research done so far? 
Chapter 4 presented one aspect: the lung complications associated with CF in the CF 
population of the Western Cape province. Given that lung disease largely detennines the 
mortality from CF, the influence of changes wrought in medical therapy may be 
measurable in tenns of survival in CF over the period under review. This aspect of lung 
disease was explored in a 1999 paper52 and is further explored in the chapter on the 
prognosis of CF in the Western Cape province (Chapter 9). The microbiology of lung 
disease in CF in our population is reported in an unpublished study (Study 7.1). 
Lung disease in cystic fibrosis in South Africa: a literature review. 
The literature on CF lung disease in SA is limited to case reports, reviews of whole 
populations and cross sectional descriptions. Super's cases were all reported as case 
reports in his thesis with no attempt to group patients.31 The first overall analysis oflung 
disease in a South African CF population came from a review of experience at a newly 
formed adult clinic in Johannesburg.32 In this review in the early 1980s, summaries from 
33 white CF patients ranging in age from 14 to 32 years were given. The article also 
described typical practice at the time and was not intended as a scientific review. A 
picture was given of variable degrees of lung disease with a minority (7%) needing 
recurrent admission. Pseudomonas aeruginosa was grown from the sputum of 82,8% of 
these patients and Staphylococcus aureus from 63,7%. Details of lung function were not 
given. Radiographic changes were reported as consistent with other larger series. No 
scoring was done. 
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The second study to report lung disease was Hill and colleagues' paper from Cape Town 
in 1988.33 Again this was a review of all patients seen in a service. Sixty four patients 
were reviewed cross-sectionally. Lung function was not reported but Shwachman scores 
(that include clinical pulmonary parameters) were. This was a very young population 
(67% <10 years of age) and P aeruginosa colonisation was uncommon (11164). One 
year's worth of sputum cultures associated with pulmonary exacerbations was measured. 
Typically, S aureus and P aeruginosa infections dominated. 
These two studies allow only limited insight into lung disease in CF in SA. From the 
information given, one can broadly say that CF lung disease in children, adolescents and 
adults had the typical features described for CF in other parts of the world. 
Zar and the team at the RCCH undertook the most detailed study yet of lung function in 
CF in the mid-1990s.258 Perhaps reflecting its origins in the field of gastroenterology, the 
RCCH CF Service did not measure lung function routinely in CF patients until the 
beginning of the 1990s. The forced expiratory manoeuvre has been used as a clinical tool 
in patients attending the outpatient clinic. The most recent data from this clinically based 
procedure formed the basis for the study which was published, with an editorial updating 
readers on CF and its local relevance,259 in the South African Medical Journal in 1998.258 
This study aimed to report details of the pattern and reversibility of lung function and 
related these aspects to demographic variables, CFTR genotype and infection with P 
aeruginosa. Forty two consecutive children (86% of those eligible, based on age and 
ability of perform the forced expiratory manoeuvre; ages 5,9 to 18,8 years, mean 11,8 
years) were studied when they were well. The main findings of this first view into the 
lung function of children with CF in SA were of relatively preserved lung function (69% 
had 'mild' or 'minimal' disease) and worse lung function in the presence of P aeruginosa 
colonisation. Unfortunately the influence of age on this latter finding was not studied: 
worse lung function and the likelihood of infection with P aeruginosa both increase with 
age in CF. As with the encouraging findings for nutrition reported in Chapter 6, these 
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lung function data suggested that a springboard for better health in CF existed. Apart 
from P aeruginosa infection, no other factors (gender, genotype) were associated with 
differing lung function. 
As part of my first study on the prognosis of CF in this region, I recorded age at first P 
aeruginosa infection in the 102 patients over a 20 year period. 52 The organism appeared 
earlier in coloured compared with white patients (median 1 year versus 4 years) and was 
associated with a lower 5-year survival in this group. This effect was not seen 10 years 
after colonisation (numbers surviving or followed up for 10 years after infection were 
small). Full details can be found in Chapter 9. 
A number of questions remain after these initial studies of lung disease in our CF 
patients. What happens to lung function over time? What are the patterns of 
colonisation/infection with lung pathogens? As the SAMJ article248 asked, are there other 
variables (e.g. socio-economic status, health care access) that influence lung function in 
this population? Is the mild lung disease in the earlier years of life leading to an 
improved survival outlook in CF in this province? 
Study 7.1 
The Acquisition of Bacterial Pathogens in Cystic Fibrosis in the 
Western Cape Province 
Focused literature review 
In the early years after CF was delineated as a separate clinical entity, S aureus was 
responsible for most of the respiratory morbidity associated with the disease.4 As 
infection with this organism was controlled with antibiotics, chronic P aeruginosa 
infection became a regular problem and challenge. While the exact relationship between 
these two infections has been the subject of controversy over the years, recent work 
studying the infection of children identified as having CF by newborn screening has 
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suggested that, indeed, S aureus infection is a risk factor for the acquisition of P 
aeruginosa. Prospectively studying 180 children born in Denver, Colorado between 1982 
and 1989, Maselli and colleagues found that increased numbers of oropharyngeal isolates 
of S aureus were associated with earlier acquisition of P aeruginosa (relative risk 
1,30).260 It is also clear from such studies that S aureus infection is not a sine qua non for 
P aeruginosa infection. Using bronchoalveolar lavage (BAL) to obtain respiratory tract 
samples in infants, Nixon and colleagues in Melbourne, Australia cultured P aeruginosa 
in a significant proportion of cases (42%) where there had been no prior S aureus 
cultures.26I 
P aeruginosa, an unusual infection in other settings where human subjects are 
immunocompetent, has a special affinity for the respiratory tract in CF. The organism 
appears to adhere to CF epithelial cells more easily than to non-CF cells. CFTR may 
function as a receptor for P aeruginosa.262 It is also possible that local immunological 
defences such as defensins are unable to protect the lungs against bacterial infection in 
CF subjects owing to the abnonnal composition of the mucociliary layer in the disease. 
Once established in the lungs, P aeruginosa is almost impossible to eradicate; indeed so 
important is this fact that postponement of chronic infection is vital. This was shown to 
be possible by Valerius and colleagues in the early 1990s: they showed that vigorous 
antibiotic therapy could postpone chronic infection in some patients.21 
P aeruginosa infection is associated with an acceleration of the decline of lung function 
in CF. It had been suggested that P aeruginosa was merely a marker of more advanced 
lung disease but recent work has put this notion to rest. Rosenfeld and colleagues in a 
study of very young CF subjects demonstrated that, even very early in life, the presence 
of P aeruginosa is associated with worse lung function even when changes are relatively 
mild.263 The Australian study of early acquisition also showed that early P aeruginosa 
infection led to worse outcomes at 7 years of age.261 The measures identified as worse in 
children infected with P aeruginosa included mortality, FEV I variability, National 
Institutes of Health scores and days in hospital. Likewise the Wisconsin study of new 
Chapter 7 194 
born screening showed that children's chest X-ray scores and FEV1IFVC percentages 
deteriorated accelerated with P aeruginosa infection.264 
P aeruginosa establishes a foothold in the CF lung by changing phenotype and 
developing a biofilm of exopolysaccharide ('alginate') and microcolonies of organisms. 
On the culture plate these strains appear as mucoid colonies. Once this change has taken 
place eradication is much more difficult. The organisms are effectively protected from 
antibiotics and induce a continuous and self-injurious immunological response in the 
host. This chronic response by the host to permanent infection sets the scene for 
progressive lung damage. Henry and colleagues in Australia showed that the mucoid 
fonn of P aeruginosa was associated with worse survival than its non-mucoid phenotype 
was?65 Pedersen and colleagues in Denmark presented evidence that the mucoid 
phenotype accelerated the deterioration of lung function in CF.266 This has been 
confinned by the latest prospective work associated with the Wisconsin newborn 
screening study. All measures of lung function (FEV}, FVC, FEVtlFVC ratio, FEF25-50) 
deteriorated more rapidly after the phenotypic change from non-mucoid to mucoid P 
aeruginosa.267 The recent discovery that macrolide antibiotics such as azithromycin have 
an anti-inflammatory effect on this biofilm has already been shown to have a positive 
clinical effect on lung disease in CF,268 confinning the importance of this alginate layer. 
Lee and colleagues have validated a definition for infection with P aeruginosa (Table 
7.1).269 
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Table 7.1. Stages of Pseudomonas aeruginosa infection in cystic fibrosis 
Stage Proportion of samples growing Pseudomonas . 
in last year . 
Chronic >50% 
Intermittent <50% 
FreeofPA No growth in previous year 
Never infected Never cultured 
P A == Pseudomonas aeruginosa 
It has become very clear in the last decade from studies using BAL and anti-pseudomonal 
antibody detection in screened and unscreened newborns with CF that P aeruginosa 
infects the lungs of CF patients much earlier than had previously been thought. Using 
BAL and oropharyngeal cultures, Nixon in Australia showed that 45% of 53 patients had 
become infected by a mean of 45 months of age.261 The methodology of respiratory 
sampling has been crucial in demonstrating this: when oropharyngeal cultures only are 
used even in screened children, median age at infection appears to be much later e.g. 8,1 
years.2OO 
Pseudomonal antibody testing shows the time to infection to be even shorter. Bums and 
colleagues studied yearly samples of BAL fluid from the airways of unscreened children 
under the age of3 years.270 Seventy two percent had infection either in the oropharynx or 
BAL fluid; one third had P aeruginosa in their BAL fluid in years 2 and 3 of life. All in 
all, 45% of patients had P aeruginosa detected in BAL fluid in the first 3 years of life, a 
figure very similar to the Australian BAL study. When serology for antibodies to various 
epitopes of P aeruginosa was added to the assessment, fully 97,5% of the 40 patients had 
evidence of infection. It was also evident that patients may become infected with more 
than one genotype of P aeruginosa and that there is not a unique genotype associated 
with this early infection. The vast majority of organisms were non-mucoid. West and 
colleagues in Wisconsin, USA studied CF patients identified through newborn screening. 
They showed that high antibody titres preceded cultures from the oropharynx by 6 to 12 
months as did deterioration in the chest X-ray score. This suggests that the presence of 
antibodies reflects a clinically significant pulmonary infection. In this study the most 
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sensitive antibody was that to a whole cell lysate, significant titres being found at a 
median of 17,8 months of age.271 
Using BAL, Bums and colleagues' studies270 confirmed what had already been 
demonstrated with sputwn cultures by Annstrong and colleagues in Australia272: the good 
negative predictive value (NPV) of single oropharyngeal cultures in relation to cultures 
from the lower respiratory tract (Ann strong and colleagues NPV 96%, 95% CI 91 %-
99%, Bums and colleagues NPV, 85%; 95% CI, 760/0-92%). However they suggested a 
better predictive value for multiple positive oropharyngeal cultures than Annstrong and 
colleagues: 
Isolation of P. aeruginosa from the [oropharyngeal] culture 
was less accurate in predicting lower airway P. aeruginosa 
isolation ([positive predictive value], 69%; 95% CI,48%-
86%). Combining the results of 2 [oropharyngeal] cultures 
(concurrent with and 3 months before the BAL culture) 
yielded the highest predictive values of the measures we 
analyzed (sic), The NPV of this combination of 
[oropharyngeal] cultures was 97% (95% CI, 86%-100%), 
and the [positive predictive value] was 83% (95% CI, 52%-
98%).270 
Although Bums and colleagues suggested that, in the light of these findings, two 
oropharyngeal cultures collected three months apart may be a surrogate for lower 
respiratory secretions, these CIs are very wide when seen in the light of the decisions 
required in clinical practice. Thus, until larger studies have been concluded, in 
circumstances where antibody tests are not available such as SA, lower respiratory 
secretions should be obtained to confirm clinical infection. BAL is impractical in routine 
practice; a well-collected sputwn sample is the best proxy. 
What determines whether an individual child becomes infected with P aeruginosa? The 
study of Maselli and colleagues cited above26o is the latest in a string of studies 
investigating this question. They had the advantage of a prospective view of screened 
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children. The disadvantage of their study is its dependence on oropharyngeal cultures. 
However since this method was consistent throughout the study and there is no known 
bias against a single patient group of this method of obtaining respiratory samples, time 
to positive culture, though falsely long and possibly not reflecting lower respiratory tract 
infection, is likely to have been proportionately delayed for all subjects. On multivariate 
analysis female gender was identified to lead to earlier infection during follow up 
(relative risk 1,85). This confirms the findings of a specific investigation into the role of 
P aeruginosa in the poorer clinical outcomes in CF associated with being female by 
Demko and colleagues?73 This study from Cleveland, Ohio showed that females were 
infected by P aeruginosa and became chronically infected by its mucoid phenotype about 
a year earlier than males. Doubts have been cast on the validity of the study by Maselli 
and colleagues. Workers from Tuscany in Italy questioned the meaning of 'acquisition' 
as it merely referred to first culture and not chronic infection by P aeruginosa, an 
important clinical distinction.274 Their data suggested no difference attributable to sex, 
though Accurso, one of the authors of the criticised paper wondered if the Italian study 
had the power to resolve this issue.27s It should be noted however that in the first study of 
risk factors a retrospective analysis undertaken using the Toronto patient database, female 
sex was not found to be a risk factor, but the range of details was less than in the Ohio 
study. The jury could be said to be out on this question.276 
As discussed above, in Maselli and colleagues' study, 260 more cultures of S aureus raised 
the risk of P aeruginosa colonisation. Zar with colleagues in New York had studied P 
aeruginosa adherence to CF epithelial cells harbouring different CFTR mutations.262 
Homozygosity of ~F508 led to greater adherence. Maselli and colleagues demonstrated 
that this may be leading to clinical differences: their homozygous patients bad a 123% 
increased risk for P aeruginosa infection.260 (The table in the paper contains a misprint 
and attributes this risk to ~F508 heterozygosity.) 
Health service factors may be putting children at risk of P aeruginosa infection. Maselli 
and colleagues identified days in hospital as an association260 as did Kerem and 
colleagues in Toronto.276 Whether it is a risk factor depends on causation, which remains 
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unclear. A biological risk factor not controlled for in the study may put the children in 
hospital more often. However three other studies give one pause on this issue. In their 
demonstration of the benefits of specialised centre care, Mahadeva and colleagues found 
a greater prevalence of P aeruginosa infection in patients attending a specialised centre 
when compared to a smaller clinic.247 Likewise the Wisconsin study of newborn 
screening has shown earlier P aeruginosa infection in screened children.277 It is 
hypothesised that greater exposure to the health care environment is putting the screened 
children at risk. The Danes vigorously segregate CF patients according to which lung 
pathogens they harbour. They claim that, as a result of this practice, P aeruginosa 
infection is delayed, improving survival from CF in Denmark.278 
Another risk factor for earlier acquisition of P aeruginosa appears to be antibiotic use. 
Continuous anti-staphylococcal antibiotic use in Germany has been shown in a 
retrospective study by Ratjen and colleagues to be associated with this outcome, 
particularly under the age of 6 years.279 A large 7 year prospective trial of cephalexin 
prophylaxis for S aureus by Stutman and colleagues in the USA also showed a greater 
acquisition of P aeruginosa in treated versus untreated individuals (25,6% versus 13,5% 
p <0,009).280 
The Wisconsin study of newborn screening suggested that better weight for age seemed 
to protect against P aeruginosa infection.277 Its beneficial effect on lung disease was only 
felt if P aeruginosa infection was excluded from predictive models.2M Kerem and 
colleagues suggested the deleterious effect of poor nutrition to be the mechanism by 
which their finding of increased risk associated with more gastrointestinal disease 
(meconium ileus, pancreatic insufficiency) was effected.276 Other risk factors identified 
in single studies include inhaled therap~81 and maternal educational leve1.276 Ethnic 
group has not yet been shown to be an independent risk factor for P aeruginosa infection. 
There is a number of bacterial organisms whose acquisition in the lung in CF seems to be 
associated with ecological pressures associated with the vigorous use of antibiotics. The 
Burkholderia cepacia complex is the most studied of these because it has established a 
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reputation for aggressive and invasive behaviour in CF. In fact this sometimes lethal 
behaviour is associated with particular genomovars in particular CF contexts. Many 
other strains exhibit considerably less virulence.282 Stenotrophomonas maltophilia seems 
to have a virulence profile less than that of B cepacia but can cause pUlmonary 
exacerbations and deterioration in lung function. An American study associated its 
acquisition by 58 of 308 patients with greater use of antibiotics and corticosteroids?83 
Achromobacter xylosoxidans is another such emerging pathogen. One concern about all 
these organisms is their intrinsic resistance to current antibiotics. 
As discussed above, only limited infonnation is available around lung infections in South 
Africans with cystic fibrosis. This study aimed to detail the time of acquisition of the two 
common bacterial infections in CF, S aureus and P aeruginosa, and the presence of other 
pathogens in the Western Cape province and to assess possible risk factors. 
METHODS 
Study population 
All children on the RCCH CF database from October 1974 to September 2003 as 
described in Chapter 2. Children who had not had sputum cultures were omitted. 
Study design 
Retrospective folder review. 
Data 
Demographic variables: Ethnic group (see Chapter 3 for explanation of classification), 
sex, CFTR genotype (~F508/ ~F508, ~F508/Other, Other/Other). 
CUnical variable: Pancreatic status (sufficient or insufficient) 
Bacteriology: 
1) P aeruginosa and S aureus 
The age at which either of these organisms was first detected in respiratory secretions 
was recorded. These samples were collected during inpatient or outpatient care. Over 
the years, samples were either taken owing to clinical symptoms or, in more recent years, 
for surveillance. At no time was there a systematic regime for surveillance of sputum 
cultures in the CF Service. Samples were either produced by coughing (older children) or 
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by deep pharyngeal suction after physiotherapy (younger children and infants). 
Occasional samples were from tracheal aspirates (intubated children in intensive care). 
Microbiological methods were those extant in the laboratories at the time. Over the 
whole period, plating allowed for detection of both of these organisms. 
2) Other organisms 
The presence of other bacterial organisms associated with CF was noted and the age at 
infection recorded. Routine culturing for fastidious organisms such as B cepacia began 
in the 1990s. Culture for mycobacteria was only performed if requested by the clinician. 
Aspergillus fumigatus was not studied. 
Analysis 
P aeruginosa and S aureus: Simple proportions of infected children in the population 
were calculated. Time from birth to first infection was analysed according to the Kaplan-
Meier method with incomplete data being censored at the time of the last visit or death. 
Those in whom the interval between respiratory tract samples made accurate assessment 
of time of first infection impossible were excluded from any time-dependent analysis. 
The analysis was repeated excluding children who were already infected at the time of 
diagnosis or within two months thereof. Time to first infection was compared between 
demographic variables using log-rank: statistics (StatSoft, Inc. (2004). version 7. 
www.statsoft.com). The proportions of patients who acquired P aeruginosa without or 
before S aureus were calculated. 
RESULTS 
One hundred and eighty one children entered the study. For 177 of the 181 patients there 
was sufficient information to indicate whether they had ever been tested for bacterial 
respiratory infection. Their ages at last follow up ranged from 2 months to 26 years and 6 
months (median 8 years and 10 months). In all, 118 (66,7%) patients had been infected 
with S aureus and 110 (62,1 %) had acquired P aeruginosa. Twenty four (13,6%) patients 
had never grown P aeruginosa or S aureus (median age 48 months, range 3 months - 23 
years and 10 months); 81 (45,7%) had grown both pathogens; 37 (20,9%) had only ever 
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grown S aureus; and 29 (16,4%) had only grown P aeruginosa. Twenty two of the 81 
children who were co-infected with the two organisms were infected with P aeruginosa 
before S aureus appeared in their lung secretions. One of the nine pancreatic sufficient 
patients had acquired P aeruginosa. 
In 159 cases there was sufficient infonnation to detennine the timing ofthe first S aureus 
infection. The median age was 117 months (interquartile range 53 - 197 months) when 
those already infected at diagnosis are included. If such cases are excluded, median age 
at acquisition was almost the same: 118 months (141 cases). Figure 7.1 shows 
cumulative time to S aureus infection for all 159 cases. There was no difference between 
the ethnic groups (p = 0,96 log-rank test) or sexes (p = 0,98 log-rank test). The three 
genotype groups had similar risks for acquisition of S aureus (chi square = 0,113, p = 
0,94). 
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The median age at acquisition of P aeruginosa was 150 months (interquartile range = 98 
- 239 months) if those already infected at diagnosis were included (173 cases) (Figure 
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7.2). If such cases are excluded, median time to acquisition of P aeruginosa was higher 
at 185 months (interquartile range 116 - 251 months) for the remaining 146 cases. In 
view of the large number of cases already infected when the diagnosis of CF was made 
(27 cases), analysis of time-dependent data excludes these subjects. There were no 
differences in time to acquisition of P aeruginosa by ethnic group (p = 0,66, log-rank 
test, Figure 7.3), or by sex (p = 0,97, log-rank test). 
Figure 7.2 Cumulative time to infection with Pseudomonas aeruginosa 
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Acquisition of P aeruginosa occurred significantly earlier in patients who were 
homozygous for 6F508 (chi square 7,5, p = 0,023, Figure 7.4). This difference is 
emphasised when only coloured patients (N = 50) are considered: chi square 12,2, p = 
0,002. The distribution of the 6 pancreatic sufficient patients who had had sputum 
samples sent, only one of whom, a white patient, had acquired P aeruginosa, was more or 
less equal between the two groups (4 coloured, 2 white). 
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Figure 7.4 Cumulative time to infection with Pseudomonas aeruginosa by genotype 
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B cepacia was identified in three patients, all in the 1990s: a 15 years old boy from whose 
sputum the organism was grown only once but whose lung function deteriorated rapidly 
from then on; an 8 year old girl with stable lung function who was referred from Port 
Elizabeth already infected and moved, still well, to Durban two years later; and, a single 
isolate in a 9 year old girl in the terminal phase of her CF lung disease. 
S maltophilia had only been grown once in this population. A 5 year old boy, already 
,colonised with P aeruginosa had the organism in his sputum for a few months. 
Antibiotic therapy was given and it cleared. A 6 year old girl was the only child to have 
proven infection with a non-tuberculous mycobacterium. No action was taken as specific 
symptoms were not attributed to the isolate. Two patients had tuberculosis identified. 
One boy who was pancreatic sufficient had severe pulmonary tuberculosis before the 
diagnosis of CF was made in his teen years. This infection significantly worsened his 
lung function. A second child was identified to be infected with M tuberculosis at post 
mortem but had been asymptomatic for tuberculosis when he died of a Reye-like 
syndrome at 14 months of age. 
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DISCUSSION 
This study represents the first detailed exainination of the microbiology of CF lung 
disease in a South African CF population. While it provides some insights into the 
prevalence and chronology of bacterial lung infection, the chief drawback of the study is 
the lack of systematic sampling of lung secretions. Only in recent years have samples 
been obtained with any frequency between pulmonary exacerbations. The figures 
presented thus represent the time to recognition of these infections rather than the true 
time of infection. Further insight into the actual time of infection by P aeruginosa might 
have been gained if the laboratory had routinely reported the phenotype of the isolate as 
non-mucoid strains can usually be assumed to have been present more recently than 
mucoid strains. This lack precludes any further inferences regarding the relationship 
between the time of recognition of P aeruginosa infection and the true time of first 
infection. It also makes the distinction between first infection and true colonisation 
difficult as children may have been colonised with P aeruginosa by the time the first 
isolate was detected. 
What can be learnt from these data? The overall picture is much as expected. Infection 
with S aureus occurred earlier than with P aeruginosa, but was not a sine qua non for the 
latter. Some patients were able to live for many years without acquiring these infections. 
However the median age of the uninfected group was less than 5 years, a long way below 
the median age of infection in the rest of the population. Many of them are likely to 
acquire infection as they grow older. Only six of these 24 patients had lived infection-
free beyond the median age of infection by S aureus i.e. 118 months. Two of these were 
pancreatic sufficient. Pancreatic sufficiency was shown by workers in Hanover, 
Germany to protect against P aeruginosa infection: such patients were 5,6 times less 
likely to acquire the infection than those deficient in pancreatic function?84 Likewise in 
Toronto, three of five patients surviving with no evidence of P aeruginosa infection to 37 
years of age were pancreatic sufficient, a proportion beyond that which could have been 
expected by chance.285 Thus, in this CF population, infection with either or both of these 
organisms in childhood was the norm. 
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More specific comparison of the proportion of children infected with the two organisms 
with other CF centres is not possible as other reports are cross sectional as in those from 
the North American CF Foundation's Patient Register!40 describe populations in whom 
surveillance of respiratory secretions was done260 276 277 or study populations in whom 
there are decreasing rates of infection over the period in this study.278 286 
The time to first P aeruginosa infection in the non-screened CF population has been well 
shown by the CF Clinic in Copenhagen, Denmark.287 Routine regular culture of 
respiratory secretions has been practised there since the mid-1970s. A median of 4,35 
years has not changed in 20 years despite changes in clinical practice, including cohort 
segregation by P aeruginosa infection status. The median age of over 12 years shown for 
the Western Cape province is therefore very likely to reflect delayed recognition brought 
about by waiting for clinical symptoms. It should also be noted that a significant 
proportion of our children (10%, Study 9.2 p259) had died before reaching the four years 
of age median for P aeruginosa acquisition. Since eradication of early non-mucoid P 
aeruginosa infections has been shown to be possible, the practice of surveillance, 
introduced in our service in the 1990s, is more than justified. (preliminary data from this 
changed approach is presented on p213.) 
While the Danish study gives the most consistent results for time to first acquisition for 
the whole of our study period, it is important to consider data from other centres as 
ecology and epidemiology may vary between geographical sites. As discussed in the 
literature review, recent studies using BAL and serology have established a very early 
time of infection in two sites on two continents. It is likely that this is the norm and 
studies that depend on oropharyngeal or sputum specimens do not reflect the true state of 
affairs. Nonetheless such studies do give a perspective more related to clinical decision-
making. Time to acquisition of P aeruginosa when studied by these methods varies 
greatly. If the median age in Denmark was 4 years,287 it was 15 years in a non-screened 
popUlation in Hanover, Germany284 and 8 years in a screened population in Colorado, 
USA.260 The mean age in Manchester, UK (unscreened) was 11 years247 and the median 
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age in Wisconsin, USA (screened) was either 1 years or 5 years, depending on the CF 
centre. 277 
The RCCH median of 150 months (12 and a half years) to infection with P aeruginosa 
included many patients who were infected at the time of diagnosis. The considerably 
higher median when these patients were excluded (15 years and 5 months) indicates that 
such patients were young. It can thus be said with confidence that most patients in this 
study were infected with P aeruginosa well before 12 years of age. 
The data regarding demographic and genetic risk factors for acquisition of S aureus are 
consistent with the literature in that none have been described. The lack of difference in 
time to infection with P aeruginosa between the two ethnic groups in this popUlation 
contrasts with the earlier acquisition in coloured patients (median 1 year versus 4 years 
for white patients) identified in the 1999 study of the prognosis of CF in this province 
(Study 9.1).52 The number of CF patients in the database has increased by nearly 80% 
since then with the proportion of coloured patients increasing (29% to 43%, see Chapter 2 
p21). To explain this change infection (or detection) must have been occurring later since 
1994, the last year that children were enrolled in that study,. Detection might have been 
expected to have occurred earlier in recent years owing to better surveillance. Thus it is 
likely that time to infection has been longer in coloured children in the years after 1994. 
My suspicion is that coloured infants have not been as sick and have spent less time in 
hospital in recent years. They thus have less nosocomial exposure to P aeruginosa but, 
being healthier, they also will have had fewer specimens of sputum sent in the very early 
years of life. 
No differences for time to P aeruginosa acquisition between the sexes were found. 
Given small numbers and the relative narrowness of the gap between girls and boys 
shown in the studies that have shown female sex to be a risk factor,260 273 such a finding 
does not exclude a difference. 
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That the homozygous 6.F508 genotype has led to earlier acquisition of P aeruginosa is 
consistent with the apparent affinity of the mutation for epitopes of the organism as 
shown by Zar and colleagues.262 It is also consistent with Maselli and colleagues' recent 
prospective study of infection in CF where 6.F508 homozygosity conferred a 123% 
greater risk for infection?60 That this phenomenon is demonstrable in the coloured 
patients but not the white ones is probably a mathematical function of the greater 
proportion of non-homozygotes among these patients. 48 Studying a Quebecois 
population in Canada, de Braekeleer and colleagues were unable to distinguish a 
particular risk from 6.F508 homozygosity but could demonstrate decreased colonisation 
in those with the A455E mutation, a variant that is associated with the retention of 
pancreatic function.288 
The comprehensive Danish study of P aeruginosa infection over two decades recorded 
the effect of cohort segregation on rates of chronic infection?87 Introduced because rates 
of first acquisition rose following the introduction of regular admission for intravenous 
antibiotics in patients with P aeruginosa infection, probably through cross-infection, it 
was associated with a very large drop in rates of chronic infection. While controversy 
still exists regarding the role of cross-infection in CF, it is important to state the context 
of our results in this respect. Cohorting, apart from patients infected with B cepacia, has 
never been practised at the RCCH. Patients all attended the same clinic in the hospital's 
Physiotherapy department, and waited in the same area. Admissions have been to the 
same ward, though small patient numbers have meant that it has been unusual, especially 
in the latter years of the study period, to have more than one patient admitted at a time. 
Pulmonary function testing, only regularly performed since the early 1990s, has been 
subject to strict infection control. Rates of P aeruginosa infection have now been shown 
to be greater in CF centres. Comparing patients attending an established CF centre and 
those from a regional hospital, Mahadeva and colleagues found earlier acquisition of P 
aeruginosa infection in the former group (mean: 11 versus 16 years), although clinical 
outcome was better at the established centre.247 The Wisconsin prospective study of 
newborn screening found a lower age at acquisition of P aeruginosa in children from the 
more rural site in the state (median: 52 versus 289 weeks)?77 Fewer social contacts 
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between CF patients were thought to explain this, especially as allowing for differences 
in respiratory therapies did not remove the increased risk in the urban setting. The role of 
cross infection in our service up till now is difficult to judge. A more detailed and 
rigorous review of the possible contribution of cross-infection in our setting would be 
difficult given small numbers, a predominance of urban patients and limited laboratory 
resources. Staff and space constraints have not allowed segregation in our context. In 
Geddes' view, the case for general application of segregation has not yet been made: 
There are risks in doing too little but it may be worse 
to do too much.289 
This study gives a first view of the place of unusual pathogens in CF in SA, and it 
appears to be a small place. B cepacia has been sought routinely in sputa from CF 
patients by the microbiology laboratory since the early 1990s and was only found in three 
patients. The view from other centres in the country is consistent with this low 
prevalence (personal communications, members of the Medical and Scientific Advisory 
Committee on CF in SA). This was a young population. Infection with B cepacia is 
thought to reflect the ecological pressure of repeated courses of intravenous antibiotics 
and thus its appearance would be expected to rise with age. However there must be other 
factors that lead to infection: Toronto, Canada has had a much higher prevalence than 
Copenhagen, Denmark (39% versus 3%) despite the systematic 3-monthly use of 
intravenous antibiotics for those infected with P aeruginosa in the latter centre.285 The 
rapid decline in lung function associated with this organism may have occurred in one 
case in our series but it is difficult to prove since only one sputum sample yielded the 
organism. The strains that produce such rapid progression of lung disease are often 
epidemic, a phenomenon Cape Town has been spared. S maltophilia and non-
tuberculous mycobacteria have only appeared as curiosities in this population so far. 
Only one patient had symptomatic tuberculosis. Cape Town is a high prevalence area for 
tuberculosis, but one in 177 cases over 29 years cannot be said to represent an unusually 
high (or low) incidence of tuberculosis in CF. The child probably suffered aggressive 
disease because he was on steroid therapy for 'asthma' at the time. 
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This report provides evidence that the past approach to sampling of respiratory secretions 
was inadequate for early identification of P aeruginosa infection. Regular surveillance of 
lower respiratory tract secretions will be required in future, especially in the youngest 
children who recent research shows are becoming infected at a greater rate and earlier 
than had been understood.261 271 It is important to have accurate data on this subject; it 
cannot be assumed that SA will have the same pattern of infection as other centres given 
the county's ethnic and socio-economic uniqueness. Now that there are therapeutic 
techniques for postponing P aeruginosa infection using inhaled and oral antibiotics as 
demonstrated in Denrnark,290 it will be important to continue monitoring lung infections 
in SA, both to identify first infections and the return of the organism after apparent 
eradication with antibiotics and also to monitor the efficacy of our regimes. 
Further study of respiratory health in cystic fibrosis in South Africa. What are the 
options? 
The studies reviewed and reported here have given a limited insight into the respiratory 
health of patients with CF in SA. If Zar's study of lung function and this study of 
respiratory pathogens are the start of a quest to know more about this subject, what 
should follow? The rationale for clinical studies must always be the well being of 
patients, present and future. In the clinical setting, audit is a mandatory form of study 
that should be patient-centred. The least our services should be doing is monitoring their 
effect on patients and adjusting practices in a continuous cycle of evaluation and change, 
but what is the role of measures of respiratory health in this process? In the case of CF, 
lung health has best been defined by measures of lung function. Unfortunately 
pulmonary function tests, while very useful in monitoring the respiratory health of an 
individual with CF, are a much blunter instrument in measuring populations or the effects 
of new therapies or changes in service delivery. Cross sectional data such as that 
produced in Zar's study would be more useful if related to age and compared over time. 
Even better, longitudinal data could be recorded and analysed. The limitations here are 
both practical and statistical in our context. Pulmonary function testing has only been 
performed regularly for just over a decade. With a clinic size of about 80 young 
adolescents and children, with a proportion of these being below an age at which a 
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reasonably reproducible forced expiratory manoeuvre can be expected, limited numbers 
of children would be found in each age bracket (however defined). This would 
significantly reduce the power of any statistical analysis. Moreover annual declines in 
FEF25-75% averaged about 8% per annum in the developed world at a time when the 
outlook for CF was about where it is in SA no~9); and the healthier patients who are 
benefiting from the most recent advances in therapy may have declines in FEY) of as 
little as 2-3% per annum.257 Long time spans would be required to measure the effect of 
service or therapeutic change in this population. Table 7.2 gives data from an analysis of 
pulmonary function tests from the 1990s to the present in this population at ages 5 years 
apart to illustrate this difficulty. While mean FEY) is seen to decrease with age, the 
range of the readings increases producing very high standard deviations. The number of 
subjects decreases dramatically in the teenage years, a fact much more stark in its 
implications for health services than the lung function deterioration in the survivors. An 
attempt to follow the fortunes of females or coloured patients, both vulnerable groups in 
CF, is shown in Table 7.3. Are female and coloured 16 year olds really worse off as 
suggested by the basic data in Table 7.3 or is it merely the presence of one coloured 
female patient with FEY) of 15% that produces such a poor mean? Sadly, small numbers 
and wide ranges within each group again preclude any definite conclusions about the 
effect of sex or ethnic group on lung function in the Western Cape province. 
Table 7.2 Percentage expected FEY) at ages six, eleven and sixteen years 
6 years 11 years 16 years 
N of subjects 23 25 10 
Mean 92.9 85.8 63.7 
SO 12.3 20.3 26.9 
Median 97 86.5 64.5 
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Table 7.3 Percentage expected FEV. at ages six, eleven and sixteen years by sex ~d 
ethnic group 
6 years 11 years 16 years 
Male Female Coloured White Male Female Coloured White Male Female Coloured 





90.7 94.8 93.9 92.1 88.4 82.7 85.7 85.8 69.9 49.3 49.3 
11.5 13.2 12.7 12.5 20.1 20.8 14.8 23.6 18.8 41.9 41.9 
95 100 100 95 87 86.5 86.5 87 65 37 37 
63·105 82·115 66-108 63-114 67·115 30·127 54·100 30-127 37-106 15-80 15-96 
Longitudinal data suffers from similar weaknesses. In just over a decade few children 
will have aged enough for the small number of values available in this population to give 
a meaningful picture of decline in lung function. Even the complexities of the mixed 
model analysis that is now advocated for such longitudinal studies257292 are unlikely to be 
able to compensate for this. Longitudinal data covering periods of 5 years (6 to 11 years, 
11 to 16 years) was only available for 14 children in this popUlation. 
Respiratory health in CF depends to a great deal on the control of P aeruginosa infection 
and the associated inflammation. The RCCH CF Service has tried to keep abreast of 
advances in this area. An example was the demonstration by Valerius and colleagues in 
1991 that a regime of antibiotics might postpone chronic infection by P aeruginosa?1 
Our first patient to have an attempted eradication was admitted to hospital in 1993. 
Subsequently 20 patients have had such attempts. Such regimens involve a lot of input 
from parents and the health service and have unknown risks and therefore are ripe for 
audit. I reviewed these 20 patients (23 eradication attempts). Regimes instituted 
included admission for IV therapy when the children were symptomatic sometimes 
followed by inhaled gentamicin, or oral ciprofloxacin for 3 to 6 weeks associated with 3 
to 6 months of inhaled gentamicin. Delay in noting the positive laboratory result 
happened twice. The medication was not written up for one patient. One patient had 
only oral ciprofloxacin for three months. All others did receive either IV antibiotics with 
or without follow up inhaled gentamicin, or a combination of oral and inhaled antibiotics. 
In one case too few sputa were sampled to be sure that eradication had taken place. In 
two cases the child had grown P aeruginosa years before which had cleared. Chronic 







infection at its reappearance was not prevented in either case. Eradication (defined as no 
growth of P aeruginosa one year after initiation of the regimen) was achieved in 8 of the 
remaining 16 completed first attempts (50%). However on an intention to treat basis the 
proportion with a successful eradication was 38,1% (8/21). This audit identifies 
problems with implementation that require review of procedures for capturing results and 
acting on them. It also demonstrates that the effort is probably worthwhile. If this 
regimen were to be combined with greater attention to surveillance of lower respiratory 
tract infection as advocated above, benefits in line with those demonstrated in 
Denmark290 may accrue to this popUlation. 
Recently alternate month (as opposed to continuous) gentamicin therapy and thrice 
weekly azithromycin therapy have been introduced in the CF service for patients with 
chronic P aeruginosa infection. In these cases, audit can only measure how well we are 
implementing our policy on suppression of P aeruginosa chronic infection as 
measurement of outcomes is very difficult since it depends on lung function (only small 
but 'significant' changes were demonstrated in the studies that have shown the benefit of 
these regimes, about 6% increase in FEVt20268) and patient well being. 
Another measure of respiratory health in a South African population might be days in 
hospital or courses of intravenous antibiotics for pulmonary exacerbations. Unfortunately 
regimens have varied over time and the public/private mix of patients makes accurate 
measurement difficult. It is my impression after 16 years of interaction with CF patients 
on IV therapy in the Western Cape province that children's respiratory health as 
measured by number of courses of IV therapy has improved in that time, despite a more 
aggressive approach to treating P aeruginosa infection and declines in pulmonary 
function measures. It may be possible to measure such trends prospectively by routine 
data collection. This could coincide with the tightening up of the other approaches to 
maintenance of respiratory health in this population discussed above. 
It must be noted that while these new antibiotic regimes have entered routine CF care, a 
number of other changes have occurred simultaneously: 
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More aggressive nutritional care (see Chapters 6 and 8) 
A greater range of physiotherapy techniques 
Routine influenza vaccination 
Multidisciplinary care (see Chapter 8) 
An emphasis on general physical fitness and exercise2so 
Systematic and routine data collection has the potential to assist in the evaluation of the 
overall effect of these modalities of care. Despite the caveats expressed above regarding 
lung function testing, it would seem that the Western Cape province has not reached a 
point where the lung function of young CF patients and mortaliryS2 no longer reflect 
where change is occurring. It is my view that changes (or lack of changes) in decline in 
lung function over time (and in mortality, see Chapter 9) still have the potential to tell us 
about the degree of access to efficacious CF care that patients with CF are receiving in 
SA, especially in the Western Cape province with the unique socio-economic challenges 
that face many of its CF patients. 
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CHAPTERS 
HEALTH SERVICE ASPECTS 
OUTLINE OF CHAPTER 
This chapter will describe what is required of health services for a long tenn 
health condition like CF. Some aspects of how the RCCH CF Servic'e has 
endeavoured in recent years to provide a progressively improving service to 
meet the changing needs of patients with CF will then be detailed. Transition 
to adult care is the subject of the main study described in this chapter. The 
chapter ends with consideration of End-of-life care in CF. 
INTRODUCTION 
Achieving optimal health status for almost all patients with CF is dependent on an 
extensive use of health services. While health service interventions such as surgery 
and inpatient care may be needed, the main purpose of health care in CF is 
surveillance, anticipatory guidance and early intervention. This is particularly the 
case for younger persons with CF as modern CF care has led to the postponement of 
severe complications to later life for many of them. Surveillance includes close 
monitoring of physical growth, lung symptoms and function, patient understanding, 
and monitoring for complications. Anticipatory guidance covers reproductive choices 
and genetic counselling, seeing the child and family through life's milestones and the 
development of the manifestations of CF that come with time. Early intervention 
includes recognition and management of deteriorating nutrition, lung infections and 
complications of CF as well as psychosocial consequences of the disease. These are 
all classic parts of preventative medicine; they are the backbone ofCF care. Without 
them the patient and family would stumble from crisis to crisis or progressive 
deterioration would take place unnoticed leading to much worse health status and 
outcomes. 
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Research and experience have shown that this form of CF care is best led by centres 
of expertise in CF care. This was shown very effectively by a study of patients in 
East Anglia in England.247 Centre care was compared with that in a regional hospital 
and that away from hospital care. Patients attending the centre had better health 
status. The only identified drawback was an higher rate of P aeruginosa infection 
among patients who attended the CF centre. The CF Service at the RCCH is such a 
service. Established in 1973 it has concentrated expertise in a team, mainly medical 
to start with but now multidisciplinary, that has offered expert outpatient, inpatient 
and emergency care in a tertiary health care setting to any patient with CF in the 
western Cape Province. 
Cystic Fibrosis as a Long Term Health Condition 
The last three decades have seen a large growth in chronic diseases of lifestyle among 
adults. The large numbers of older persons with often multiple ongoing disorders 
have challenged health services to respond to a very different set of health care needs 
from persons with acute health problems. For children there has also been a 
recognition that numbers of children with health conditions that are not cured but 
controlled are rising. Children's health services in developed countries (where the 
proportion of children seeking curative health care for acute conditions has dropped) 
have begun to adjust to this. A whole edition of Pediatric Clinics of North America 
was dedicated to this phenomenon in 1984. In an oft-quoted paper, Gortmaker and 
Sappenfield spelt out the size of the issue of children with chronic conditions.293 
Unlike with adults, chronic conditions in children are more often genetic than 
degenerative. Cystic fibrosis, one of the commonest single gene disorders, merited a 
chapter of its own?94 
Stein and other workers in the USA have made an extensive study of the issues health 
services face in providing appropriate care to children with 'long term health 
conditions' , a term they coined.295 Such a condition is defined as follows: 
A disorder that 
1. has a biologiC, psychologic or cognitive basis, and 
2. has lasted or is virtually certain to last for at least a year, and 
3. produce one of more of the following sequelae 
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a. limitation of function 
b. dependency on medications, special diet, medical 
technology, assistive device, or personal assistance 
c. need for medical care or related services, psychologic 
services or educational services over and above the usual for 
the child's age 
Essentially such conditions threaten nonnal development of the child, both physically, 
emotionally and socially. Health services need to be able to optimise the child's 
development and prevent secondary disability (e.g. emotional or behavioural 
disorders). These needs are 'non-categorical' i.e. they do not depend on the 
individual health condition, rather it is the fact that the condition is long tenn that 
dictates the child's potential special health care needs. 
Cystic fibrosis in an incurable, genetic, progressive, multi-system, life-shortening 
disorder. Each of these characteristics brings with it a multiplicity of challenges and 
risks for the child and family to which health and other services should respond. Its 
incurable nature means that there is no life without CF. Psychological adjustment for 
child and family must be promoted; life's milestones must be anticipated and the 
potential effect of CF at these points discussed with the child and family. Its genetic 
cause impacts on reproductive choices for child and parents and extended family. Its 
progressive nature brings a constant battle to maintain health through complex health 
promoting and disease modifying medical interventions, each of which may impact on 
the child and family's lifestyle and choices. More battles are lost than won with CF; 
health care and other services needs to be able to deal with this and help the family 
deal with this. Its multi-system nature makes it medically complex, requiring highly 
specialised health care often concentrated in a health service far from the family 
home. Its life-shortening nature is known from the time of diagnosis. The 
psychological impact of this fact is ever present with the family and health care team. 
THE RED CROSS CHILDREN'S HOSPITAL CF SERVICE 
I have been closely involved with the RCCH's CF Service since 1992. The prior 
work of Malcolm Bowie, Robert MacDonald, Ivor Hill, John Ireland, Mike Gold, 
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Colin Wallis, Lesley Henley, Shanaaz Matthews, Lorna Gale and others over two 
decades had led to a high standard of service. A weekly clinic took place in the 
Physiotherapy department on Tuesday afternoons. All doctors were attached to the 
hospital's Gastroenterology Service. Patients were discussed by the doctors after the 
clinic. Lung function testing was done at the Allergy Clinic by the Respiratory 
technologist. Pulmonology Services were only available on a consultation basis. A 
dietician (the only one employed by the hospital!) attended the Clinic when she could 
and a social worker was available. The head physiotherapist gave input if requested 
to. Inpatient care was concentrated in Ward B2 and a 24 hour consultation service 
was available. A service for adults with CF already existed in the Respiratory Clinic 
at GSH. 
When John Ireland took over as head of the Service on Malcolm Bowie's retirement 
in 1994, a pulmonologist (initially Andrew Argent) was invited on to the team. A 
junior physiotherapist became part of the team as did a dietician once the hospital 
staff complement increased to two. Another innovation was a weekly meeting of all 
members of the therapeutic team. This added greatly to the depth of assessment and 
planning of care for individual patients and to protocol development and service 
development. A new clinic form was introduced to improve systematic clinical care 
.. 
and anticipatory guidance. The form, which had features that aimed to allow better 
longitudinal monitoring and contained prompts for the clinician has been adapted a 
few times at the suggestion of team members. It is reproduced as Appendix B. With 
the loss of the Respiratory technologist to a Severance Package in the mid-1990s the 
physiotherapist took over the lung function testing on a machine that had been 
donated to the Service by Round Table, Somerset West at the instigation of the parent 
of a child with CF. 
A nurse joined the team part time in 2000 but this proved difficult to sustain owing to 
staff rotations and nurse shortages. The potential of this cadre has yet to be met in 
Cape Town despite repeated motivations. 
The team has continued to produce leaders in CF care in the country (and beyond). 
Members regularly participate in SA's CF Symposia as speakers and John Ireland and 
I have been members of the Medical and Scientific Advisory Committee of the SA CF 
Chapter 8 219 
Association. The team wrote a nutrition booklet for patients and parents to use2SO and 
contributed to two editions of the national Consensus statement on CF care in SA. 
The team has been aided in its work by the local branch of the CF Association and 
individual parents. For example, in recent years a donation has been made to help 
poorer children attend the clinic by supplying their parents with taxi or bus fare. 
There are factors that the team feels undennine its work. Policies on state funding of 
patients with expensive and complicated conditions such as CF has changed to the 
detriment of pati~ts in the last decade. Free care for CF was removed in the early 
1990s.296 [It must be acknowledged that the dispensation had only existed because 
most CF patients were White.] Free care for children under 6 years of age introduced 
in 1994 did not cover 'private' patients. More and more, private patients have been 
expected to fund their own care despite it being patently obvious that this is 
unaffordable for most. Hospital budgets have progressively shrunk. New therapies 
such rhDNase have only been used in exceptional circumstances because of their cost. 
Even mainstream therapies are under constant scrutiny by hospital administrators. 
The team has fought a number ofrearguard actions to maintain good standards of care 
for patients. 
The research described in the preceding chapters has been part of the Service's audit 
process. We wished to ensure that steady improvement of health status continues as it 
has been in developed countries. We wished to know if there were local differences 
in CF manifestations that should influence how we adapt CF care to our unique 
circumstances. 
There are two health service aspects of clinical care of CF that have also been studied 
as part of our self-assessment: transition from paediatric to adult-oriented CF care and 
End-of-life-care. 
TRANSITION FROM PAEDIATRIC TO ADULT-ORIENTED 
CYSTIC FmROSIS CARE 
Transition has become a buzzword in health services and related medical literature. In 
relation to health, it refers to the process of change from paediatric to adult-oriented 
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health care. Its particular focus is on children and young persons with long term 
health conditions. Transition has risen to prominence in recent years owing to the 
success paediatric health care services have had in prolonging the healthy lives of 
children with many health conditions that used to be associated with death in 
childhood. CF is one such condition. 
This phenomenon of an increasing number of CF patients passing through childhood, 
then adolescence to adulthood became part of life in Cape Town in the 1980s. The 
increasing demands placed on the RCCH CF Service by older patients led to Prof. 
Bowie negotiating the establishment of a CF service for adults at GSH. This officially 
opened its doors in 1989 although a few adults with CF were already attending the 
hospital. The new clinic underwent some rapid changes of staff in its early years and 
only stabilised when Dr Paul Willcox returned to the Respiratory Service at GSH. 
Back on the RCCH side, I was rapidly learning that CF among adolescents presented 
challenges I had not encountered before. I noted that many did not attend regularly, 
were often at odds with their parents and had a different relationship with health care 
professionals from younger patients. A particular concern seemed to be their and 
their parents' negative attitude to moving to GSH. This appeared to be having a 
deleterious effect on the young people's health in some cases. 
Fortunately for me, Dr Lesley Henley, a social scientist, was in the Department of 
Paediatrics and Child Health of the University of Cape Town. Although she was no 
longer part of the CF team, she maintained her interest in the health issues 
surrounding children with long term health conditions. My discussions with her led to 
a survey of the attitudes of the CF 'family' to growing up with the disease and 
changing health providers. 
This section contains the paper that was one of the outcomes of this survey. This is 
preceded by a more detailed discussion of transition than was possible in the 
constraining atmosphere of a journal article. The reproduction of the paper that was 
published in 1999 in the Journal of Paediatrics and Child Health57 is followed by an 
updated view of the CF-related transition literature and a description of our most 
recent attempts to improve transition for patients who attend the CF services. 
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Transition in Cystic Fibrosis: a literature review 
Despite the dismal prognosis of CF in the 1950s not all patients died early. Issues 
arising out of the presence in health systems of survivors of the disease were 
recognised in the early 1960s. Shwachman and colleagues described 65 patients over 
the age of 17 years in 1965. They put this new phenomenon down to 
.... greater awareness of cystic fibroSis ..... (i)mproved 
diagnostic techniques ...... effective therapeutic 
measures, notably antibiotics ..... mild manifestations 
of the disease .... exist. ... 297 
The number of adults with CF has risen steadily since then in developed countries 
until the present day when about half of all prevalent CF cases are adults. Even in 
SA, adults were present in good numbers in the early 1980s32 and, as described above, 
Cape Town also needed to deal appropriately with a steady stream of patients 
surviving beyond teenage. 
With this excellent medical success story came a new challenge to health sexvices. 
Who was to look after this new breed of adolescents and young adults? That new 
challenges were arising was noted in a short paper 'to alert the medical community 
to the need for a change in the type of service presently delivered to 
teenagers with cystic fibrosis' in the Annals of Internal Medicine in 1973.298 
Rosenlund and Lustig in Philadelphia, USA, the authors, had piloted a programme for 
older patients with CF, encouraging independence and dealing with psychosocial 
issues facing them. 
This 'new breed' of survivors of severe paediatric disease was not unique to CF. In 
the 1980s papers describing the issues in cancer,299 diabetes,300 and renal disease301 
appeared. Gortmaker and Sappenfield demonstrated the high number of children with 
long term health conditions in the opening paper of an edition of The Pediatric Clinics 
of North America in 1984.293 Interestingly this edition of the journal, while taking up 
many issues of 'chronic childhood disorders', did not take up the issue of transition. 
1989 was the year transition came of age (so to speak!), at least in the USA. The 
Surgeon General, C. Everett Koop convened a conference on the issue. This moved 
transition into the mainstream of health policy. Blum gave an oVeIView of transition 
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in 1991 in Pediatrician. Increasing numbers of children were surviving to 20 years 
and beyond; adolescents have special needs; they use health services more than their 
'healthy' peers; transition, he stated, was 'more by default than by design,.302 
Soon after this (1993) The Society for Adolescent Medicine published a "Position 
Paper" in the Journal of Adolescent Health. Blum was the first author. This paper 
presented a definition: .... the purposeful planned movement of adolescents and 
young adults with chronic physical and medical conditions from child-centered 
to adult-centered health-care systems' that has generally been taken up by authors 
in the field in subsequent years.303 It was acknowledged that much was unknown 
about the process. The need for the process to be studied and evaluated was 
emphasised. The Society wished to place transition on the research, service 
development and training agenda. 
Apart from Cameron who wrote about renal disease, 30 1 the European literature was 
almost silent on this issue at this time. As we were preparing to launch our research 
into transition issues in our services, Landau, an Australian paediatrician, penned a 
lengthy and comprehensive editorial in Thorax (1995) about transition in CF. 304 
Writing in an 'adult' journal he emphasised the qualities required by adult-oriented 
CF services that were required to ensure a smooth transition to good adult care in CF. 
CF had been the subject of more transition articles than any other disease in the USA 
and Australian literature in the 1980s and early 1990s. One of the most perceptive 
articles, although it contained and referred to very little empiric or controlled data 
(because there was not much to be found), was written in Medical Clinics of North 
America in 1990 by Schidlow and Feil from Philadelphia, USA.30S They spelled out 
factors that enhanced or hindered a successful transition. These factors related to each 
of the players in the process: the young person with CF; the parents; the paediatric 
team and setting; the adult team and setting (Table 8.1, taken from Table 2 in the 
article). This set a template on which much subsequent thinking and research has 
been based. Its American bias is given away by the prominence given to 'economic 
concerns' of caregivers in giving up or taking on older CF patients. Nevertheless, 
until later research (see below) suggested that the 'patient-related' factors had over-
emphasised the adolescent's view oftransitionltransfer, this model rang true. 
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Table 8.1 Obstacles to Transition from Pediatric to Adult Health Care Systems (from 
Reference 305) 
The Dependent behaviour The Paediatric Economic concerns about programme 
patient Immaturity Caregivers Emotional bonds with patient and family 
Severe illness or disability Comfort with status quo 
Psychopathology Perception of own skills as caregivers of 
Lack of support systems adults 
Lack oftrust in caregivers Perception of potential survival of 
Poor adherence to treatment patients 
regimes Distrust of adult caregivers 
Ambivalence towards transition and 
transfer of care 
The family Excessive need for control The Adult Caregivers Economic concerns 
Emotional dependency Lack of understanding of congenital 
Psychopathology disease 
Parenting styles leading to Lack of familiarity with disease entities 
overprotection Heightened perception of care demands 
Heightened perception of Lack of institutional commitment 
disease severity 
Lack of trust in caregivers 
Mistaken perception of 
potential survival 
Rosen, in an article published in 1995 in the Journal of Adolescent Health, expanded 
on these themes by teasing out the cultural differences between paediatric and adult 
medicine that have the potential to trip up the young person on the transition path?06 
In essence, the paediatric environment is nurturing while the adult one expects 
independent behaviour of the patient. In the chronic illness arena, the former inhibits 
maturation; the latter expects too much maturity. 
Sawyer and colleagues in Victoria, Australia conducted a series of studies of the 
insights young person with CF had into their disease and its effect on puberty, 
sexuality and reproduction and attitudes to caregivers.30? It became clear that 
paediatric settings were not adequately conveying information important to the 
potential adult. This has implications for the efficacy of transition and adult coping. 
Transition reached the mainstream (at least in paediatrics) when the American 
Academy of Pediatrics published statement of transition in Pediatrics in 1996. In 
essence, the Academy said: 
• Begin early 
• Promote independence 
• Involve patient and family in the process 
• Encourage patients acceptance 
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• Have adult and paediatric health care practitioner work together for a period308 
It was in this year that we undertook our study, attempting to explore a number of 
these themes with a questionnaire aimed at CF patients and their families. Our 
particular focus was on attitudes to' growing up with CF, transfer to adult-oriented 
care and need for knowledge of CF in adulthood. There was limited literature on 
these aspects at that time. Our study was largely undertaken to help us plan and adapt 
services in Cape Town. It is a comment on the relevance of the 'non-categorical 
approach' to chronic illness in children of Stein and colleagues that we were able to 
adapt a protocol used in sickle cell anaemia in the USA without much difficulty to our 
purposes with CF in SA. 
Study 8.1 
The Transition from Paediatric to Adult Care 
for Persons with Cystic Fibrosis: 
SUMMARY 
Patient and Parent Perspectives 
Westwood A T R FCP (SA) 
Henley L D Ph.D. 
Willcox P FCP (SA) 
J Paediatr Child Health 1999;35:442-445 
Objectives: To gauge the perspectives of adolescents and adults with cystic fibrosis 
(CF) and their parents regarding the transition from paediatric to adult-oriented health 
care. 
Methods: Cross-sectional survey using an anonymous, semi-structured questionnaire. 
The study population consisted of adolescents and adults attending a paediatric and an 
adult CF clinic in Cape Town, South Africa and their parents. 
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Results: Forty-seven of the 61 subjects completed the questionnaire (response rate 
77%). Autonomy in health care was "extremely important" to most persons with CF. 
Transfer at the age of 16-18 years was the preferred option for most respondents. 
Whereas over 80% of parents felt their children needed more CF-related information, 
only 38% of adolescents expressed this need (p<0.05). Adolescents also reported little 
need for general health information. More than 80% of respondents were "unsure" 
about transfer. Over 90% felt that a transition clinic would be useful. As viewed by 
the respondents, its main purpose would be to provide information about the adult 
clinic and an opportunity to meet the CF doctor in the adult clinic. 
Conclusions: There are significant concerns about the transition process in this 
population. Given the expressed need for autonomy and a transition clinic, the basis 
for a smoother transition in the future has been laid. 
Key words: Adolescence, cystic fibrosis, health services; transition. 
Cystic Fibrosis (CF) is one of many chronic life-threatening conditions in which the 
expected life span has increased considerably in recent years [1]. Median survival for 
persons with CF now extends to the third or fourth decade of life in many countries 
and the issue of how and where older CF patients are best cared for has evoked much 
debate. A particular concern is how best to manage the transfer from child- to adult-
centred care as there are many potential service, patient and staff related pitfalls 
associated with the move [2-5]. This in turn has given rise to the concept of 
"transition" in which the transfer becomes part of a planned process of change in the 
orientation of care [4-7]. 
In Cape Town, South Africa where most persons with CF survive to adulthood [8], 
almost all CF patients attend public hospitals for their CF-related care. An adult-
oriented clinic, but no formal transition process, was set up in 1989. Transfer from the 
paediatric CF Clinic at the Red Cross War Memorial Children's Hospital (RXH) to 
the adult CF Clinic in the Department of Medicine at Groote Schuur Hospital (GSH), 
a general hospital, necessitated a change in hospital and caregivers. The RXH Clinic 
which cares for about 75 patients is staffed by three paediatricians, a social worker, a 
dietitian and a physiotherapist. The GSH Clinic, with 20 patients, is run by a 
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pulmonologist and a physiotherapist. At neither clinic are the staff engaged in CF 
service full time. 
In the years preceding this study, transfer occurred sometime in the adolescent or 
early adult years. Patients were given an appointment for the GSH Clinic and a 
summary letter from the paediatric doctor who had arranged the transfer. Problems 
surrounding the transfer from the RXH Clinic became clear as some patients and 
parents postponed transfer or failed to attend follow-up appointments. Such 
discontinuity of care threatened the adolescents' health and development. 
As part of a remedial process and to identify areas in the clinical services which might 
benefit from organizational change, a survey designed to gauge the perspectives of 
adolescents and adults with CF and their parents was undertaken. 
METHODS 
Cross-sectional study data were obtained from four groups of subjects: 
- adolescents with CF (ages 14-21) attending the RXH Clinic (Group RXH1) 
- parents of children and adolescents (ages 10-21) attending the RXH Clinic 
(Group RXH2) 
- adults with CF who had transferred to the GSH Clinic (Group GSH1) 
- parents of adults with CF who had transferred to the GSH Clinic (Group GSH2) 
Anonymous semistructured questionnaires were posted to all subjects during January 
1996 followed by a second posting 3 months later. The questionnaires were sent to 
patients and parents in separate envelopes. Covering letters stressed the voluntary 
nature of participation. 
The questionnaire was adapted, with permission, from a previous study [9, Telfair -
personal communication]. Items on the revised questionnaire were pre-tested for 
clarity and local relevance. English and Afrikaans versions of the questionnaire 
covered: 
1. demographics including a brief health self-assessment. 
2. attitudes to growing up (independence, the need for information related to CF 
and lifestyle). 
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3. attitudes to the transfer (timing, feelings). 
4. the transition process (needs, wishes). 
Descriptive data were analysed using Epi-Info Version 6 (Centers for Disease 
Control. Atlanta, GA, USA). Where appropriate, the Chi-square test was used to 
compare groups. 
Permission for this study was granted by the Research Ethics Committee of the 
University of Cape Town, South Africa. 
RESULTS 
Of those eligible, three adolescents were not sent questionnaires (two intellectual 
disability, one preterminal). Response rates were: RXH1 13/15 (87%); RXH2 21126 
(81%); GSH1 8111 (73%) and GSH2 5/9 (55.5%). This reflects a total response rate of 
77% (47/61). The mean ages of CF patients (50% female) were 16 years and 27 years 
at RXH and GSH, respectively. Five were employed and 13 were at school or 
university. Five patients lived away from their parents. Twenty-three percent of 
adolescents rated their health as "excellent" and 77% as "good". Adults with CF rated 
their health as "excellent" (25%), "good" (37.5%) and "poor" (37.5%). 
Attitudes to growing up 
Independence 
Patients were asked to rate how important (response options: extremely important, 
quite important, not so important, not at all important) autonomy (independent and 
looking after yourself) was to them at their present age. Parents were asked to rate 
how important it was to them that their children exercised autonomy (independent and 
looking after himself). Table 1 shows the areas of autonomy included in the 
questionnaire and the proportion of respondents who considered them to be 
"extremely important". Unlike those who had transferred, adolescents did not 
consider "making their own clinic appointments" and "speaking alone to the doctor" 
to be very important. Moving to the GSH Clinic was considered to be "not so 
important" by 54% of RXHI and 33% of RXH2 (their parents). Twenty-four percent 
ofRXH2 felt that it was "not at all important". 
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TABLE 1 
Areas of autonomy and the proportion of respondents who 
deemed "extremely important" (% distribution)* 
RXHI RXH2 GSHl GSH2 
Making own decisions about treatment 77 57 75 40 
Personally responsible for physiotherapy 46 62 87 60 
Personally responsible for medicines 85 76 100 100 
Making own clinic appointments 8 24 63 80 
Speaking alone to doctor 31 43 87 80 
Moving to adult CF clinic 8 19 
Meeting other young people with CF 31 43 o 0 
I Taking charge of own life 61 67 87 80 
RXH, Red Cross War Memorial Children's Hospital; GSH, Groote Schuur Hospital; CF, cystic fibrosis 
Information needs 
There were significant differences between parents' (RXH2) views of their childrens' 
information needs (response options: a great deal more, a little more, no more) and the 
adolescents' reported needs on subjects related to CF (Table 2). Most adolescents 
reported needing "no more" information on smoking and drinking (85%), puberty 
(69%), dating (69%) and contraception (69%). 
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TABLE 2 
Information needs C% distribution)s 
"A great deal more information" 
RXHI RXH2 
Complications in CF adults 38 90* 
# 
New developments in CF treatment 38 80 
Latest research findings in CF 54 80 
*p = <0.002, lip = <0.02: RXH, Red Cross War Memorial Children's Hospital; GSH, Groote Schuur 
Hospital; CF, cystic fibrosis 
Attitudes to the transfer 
Timing 
Respondents were asked what they considered to be the "best" age (minimum and 
maximum) for a young person with CF to transfer to the GSH clinic. In all groups a 
majority proposed 16 to 18 years (RXHI 65%, RXH2 61%, GSHI 75%, GSH2 80%). 
Two respondents did not proffer an opinion. 
Feelings 
Respondents were asked to rate the extent to which they shared a range of potential 
concerns related to transfer ("a big concern", "a slight concern", "no concern"). Table 
3 shows areas relating to the transfer which were identified as "a big concern" by at 
least half of RXHI and RXH2 respondents. When asked to choose from a list of 
possible reactions how they might feel about an imminent transfer, 86% (RXH1) and 
85% (RXH2) of respondents reported being "unsure". The second most common 
feeling reported by all groups was "worried". Positive or neutral emotions ("excited", 
"okay about going", "it's the right time to move on") were indicated by fewer than 
20%. 
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TABLE 3 
Concerns about moving to the adult CF clinic identified by 50% or more of 
respondents from RXH 
PARENTS (RXH2) 
Not knowing what to expect 
Paying for adult medical care 
Is my child ready to be treated as an adult? 
What do we do if we don't like the adult CF clinic? 
How much do the adult caregivers know about CF? 
Being admitted to an adult ward 
ADOLESCENTS (RXHl) 
What do I do if I don't like the adult CF clinic? 
Not knowing what to expect 
How much do the adult caregivers know about CF? 
RXH, Red Cross War Memorial Children's Hospital; GSH, Groote Schuur Hospital; CF, cystic fibrosis 
The transition process 
Respondents were asked if it would be helpful to have a transition clinic at the RXH 
CF Clinic which the doctor from GSH would attend. All but 4 respondents (RXH 3, 
GSH 1) thought that it would be helpful to have a transition clinic. Respondents were 
asked to choose the kinds of help they would like from a transition clinic. Table 4 
shows the possible functions of a transition clinic which appeared in the questionnaire 
and the proportion of respondents who would find those functions helpful. In response 
to an open ended question, further suggestions included a brochure about the GSH 
clinic and visits to GSH to see the clinic and ward. Two RXH respondents 
recommended a special adolescent CF clinic at the children's hospital. 
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TABLE 4 
Help a transition clinic should offer (% distribution) 
RXH1 RXH2 GSH1 GSH2 
Provide information about the adult clinic 69 86 87 80 
Opportunity to meet the new CF doctor 77 86 87 100 
Opportunity for the new doctor to learn 46 71 87 80 
about me/my child 
Deal with my worries about transfer 46 57 63 80 
Opportunity for me/my child to meet others 46 52 63 60 
who are being transferred 
Provide information about CF in adulthood 54 71 100 100 
RXH, Red Cross War Memorial Children's Hospital; GSH, Groote Schuur Hospital; CF, cystic fibrosis 
DISCUSSION 
Requirements for and impediments to a successful transition from paediatric to adult 
care for persons with chronic health conditions have been the subject of many articles 
in recent years. Blum et al. [6], writing for the Society of Adolescent Medicine point 
out that, while many transition programmes exist, 'the failure to collect systematic 
data leaves us with only anecdotal evidence ... .' (p 573). Only three studies present 
data on transition in CF. Abdale et al. [10], examining satisfaction with the move 
from a paediatric hospital to an adult centre amongst adults with CF found that, of the 
63% who responded, those who had been through a transition process were more 
satisfied with the adult clinic than those who had not. Nasr et al [11], from Michigan 
in the USA, reported that the transition programme made the change to adult care 
easier. Campbell [12] in Scotland was unable to obtain an adequate data set. Our 
study presents data that gives further insight into problems surrounding transition and 
their potential solutions. 
The recognition of the deleterious health and developmental effects of not having a 
planned transition between the CF clinics in Cape Town enabled us, as part of a 
remedial process, to gather data which would allow us to tailor the transition to our 
patients' perceptions and needs. The high response rate is encouraging both from the 
point of view of the data it generated and also its indication of the extent to which 
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those using the services wished to have their voices heard on this issue. The high rate 
may also represent a response to the perceived threat to specialized services in South 
Africa as the health service is restructured [13]. 
Adolescents showed a marked degree of reluctance to transfer. Fear of "not liking" 
the GSH Clinic seemed to be the dominant factor. This mirrors their parents' feeling 
and may be directly influenced by it. These attitudes are much more negative than 
those found in a similar study in sickle cell disease where fewer than half of the 
respondents expressed negative emotions [9]. This may also reflect the spread of 
attitudes amongst the CF community in Cape Town. The range and depth of concerns 
expressed by a majority of our respondents will need to be addressed if a transition 
programme is to be successful. This will require information to allay uncertainties and 
further exploration of possible specific concerns (e.g. the smaller staff complement at 
GSH, differing treatment protocols). 
Adult-centred care requires adolescents to take more responsibility for decisions 
surrounding their care [14]. Adolescents will be unable to do this if they have not 
attained a degree of autonomy by the time of transfer. The achievement of 
independence is often delayed or incomplete in those with chronic health conditions 
owing, in part, to parental anxiety and inability to hand control to the adolescent. 
Adolescent respondents showed mixed feelings towards autonomy: on the one hand, 
valuing making their own decisions about treatment and, on the other, not considering 
speaking alone to the doctor to be of great importance. This dichotomy is probably a 
function of maturity as only one adult with CF rated speaking alone with the doctor as 
less than "extremely important". Parents' responses generally suggested the 
recognition of the need for independence in their children although they probably 
have difficulty translating this into action. 
The negative emotions surrounding transfer and the need to build patient autonomy 
argue forcefully for a transition clinic in our setting, the offer of which received strong 
endorsement from all groups of respondents. It has been pointed out that the exact 
nature of a transition process must depend on the circumstances of the health services 
involved [4,7]. Respondents were presented with a single form of transition clinic as 
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this model is the only practical option given the scarce resources and the limited 
number of patients transferring to GSH each year. 
A dominant purpose of the clinic, as seen by respondents, is to provide two kinds of 
information. Firstly respondents wanted information about the GSH Clinic. There are 
strong indications that the more those facing transfer know about "the other side", the 
easier the process will be [11]. Abdale et al [10] found that such information 
contributed significantly to patients' comfort with and confidence in the transfer. 
Given the degree of uncertainty about the GSH Clinic, such information becomes vital 
in promoting a smooth transition between our clinics. 
Information on growing up with CF was the second area surveyed. In the 
questionnaire, we gave particular emphasis to this as there is evidence that knowledge 
in many areas (for example, reproductive issues [15]) is deficient amongst adults with 
CF. Adolescents in this study expressed little need for information on most subjects. 
Given that adults post-transfer feel that paediatric clinics give too little weight to 
issues such as alcohol, smoking and reproduction [10], this is surprising. These 
responses may not indicate their true feelings on subjects which their parents 
indicated should not be discussed at the clinic. Alternatively they may feel that 
paediatricians are not equipped to give them this information or, as found by Sinnema 
et al [16], there may be a delay in the development of sexuality in persons with CF. 
In keeping with a previous finding [17], adolescents with CF showed little enthusiasm 
for "a great deal more information" on CF related subjects. This contrasted sharply 
with parental assessments of their information needs and is incongruent with the 
adolescents' degree of uncertainty about transfer. These differences probably reflect 
parental anxiety about the future of their children and the adolescents' optimism [16] 
or denial [18]. The fact that adolescent responders rated their health status as "good" 
or "excellent" supports this explanation. The GSH responders, looking back, felt that 
imparting this information to adolescents would be an important part of the transition. 
They also felt it was important that adolescents learn to make their own health 
decisions, an ability that presupposes insight born of knowledge. 
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Based on our findings, changes are being been made to our practice. Early in the 
child's life parents are informed of the continuum of CF care, given at different sites, 
through childhood, adolescence and adulthood. Children are encouraged to be active 
in decision making from an early age. From their midteens, adolescents are seen on 
their own for at least part of the consultation. Transfer will usually occur before the 
age of 18 years. The doctor from the GSH Clinic attends the RXH Clinic 2 to 3 times 
a year to share in consultations with adolescents and give families information about 
the adult clinic. The provision, currently under negotiation, of dedicated adolescent 
beds at RXH or GSH will further facilitate this transition. This study has raised 
awareness of transition issues amongst the CF population we serve. Additionally it 
provides a baseline for evaluating current and future changes in our adolescent and 
adult services as recommended by the Society for Adolescent Medicine position paper 
[6]. 
Although the study included all eligible adolescents and adults with CF in our 
services, the sample size was small and findings may not be readily generalized to 
other CF centres. However, the study underscores the need for CF services to assess 
patient and parent perceptions regarding transition, partiCUlarly where paediatric and 
adult CF care are located at separate sites. South Africa is poor compared to many 
places where CF is common, nevertheless, the issues and concerns of the increasing 
numbers of patients facing adulthood with CF [8] and those of their parents as 
examined in this study will be similar. 
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Transition in cystic fibrosis: the ongoing story 
Since we published our article the debate around transition has shifted. In the 1990s 
and 1980s the discussions were largely on the need of transition and the impediments 
to smooth passage between child- and adult-oriented services. While 'overview' -type 
articles still appear, much more is to be found on patient and caregiver perspectives 
i.e. the aspects we studied. Best practice is a subject of intense interest. 
Interestingly these debates still largely take place in the paediatric and adolescent 
health journals. Mainstream medical speciality journals have hardly aired the issues. 
Schidlow and Feil's article305 and Landau's editorial in Thorax304 are rare exceptions. 
We attempted to break this mould by submitting our article to Respiration. We were 
not successful in raising the debate there and had to resort to a paediatric journal. 
This holds true for most transition literature. Until the idea of this new breed of adult 
patient is embraced by the world of internal medicine, the difficulties and issues 
repeatedly raised in the paediatric literature and in the clinics of tertiary hospitals will 
continue. Bye from Australia has attempted to do this recently, even using a 
exclamation mark in his title to encourage enthusiasm!309 
In the late 1990s the Europeans took transition issues to heart and at the time of 
writing are looking down their noses at the Americans' inability to have all adults 
with CF cared for by adult-oriented teams!310 
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Viner, a fonner Australian paediatrician turned adolescent specialist, has led the way 
in orienting UK services to the transition ethic. In 1999 he penned a 'Current Topic' 
article in the Archives of Disease in Childhood. 'Efficient and caring transfer' is 
'one of the great challenges facing paediatriCS in the (then) coming century', 
he wrote.311 He placed transition in health care in the context of a wider set of 
transitions facing adolescents, those with health issues and those without. This is now 
a major theme in the USA, too. Viner pointed out that much of the work had been 
done in North America and Australia and repeated much of Schidlow and Feil's305 
1990 paradigm. He added hospital policies as an extra factor in the mix. His view of 
over 18 years as the best time to transfer to adult-oriented care is out ofki1ter with the 
Americans and what our patients thought. His adolescent-oriented context probably 
explains this difference. But, as he stated, there is no 'right time' and flexibility must 
be the order of the day. The essentials of an effective transition in his view were: 
• Preparation 
• Coordination 
• An interested and capable adult service 
• Primary care involvement. 
Models include disease/system based and adolescent-oriented transition services. His 
experiences had been within the latter fonn at the Middlesex Hospital in London, UK. 
Within a year of this article, the annual meeting on CF of the Royal Society of 
Medicine debated transition issues in CF. Viner repeated his message (almost word 
for word).312 Bryon and Madge from the Great Ormond Street Children's Hospital, 
examining the psychological principles underlying transition, stated fIrmly that the 
young person needs the change of approach that comes with change of care givers.3I3 
Staying with paediatric caregivers emphasises the young person's difference from his 
or her peers. Complementing this view was that from the adult CF team in 
Manchester, UK. Webb and colleagues made the case for adult-oriented care but 
noted that the model depends on resources.314 However what must happen is the 
adequate transfer of infonnation from the paediatric to the adult service. This should 
include annual review reports, microbiology results, lung function trends, oral glucose 
tolerance test results, infonnation on activities/sport. Fertility and reproduction 
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should not be left to the adult team to discuss, they believed. They found that their 
patients found taking responsibility for their own care was the most difficult aspect of 
growing up to adulthood with CF. Drugs, crime, alcohol and general deviant 
behaviour seem to have been common in Manchester! In a questionnaire survey they 
had found that patients noted a difference in the 'approach to care' between the 
child and adult services, bringing some empiric data to the earlier assertions of 
Rosen.306 
At about the time Viner was bringing transition into the mainstream of British 
paediatrics, the Americans were analysing the structure and content of transition 
'programs' in the USA. Blum and co-workers attempted to survey all such 
'programs' in the country.31S They succeeded in obtaining a 46% sample. This 
allowed a good feel of what was going on to be gained but could not be definitive. 
Most 'programs' were body system or condition specific (as with CF); 38% were 
offered generic services to adolescents regardless of which health condition they had. 
While all had multidisciplinary teams, few involved the families and patients in 
planning of the services. Not swprisingly the adolescent-oriented services were more 
likely to do this. The latter were less likely to contain sub-specialists. Funding for 
health service development was rare and most running costs were based on fee-for-
service. Funding was seen as one of the main barriers to success in the 'programs'. 
Access to adult specialists was a significant problem, too. One third of 'programs' 
did not have access to adult primary care physicians, one fifth had no access to adult 
sub-specialists. The authors interpreted these findings in the following way: 
.... self-identified transition health care programs (sic) do 
not achieve the goal of collaborative, coordinated and 
integrative services ....... barriers to attaining the goal 
are the limitations of the health care system itself.314 
Within this less than satisfactory system, how were CF services doing? 
In a context in which only 33 of 50 states had CF Foundation-approved adult 
'programs', Boyle, Farukhi and Nosky, in a study not unlike ours, studied patient and 
parental views in their service at Johns Hopkins Medical Center in Baltimore, 
Maryland.316 Like us, their aim was to use this information to improve their transition 
service. The context was of a newly established adult-oriented service. This resulted 
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in most 'pre-transition' patients, 52 in all, being in late adolescence and early to mid-
adulthood (age range 18-63 years, median age 25,5 years). Unusually in this literature 
they studied the same patients and parents before and after transfer. The main areas 
of concern expressed by patients and parents alike were potential exposure to 
infection, leaving their previous physician and potential decrease in quality of care. 
Parents were more concerned than their children themselves were about the patients' 
ability of care of themselves. Concerns about the adult team and facilities did not 
feature prominently. Most concerns had been allayed by the time of the second part 
of the survey, but concerns regarding infection remained. A factor that particularly 
decreased concerns (decreases of about 1,4 in a 5 point scale and statistically 
significant) was having met the adult team or a member of it prior to transfer. Having 
spent more than three years with the paediatric team increased the level of concern. 
Having telephone access to a nurse once the transfer had been effected was seen as 
very important by the respondents (4,9 [SD 0,6] on a 5-point scale). The patient 
respondents expected education on adult CF issues to be important parts of the adult 
programme. Their parents were more specific, citing fertility and transplant expertise 
as important aspects expected of adult care. The whole process was seen in a positive 
light (4,5 SD 0,3). 
Comparison of this study with ours demonstrates the influence circumstances of 
individual services can have on patient and parent perceptions. We studied existing 
services sited in separate hospitals with little contact between them. Our adult service 
was an established service. We studied younger patients who would transfer at a 
younger age. A nurse coordinator was part of neither team. We found major 
concerns regarding moving to the adult service; Boyle and colleagues found little.316 
Only the differential view of the young person's ability to cope between patient and 
parent coincided. This specificity of circumstances bedevils transition research, yet 
points to the need for locally-appropriate solutions. The value of the adult team being 
introduced before transfer is a potentially useful finding of the Johns Hopkins 
Hospital study. It has been seen as part of our solution to the problems highlighted in 
our study. A review of attitudes in Cape Town following the introduction of a 
transition plan would be helpful in strengthening the view that this is helpful part of 
achieving successful transition. 
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Another single centre American study of patient attitudes came from Boston. Zack 
and colleagues, in a service without a transition programme, explored their Children's 
Hospital patients' sources of health care, receipt of preventive counselling 
(anticipatory guidance) and attitude to such counselling.317 As with Boyle and 
colleagues' study,316 patients were mostly adults (median age 25,5 years, range 16-
43). Unfortunately the sample size was only 32 despite there having been 180 
potential subjects. As this was a prospective sample, study power rather than bias 
would be the main effect of this shortcoming. Fewer than half of the interviewees 
recalled preventative health care discussions. Patients felt that the ages of 13 to 16 
years represented the best time for them to start seeing the doctor alone. The findings 
of our study (that young people were not interested in seeing the doctor alone) are 
referenced as a contrasting experience on this point. Of perspectives on growing 
older with CF only half of the patients noted 'increased independence' Most 
responses to this 'transition' area related to comfort with current health care providers 
and their expertise with CF. Perhaps reflecting this, two thirds of this largely adult 
population had not considered transferring to an adult-oriented service. 
The findings in this centre contrast somewhat with those at the Baltimore centre. Is 
this because the adult centre in Boston was on another site? Did the paediatric experts 
have a role in producing this 'conservative' attitude amongst their older patients? 
Indeed adult pulmonologists were being drafted into this paediatric site to continue 
care for adults with CF. An eyebrow or two would be raised across the Atlantic at 
what was happening in Boston Children's Hospital. Did it represent a prominent 
strand in the care of older patients with CF in the USA? 
The question of how CF services were approaching transition issues overall in the 
USA was investigated in a comprehensive set of studies undertaken by Flume and 
colleagues at the beginning of the new century, first appearing in abstract form 
associated with the 2000 North American CF Conference and then in a number of 
related papers (in the paediatric literature!).318-20 
There were 110 CFF-approved CF centres in the USA. In the first study 104 (67% of 
the total) programme directors were surveyed.318 In the second, 1288 adult patients 
were contacted of whom a quarter replied.319 The third study used the internet to 
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survey team members apart from directors.32o Two hundred and ninety responses, 
nearly half of them from nurses, were received. Perhaps the most revealing aspect of 
these surveys was how out of step paediatric programme directors were with the 
perceptions of patients and their adult-oriented colleagues. They tended to want their 
patients to transfer (if at all) at ages up to and beyond 21 years citing lack of 
'maturity' being a reason for 'holding on to these patients. Adult patients and adult-
oriented directors did not see it this way; patients waqted to be seen as mature and 
capable. Boyle's study from Baltimore316 also gave this view from patients. Team 
members felt that transfer by 21 years was to be encouraged. Adult patients claim to 
have had far fewer concerns about transfer than the paediatric directors attributed to 
them. Team members also perceived patient concerns as only 'mild' to 'moderate'. 
The idea of transfer tended to be introduced to patients and families in mid to late 
teens, with many not meeting the adult team till the time of transfer. The quasi-
parental attitude of paediatricians needs to be challenged; it is likely to be acting as an 
impediment to successful development and transfer of mature young CF patients. 
The other significant finding was the large gap in adult services in the USA. Almost 
two in five (38,9%) of paediatric CF services had no associated adult service (either 
within their service or independent of it). A quarter of adult respondents who 
received centre care obtained it from paediatric centres. The authors comment that 
CFF directives aim to develop adult-oriented services in all centres. In a guest 
editorial associated with the 2004 paper, Conway from the adult CF service in Leeds 
in the UK opines that 
... without exception, all patients in the center (sic) 
(should) move on to an established adult unit.31o 
In this way, transition is established as an expected norm in CF care. He thus found it 
'scarcely credible' that so many adult American CF patients continued to receive 
care in the paediatric setting. The studies of Flume's group receive his commendation 
as their description of the current situation allows redress and points the way to 
improving transition through addressing attitudes and skills. 
The new century has seen transition in general being encapsulated in three major 
policy documents. The American Academy of Pediatrics together with the 
Academies of Primary Health and Internal Medicine put out a Consensus statement in 
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December 2002 in association with a special supplement to Pediatrics on the 
subject.32! This was one of the outputs of a special Consensus Conference on the 
subject held in 2001 and, through its involvement of representatives of adult services, 
demonstrated a new commitment to improving transition services. The 1993 
statement in Pediatrics only involved the Pediatric Academy. In essence, the new 
statement said, the goal of transition in health care is 
... to maximize lifelong functioning and potential 
through the provision of high-quality, 
developmentally appropriate health care services 
that continue uninterrupted as the individual moves 
form adolescence to adulthood.321 
Specifically the statement proposes the following six things: 
• That each young person has a health care professional who attends to the 
issues of transition 
• Make training in transition services part of certification of primary care 
residents and physicians' training 
• Maintain an up-to-date medical summary 
• Create a written transition plan by the time the child is aged 14 years 
• Include general guidelines for primary care and preventive health care in 
the care of young persons with 'special health care needs' (the official 
American phrase for long term health conditions such as CF) 
• Appropriate health insurance321 
The Society for Adolescent Medicine put out a second Position Paper on transition in 
2003 in the Journal of Adolescent Health.322 It also followed the Consensus 
Conference and reiterated the six "critical first steps" to ensuring successful 
transition. The Society added the need for all stakeholders to take responsibility for 
coordinating health care, continuing education of stakeholders, adults to receive 
appropriate primary care, further steps to improve adult health care, the continuing 
need to develop models of 'best practice', the elimination of restrictions by health 
centres and funders, and further research. 
Chapter 8 243 
In the UK in 2003, the Royal College of Paediatrics and Child Health in association 
with a number of other expert bodies put out a document entitled "Bridging the Gaps: 
Health Care for Adolescents".323 Coming from a tradition of strong primary care, the 
UK experts confined transition to 'Secondary Care'. It was felt that theonus was on 
specialist services to adapt themselves to promote good transition practice. The role 
of Primary Care services in the care of young persons in transition was unexpectedly 
considered to be in the future, 'as the overall services are developed' (p28). 
Unlike the Americans, the UK document states that full transfer to adult-oriented care 
should not occur until the young person has 'finished growth and puberty' (p40), 
perhaps reflecting the views of Viner, a major role player in the production of this 
document. He had expressed this view in his earlier annotation in Archives of 
Diseases in Childhood. 3 I I 
Transition services in Cape Town in the light of these recent trends 
Here in Cape Town a very good relationship has developed between the paediatric 
and adult CF services since the need for a transition service and the associated 
orientation of professionals was recognised and a response planned and implemented. 
In parallel the Cape Cystic Fibrosis Association has also put a lot of effort into raising 
adolescent issues among their membership. Their administrator often attends the 
adult clinic and has encouraged one gregarious female adult to welcome younger 
neophytes to the GSH service. On the RCCH side we arrange days on which families 
and patients can meet Prof. Paul Willcox and we can discuss these young persons with 
him. This may be more than a year before transfer takes place. Teenagers are 
transferred in 'batches' at around 17 years of age to help them feel more' at home' in 
the new surroundings. Whether this 'model', which has grown only partly by design, 
is fulfilling the aims of transition as voiced in recent statements remains to be seen. It 
contains the elements for success as suggested by the studies reviewed above: belief 
by both CF teams that transition to adult oriented care is appropriate; preparation from 
the time of diagnosis; more detailed preparation in the years immediately preceding 
transfer; introduction of the adult physician to family and patient before transfer, a 
familiar face on the adult side. Involvement of youth themselves has occurred 
indirectly through the Cystic Fibrosis Association and, for a short while, adolescent 
group work conducted by our social worker, Ms Margie Gibbons. 
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From the beginning of 1996 when our study of transition began to September 2003 
when this cohort was completed, 16 young persons with CF have been transferred to 
GSH. The average age at transfer was 17,8 years (range 10 - 19 years). 
As this review of the literature shows, any claim to success needs to be measured. 
The year 2006 will be 10 years on from the data gathering phase of our study. It 
behoves us to measure the effects of the changes wrought to our services aimed at 
improving transition for young people with CF in the Western Cape province and 
producing a healthier, happier, more independent adult. 
END-OF-LIFE CARE IN CF 
Death is rarely a sudden event in CF. There is a need for end-of-life care to be 
anticipated and prepared for by the health care team. This is less simple than it seems. 
Most deaths in CF relate to respiratory failure. However, the progressive decline of 
lung function is not linear. When FEV 1 measurements reach below 30% of expected 
correlation between lung function and the onset of the terminal phase of the disease is 
very difficult to determine. Patients can deteriorate clinically and then, with treatment 
for a pulmonary exacerbation, rally and return to baseline. Disease severity can 
appear to plateau; the patient adjusts to his or her disability and maintains a seemingly 
good quality of life. Sometimes lung deterioration can occur very rapidly with one 
bad exacerbation precipitating the patient into the tenninal phase, UIlanticipated. For 
these reasons, deciding at which point "end-of-life" care begins is often very difficult. 
Yet not to make adjustments to therapies and choices would be to deny a patient 
appropriate quality of life in the final phases of the disease. Thus it may be more 
helpful to think of the tenninal phase as a process rather than a point; a gradual 
adjustment of the goals of each element of the therapeutic regime. 
As pointed out in an article by Robinson and colleagues, the tenninal phase of CF 
may contain elements of preventative, therapeutic and palliative care.53 For example 
vitamin therapy aims to prevent complications of malabsorption may never be 
stopped; antibiotics may be used to reduce the burden of infection in the lungs; 
opiates or hypnotics may be prescribed for dyspnoea or insomnia. Antibiotics were 
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found to have been used right up to a few hours before death in many cases in this 
study. 
This article is one of very few on the subject of end-of-life care in CF. This being the 
case and, because I was struck by the very different experience of some aspects of 
end-of-life care they described in the USA compared with what I had been part of at 
the RCCH, I decided to contribute to the literature on the subject with the following 
letter:54 As before, references are given at the end of the letter. 
TERMINAL CARE IN CYSTIC FIBROSIS: HOSPITAL OR HOME? 
Pediatrics 1998;102:436 
As a member of a pediatric CF care team, I was struck by the contrast between my 
experience of the end-of-life care of those with CF and that of Robinson et all. 
Whereas all but one of their child and adult patients died in hospital, in the last 10 
years only 43.8% (9/2l) of our patients (ages 5-21 years) have died there. In Cape 
Town, death has tended to occur in hospital for those living far from our center where 
home-based care is more difficult to administer (N=2), those with rapid deterioration 
(N=6) and where care in hospital has been chosen (sometimes not in so many words) 
by the child/young person and family (N=1). The small number choosing in-hospital 
care may result from differing parental or staff attitudes to dying or from differing 
physical facilities in the children's hospitals in Boston and Cape Town. The potential 
availability of lung transplantation in conjunction with an older patient group will 
account for some of this difference. In highlighting the complex mixture of 
preventive, therapeutic and palliative care that occurs in the late stages of CF, 
Robinson et al. draw a contrast with the end-of-life care in cancer patients. As they 
point out, time of death in CF can be unpredictable. However, we need to note that 
home care for those with cancer can have positive effects2• In balancing therapy and 
palliation in CF, it is vital for us to gain insight into patient and family perspectives 
beyond those hinted at in the article3• Are our practises meeting the needs of patients 
and families facing the final phases ofCF? Are some of those in ICU on BiPAP, for 
example, not among that "proportion of patients" who "die deprived of the final 
comforts of actively managed terminal care"?4 The contrasts I have drawn attention to 
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adjure us to ensure as scientifically as possible that, in our different settings, in the 
final phase of CF the broad needs of the children/young people and the families with 
whom we deal are being addressed. 
DR A T R WESTWOOD 
FCP(SA) 
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In the article I cited (Reference 3 above), Warner from Southampton in the UK. was 
concerned that patients being assessed for transplantation yet rarely receiving it was 
denying them the choices that a realistic approach to end-of-life care can offer.224 I 
was concerned to discuss this in relation to the American experience of the terminal 
phases of CF. 
A subsequent article from Canada published in Chest in 2000 reported a survey of CF 
centres in that country.324 Most of the 45 patients who had died in 1995, the year 
under survey, died as adults. Notably 77,8% of these died in hospital, and again the 
prospect of transplantation was a factor. Many were assessed but few were actually 
transplanted. Three quarters of the patients received some form of end-of-life 
medication. Only 35% of patients had had end-of-life care discussed more than one 
month before death. This being the case it is not surprising and is somewhat 
reassuring that 
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The phYSicians ....... indicated a desire for 
assistance in providing palliative care.324 
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Despite my assertion that home end-of-life care should be considered, my experience 
in this province has been of many impediments to this. Support services are not 
readily available. In only three cases was successful hospice-supported care achieved, 
all three in Somerset West. In a number of cases when home care was chosen by the 
family. I felt support was far from ideal. The hospital team was constrained in its 
ability to visit homes; few services were available to entrain for patients who had 
received most of their care from the hospital. General practitioners assisted in two 
cases. Many hospital deaths were because the family could not cope at home even 
though they wished for an expected death to occur there. With about four deaths 
occurring a year in patients who come from diverse areas it is difficult to set up 
services to adequately deal with the complex end-of-life needs of young persons with 
CF. The addition of a nurse to the team could significantly help in this area.325 How 
complex end-of-life needs are is illustrated in the following case study with which this 
chapter will end: 
The Story of N 
N was 16 when the point came to discuss the change in focus of his CF care. 
Always a quiet and uncomplaining child and now a young man of similar 
character, he was cyanosed but was not troubled by dyspnoea at rest. His 
parents who lived with him in a village out of Cape Town had a long 
discussion with the CF doctor. "Quality time" was now the name of the game. 
N, in his quiet way asked no questions, made no fuss. Home oxygen was 
arranged via a concentrator; the local hospital was informed of his condition. 
We spoke to the Medical Superintendent of his local hospital to facilitate 
access to any care he might need. The Reach for a Dream Foundation 
supplied him with woodworking tools and over the next four year (yes, four 
years) during admissions for pulmonary exacerbations and unpleasant back 
pain caused by osteoporosis (he was always sent home as soon as he was 
comfortable) and when he visited the CF Clinic, he would bring little products 
of his workbench. During one of his admissions (about two years after the 
talk) his parents wanted to discuss lung transplantation again. After discussion 
of this with them and N, the impossibility of this was accepted. Once he 
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arrived nearly dead because his oxygen transport cylinder ran out in the car in 
a mad dash to hospital. But N continued to live. Despite contact with the local 
GP and hospital, N's parents always wanted him to come to the Red Cross 
Hospital. Progressively his shortness of breath increased. He went in to right 
heart failure. He developed diabetes. And one day (yet gradually) his oxygen 
dependence and dyspnoea were such that further palliation and symptom 
relief would be needed. N though quiet and very much in love with his dog 
who always slept on his bed at home, made it clear that he did not wish to 
return home. Morphine was started; he found that his nebulised 
bronchodilators made him shaky and anxious - staff needed a lot of 
persuasion not to administer them. The Social worker and CF and ward 
doctors spent time with him encouraging him to call the shots of his care. His 
psychic turmoil increased. He talked as he'd never talked before. He seemed 
to have so much to resolve. I found that my poor command of Afrikaans let 
him down at times. He was frightened of death yet wanted release. He didn't 
want his parents to suffer. I told him that it was only the oxygen that was 
keeping him alive. We wanted him to be released from the strain of breathing 
but morphine administration and attempts to reduce the oxygen flow rate did 
not give release. He lived on. Then one day, knowing that his parents were on 
the way from home, while alone, not half an hour after the last discussion with 
one of us, he pulled off the oxygen quite deliberately and in five minutes was 
dead. N, the quiet, undemanding adolescent had chosen his moment of death 
as he saw best for himself and his family. His parents, although devastated by 
his death that they had known was imminent for four years, were quick to see 
the magnanimity of his act. 
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CHAPTER 9 
PROGNOSTIC ASPECTS 
OUTLINE OF CHAPTER 
This chapter presents a South African perspective on survival in CF. A 
review of local literature is followed by my study of the subject in the 
Western Cape CF population, published in 1999. The chapter ends with 
updated figures on survival covering 29 years and an associated discussion of 
international comparisons and the role of socio-economic and other factors in 
CF survival in this region. 
INTRODUCTION 
Cystic fibrosis is a lethal disease. Few persons with the disease live a normal life 
span, even in the 21 51 century. In 50 years CF has gone from being a condition 
associated almost uniformly with death in infancy to one in which a majority of 
sufferers reach adulthood and in which a reasonable quality of life may be expected 
for many years. A major contributor to this improvement has been advances in health 
care. This chapter explores whether persons with CF in the Western Cape province 
have benefited from these improvements and what factors influence longevity in this 
population. In CF overall survival is, in large part, a proxy for the quality of health 
services: how have South African health services been doing over the last three 
decades? 
The first study of longevity in a South African CF population was that of Hill and 
colleagues.33 In this study, survival was part of a general description of CF as seen in 
Cape Town. The prognosis data were limited to average length of survival. Mean 
survival is a very crude and misleading statistic in the study of longevity. Survival 
times are not normally distributed and no account is taken of the age of those who are 
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alive at the time of the study. In CF, mean survival would have given a particularly 
misleading figure as those still alive would be likely to survive much longer than 
those born early in the study period, owing to the advances made in treatment 
between the 1960s and the 1980s. No statistical method can completely overcome the 
difficulty in measuring survival (which, as Corey in Toronto pointed out, is a moving 
target326) but Life Table or Kaplan-Meier product limit survival analysis give much 
better approximations. The latter method is the one I employed when studying the 
prognosis of CF in the 1990s. This chapter reproduces, unchanged, the report of this 
study as it was published in the Journal of Paediatrics and Child Health in 1996.52 
Nine years have passed since the period studied in that report ended. The second part 
of this chapter presents updated survival curves covering 29 years of follow up of this 
CF population. Factors that might have influenced survival are also explored further 
in this section. 
Study 9.1 
THE PROGNOSIS OF CYSTIC FIBROSIS IN THE WESTERN 
CAPE REGION OF SOUTH AFRICA 
DR ATR WESTWOOD 
DEPARTMENT OF PAEDIATRIC AND CHILD HEALTH, RED CROSS WAR 
MEMORIAL CHILDREN'S HOSPITAL, RONDEBOSCH AND UNIVERSITY OF 
CAPE TOWN, CAPE TOWN, SOUTH AFRICA 
1. Paediatr Child Health (1996) 32; 323-326 
ABSTRACT 
Objective: To study the prognosis of cystic fibrosis (CF) in South Africa. 
Methods: Retrospective chart review of 102 children with CF over 20 years. 
Results: Survival at 18 years was 54% (95% confidence intervals 30-79). Prognosis 
was not influenced by gender or genotype but survival was noted to be worse for 
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Cape Coloured children than for European children. This appeared mainly to be due 
to the death of 8 Cape Coloured infants, 4 of whom presented with oedema and 
anaemia, mimicking kwashiorkor. Infection with Pseudomonas aeruginosa occurred 
earlier in Cape Coloured children than European children (Median 1 vs 4 years) and 
they had a worse 5-year survival (56% vs 89% p<0.05) after infection. Of the 40 
children born in the second decade studied, 6 Coloured and no European children 
died. 
Conclusions: Ethnic differences in prognosis exist and are probably relate to 
underrecognition of CF and socio-economic status. 
Key words: Cystic fibrosis; prognosis 
Cystic Fibrosis (CF) is one of the commoner life-threatening genetic diseases in 
people of European descent and in South Africa also occurs people of mixed ancestry 
(a heterogeneous group of Malay/HottentotlEuropean/Khoi ancestry known as Cape 
Coloured) 1. Since the identification of CF as an entity in the 1930s the average 
survival of people with the disease has risen rapidly. In the United States of America 
the Cystic Fibrosis Foundation reports a change in median survival from 14 years in 
1969 to 28 years in 19902. This increase has been ascribed to advances in 
management, specifically pancreatic enzyme replacement, attention to nutrition, 
physiotherapy and new antibiotics for Pseudomonas. The influence of better 
ascertainment of mild cases on these figures is uncertain. Projected median survival 
for those born since 1990 is 40 years in the United Kingdom3. In contrast in Latin 
America over the last 15 years half of the children with CF died within 7 years of the 
diagnosis being made4. 
In 1988 Hill et al., in a report outlining the clinical and epidemiological features of 
CF in Cape Town, noted that 21 % of 106 patients had died with a mean age at death 
of 4,7 years. 1 The present study aimed to explore the prognosis of CF further and to 
examine the factors which influence the survival of those with CF in the Western 
Cape region, the capital of which is Cape Town, of South Africa. 
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METHODS 
All cases ofCF (confirmed with 2 sweat tests) born in the 20 year period between the 
beginning of October 1974 and the end of September 1994 and who were seen 
regularly at the Cystic Fibrosis Clinic at the Red Cross War Memorial Children's 
Hospital were included in the study. Any patient who had been admitted and died, 
the diagnosis having been made shortly before death or post mortem, were (sic) also 
included. 
For each child demographic details were recorded. The date of death or the date of 
last contact with the clinic was recorded with data on children who were referred 
elsewhere or who had been lost to follow up being censored at the date of last contact. 
Cause of death was ascertained from the clinical record. Variables examined were 
gender, ethnic group (European or Coloured, which in the present study was made up 
of Cape Coloured children, one Xhosa child and three Asian children), deltaF508 
(DF508) status and age (in completed years) at first colonisation of respiratory 
secretions (nasolaryngeal aspirates in infants; expectorated sputum in older children) 
with Pseudomonas aeruginosa. 
Data was captured and analysed, with the exception of survival curves, using Epi-info 
Version 6 (Centers for Disease Control, USA). Survival curves were generated using 
Kaplan-Meier product limit methods and significance levels were calculated using 
logrank statistics (Statgraphics Version 6.1, Manugistics Inc., 1992). For those who 
had been colonised with P. aeruginosa 5- and 10-year survival rates after colonisation 
were calculated. 
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RESULTS 
One hundred and two children 
(52 male) fulfilled the study 
criteria. Twenty six children had 
died, of whom 18 had died in the 
first decade of life. All deaths 
after the first year of life were 
due to CF lung disease. 
Cumulative survival for the 
whole cohort is shown in Fig. 1. 
There was no statistically 
significant difference in 
prognosis between males and 
females (p = 0.4; Fig. 2a). 
There was a significant 
difference in the mortality rates 
of European and Coloured 
children (10/57 vs 16/45, Chi· 
square = 4,25, P = 0,04 Mantel-
Haenszel). Cumulative survival 
analysed by ethnic group is 
shown in Fig. 2b. Nine infants 
died; all except one were 
Coloured and their clinical 
histories are shown in Table 1. 
If infant deaths are excluded, the 
ethnic difference in prognosis 
fails to reach statistical 
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FTT = Failure to thrive, C Coloured, E = European 
The DF508 status was known for 82 of the 102 children; 12 children died and 6 were 
transferred before genotyping became available and 2 had had testing deferred. 
Genotype did not influence mortality (Table 2). 
Data for P. aeruginosa colonisation could not be ascertained for 5 children. The ages 
at colonisation for European children and Coloured children differed (Kruskal-Wallis 
H = 11,3, P = 0,0008). The medians were 4 years and 1 year, respectively. Survival 
in those colonised with P. aeruginosa was worse for Coloured children than for 
European children (56% vs 89%) 5 years after colonisation. This difference was not 
evident at 10 years (Table 3). 
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TABLE 3 SURVIVAL, PSEUDOMONAS COLONISATION AND ETHNIC 
GROUP 
5 year survival* 10 year survival 
European Coloured Total European Coloured Total ------~==~~~~~9~~~~2~6=---------~3~--~~4~-----7 
Alive 17 
~D~e=ad~ ____ ~2~ ____ ~7 ______ ~9 __________ ~8=-____ ~10=-_____ 18 
* p = <0.05 (Fisher exact) 
To test whether advances in survival recorded in other countries were reflected in this 
cohort, it was split by decade of birth. There was no change in prognosis in the first 
10 years of life for the whole group (Figure 2c) but all six children born in the second 
decade who died were Coloured. Three died in infancy (Patients 2, 3 and 6 in Table 
1) and the other 3 died at 15, 22 and 61 months of age, respectively. 
DISCUSSION 
Cystic fibrosis occurs in 1 per 2000 European births and 1 per 12000 Coloured births 
in South Africa 1. Specialised CF Clinics exist in a number of centres. In Cape Town 
the Cystic Fibrosis Clinic at the Red Cross War Memorial Children's Hospital, non-
racial from its inception, was set up in 1972. Until 1989, when an adult facility was 
started at Groote Schuur Hospital, it was the only specialised CF Clinic in the 
Western Cape region. It is reasonably certain that all the individuals born in this 
region since 1974 in whom CF has been diagnosed have been followed up at the 
Clinic. Cases diagnosed post mortem at peripheral hospitals may have been missed 
although the genetic implications of the disease make it unlikely that these cases 
would not have come to the attention of the Clinic. There may be under-recognition 
ofCF in rural Coloured people 1 , 
The present study, the first to assess prognosis in a South African CF population, 
although limited by the relatively small number of cases, does allow some 
conclusions to be drawn. There is a cumulative survival of 54% at 18 years meaning 
that, as in other countries, provision of services for an increasing number of adults 
with CF will be necessary. Survival proportions for the first 10 years of life in 
children born between 1974 and 1985 were lower than those for the United Kingdom 
reported by Dodge et a15 with 77,5% versus over 80% surviving to 10 years of age. 
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Infant deaths appear to be playing a significant role in the mortality rate of CF in 
South Africa. While for the European group the impact was minimal, in the Coloured 
group 50% of deaths occurred in infancy. One factor responsible for this appears to 
be the underrecognition of the anaemia-oedema presentation of CF. All babies with 
this presentation except one (in whom the anaemia was extensively investigated 
before the diagnosis was recognised) were diagnosed as having kwashiorkor, which is 
a much more common problem in the Western Cape region. Poor prognosis is often a 
feature of the anaemia-oedema presentation6 but delayed and inadequate treatment 
would have reduced the chance of survival. Three of the nine infants who died had 
the diagnosis made post mortem. It had not been suspected ante mortem. This lends 
credence to Hill et al. IS contention that there is underrecognition of CF in the 
Coloured population1. 
Although there was a trend, in line with other reports, for females to die earlier, this 
did not reach statistical significance. There are significant differences in genotype 
between the European and Coloured populations 7 but, owing to small numbers, it was 
not possible to show whether this influences prognosis. Testing for the DF508 and 
other mutations began in 1990. With time any influence genotype has on prognosis in 
this population may become apparent. 
No difference in cumulative survival was found between the two ethnic groups after 
infancy. The three post-infancy deaths that occurred in the Coloured group in the 
second decade studied, without any in the European group, might be ascribed to 
chance but in all three cases there were social and educational factors which disrupted 
effective management from a central clinic. Ethnic group as a risk factor probably 
exerted its effect through its socio-economic implications although this effect is not 
demonstrated for children who survive the early years. Britton8 showed that lower 
social class independently worsened the prognosis of CF in England and Wales. 
Diminished access to and use of specialist CF clinics may result in the benefit of such 
centres not being felt by those who are socio-economically deprived. 
First identifIcation of P. aeruginosa in respiratory secretions occurred earlier in the 
Coloured group. This may be due to these children being more ill and therefore 
Chapter 9 257 
having respiratory secretions cultured more frequently. Alternatively, sick children 
may be exposed to nosocomial infection with P. aeruginosa at CF clinics or in 
hospital wards. This group of patients is economically worse off than their European 
peers. Overcrowding and inadequate housing lead to greater exposure to respiratory 
pathogens. The poorer outcome for this group at 5 years may, in part, be due to 
earlier colonisation with P. aeruginosa. Given that mucoid strains of P. aeruginosa 
are associated with a worse prognosis9 it would be important to ascertain the nature 
of the isolates. This information was not available for samples obtained in the earlier 
part of the study period. All these aspects will need to be examined in further studies. 
The 20 years reviewed in the present study saw many advances in the management of 
CF. Most children in South Africa appear to have benefited but underrecognition of 
the disease in Coloured children and suboptimal management of children from 
deprived backgrounds need to be addressed. The study reported here has provided a 
basis from which to assess the impact of recent progress in the understanding and 
management of the disease. People with CF in South Africa deserve to benefit from 
such progress. 
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Despite having relatively low numbers of subjects, the 1996 paper was able to show 
that persons born with CF and living in this region in the late 1970s and early 1980s 
had an approximately 50% chance of reaching their late teen years or adulthood. 
Having only 20 years of follow up the survival curve could not go beyond this point. 
However it also demonstrated that infant death in the coloured group was a serious 
problem (8 out of the 26 overall deaths; half of the deaths among coloured patients). 
Small numbers and the relatively short period of follow up prevented any conclusions 
being drawn on improvements in prognosis over time. 
Study 6.2 has shown that nutritional status improved between 1986 and 1996. Zar 
and colleagues' cross sectional study of lung function indicated that it was well 
preserved in children with CF in the mid-1990s?58 This is corroborated by data 
presented in Chapter 7. Nine years have elapsed since the period studied in the 1996 
paper on prognosis. In that time the number of patient in the database has risen by 
nearly 80% from 102 to 181. As I wrote in the 1996 paper: 
'The study reported here has provided a basis from which 
to assess the impact of recent progress in the 
understanding and management of the disease. People 
with CF in South Africa deserve to benefit from such 
progress,.52 
It may now be possible to tease out trends and explore whether CF patients in the 
Western Cape province have indeed benefited in terms of survival from the progress 
that has been made in CF care in recent years. 
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Study 9.2 
The prognosis of cystic fibrosis in the Western Cape province: a 29 
year study 
Objectives 
To determine overall survival and the causes of death of patients with CF in the 
Western Cape province 
To detennine if there have been changes in survival between the 1970s and the 
1990s 
To detennine if there has been progress in reducing the infant mortality due to 
CF 
To determine the influence of ethnic group on the prognosis ofCF in this region 
To determine if age at diagnosis influences survival in this population 




All cases of CF, the diagnosis having been made as described in Chapter 2 and 
who were born in the 29 year period between the beginning of October 1974 
and the end of September 2003 and who were seen regularly at the Cystic 
Fibrosis Clinic at the Red Cross War Memorial Children's Hospital, were 
included in the study. Any patient who had been admitted and died, the 
diagnosis having been made shortly before death or post mortem, was also 
included. 
Study data 
The following demographic and clinical data were obtained for each subject 
from the CF database described in Chapters 2, 3 and 4: gender, ethnic group 
(see Chapter 3 p33), whether the child lived in the Western Cape province from 
before the age of 2 years, P aeruginosa status (ever infected or never had the 
organism cultured from respiratory secretions). The date of death or the date of 
last contact with the clinic was recorded. Data on children who had left the 
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province or who had been lost to follow up were censored at the date of last 
contact. In an attempt to examine changes over time, the 29 year period was 
divided into 2 equal parts (October 1974 - March 1989 and April 1989 -
September 2003). Cause of death was obtained from the clinical record. 
Data was captured and analysed using the Statistica computer package 
(StatSoft, Inc. (2004) version 7. www.statsoft.com). Survival curves were 
generated using Kaplan-Meier product limit methods and significance levels 
were calculated using log rank statistics. 
Results 
In the 29 years studied, 61 of the 181 CF patients (33,7%) had died. Mean age at 
death was 9,7 years. The mean for coloured patients was 7 years and 5 months and 
for white patients was 14 years and 4 months. Cumulative survival is shown in 
Figure 9.1. Median survival was 19,8 years with a 25 th percentile of 11,4 years. If 
only those who had lived in the Western Cape province from before their second 
birthday were included (N = 160), the median survival was 18,1 years (25th percentile 
10,6 years, 75 th percentile 22,4 years). 
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There was no significant difference in survival between males and females (p = 0,089, 
Figure 9.2). However if infants were excluded from the analysis (N 162) as gender 
has not been shown to influence very early survival, the lesser survival of females 
almost reached statistical significance: p = 0.056. 
Figure 9.2 Cumulative survival by sex 
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There was a highly significant difference in prognosis between white and coloured 
CF patients (p = 0,00005) (Figure 9.3). Twenty three of the 101 white patients 
(22,8%) had died while 37 of the 75 coloured patients (49,3%) had died (Chi2 14,5, P 
0,00014). The median age of survival for white patients was 21 years with a 25th 
percentile of 17 years; the figures for coloured patients were 14,6 years and 5,6 years. 















0.4 ~ (13 
::3 





0 2 4 
Survival by"Ethnic Group" 
o Deaths 
0.-_ .. ; ...... ~. White patients .. ' 
". : . . 
·c oloured patients: 
6 8 10 12 14 16 18 20 22 24 26 28 30 
Survival Time (years) 
Of the 61 deaths all but 9 (14,8%) were due to respiratory disease. Two patients died 
in their teens owing to hepatic complications of CF; one teenager committed suicide; 
one child died at 14 months of a Reye-like syndrome; one infant died of an 
unexplained colitis. One infant died of sepsis associated with the anaemia/oedema 
complex. He had undergone extensive investigation for anaemia and died soon after 
the diagnosis of CF was made (see Table 9.1). One other infant had congenital 
hydrocephalus with severe neurological sequelae. He died of marasmus soon after 
the additional diagnosis ofCF was made (see Table 9.1). 
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There were 13 deaths in infancy (21 % of all deaths). Infant deaths accounted for 2/23 
deaths in white patients versus 11/37 deaths in coloured patients (p 0,1). There 
have been 4 infant deaths since those reported in Study 9.1, Table 1. Table 9.1 shows 
all 13 infant deaths. Seven infants died in the first study period and 6 in the second. 
TABLE 9.1 INFANT DEATHS 
Age at Ethnic Presentation Year Age at Cause of 
diagnosis group of death of death death death 
(months) (months) 
1. Birth C Meconium ileus 1981 3 Pneumonia 
2. 3 C Anaemia/oedema 1993 3 Aspiration pneumonia" 
3. 3 C Anaemia/oedema 1981 3 PA pneumonia# 
4. 3 C FIT/pneumonia 1983 3 Pneumonia 
5. 4 C Pneumonia 1981 4 Pneumonia# 
6. 3 C FIT/pneumonia 2001 4 Pneumonia 
7. 3 C FIT/pneumonia 2000 4 Pneumonia 
8. 4 C Anaemia/oedema 1988 5 Septicaemia" 
9. 4 C Hydrocephalus/FTT 1995 5 Marasmus 
10. 6 C Anaemia/oedema 1992 6 Pneumonia# 
11.. 3 C Severe pneumonia 1981 7 PA pneumonia 
12 4 W FTT /Chestiness 1994 8 Colitis 
13. Birth W Meconium ileus 1977 9 Marasmus/pneumonia 
# 
Siblings 
Diagnosis of cystic fibrosis made post mortem 
FIT = Failure to thrive, C coloured, W = white, PA Pseudomonas aeruginosa 
When infants were excluded from the analysis, thus excluding the infant deaths, the 
difference in survival between the ethnic groups remained (p = 0,003). This is shown 
graphically in Figure 9.4. Median survivals were 21,1 years for the 94 remaining 
white patients and 17,9 years for the 64 coloured patients in this analysis. This 
represents a 3,3 year greater median survival for coloured patients than when infants 
were included. 
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Ninety five patients were born in the first 14,5 year period and 86 in the second. In 
the first period 26 patients had died by 14,5 years of age; the figure for the second 
period was 18. There was no significant difference in survival between the two 
periods (p = 0,31) with survival at 14,5 years being about 70% for both periods. 
Figure 9.5 combines the curves for the two periods. There was also no statistical 
difference between the two periods for survival of coloured patients (p = 0,17). The 
difference in survival between coloured and white patients was significant for both 
periods, though only for the second period if infants were omitted from the analysis (p 
= 0,00035). Of the 23 deaths among white patients in the 29 years, only one was a 
child born in the second period. This child (the infant with colitis) was the only one 
of the 40 (2,5%) white children born in the second period to die compared with 17 of 
the 42 (40,5%) children in the coloured group (p = 0,00011). One of the four black 
children died. This death occurred in the first period, the diagnosis of CF only having 
been confirmed post mortem (Case 1, p67). 
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Figure 9.5 Cumulative survival comparing the first and second periods 
Cumulative survival by Period 
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The Pseudomonas status ofthree patients could not be determined. The presence of P 
aeruginosa was significantly associated with a worse prognosis (p = 0,019). Figure 
9.6 shows that this deleterious effect of P aeruginosa colonisation was not a factor in 
infancy but it increased with time. Only 6 patients uninfected with P aeruginosa died 
after infancy, all of them in the second decade or beyond. In contrast P aeruginosa 
infection was associated with deaths throughout childhood and the teenage years. 
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Figure 9.6. Cumulative survival according to Pseudomonas status 
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Discussion 
The first examination of the prognosis of CF in the population of the Western Cape 
province covered 20 years and involved 102 patients. In the subsequent nine years of 
recruitment and follow up the cohort has enlarged by over 75% to 181 patients. This 
is not accounted for by migration or demographic shift and therefore must arise from 
increased recognition of CF in the province. Although, as demonstrated in Chapter 4, 
this increase has not been accompanied by a demonstrable decrease in the age at 
which CF is being diagnosed, it must be taken as an encouraging sign. It suggests 
that one is moving closer to measuring the real prognosis of CF in this region, at least 
among coloured and white patients. The disproportionate increase in the size of the 
cohort also increases the chance that deeper analysis of survival and trends in this 
population may be possible. 
Despite the 'moving target' nature of survival analysis,326 it has the potential to 
influence practice and policy. For example, the demonstration that about half of those 
with CF born between 1974 and 1993 survived to adulthood has been used when 
counselling parents in the clinical setting and in motivating for appropriate adult-
oriented services for CF. Similarly concerns around infant deaths and ethnic 
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differences in prognosis have led to reviews of clinical practice e.g. a more aggressive 
approach to GOR in infants with CF; greater social work involvement in the CF 
Service. In a decade much can change and it may have become possible to tease out 
further helpful information on trends. 
Overall survival remains within the range identified in the first study. The attempt to 
measure the efficacy of CF services in the Western Cape province by excluding 
imported cases produced a slight but non-significant lowering of overall survival. 
This will largely have been due to a stronger effect of the very early deaths as no 
imported cases died in the first two years of life. Mean survival for the whole cohort 
was 9,7 years. This 'improvement' over the figure for mean survival of 4 years given 
by Hill and colleagues for the 1960s to 1980s33 shows the value of a longer period of 
follow up. Despite this, what is new and could not be shown in the earlier study was 
the dramatic fall off in survival as patients entered the third decade of life. While this 
is partly a product of the small numbers of patients who have reached this age, the 
cluster of deaths at around the age of 20 years is a cause for concern. By definition 
these have all happened in the last decade of the study. This phenomenon represents 
a strong post hoc justification for the investigation into the circumstances of transition 
to adult-oriented care we undertook in the 1990s57 and the changes we made to this 
process. 
How does survival in this South African CF cohort compare with other countries. As 
an example of a developed country, comparison with the UK was made in the first 
study (Study 9.1) and will not be reiterated here. Survival continues to improve in 
such countries reaching into the 5th decade in some centres. Given the large 
discrepancy in per capita income levels and health service sophistication between SA 
and developed countries, such comparisons are of limited value beyond emphasising 
the significant influence of these 'environmental' factors on the prognosis of CF. 
What is the situation in other countries? 
Prognosis of CF beyond the developed world 
That the survival of persons with CF that has been achieved in North America, 
Western Europe and Australia has not been reproduced in countries that are poorer 
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and have less sophisticated health infrastructures is clear. Even in Eastern Europe 
where living standards were good compared with the developing world, survival of 
those with CF has not kept pace with Western countries. In fact it would appear to 
have lagged behind SA. CF centres only appeared in Russia in 1989. A study of 186 
patients showed 41 deaths in infancy and life expectancy was thought to be about 14 
years.327 
The results presented here are a sample of what happens where CFTR mutations are 
less common than countries with a Western Caucasoid majority, per capita incomes 
are lower and health infrastructure is less able to meet the health needs of the 
popUlation. 
It is instructive to compare survival in the Western Cape province of SA with that in 
Latin America. There, as in SA, populations are ethnically mixed, CFTR mutations 
are less common than in the West and poverty is common. An initial report from 
Latin America suggested very poor outcomes for patients with CF: Macri and 
colleagues pooled information covering the period 1968 to 1989 from a number of 
Latin American countries in a 'preliminary communication' published in 1991.328 
In all countries survival after diagnosis (mean age at diagnosis was over 3 years) fell 
off rapidly, reaching from less that 20% survival at 6 years in Chile to 50% survival 
over the same period in Argentina. As the authors commented, these rates were 
'disappointingly low'. It is difficult to compare our figures for the Western Cape 
province with these owing to earlier mean age at diagnosis in our region and the 
inclusion of 1968 to 1973, a period when the worst survival figures could have been 
expected, in the Latin American figures. However the South African data in Figure 
9.5 for the period 1974 to 1989 (the' 1 st period') only reach comparable percentage 
cumulative survivals in the late teens, suggesting that there was better survival in SA 
than in Latin America in the 1970s and 1980s. 
More detail from one area in Latin America, Minas Gerais state in Brazil, has 
subsequently been published by Reis and colleagues from Bela Horizontale. They 
run a CF centre that is the only centre for an area 300 miles in diameter. Bela 
Horizontale has a population of 3,5 million and about half of the CF patients seen at 
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the centre come from the metropolitan area. Four papers concerning swvival in CF 
have come from this area. 
The first, published in 1998, attempted to put a figure to cumulative swvival. 329 The 
cohort of 111 patients, 16 (14,4%) of whom had died, had been seen between 1970 
and 1994. Unfortunately the data were severely skewed by short follow up times. 
Only 16% of patients had been followed up for more than 6 years and half had follow 
up times of fewer than two years. Apparently this was not due to early deaths as 
swvival rate was reported to be 77% at 14 years of age. Mean swvival was given as 
12,6 years. It must therefore have been that patients were entering the cohort well 
into their first decade of life and therefore represented swvivors; indeed 55% of 
patients were diagnosed with CF after the age of 3 years. It is likely therefore that 
many CF patients were dying early in life undiagnosed. While this issue is not 
directly addressed in the paper (indeed the authors optimistically state that 
'undiagnosed patients are possibly mild and moderate cases and, 
theoretically, have a better prognosis'), the authors do note that 
There is a lack of awareness and experience in (sic) many 
physicians in Brazil for suspecting and recognizing the early 
manifestations of this disease .... 329 
These factors all contribute to questions as to the validity of the results of this study. 
Thus the cumulative swvival given in this paper, poor as it was and despite the 
authors' views. is likely to have been an over-estimate of true swvival in Brazil. 
In a later paper using the same cohort Reis' group attempted to explore factors that 
predicted outcomes in their CF population.33o The results were presented in a slightly 
different way. For example, follow up times were given as a mean of 8,85 years. 
Data from the previous paper shows that the median must be nearer to 2 years of 
follow up since 46,9 % of patients were followed up for fewer than 2 years. Given 
the caveats expressed in the preceding paragraph, it is difficult to use these data to 
compare with the situation in our region. The infant death data from this article are 
discussed below (P279). Camargos and colleagues noted that ethnic group classified. 
much as ours was, on skin colour did not influence outcome. 330 Ten out of 55 
(18.2%) 'whites' died and 7/55 (12,7%) 'non-whites' died (p = 0,49). Proportional 
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hazards methodology could not tease out a difference. Relative hazard for death of 
being 'white' was 1,65 on univariate analysis and 1,10 (95% CI 0,40-3,01, P = 0,853) 
on multivariate analysis. Mean ages at death were 4,01 and 4,86 years respectively, a 
figure very similar to Hill and colleagues report on CF in the western Cape Province 
in the 1960s to 1980s.33 In the Brazilian population, Camargos and colleagues 
comment, 'socioeconomic status is indirectly related to ethnic group',330 a 
situation similar to SA. It is possible that with longer follow up times these 
difference will appear as strongly in Brazil as they have in the Western Cape 
province. 
In their third paper the Brazilians attempted further analysis of prognostic factors in 
CF. Oliveira and colleagues used a later but overlapping cohort of 127 patients who 
had been seen between March 1977 and December 1997.251 That this was largely a 
recent cohort is indicated by the fact that over three quarters of these patients (78%) 
were seen after 1990 and median follow up was 44 months. Again only a small 
proportion had died (16%) meaning that comparison with our longer and more 
unifonn (in tenns of stable patient numbers over time) study is not really valid. 
Length of follow up was so much shorter than that reported here that cumulative 
survivals are not comparable and do not indicate real outcomes in a middle income, 
ethnically diverse society. Thus our South African data seems to represent the best 
assessment yet of real survival from CF in such non-Western societies. 
Despite this, in tenns of prognostic factors in such a society, the study is not devoid 
of interest. In the light of the prognostic differences in survival with CF between 
socioeconomic/ethnic groups in SA, Oliveira and colleagues' observations regarding 
nutritional status are interesting. Birth weight seems to have had prognostic 
significance with weights below 3000g having a survival probability of 59% (95%CI 
41-77) versus 87% (95%CI 77-97) for birth weights 3000g and above.251 The relative 
risk of birth weight below 3000g was 5,95 (95%CI 1,7-15). Low birth weight is 
common is SA's coloured population.33! Could this not be influencing outcomes 
from CF in this group? Other nutritional factors such as wasting and low height for 
age also carried a worse prognosis but this is not unique to Brazil or Cape Town (see 
below and Chapter 6). In Brazil the presence of P aeruginosa was also associated 
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with worse prognosis in univariate analysis (though not in multivariate analysis), but 
again this is not unique to poorer countries. At variance with modem CF experience 
in developed countries was an association between early diagnosis (specifically 
diagnosis before 3 months of age) and poor outcome. This is likely to have been in 
part due to MI. In the fourth paper, using the same 127 patients, the same authors 
showed that the 9 patients with MI had lesser survival than those without MI.332 In a 
society where poverty plays a role in the rapid progression of CF-related disease 
owing to poor nutrition, hygiene and environment, the youngest children are likely to 
be most vulnerable to these adverse circumstances. This Brazilian data has resonance 
in the population we have studied: except for MI and siblings, early diagnosis was 
associated with early severe disease, and increased likelihood of very early death. 
Later diagnosis means that for genetic or other reasons the children were less 
symptomatic. To study this in more depth using proportional hazards methodology 
could be informative in SA. 
Trends in survival 
Once again change in survival over time was not found (or was not demonstrable). 
The shapes of the two curves in Figure 9.5 are very similar. Infant deaths wiped out 
10% of patients in both periods and just under 70% of patients were alive at 14,5 
years. It is to be hoped that later survival of the second cohort will exceed that of the 
first. This has already occurred for the white group with only one death occurring 
and that an unusual one in infancy. 
This widening gap between the two main 'ethnic' groups requires further 
examination. This second study has been able to demonstrate what was suspected at 
the time of the first study: coloured patients do not survive as long as white ones. The 
phenomenon exists in the present more than it did in the first half of the study period. 
This represents the most important challenge to the health service and the CF Service. 
What factors are leading to this difference? The large number of infant deaths will be 
dealt with separately (see p278). As this study shows, deaths among coloured 
patients exceeded those among white patients for the whole study period. My 
experience would suggest that rather than biological factors, social factors were 
leading to this differential survival. 
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The role of social factors: socio-economic status, ethnicity 
In the first study reported in this chapter I noted the likely role of social factors in the 
early deaths of coloured children with CF. Now that overall mortality and not only 
early mortality has been shown to be worse in the coloured CF population the role of 
social factors deserves further scrutiny. No formal assessment of social factors has 
been undertaken in this population in recent years. In her study of the CF knowledge 
of persons with CF and their families in Cape Town in the 1980s, Henley took 
parental occupation as a proxy for social class.38 Of sixty families, 45% were in 
social classes I and II. The ethnic make up of these social class groups was not given. 
Henley found that parents from lower occupational classes had greater need for 
information about CF than those in the higher groups and seemed to have received 
less such information.39 
As discussed in Chapter 3, the exact influence of ethnic group on CF phenotype and 
survival has been difficult to tease out. The CFF registry study of 601 African 
American CF subjects111 suggested that most differences (including worse nutritional 
status) were not likely to be of biological origin, but rather were mediated through 
socio-economic status. Another registry-based study published in 2001 was unable to 
identify African-American 'race' as an independent risk factor for worse pulmonary 
function333 (see p275). Non-Caucasoid populations outside of the USA have been 
small making it difficult to dissect out differences. Bowler and colleagues in Leeds in 
the UK. studied nine Asian patients each of whom was age- and sex-matched with two 
white patients.334 They noted a number of differences that may have had prognostic 
significance (e.g. earlier acquisition of P aeruginosa, lower respiratory function test 
results, lower weight for age and weight for height). Again socio-cultural or 
socioeconomic factors confounded any assigning of direct causality: a significant 
proportion of these patients attended clinics less regularly and some mothers did not 
speak English. Likewise in SA, although the coloured group represents one of the 
largest non-Caucasoid CF groups in the world, it is impossible to separate ethnic 
group from social factors. Apartheid specifically dictated a lower socio-economic 
level for coloured people and high rates of deprivation are found in many 
communities. Although as discussed in Chapter 3 coloured patients in the Western 
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Cape province are genetically distinct, their poorer prognosis of CF cannot be 
attributed to their ethnicity. 
Indicators of lower socio-economic status have been shown to influence morbidity 
from and survival in CF in other settings. In the UK, Britton published a paper in 
1989 in which he attempted to study the effect of social class on CF survival.m His 
study appears to have been stimulated by a report from the Brompton Hospital in 
London that showed a disproportionate attendance at the CF clinic of patients from 
higher social classes. 336 Was differential access to such centres of expertise 
discriminating against poorer patients and thus adversely influencing their survival 
(and overestimating the value of such centres)? Using death certification data that 
included a measure of social class (parental occupation), his data suggested .that 
social class associated with manual labour independently led to an age at death above 
the median when compared with non-manual employment. The odds ratio for death 
for males was 1.47 (95%CI 1,16-1,87) and for females was 2,75 (95%CI 2,16-3,52). 
Britton himself recognised that the presence of CF in a family may influence social 
class itself through choices the mother (e.g. foregoing a highly paid career) or adult 
CF patient (e.g. unable to undertake manual labour) has to make, but felt that this was 
unlikely to have confounded the validity of his conclusions. He also showed that, 
with the increase in survival from CF from the 1960s to the 1980s, these differences 
appeared to be growing. Subsequent letters in response to this paper suggested that 
the reason for the Brompton Hospital's higher social class clientele related to a 
tendency for higher class patients to gravitate to London and did not in itself negate 
the positive effects of centres of expertise.337 While the premise for Britton's study 
may have been less valid, his results are not. Even in the UK, lower social class was 
influencing survival among persons with CF. How this detrimental effect was 
mediated was not studied. Reduced access to specialised expertise for poorer 
families, as suggested by Britton, may be one factor. This aspect has been studied in 
three papers from the USA. 
Curtis and colleagues published the first study on socio-economic factors in CF in 
1997.338 They studied both socio-economic status (SES) and health insurance in a 
cohort of 189 CF patients who had been born between 1959 and 1970 in the North 
Chapter 9 274 
Eastern USA. SES was measured using parental occupation. Health insurance 
compared no insurance, Medicaid (which is offered to poor families in the USA) and 
private insurance. Factors controlled for were those known to influence prognosis 
adversely: female sex and presentation with MI. Age at diagnosis was also controlled 
for, although whether it adversely affects prognosis equally in all situations is not 
clear. Health insurance as an independent risk factor was assessed by controlling for 
SES. Year of birth was entered into the analysis to check for a cohort effect given the 
long time of recruitment and follow up. None was found. Patients without health 
insurance were twice as likely to die as those on Medicaid or with private insurance. 
In the USA, not to have insurance is associated with being in the gap between 
eligibility for Medicaid and being able to obtain private insurance through one's 
employer. This equates to low income status but also is likely to deter patients from 
accessing health care even in the centre under study, a CFF-sponsored centre 
'accepting referrals independent of ability to pay,.m This supports Britton's 
contention33S but adds the idea that access to any form of health service a CF patient 
might require may be affected by low income. In the study, lower SES was also 
associated with worse survival. The authors note that this situation is not unique to 
CF, though the examples they cite (breast cancer, AIDS, cardiovascular disease) have 
aetiologies that include factors related to SES. CF being a single gene disease is 
therefore different; social factors exert their influence on severity only after the onset 
of the disease (pace birth weight, see p270). 
A second paper was published in the same edition of The Journal of Pediatrics as the 
registry-based study of CF among African Americans by Hamosh and colleagues, III 
cited above in the discussion of ethnicity. This juxtaposition was noted in an editorial 
by Harris from Cincinnati. 339 He took the differences noted in the care of poor and 
African American CF patients very seriously, noting that they were not unique to CF. 
They suggested that 'medicine .. [was]..failing in some very Significant ways.339 
This applies just as much to health services in the Western Cape province of SA, 
despite the efforts to improve the situation that were presented in Chapter 8. Every 
effort must be made to compensate for the health effects of poverty. However it must 
be asked whether health services can ever completely compensate for socio-economic 
deprivation and cultural factors. In the paper Harris was referring to, Schechter and 
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colleagues from North Carolina in the USA studied CF in those on Medicaid (a proxy 
for SES) compared with those who did not use it and found reduced lung function in 
the Medicaid group.340 This group was also more likely to be African American. 
Later Schechter and colleagues took this further and studied survival in CF in more 
detail using a much larger cohort - the CFF Patient Registry. They published their 
paper in 2001 using data on 20 390 CF patients below the age of 20 years between 
1986 and 1994.333 Again health insurance status ('Always on Medicaid' versus 
'Never on Medicaid') was used as a proxy for SES. Added socio-economic factors 
were rural residence and 'race'. The large number of patients allowed the influence 
of SES on outcomes other than survival to be assessed. Health service utilisation 
(controlled for pulmonary function status) was one of these. Regarding survival, 
those 'always on Medicaid' did poorly compared with the 'never on Medicaid' group. 
Over the age of 5 years, the relative risk for the fIrst group was 2,02 compared with 
the second. Contrary to the 1997 USA study,336 the 'no insurance' group did no 
worse in terms of survival than those 'fully insured'. However there was no 'never 
insured' group so comparison of the two studies is difficult. 
When controlling for a number of potential confounding variables, analysis showed 
that pulmonary function was worse in the Medicaid group, as had been shown in 
Schechter and colleagues' fIrst study.340 The Medicaid group also had lower weights 
and heights. They were more likely to be below the 5th percentiles for weight (odds 
ratio 2,31) and height (odds ratio 2,22). Medicaid patients had more admissions for 
pulmonary exacerbations than non-Medicaid patients (odds ratio 2,38). This persisted 
even when their worse pulmonary function status was controlled for. Ambulatory 
visits to speciality care (about four visits per year) did not differ between the groups. 
Thus in this, the largest study ever undertaken of SES in CF, SES produces 
signifIcant relative worsening of biological indicators that predict survival. 
The role of biological factors in survival 
As discussed above, non-biological factors such as income levels and health services 
provide the most likely and strongest explanations for lower life expectancy for CF in 
SA relative to Western countries. The large numbers of CF patients seen in the 
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developed world has enabled studies of biological factors that influence survival in 
CF to be studied. Could any of these factors be exerting a strong influence here? 
Hudson and Phelan presented some of the first work on survival factors in CF. They 
studied 622 patients in Victoria, Australia, looking at the effect of age at diagnosis, 
sex and mode of presentation on survival.341 Their work which covered the years 
1953 to 1981 was published in 1987. If deaths under 6 months were excluded, the 
main risk factors at that time were a 'predominantly respiratory' presentation and 
MI. The lack of improvement in lung disease soon after diagnosis led to worse lung 
function later in life compared to those in whom it improved. As shown in Chapter 4, 
beyond a higher incidence of the anaemia-oedema complex, there was nothing 
exceptional in the way CF manifests itself in SA; specifically, respiratory presentation 
were not unusually common. Thus these factors are unlikely to have contributed 
significantly to the relatively poor outlook for CF patients in the Western Cape 
province. 
A number of studies have shown that nutritional status at diagnosis and beyond 
influences prognosis. In older CF subjects wasting has been shown to be an 
independent predictor of survival. Sharma and colleagues in London, UK 
demonstrated that patients who were less than 85% predicted ideal weight had a 
worse 5-year survival than those above this level. 342 This was independent of lung 
function. As shown in Chapter 6, low weight for height, a measure of wasting, was 
found in one third of SA CF subjects, the proportion increasing with age. Two 
studies have shown relatively short stature to influence survival in CF. This measure 
was part of a prognostic model developed by those studying transplantation in CF, 
again in London. Height was entered as a continuous variable in this study. Together 
with lung function, white blood cell count and the presence of liver disease, it 
accurately predicted I year survival in an older population of CF subjects (median age 
20,17 years).343 A study from Washington DC in the USA that used 19 000 CF 
subjects in the years 1980 to 1989 from the CFF Patient Registry investigated the role 
of stature in the survival of children who had reached the age of 7 years.344 Height 
below the 51h percentile gave a relative hazard of dying after the age of 5 years of 2,9 
in males and 4,3 in females. The risk increased for children who had short stature at 7 
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years of age. While the authors of this paper do not give the proportion of children 
who were stunted at these ages they quote the 1988 CFF Patient Registry data: a 
stunting rate of 23% for all patients. The figure we reported from Cape Town for 
1996 was 16,2%,55 but this figure omitted the patients with the worst lung disease. 
Weight for age z-score has also been implicated as a survival factor. Liou and 
colleagues, also using the CFF Patient Registry, found it to be part of 5 year 
survivorship model not unlike the one produced in London using stature.345 The 
studies presented in Chapter 6 illustrate that while improvements were taking place in 
the Western Cape province, the nutritional status of young CF patients in the 1980s 
and 1990s left much to be desired. In SA this factor is difficult to disentangle from 
socio-economic and health service influences. As suggested in Chapter 6, a simple 
health service intervention such as regular height measurement may have improved 
average nutritional status and therefore survival. So, despite the well demonstrated 
influence of nutritional status on survival in Western countries,16 346 whether it is 
independently responsible for poorer median outcomes in SA is questionable. It must 
be noted that, whether independent or not, nutritional factors are particularly likely to 
have exerted their malign influence on the coloured CF patients. Further study using 
proportional hazards methodology might be helpful. 
Lung function, particularly FEV" has been used in predictive models for survival in 
CF.347 This has usually been in the context of optimising the timing of lung 
transplantation in older subjects, which is not relevant to a birth cohort such as this. It 
is also not an independent factor, being dependent of other factors such as nutritional 
status and P aeruginosa infection. P aeruginosa infection itself has been shown to be 
associated with earlier mortality by Henry and colleagues in Australia.265 Its 
deleterious effect on lung function, the final common pathway to death for most 
patients with CF, has been outlined in Chapter 7. Rates of infection in SA were not 
higher than those seen elsewhere. If it has been a factor in the relatively early demise 
of CF patients in this region its effect may have been through reduced access to 
appropriate treatment, another socio-economic effect. 
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Other factors that have been found to influence survival in CF are CFRD348 and 
infection with B cepacia.347 Neither of these complications was common enough to 
have influenced overall survival in this cohort. 
Infant deaths 
The large number of deaths in infancy in this cohort deserves special attention. In 
developed countries infant death from CF is now rare. The survival curves generated 
for this population for the years 1974 to 2003 show a remarkable parallel with those 
from Victoria, Australia from 1955 to 1980 as reported by Hudson and Phelan.341 
Both have many deaths in infancy and. a median survival of 18 to 20 years. The 
causes and trend in early deaths are different. MI accounted for most of the 
Australian infant deaths and almost disappeared as a cause of death in the 1970s, 
while in Cape Town MI-related deaths were few and deaths in infancy continued at 
an unchanged rate to the present. In Victoria the number of deaths under 6 months of 
age in the 10 years 1955 to 1965 was 65; only 10 children died by that age in the 
subsequent 15 years to 1980. Hudson and Phelan give MI as the cause of 5 of these 
latter deaths i.e. half; respiratory causes numbered 3 and the cause of death was 
unknown in the other two cases. 
In Sweden, a European example, a similar reduction in infant mortality from CF has 
been achieved.349 Survival curves generated in a survey of all patients with CF in the 
country between 1961 and 1999 showed a significant infant mortality in the 1970s but 
almost none from the 1980s onwards. Causes of death in infancy were not given in 
the paper. Analysis of the USA's CFF Register by Kulich and colleagues in 2003 
showed very few infant deaths in the decades reviewed here e.g. 4/1000 CF births in 
1985 and 10/1000 CF births in 1999.350 Again causes of infant death are not given. 
Britton, studying the effect of social class on CF mortality through death certification, 
tabulated a change from 106 infant deaths in England and Wales in 1959 to 4 in 
1986.335 Dodge and colleagues' study of the incidence, popUlation and survival 
related to CF in the UK showed a progressive reduction of infant deaths from 90 in 
1974 to 1976 to 11 in 1992 to 1994.351 These 11 infant deaths were out of an 
estimated 949 CF births in those three years, or a cause specific infant mortality rate 
of 11 per 1000 CF births. The equivalent figure for the Western Cape province in the 
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1990s was 62,5 per 1000 CF births (3/64). An analysis of the role ofCF screening in 
reducing infant deaths from CF was undertaken in Wales in the 1980s. In a study of 
the cause of deaths before the age of 5 years, five infant deaths occurred in a five year 
period during which 176 children with CF were born.352 Causes of death were cot 
death (1), respiratory failure (2), MI and chest disease (1) and prematurity with MI 
(1). Interestingly 3 of the 5 infants were not from the screened group but were 
diagnosed before the screened group. The most recent data from the UK suggests that 
since 1994 one infant death due to CF occurs every three years.353 
As discussed above, CF prognosis is poorer in non· Western countries. Infant deaths 
as found in Cape Town are likely to contribute to this. In Arab countries infant 
mortality from CF is reported to be high. For example, in Jordan, Rawashdeh and 
Manal reported that 38 of 202 children with CF died, 'most of them below 1 year 
of age,.354 Following other authors from Arab countries, the authors ascribe this to 
severe mutations and consanguinity. They also noted another 110 deaths, mostly at 
less than 6 months of age, in extended families with high levels of consanguinity that 
probably were due to CF. Other factors called on to explain these early deaths were 
Poor physiotherapy. lack of nutritional support and the 
limited supply of enteric.coated pancreatiC enzymes ... 353 
suggesting major deficiencies in health services for CF. 
The study from Brazil by Camargos and colleagues reported 5 infant deaths out of the 
111 CF patients seen at a referral centre in the years 1970 to 1994.330 This was 29,4% 
of the 17 deaths which is not unlike the 21,3% (13/61) of the deaths in the Western 
Cape province over much the same decades. As noted above, very early deaths from 
CF may be being missed in Brazil but the persisting urban/rural difference in 
incidence in CF for coloured patients in the Western Cape province (see Chapter 3) 
suggests that the same phenomenon exists in SA. MI was not implicated in the 
Brazilian deaths but no further details were given preventing further comparison. 
The first study reported in this chapter brought the extent of the contribution of deaths 
in infancy to the mortality of CF in our region to our attention. Improved post· 
operative care and the T -tube procedure were already bringing down morbidities and 
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mortalities in infants with MI when the study report was published. In the 1990s we 
had recognised the contribution of uncontrolled gastro-oesophageal reflux (GOR) to 
the rapid progression of lung disease in some infants and had adopted a more 
aggressive approach to investigation and treatment of this association. In the light of 
this, the four subsequent infant deaths and two deaths in the second year of life 
deserve further scrutiny. 
As Table 9.1 shows, two patients died of unusual conditions: hydrocephalus (not 
known to be associated with CF) and a severe enterocolitis. Details of the latter case 
are sketchy as the child died in a private hospital. According to his paediatrician he 
had a rapid onset of severe abdominal distension associated with bloody diarrhoea 
and died on a ventilator. This could have been due to intussusception, a complication 
of CF, but could also have been due to an unrelated infection. Pseudomembranous 
colitis is less likely as he had not been on antibiotics at the time. Case 163 (Appendix 
A) who died at 14 months had a Reye-like syndrome with lethal cerebral oedema, not 
a known association with CF. 
The remaining three patients all had rapidly evolving lung disease. Case 141 had his 
early care at TBH and required prolonged ventilation for severe chest disease early in 
infancy. On transfer at the age of 11 months he had severe obstructive lung disease 
and carried a methicillin resistant S aureus. This combined with a home in a poor 
rural Karoo town proved lethal within two months of transfer. 
The other two infants, both born in the new century had remarkably similar courses. 
They presented with severe pneumonia with peripheral airways obstruction and 
failure to thrive at three months of age. Neither left hospital alive despite relatively 
rapid recognition of the underlying CF, nasojejunal feeding, airway clearance and 
vigorous antibiotic therapy under the care of the CF service's pulmonologist. In the 
light of current norms in Western countries, cases such as these remain a challenge to 
the CF service. Is it a factor intrinsic to the children's genetics (all three were 
coloured infants) or is there something missing in our therapeutic regime? Regarding 
CF genetics, all three of these children had one copy of the ilF508 mutation and two 
had a copy of the 3120+1G A mutation i.e. CF mutations were not unlike many of 
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the other children. Studies of immunological allotypes in coloured children in the 
Western Cape province have identified that their genotypes differ from white 
children.3ss It is possible that a key gene that regulates the immunological response in 
the presence of CFTR mutations has a differing form and therefore effect in some 
coloured CF children who do particularly badly, even with modem CF care. Such 
interactions are being recognised as contributing to the variability of the 
phenotype/genotype relationship in CF. With regard to clinical care, the full range of 
antibiotics, laboratory and other testing, monitoring and nutritional care is available at 
the RCCH. Only screening is likely to have such children diagnosed earlier than they 
were and this is not practical for these children given the relative rarity of CF in SA 
and the cost of mutation analysis. Careful attention to clinical features and the effects 
of each aspect of management in future children may give clues to factors (e.g. low 
birth weight) that have been leading to such poor outcomes. 
The role of gender 
Female gender has been associated with a worse prognosis in CF particularly after the 
first decades of life. Factors suggested to explain this phenomenon have included 
higher resting energy expenditure,356 gender roles357 and body image.358 As discussed 
above (P92) there is marginal later diagnosis of CF in females in the USA. Whether 
there is earlier infection with P aeruginosa is not proven (P282). In both studies 
reported in this chapter no gender factor could be demonstrated using survival 
analysis though there is a trend for worse survival among females (Figure 9.2). As 
shown in Chapter 4, females were diagnosed earlier than males in this province. This 
may have represented worse early symptoms in females, the predominance of late 
diagnoses in males or may have been a product of chance. The survival curves were 
widest apart during the teenage years (Figure 9.2), reflecting one's personal 
experience of females doing worse at this age but this cannot be demonstrated 
statistically. 
Future survival in the Western Cape province 
What can be expected in the next 10 years? In the concluding paragraph of the first 
study (Study 9.1) I stated that '(P)eople with CF in South Africa deserve to benefit 
from such progress.' (i.e. recent progress in the understanding and management of the 
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disease). It seems as if most white patients have been. They have been benefiting 
from new PERT formulations, new antibiotics and new ways of using them (e.g. early 
eradication of P aeruginosa, long term inhaled aminoglycosides or colistin), support 
and knowledge from participation in peer groups such as the Cystic Fibrosis 
Association and the excellent comprehensive services offered at the RCCH. Rural 
residence has been no object to this group. Despite problems in SA's public health 
system on which most CF patients depend, middle class children with CF can expect 
to enter adulthood, probably with good lung function. It may be difficult to 
distinguish some of these children and adolescents from the European counterparts. 
Simultaneously for others, despite the availability of the medications and services 
described above, the risk of death in infancy or rapid deterioration is likely to remain 
as strong as it did in the 1980s and 1990s, unless new ways are found of overcoming 
the malign effects of poverty and deprivation. This challenge must be taken up at 
local, regional and national level for all poor children with long term health 
conditions. Since my statement in the 1996 pape~2 few of the (potentially expensive) 
breakthroughs in management of CF that were promised at the time (e.g. gene transfer 
therapy, new pharmacological agents to stimulate CFTR) have come about. A 
quantum leap forward in this area might not be affordable in SA. This would lead to 
an increase in the differential survival between developed and resource poor nations. 
In the mean time SA health services and CF services particularly must continue to 
strive to deliver optimal standard care, at least that set out in the SA Consensus 
Document on CF in SA,3S9 to all CF patients. 
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REFERENCES 
1 Fanconi G, Uehlinger E, Knauer C. Das Coeliakiesyndrom bei 
angeborener zysticher pankreasfibromatose und bronchiektasien. Wiener 
Medizinische Wochenschrift 1936;86:753-756 
2 Andersen DH. Cystic fibrosis of the pancreas and its relation to celiac 
disease: Clinical and pathological study. Amer J Dis Child 1938;56:344-
399 
3 Farber S. Pancreatic function and disease in early life. Pathologic changes 
associated with pancreatic insufficiency in early life. Arch Pathol 
1944;37:238-250 
4 di Sant'Agnese PEA, Andersen DH. Celiac syndrome. IV. Chemotherapy 
in infection of the respiratory tract associated with cystic fibrosis of the 
pancreas: observations with penicillin and drugs of the sulfonamide group, 
with special reference to penicillin aerosol. Amer J Dis Child 1946;72:17-
61 
5 Andersen DH, Hodges RG. Celiac syndrome. V. Genetics of cystic 
fibrosis of the pancreas with consideration of etiology. Amer J Dis Child 
1946;46:62-80 
6 Farber S. Some organic digestive disturbances in early life. J Mich Med 
Soc 1945;44:587-594 
7 Bodian M. Fibrocystic disease of the pancreas. A congenital disorder of 
mucus production - Mucosis. London, Heinemann, 1952. 
8 di Sant'Agnese PA, Darling RC, Perera GA, et al. Sweat electrolyte 
disturbances associated with childhood pancreatic disease. Amer J Med 
1953; 15:777-784 
9 Gibson LE, Cooke RE. A test for electrolytes in sweat in cystic fibrosis of 




Shwachman H, Kulczycki LL. Long-term study of one hundred five 
patients with cystic fibrosis. Amer J Dis Child 1958;96:6-15 
284 
11 Shwachman H. Preface to Textbook of Cystic Fibrosis. Editor Lloyd-Still 
JD. John Wright PSG Inc. Bristol 1983 
12 Knowles M, Gatzy J, Boucher R. Increased bioelectric potential difference 
across respiratory epithelia in cystic fibrosis. N Engl J Med 
1981 ;305: 1489-1495 
13 Quinton PM. Chloride impermeability in cystic fibrosis. Nature 
1983;301 :421-422 
14 Riordan JR, Rommens JM, Kerem B, et al. Identification of the cystic 
fibrosis gene: cloning and characterisation of complementary DNA. 
Science 1989;245: 1 066-1 072 
15 Kerem B, Rommens JM, Buchanan JA, et al. Identification of the cystic 
fibrosis gene: genetic analysis. Science 1989;245:1073-1080 
16 Corey M, McLaughlin FJ, Williams M, Levinson H. A comparison of 
survival, growth and pulmonary function in patients with cystic fibrosis in 
Boston and Toronto. J Clin EpidemiolI988;44:583-591 
17 Smythe RL, van-Velzen D, Smyth AR, Lloyd DA, HeafDP. Strictures of 
ascending colon in cystic fibrosis and high-strength pancreatic enzymes. 
Lancet 1994;343:85-86 
18 Hodson ME, Penketh AR, Batten J C. Aerosol carbenicillin and gentamicin 
treatment of Pseudomonas aeruginosa infection in patients with cystic 
fibrosis. Lancet 1981 ;2(8256): 1137-1139 
19 Kun P, Landau LI, Phelan PD. Nebulized gentamicin in children and 
adolescents with cystic fibrosis. Aust Paediatr J 1984;20:43-45. 
20 Ramsey BW, Pepe MS, Quan JM, et al. Intermittent administration of 
inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled 
Tobramycin Study Group. N Engl J Med 1999;340:23-30 
21 Valerius NH, Koch C, Hoiby N. Prevention of chronic Pseudomonas 
aeruginosa colonisation in cystic fibrosis by early treatment. Lancet 
1991 ;338:725-726 
References 285 
22 Khan TZ, Wagener JS, Bost T, Martinez J, Accurso FJ, Riches DW. Early 
pulmonary inflammation in infants with cystic fibrosis. Amer J Respir Crit 
Care Med 1995;151:1075-1082 
23 Eigen H, Rosenstein BJ, FitzSimmons S, Schidlow DV. Cystic Fibrosis 
Foundation Prednisone Trial Group: A multicentre study of alternate-day 
prednisone therapy in patients with cystic fibrosis. J Pediatr 1995;126:515-
523 
24 Konstan MW, Byard PJ, Hoppel CL, Davis PB. Effect of high-dose 
ibuprofen in patients with cystic fibrosis. N Eng} J Med 1995;332:848-854 
25 Tsang V, Hodson ME, Yacoub MH. Lung transplantation for cystic 
fibrosis. Brit Med Bull 1992;48:949-971 
26 Fogarty A, Hubbard R, Britton J. International comparison of median age 
at death from cystic fibrosis. Chest 2000;117:1656-1660 
27 Catzel P. The finger-print sweat test. S Afr Med J 1958;32:325-327 
28 Super M. Cystic fibrosis in southern Africa: Including the preparation of a 
register of carriers and potential carriers. S Afr Med J 1978;54:18-21 
29 Super M. Cystic fibrosis in the South West African Afrikaner. An example 
of population drift, possibly with heterozygote advantage. S Afr Med J 
1975;49:818-20. 
30 Botha MC, Beighton P. Inherited disorders in the Afrikaner population of 
southern Africa. Part 1. Historical and demographic background, 
cardiovascular, neurological, metabolic and intestinal conditions. S Afr 
Med J 1983;64:609-612 
31 Super M. Cystic fibrosis in South West Africa. Factors which have 
influenced the high frequency among the Afrikaner population. Thesis 
submitted for Doctor of Medicine degree, University of Cape Town, 1978. 
32 Lewis MI, Zaltzman M, Reef I, Pettifor JM, Kallenbach JM, Zwi S. 
33 
References 
Experience at an adolescent and adult cystic fibrosis clinic. An analysis 
and overview. S Afr Med J 1984;65:641-648. 
Hill ID, MacDonald WB, Bowie MD, Ireland JD. Cystic fibrosis in Cape 
Town. S Afr Med J 1988;73:147-149 
286 
34 Super M. Cystic fibrosis in South West Africa. Factors which have 
influenced the high frequency among the Afrikaner population. Thesis 
submitted for Doctor of Medicine degree, University of Cape Town, 1978 
pp 109-110 
35 de Wet B, Cywes S. The birth of a child with a congenital anomaly. Part I. 
Some difficulties experienced by parents in the maternity home. S Afr 
Med J 1985;67:292-296 
36 de Wet B, Cywes S. The birth of a child with a congenital anomaly. Part 
II. The prediagnostic phase after discharge from the maternity home. S Afr 
Med J 1985;67:340-343 
37 de Wet B, Cywes S. The birth of a child with a congenital anomaly. Part 
III. Response of parents to the diagnosis. S Afr Med J 1985 ;67:370-373 
38 Henley LD, Hill ID. Errors, gaps, and misconceptions in the disease-
related knowledge of cystic fibrosis patients and their families. Pediatrics 
1990;85:1008-1014 
39 Henley LD, Hill ID. Global and specific disease-related information needs 
of cystic fibrosis patients and their families. Pediatrics 1990;85: 1 015-1021 
40 Nelson MM, Berman PAM, Davidson JS, Petersen EM. Prenatal diagnosis 
of cystic fibrosis in South Africa. S Afr Med J 1984;66:688-693 
41 Brock DJH, Hayward C. Amniotic fluid esterases as markers for cystic 
fibrosis. Lancet 1982;i:619-620 
42 Hitzeroth HW, Petersen EM, Herbert J, Denter M. Preventing cystic 
fibrosis in the RSA. S Afr Med J 1991 ;80:92-98 
43 Denter M, Ramsay M, Jenkins T. Cystic Fibrosis Part I. Frequency of the 
delta F508 mutation in South African families with cystic fibrosis. S Afr 
Med J 1992;82:7-10 
44 Denter M, Ramsay M, Jenkins T. Cystic Fibrosis Part II. New 
developments in cystic fibrosis - implications for carrier detection and 
genetic counselling. S Afr Med J 1992;82:11-13 
References 287 
45 Herbert JS, Retief AE. The frequency of the delta F508 mutation in the 
cystic fibrosis genes of 71 unrelated South African cystic fibrosis patients. 
S Afr Med J 1992;82:13-15 
46 Goldman A, Jenkins T, Ramsay M. Analysis of 40 known cystic fibrosis 
mutations in South African patients. Clin Genet 1994;46:398-400 
47 Goldman A, Labrum R, Claustres M, et al. The molecular basis of cystic 
fibrosis in South Africa. Clin Genet 2001 ;59:37-41 
48 Goldman A, Graf C, Ramsay M, Leisegang F, Westwood ATR. Molecular 
diagnosis of cystic fibrosis in South African populations. S Afr Med J 
2003;93:518-519 
49 Carles S, Desgeorges M, Goldman A, et al. First report of CFTR 
mutations in black cystic fibrosis patients of southern African origin. J 
Med Genet 1996;41 :482-485 
50 Padoa C, Goldman A, Jenkins T, Ramsay M. Cystic fibrosis carrier 
frequencies in populations of African origin. J Med Genet 1999;36:41-44 
51 Westwood ATR, Ireland JD, Bowie MD. Surgery in cystic fibrosis: a 20 
year review. S Afr J Surg 1997;35:181-184 
52 Westwood ATR. The prognosis of cystic fibrosis in the Western Cape 
Region on South Africa. J Paediatr Child Health 1996;32:323-326 
53 Robinson WM, Ravilly S, Berde C, Wohl ME. End-of-life care in cystic 
fibrosis. Pediatrics 1997; 1 00:205-209 
54 Westwood ATR. Terminal care in cystic fibrosis: hospital versus home? 
Pediatrics 1998; 1 02:436 
55 Westwood ATR, Saitowitz R. Growth and nutrition in South African 
children with cystic fibrosis. S Afr Med J 1999;89:1276-1278 
56 Westwood ATR, Ireland JD. Children with cystic fibrosis in South Africa: 
an improving nutritional picture. J Trop Pediatr 2000;46:116-121 
57 Westwood ATR, Henley LD, Willcox P. The transition from paediatric to 
adult care for persons with cystic fibrosis: patient and parent perspectives. 
J Paediatr Child Health 1999;35:442-445 
References 288 
58 LeGrys VA. Sweat testing for the diagnosis of cystic fibrosis: practical 
considerations. J Pediatr 1996: 129;892-897 
59 Hodson ME, Beldon I, Power R, Duncan FR, Bamber M, Batten JC. 
Sweat tests to diagnose cystic fibrosis in adults. BMJ 1983;286:1381-1383 
60 Rosenstein BJ. What is a cystic fibrosis diagnosis? Clin Chest Med 
1998;3 :423-441 
61 Groman JD, Meyer ME, Wilmott RW, Zeitlin PL, Cutting GR. Variant 
cystic fibrosis phenotypes in the absence of CFTR mutations. N Engl J 
Med 2002;347:401-407 
62 Mickle JE, Macek M, Fulmer-Smentek, et al. A mutation in the cystic 
fibrosis transmembrane conductance regulator gene associated with 
elevated chloride concentrations in the absence of cystic fibrosis. Hum 
Molec Genet 1998;4:719-735 
63 Rosenstein BJ, Cutting GR. The diagnosis of cystic fibrosis: A consensus 
statement. J Pediatr 1998;132:589-595 
64 Wallis C. Diagnosing cystic fibrosis: blood, sweat and tears. BMJ SA 
edition 1998;6:279-283 
65 Bush A, Wallis C. Time to think again: cystic fibrosis is not an "all or 
none" disease. Pediatr Pulmonol 2000;30: 139-144 
66 World Health Organisation Human Genetics Programme. Classification of 
cystic fibrosis and related disorders. Report of a joint 
WHOIICF(M)AJECFTN meeting, Stockholm, Sweden, 3 June 2002. 
Human Genetics Programme WHO 2001 
67 Cavalli-Sforza LL, Monozzi P, Piazza A. The history and geography of 




Chikte UM, Gilbert L, Brand AA, Lewis HA. Racial classification in 
dental literature: is it always necessary? J Dent Assoc S Aft 1989;44:337-
339 
Ellison GTH, de Wet T. The use of 'racial' categories in contemporary 
South African health research. S Aft Med J 1997;87:1671-1679 
289 
70 Walker ARP, Sitas F, Cleaton-Jones PE, Vorster HH, Whittaker DE, Segal 
I. Desegregating health statistics and health research in South Africa. S 
AfrMedJ 1997;87:1701-1702 
71 Ellison GTH, De Wet T, Ijsselmuiden CB, Richter LM. Desegregating 
health statistics and health research in South Africa (Reply). S Afr Med J 
1997;87:1702-1704 
72 Ramphele M. Health in South Africa's future. S Afr Med J 1992;82:377 
73 Botha MC, Pritchard J. Blood group gene frequencies: An indication of 
the genetic constitution of populations samples in Cape Town. S Afr Med 
J 1972;46 Suppl April: 1-27 
74 Venter AL. Coloured: A profile of two million South Africans. Human 
and Rousseau, Cape Town 1974 p 131 
75 Jenkins T, Nurse GT. Blood group gene frequencies. S Afr Med J 
1971 ;46:560 
76 Nurse GT, Weiner JS, Jenkins T. The peoples of southern Africa and their 
affinities. Clarendon Press, Oxford 1985 p219 
77 Weber W, Nash DJ, Motulsky AG, et al. Phylogenetic relationships of 
human populations in sub-Saharan Africa. Hum BioI 2000;72:753-772 
78 Loubser 0, Marais AD, Kotze MJ, et al. Founder mutations in the LDL 
receptor gene contribute significantly to the familial hypercholesterolemia 
phenotype in the indigenous South African populations of mixed ancestry. 
Clin Genet 1999;55:340-345 
79 Scholtz CL, Odendaal HJ, Thiart R, et al. Analysis of two mutations in the 
MTHFR gene associated with mild hyperhomocysteinaemia -
heterogeneous distribution in the South African population. S Afr Med J 
2002;92:464-467 
80 Nannan N, Bradshaw D, Mazur R, Maphumulo S. What is the infant 
mortality rate in South Africa? The need for improved data. S Afr Med J 
1998;88: 1583-1587 
81 Community profiles. Census 1996 CD ROMs. Statistics SA Pretoria, 1998 
References 290 
82 South African Health and Demographic Survey. Department of Health, 
South Africa. Pretoria. 1998 
83 Dodge JA, Morison S, Lewis PA, et al. Incidence, population, and survival 
of cystic fibrosis in the UK, 1968-95. UK Cystic Fibrosis Survey 
Management Committee. Arch Dis Child 1997;77:493-496 
84 Scotet V, Audrezet MP, Roussey M, et al. Impact of public health 
strategies on the birth prevalence of cystic fibrosis in Brittany, France. 
Hum Genet 2003;113:280-285 
85 Scotet V, Gillet D, Dugueperoux I, et al. Spatial and temporal distribution 
of cystic fibrosis and of its mutations in Brittany, France: a retrospective 
study from 1960. Hum Genet 2002;111:247-254 
86 Farriaux, Dorche C, Travert G. La mucoviscidose: queUe incidence? Arch 
Fr Pediatr 1993;50:540-541 
87 de Vries HG, CoUee JM, de Walle HE, et al. Prevalence of delta F508 
cystic fibrosis carriers in The Netherlands: logistic regression on sex, age, 
region of residence and number of offspring. Hum Genet 1997;99:74-79 
88 Statistics South Africa Census 2001: Census in Brief. Pretoria: Statistics 
South Africa, 2003 
89 Cutting GR, Antonarakis SE, Buetow KH, Kasch LM, Rosenstein BJ, 
Kazazian HH. Analysis of DNA polymorphism haplotypes linked to the 
cystic fibrosis locus in North American black and Caucasian families 
supports the existence on multiple mutations of the cystic fibrosis gene. 
Amer J Hum Genet 1989;44:307-318 
90 European Working Group on CF Genetics (EWGCFG). Gradient of 
distribution in Europe of the major CF mutation and of its associated 
haplotype. Hum Genet 1990;85:436-445 
91 Lucotte G, Hazout S, De Braekeleer. Complete map of cystic fibrosis 
mutation DF508 frequencies in Western Europe and correlation between 
mutation frequencies and incidence of disease. Hum BioI 1995;67:797-803 
92 
References 
Cystic Fibrosis Genetic Analysis Consortium. The CFTR mutation 
database. http://www.genet.sickkids.on.caJcftr (accessed Aug 2003) 
291 
93 The Cystic Fibrosis Genetic Analysis Consortium. Worldwide survey of 
the .6.F508 mutation - Report from the Cystic Fibrosis Genetic Analysis 
Consortium. Amer J Hum Genet 1990;47:354-359 
94 Schwarz MJ, Super M, Wallis C, et al. .6.F508 testing of the DNA bank of 
the Royal Manchester Children's Hospital. Hum Genet 1990;85:428-430 
95 Casals T, Vazquez C, Lazaro C, Girbau E, Gimenez FJ, Estivill X. Cystic 
fibrosis in the Basque country: high frequency of mutation delta F508 in 
patients of Basque origin. Amer J Hum Genet 1992;50:404-410. 
96 Kerem B, Buchanan JA, Durie P, et aI. DNA marker haplotype association 
with pancreatic sufficiency in cystic fibrosis. Amer J Hum Genet 
1989;44:827-834 
97 Kerem E, Corey M, Kerem BS, et aI. The relation between genotype and 
phenotype in cystic fibrosis--analysis of the most common mutation (delta 
F508). N Engl J Med 1990;323:1517-1522 
98 The Cystic Fibrosis Genotype-Phenotype Consortium. Correlation 
between genotype and phenotype in patients with cystic fibrosis. N Engl J 
Med 1993;329: 1308-1313 
99 Macek M, Mackova A, Hamosh et aI. Identification of common cystic 
fibrosis mutations in African-Americans with cystic fibrosis increases the 
detection rate to 75%. Amer J Hum Genet 1997;60:1122-1127 
100 Cabello GMK, Cabello PH, Llerana J, Fernandes 0, Harris A. The 
3120+ 1 G-+ A splicing mutation in CFTR is common in Brazilian CF 
patients. Hum Bioi 2001 ;73:403-409 
101 EI-Harith EA, Dork T, Stuhrmann M, et aI. Novel and characteristic CFTR 
mutations in Saudi Arab children with severe cystic fibrosis. J Med Genet 
1997;34:996-999 
102 Banjar H, Kambouris M, Meyer BF, al-Mehaidib, Mogarri I. Geographic 
distribution of cystic fibrosis transmembrane regulator gene mutations in 
Saudi Arabia. Ann Trop Paediatr 1999; 19:69-73 
References 292 
103 Tzetis M, Kanavakis E, Antoniadi T, Adam 0, Kattamis C. 
Characterization of more than 85% of cystic fibrosis alleles in the Greek 
population, including five novel mutations. Hum Genet 1997;99:121-125 
104 Dork T, el-Harith EA, Stuhrmann M, et al. Evidence for a common ethnic 
origin of cystic fibrosis mutation 3120+10~A in diverse populations. 
Amer J Hum Genet 1998;63:656-662 
105 Purves LR, Rubinstein R, Maxwell J, Leisegang F, Ireland J. Robust and 
inexpensive equipment design for polymerase chain reaction detection of 
sequence mutations. Cystic fibrosis in a mother and 2 children analysed. S 
Afr Med J 1993;83:25-27 
106 Steinberg AG, Brown DC. OIl the incidence of cystic fibrosis of the 
pancreas. Amer J Hum Oenet 1960;12:416-424 
107 Di Sant' Agnese P A, et al. Cystic fibrosis of the pancreas: Clinical staff 
conference at the National Institutes of Health. Ann Intern Moo 









Kulczycki LL, Guin GO, Mann N. Cystic fibrosis in Negro children. Clin 
POOiatr 1964;3:6 92-705 
Kulczycki LL, Schauf V. Cystic fibrosis in blacks in Washington, DC. 
Amer J Dis Child 1974;127:64-67 
Stern RC, Doershuk CF, Boat TF, et al. Course of cystic fibrosis in black 
patients. J Pediatr 1976;89:412-417 
Hamosh A, FitzSimmons SC, Macek M, Knowles MR, Rosenstein BJ, 
Cutting GR. Comparison of the clinical manifestations of cystic fibrosis 
in black and white patients. J POOiatr 1998;132:255-259 
Reed TE. Caucasian genes in American Negroes. Science 1969;165:762-
768 
McColley SA, Rosenstein BJ, Cutting OR. Differences in expression of 
cystic fibrosis in blacks and whites. Amer J Dis Child 1991;145:94-97 
Schechter MS, Margolis P A. Relationship between socioeconomic status 
and disease severity in cystic fibrosis. J POOiatr 1998; 132:260-264 
293 
115 Senecal JJ, Toury M, Camain R. Deux cas de fibrose kystique du pancreas 
chez I'enfant africain realisant Ie syndrome de kwashiorkor. Bull Med Aft 
Occident Fr 1954;11 :95-99 (quoted in Reference 120) 
116 MacDougall LG. Fibrocystic disease of the pancreas in African children. 
Lancet 1962;2:409-410 
117 Grove SS. Fibrocystic disease of the pancreas in the Bantu. S Aft J Lab 
Clin Med 1959;5:113-119 
118 Levin SE, Blumberg H, Zamit R, Schmaman A, Path MC, Wagstaff L. 
Mucoviscidosis (cystic fibrosis of the pancreas) in Bantu twin neonates. S 
Aft Med J 1967;41 :482-485 
119 Fall M, Mba, Sarr M, Senghor G. Mucoviscidose chez l'enfant (a propos 
de 3 cases) Dakar Med 1981;26:478-493 (quoted in reference 120) 
120 Demay G, Cheron G, Challier P, Lenoir G, Mbede M. Mucoviscidose chez 
un enfant africain: A propos d'un cas. Arch Fr Pediatr 1984;41 :370 
121 Beighton P, Botha MC. Inherited disorders in the black population of 
southern Africa. Part II. Gene disorders. S Aft Med J 1986;69:293-296 
122 Du Toit G, Westwood ATR. A Xhosa child with chronic obstructive 
pulmonary disease and abnormal sweat tests. A case of cystic fibrosis? S 
Aft Resp J 2001;7:113-114 
123 Statistics South Africa. Census 2001: Census in Brief. Pretoria: Statistics 
South Africa, 2003 
124 Baird C. Black cases of CF in Johannesburg. 5th South African Cystic 
Fibrosis Symposium. Wild Coast. October 2002 
125 Casals T, Bassas L, Ruiz-Romero J, et al. Extensive analysis of 40 infertile 
patients with congenital absence of the vas deferens: in 50% of cases only 
one CFTR allele could be detected. Hum Genet 1995;95:205-211 
126 Lloyd-Still JD, Khaw KT, Shwachman H. Severe respiratory distress in 
infants with CF. Pediatrics 1974;53:678-682 
127 Corteville JE, Gray DL, Langer JC. Bowel abnormalities in the fetus -
correlation of prenatal ultrasonographic findings with outcome. Amer J 
Obstet GynecoI1996;175:724-729 
References 294 
128 Shwachman H, Redmond A, Khaw K. Studies in cystic fibrosis: report of 
130 patients diagnosed under 3 months of age over a 20 year period. 
Pediatrics 1970;46:335-343 
129 Coughlin IP, Gauderer MWL, Stern RC, Doershuk CF, Izant RJ, Zollinger 
RM. The spectrum of appendiceal disease in cystic fibrosis. 1 Pediatr Surg 
1990;25:835-839. 
130 Ruddy R, Anolik R, Scanlin TF. Hypoelectrolytemia as a presentation of 
cystic fibrosis at autopsy. Clin Pediatr 1982;21 :367-369 
131 Lykavieris P, Bernard 0, Hadchouel M. Neonatal cholestasis as the 
presenting feature of cystic fibrosis. Arch Dis Child 1996;75:67 
132 Phillips RJ, Crock CM; Dillon MI, Clayton PT, Curran A, Harper II. 
Cystic fibrosis presenting as kwashiorkor with florid skin rash. Arch Dis 
Child 1993;69:446-448 
133 Colin AA, Sawyer SM, Mickle IE, Oates RD, Milunsky A, Amos IA. 
Pulmonary function and clinical observation in men with congenital 
bilateral absence of the vas deferens. Chest 1996; 11 0:440-445 
134 Gilljam M, Ellis L, Corey M, Zielenski 1, Durie P, Tullis DE. Clinical 
manifestations of cystic fibrosis among patients with diagnosis in 
adulthood. Chest 2004;126:1215-1224. 
135 Nazer H, Rahbeeni Z. Cystic fibrosis and the liver--a Saudi experience. 
Ann Trop Paediatr 1994;14:189-194 
136 Rosenfeld M, Davis R, Fitzsimmons S, et al. Gender gap in cystic fibrosis 
mortality. Amer 1 EpidemioI1997;145:794-803 
137 Lai H-C, Kosorok MR, Laxova A, Makholm LM, Farrell PM. Delayed 
diagnosis of US females with cystic fibrosis. Amer 1 Epidemiol 
2002; 156: 165-173 
138 Westwood AT, Ireland ID. Cystic fibrosis and 'kwashiorkor'. S Afr Med 1 
1996;86:371 
139 Farrell PM, Kosorok MR, Laxova A, et a1. Nutritional benefits of neonatal 
screening for cystic fibrosis. Wisconsin Cystic Fibrosis Neonatal 
Screening Study Group. N Eng! 1 Med 1997;337:963-969. 
References 295 
140 FitzSimmons SC. The changing epidemiology of cystic fibrosis. J Pediatr 
1993;122:1-9 
141 Savasan S, Bhambhani K, Abdulhamid I, Ravindranath Y. Cystic fibrosis 
and anaemia in infancy. Lancet 1997;350:295 
142 Maya PP, Hill PG, Sudarsanam D, Jadhav M. Cystic fibrosis in South 
India. Trop Geogr Med 1980;32:45-49 
143 Gunn T, Belmonte MM, Colle E, Du Pont C. Edema as the presenting 
symptom of cystic fibrosis: difficulties in diagnosis. Amer J Dis Child 
1978;132:317-318 
144 Nielsen OH, Larsen BF. The incidence of anemia, hypoproteinemia, and 
edema in infants as presenting symptoms of cystic fibrosis: a retrospective 
survey of the frequency of this symptom complex in 130 patients with 
cystic fibrosis. J Pediatr Gastroenterol Nutr 1982; 1 :355-359 
145 Abman SH, Accurso FJ, Bowman CM. Persistent morbidity and mortality 
of protein calorie malnutrition in young infants with CF. J Pediatr 
Gastroenterol Nutr 1986;5:393-396 
146 Kessler WR, Andersen DH. Heat wave prostration in fibrocystic disease of 
the pancreas and other conditions. Pediatrics 1952;8:648-656 
147 Beckeman RC, Taussig LM. Hypoelectrolytemia and metabolic alkalosis 
in infants with cystic fibrosis. Pediatrics 1979;63:580-583 
148 Fustik S, Pop-Jordanova N, Slaveska N, Koceva S, Efremov G. Metabolic 
alkalosis with hypoelectrolytemia in infants with cystic fibrosis. Pediatr 
Int 2002;44:289-292 
149 Zempsky WT, Rosenstein BJ. The cause of rectal prolapse in children. 
Amer J Dis Child 1988;142:338-339 
150 Farrell PM, Kosorok MR, Rock MJ, et al. Early diagnosis of cystic 
fibrosis through neonatal screening prevents severe malnutrition and 
improves long term growth. Pediatrics 2001 ; 1 07: 1-13 
151 Macri CN, de Gentile AS, Manteola A, et al. Epidemiology of cystic 
fibrosis in Latin America: preliminary communication. Pediatr Pulmonol 
1991;10:249-253 
References 296 
152 Farrell PM, Wisconsin Cystic Fibrosis Neonatal Screening Study Group. 
Improving the health of patients with cystic fibrosis through newborn 
screening. Adv Pediatr 2000;47:79-115 
153 Lai HJ, Cheng Y, Cho H, Kosorok MR, Farrell PM. Association between 
initial disease presentation, lung disease outcomes and survival in patients 
with cytic fibrosis. Arner J EpidemioI2004;159:537-546 
154 Schidlow DV, Taussig LM, Knowles MR. Cystic Fibrosis Foundation 
Consensus Conference report on pulmonary complications of cystic 
fibrosis. Pediatr PulmonolI993;15:187-198 
155 Taussig LM, Belmonte MM, Beaudry PH. Staphylococcal empyema in 
cystic fibrosis. J Pediatr 1974;84:724-727 
156 Flume PA. Pneumothorax in cystic fibrosis. Chest 2003;123:217-221 
157 Waters DL, Dorney SFA, Gaskin KJ, Gruga MA, O'Halloran M, Wilcken 
B. Pancreatic function in infants identified as having cystic fibrosis in a 
neonatal screening program. N Engl J Med 1990;322:303-308 
158 Gaskin K, Gurwitz D, Durie P, et al. Improved respiratory prognosis in 
patients with cystic fibrosis and nonnal fat absorption. J Pediatr 
1982; 1 00:857-862 
159 Bronstein MN, Sokol RJ, Abman SH, et al. Pancreatic insufficiency, 
growth, and nutrition in infants identified by newborn screening as having 
cystic fibrosis. J Pediatr 1992;120:533-540 





Decline in exocrine pancreatic function in cystic fibrosis patients with 
pancreatic sufficiency. Ped Res 1992;32: 179-182 
Hardin DS, Moran A. Diabetes mellitus in cystic fibrosis. Pediatr 
Endocrinol 1999;28:787-800 
Moran A, Doherty L, Wang X, Thomas W. Abnonnal glucose metabolism 
in cystic fibrosis. J Pediatr 1998;133:10-17 
Koch C, Raisano M, Madessanai U, et al. Presence of cystic fibrosis-
related diabetes mellitus is tightly linked to poor lung function in patients 
297 
with cystic fibrosis: data from the European Epidemiologic Registry of 
Cystic Fibrosis. Pediatr Pulmonol 2001 ;32:343-350 
164 Milla CE, Warwick WJ, Moran A. Trends in pulmonary function in 
patients with cystic fibrosis correlate with the degree of glucose 
intolerance at baseline. Amer J Cnt Care Med 2000;162:891-895 
165 del Rosario JF, Putnam PE, Orenstein DM. Chronic pancreatitis in a 
patient with cystic fibrosis and clinical pancreatic insufficiency. J Pediatr 
1995;126:951-952 
166 Jensen KG. Meconium ileus equivalent in a 15 year old patient with cystic 
fibrosis. Acta Paediatr Scand 1962;51 :344-348 
167 Park RW, Grand RJ. Gastrointestinal manifestations of cystic fibrosis: a 
review. Gastroenterology 1981;81:1143-1161 
168 Millar-Jones I, Goodchild MC. Cystic fibrosis, pancreatic sufficiency and 
distal intestinal obstruction syndrome: a report of four cases. Acta Paediatr 
1995;84:577-578 
169 Rosenstein BJ, Langbaum TS. Incidence of distal intestinal obstruction 
syndrome in cystic fibrosis. J Pediatr Gastroenterol Nutr 1983;2:299-301 
170 Rubinstein S, Moss R, Lewiston N. Constipation and meconium ileus 
equivalent in patients with cystic fibrosis. Pediatrics 1986;78:473-479 
171 Kulczycki LL, Shwachman H. Studies in cystic fibrosis of the pancreas; 
occurrence of rectal prolapse. N Engl J Med 1958;259:409-412. 
172 Holsclaw DS, Rocmans C, Shwachman H. Intussusception in patients with 
cystic fibrosis. Pediatrics 1971 ;48:51-58 
173 Lloyd-Still JD. Crohn's disease and cystic fibrosis. Dig Dis Sci 
1994;39:880-885. 
174 Cohn JA, Strong TV, Picciotto MR, et al. Localization of the cystic 
fibrosis transmembrane conductance regulator in human bile duct 
epithelial cells. Gastroenterology 1993; 1 05: 1857-1864 
175 
References 
Feranchak AP, Sokol RJ. Cholangiocyte biology and cystic fibrosis liver 
disease. Semin Liver Dis 2001 ;21 :471-488 
298 
176 Sokol RJ, Durie PRo Recommendations for management of liver and 
biliary tract disease in cystic fibrosis. Cystic Fibrosis Foundation 
Hepatobiliary Disease Consensus Group. J Pediatr Gastroenterol Nutr 
1999;28 Suppl I:S 1-13 
177 Tanner MS, Taylor CJ. Liver disease in cystic fibrosis. Arch Dis Child 
1995;72:281-284 
178 Stern RC, Rothstein FC, Doershuk CF. Treatment and prognosis of 
symptomatic gallbladder disease in patients with cystic fibrosis. J Pediatr 
Gastroenterol Nutr 1986;5:35-40 
179 Ramsay B, Richardson MA. Impact of sinusitis in cystic fibrosis. J Allergy 
Clin ImmunoI1992;90:547-552 
180 Abman SH, Accurso FJ, Sokol. Hypoalbuminaemia in young infants with 
cystic fibrosis. J Pediatr 1990;116:840-841 
181 Littlewood JM. Gastrointestinal complications in cystic fibrosis. J Royal 
Soc Med 1992;85 SuppI18:13-19 
182 Stamp TCB, Geddes D. Osteoporosis and cystic fibrosis. Thorax 
1993;48:585-586 






Bone mineral content in cystic fibrosis patients: correlation with fat-free 
mass. Arch Dis Child 1996;74:314-318 
Saitowitz R. Prevention of Osteoporosis in cystic fibrosis: assessing the 
calcium status in childhood. B.Sc. Dietetics. Honours Thesis. University 
of Cape Town. CapeTown 1995 
Turner MA, Baildam E, Patel L, David TJ. Joint disorders in cystic 
fibrosis. J Royal Soc Med 1997;90 SuppI31:13-20. 
Hiller EJ. Pathogenesis and management of aspergillosis in cystic fibrosis. 
Arch Dis Child 1990;65:397-398 
Laufer P, Fink IN, Bruns T, et al. Allergic bronchopulmonary aspergillosis 
in cystic fibrosis. J Allergy Clin ImmunoI1984;73:44-48 
299 
188 Wark P. Pathogenesis of allergic bronchopulmonary aspergillosis and an 
evidence-based review of azoles in treatment. Respir Med 2004;98:915-
923 
189 Eggermont E. Gastrointestinal manifestations in cystic fibrosis. Eur J 
Gastroenterol Hepatol 1996;8:731-738 
190 Ramesh S. Antibiotic hypersensitivity in patients with CF. Clin Rev 
Allergy Immuno12002;23:123-141 
191 Guy-Crotte 0, Carrere J, FigareUa C. Exocrine pancreatic function in 
cystic fibrosis. Eur J Gastroenterol Hepatol 1996;8:755-759 
192 Wallis C, Leung T, Cubitt D, Reynolds A. Stool elastase as a diagnostic 
test for pancreatic function in children with cystic fibrosis. Lancet 
1997;350(9083):1001 
193 Blethyn AJ, Verrier Jones K, Newcombe R, Roberts GM, Jenkins HR. 
Radiological assessment of constipation. Arch Dis Child 1995;73:532-533 
194 Ling SC, Wilkinson JD, Hollman AS, McColl J, Evans TJ, Paton JY. The 
evolution of liver disease in cystic fibrosis. Arch Dis Child 1999;81:129-
132 
195 Colombo C, Apostolo MG, Ferrari M, et al. Analysis of risk factors for the 
development of liver disease associated with cystic fibrosis. J Pediatr 
1994; 124:393-399 
196 Scott-Jupp R, Lama M, Tanner MS. Prevalence of liver disease in cystic 
fibrosis. Arch Dis Child 1991;66:698-701 
197 Wilschanski M, Rivlin J, Cohen S, et al. Clinical and genetic risk factors 
for cystic fibrosis-related liver disease. Pediatrics 1999;103:52-57 
198 Tanner MS, Taylor CJ. Liver disease in cystic fibrosis. Arch Dis Child 
1995;72:281-284 
199 Feigelson J, Anagnostopoulos C, Poquet M, Pecau Y, Munck A, Navarro 
J. Liver cirrhosis in cystic fibrosis - therapeutic implications and long 
term follow up. Arch Dis Child 1993;68:653-657 
References 300 
200 Gabolde M. Hubert D, Guilloud-Bataille M. Lenaerts C, Feingold J, 
Besmond C. The mannose binding lectin gene influences the severity of 
chronic liver disease in cystic fibrosis. J Med Genet 2001 ;38:310-31 
201 Nousia-Arvanitakis S, Galli-Tsinopoulou A, Karamouzis M. Insulin 
improves clinical status of patients with cystic-fibrosis-related diabetes 
mellitus. Acta Paediatr 2001;90:515-519 
202 Dobson 1, Hattersley AT, Tiley S, Elworthy S, Oades PJ, Sheldon CD. 
Clinical improvement in cystic fibrosis with early insulin treatment. Arch 
Dis Child 2002;87:430-431 
203 Koch C, Cuppens H. Rainisio M, et al. European Epidemiologic Registry 
of Cystic Fibrosis (ERCF): comparison of major disease manifestations 
between patients with different classes of mutations. Pediatr Pulmonol 
2001 ;31 : 1-12 
204 Solomon MP, Wilson DC, Corey M. et al. Glucose tolerance in children 
with cystic fibrosis. J Pediatr 2003;142:128-132 
205 Moran A, Doherty L Wang X. et al. Abnonnal glucose metabolism in 
cystic fibrosis. J Pediatr 1998;133:10-16 
206 Yankaskas JR, Marshall BC, Sufian B, Simon RH, Rodman D. Cystic 
fibrosis adult care: consensus conference report. Chest 2004; 125(1 
Suppl): 1 S-39S 
207 Haworth CS. Presentation at 26th European Cystic Fibrosis Conference, 
Belfast, 2003 





The effect of season and latitude on in vitro vitamin D fonnation by 
sunlight in South Africa. S Afr Med J 1996;86: 1270-1272 
Ziegler MM. Meconium ileus. Curr Prohl Surg 1994;31 :731-777 
Beierle EA, Vinocur CD. Gastrointestinal surgery in cystic fibrosis. Curr 
Opin Pulm Med 1998;4:319-325 
Feranchak AP. Hepatobiliary complications of cystic fibrosis. Curr 





Reilly JS, Kenna MA, Stool SE, Bluestone CD. Nasal surgery in children 
with cystic fibrosis: complications and risk management. Laryngoscope 
1985;95:1491-1493 
Levy L, Durie P, Pencharz P. Corey M. Prognostic factors associated with 
patient survival during nutritional rehabilitation in malnourished children 
and adolescents with cystic fibrosis. J Pediatr Gastroenterol Nutr 
1986;5:97-102 
214 Olsen MM, Gauderer MWL, Girz MV, Izant RJ. Surgery in patients with 
cystic fibrosis. J Pediatr Surg 1987;22:613-618 
215 Moore SW. Surgery and cystic fibrosis. S Aft J Surg 1997;35:172-175 
216 Chase HP, Cotton EK, Elliott RB. Intravenous linoleic acid 
supplementation in children with cystic fibrosis. Pediatrics 1979;64:207-
213 
217 Westwood ATR, Millar AJW, Ireland JD, Swart A. Splenectomy in cystic 
fibrosis patients. Arch Dis Child 2004;89: 1 078 
218 Thalhammer GH, Eber E, Uraniis S, Pfeifer J, Zach MS. Partial 
splenectomy in cystic fibrosis patients with hypersplenism. Arch Dis Child 
2003 ;88: 143-145 
219 Kelly DA, de Ville de Goyet J. Commentary. Arch Dis Child 
2003;88:145-146 
220 Zach MS, Thalhammer GH, Eber E. Partial splenectomy in CF patients 
with hypersplenism. Arch Dis Child 2003;88:649 
221 Chazalette JP, Feigelson J, Louis D. Partial splenectomy - worth the risk. 
Arch Dis Child 2003;88:649 
222 van der Merwe WG, Brown RA, Ireland JD, Goddard E. Percutaneous 
endoscopic gastrostomy in children--a 5-year experience. S Aft Med J 




Doull IJ. Recent advances in cystic fibrosis. Arch Dis Child 2001;85:62-
66 
Warner JO. Heart-lung transplantation: all the facts. Arch Dis Child 
1991;66:1013-1017 
302 
225 Millar AJ, Speannan W, McCulloch M, et al. Liver transplantation for 
children--the Red Cross Children's Hospital experience. Pediatr Transplant 
2004;8:136-144 
226 Gurwitz D, Corey M, Francis PWJ, Crozier DN, Levison H. Perspectives 
in cystic fibrosis. Ped Clin N Amer 1979;26:603-615 
227 Crozier DN. Cystic fibrosis: A not-so-fatal disease. Ped Clin N Amer 
1974;21 :935-950 
228 Ramsay BW, Farrell PM, Pencharz P, et aI. Nutritional assessment and 
management in cystic fibrosis:a consensus report. Amer J Clin Nutr 
1992;55:108-116 
229 Reilly JJ, Edwards CA, Weaver LT. Malnutrition in children with cystic 
fibrosis: the energy-balance equation. J Pediatr Gast Nutr 1997;25:127-
136 
230 Parrett AM, Clarke D, Edwards CA. Colonic fermentation capacity is 
reduced in children with cystic fibrosis. Proc Nutr Soc 1996;55:49A 
231 Steinkamp G, Drommer A, von der Horst H. Resting energy expenditure 
before and after treatment for Pseudomonas aeruginosa in patients with 
cystic fibrosis. Amer J Clin Nutr 1993;57:685-689 
232 Naon H, Hack S, Shelton MT, Gotthoffer RC, Gozal D. Resting energy 
expenditure: Evolution during antibiotic treatment for pulmonary 
exacerbation in cystic fibrosis. Chest 1993; 1 03: 1819-1285 
233 Stallings VA, Fung EB, Hofley PM, Scanlin TF. Acute pulmonary 
exacerbation is not associated with increased energy expenditure in 
children with cystic fibrosis. J Pediatr 1998;132:493-499 
234 Burdet L, HugH 0, Aubert JD, Schutz Y, Roulet M, Fitting JW. Effect of 
elective antibiotic therapy on resting energy expenditure and inflammation 
in cystic fibrosis. Eur J Pediatr 1999;158:711-716 
235 Agusti AG, Noguera A, Sauleda J, Sala E, Pons J, Busquets X. Systemic 
effects of chronic obstructive pulmonary disease. Eur Respir J 
2003;21 :347-360 
References 303 
236 Bines JE, Truby HD, Armstrong DS, Phelan PD, Grimwood K. Energy 
metabolism in infants with cystic fibrosis. J Pediatr 2002;140:527-533 
237 Reilly JJ, Ralston JM, Paton JY, et al. Energy balance during acute 
respiratory exacerbations in children with cystic fibrosis. Eur Respir J 
1999; 13: 804-809 
238 McCloskey M, Redmond AO, Pyper S, McCabe C, Westerterp KR, Elborn 
JS. Total energy expenditure in stable patients with cystic fibrosis. Clin 
Nutr 2001;20:235-241 
239 Stark LJ, Jelalian E, Mulvihill MM, et al. Eating in preschool children 
with cystic fibrosis and healthy peers: a behavioral analysis. Pediatrics 
1995;95:210-215 
240 Stark U, Mulvihill MM, Jelalian E, et al. Descriptive analysis of eating 
behavior in school-age children with cystic fibrosis and healthy control 
children. Pediatrics 1997;97 :665-671 
241 Lai H -C, Kosorok MR, Sondel SA, et al. Growth status in children with 
cystic fibrosis based on the National Cystic Fibrosis Patient Registry data: 
evaluation of various criteria used to identify malnutrition. J Pediatr 
1998; l32:478-485 
242 Morison S. Dodge JA, Cole TJ, et al. Height and weight in cystic fibrosis: 
a cross sectional study. Arch Dis Child 1997:77:497-500 
243 Nir M, Lanng S, Krogh Johansen H, Koch C. Long term survival and 
nutritional data in patients with cystic fibrosis treated in a Danish centre. 
Thorax 1996;51: lO23-1 027 
244 McNaughton SA, Stormont DA, Shepherd RW, Francis PWJ, Dean B. 
Growth failure in cystic fibrosis. J Paediatr Child Health 1999;35:86-92 
245 Waters DL, Wilcken B, Irwig, et al. Clinical outcomes of newborn 
screening for cystic fibrosis. Arch Dis Child Fetal Neonatal Ed 
1999;80:FI-F7 
246 Young SS, Kharrazi, M, Pearl M, Cunningham G. Cystic fibrosis 
screening in newborns: results from existing programs. Curr Opin Pulm 
Med 2001 ;7:427-433 (Abstract on OVID) 
References 304 
247 Mahadeva R, Webb K, Westerbeek RC, et al. Clinical outcome in relation 
to care in centres specialising in cystic fibrosis: a cross sectional study. 
BMJ 1998;316:1771-1775 
248 Collins C, Wicks LM, Rowe S, O'Loughlin EV, Henry RL. Normal 
growth in cystic fibrosis associated with a specialised centre. Arch Dis 
Child 1999;81:241-246 
249 McNaughton SA, Shepherd RW, Greer RG, Cleghorn GJ, Thomas BJ. 
Nutritional status of children with cystic fibrosis measured by total body 
potassium as a marker of body cell mass: lack of sensitivity of 
anthropometric measures. J Pediatr 2000; 136: 188-194 
250 Westwood ATR (Editor). Eating, enzymes and exercise: recipes and 
nutritional ideas for people with cystic fibrosis in South Africa. Creda 
Press, Cape Town 1997 
251 Oliveira MCLA, Reis FJC, Oliveira EA, Colosimo EA, Monteiro APAF, 
Penna FJ. Prognostic factors in cystic fibrosis in a single center in Brazil: a 
survival analysis. Pediatr Pulmonol 2002;34:3-10 
252 Anthony H, Bines J, Phelan P, Paxton S. Relation between dietary intake 
and nutritional status in cystic fibrosis. Arch Dis Child 1998;78:443-447 
253 Borowitz D, Baker RD, Stallings V. Consensus report on nutrition for 
pediatric patients with cystic fibrosis. J Pediatr Gastroenterol Nutr 
2002;35 :246-259 
254 Ogden CL, Kuczmarski RJ, Flegal KM, et al. Centers for Disease Control 
and Prevention 2000 growth charts for the United States: improvements to 
the 1977 National Center for Health Statistics version. 




Jelalian E, Stark U, Reynolds L, Seifer R. Nutrition intervention for 
weight gain in cystic fibrosis: a meta-analysis. J Pediatr 1997;132:486-492 
Koch C, Hoiby N. Pathogenesis of cystic fibrosis. Lancet 1993;341: 1065-
1069 
305 
257 Corey M, Edwards L, Levison H, Knowles M. Longitudinal analysis of 
pulmonary function decline in patients with cystic fibrosis. J Pediatr 
1997;131 :809-814 
258 Zar HJ, Moore B, Argent A, Ireland J, Westwood ATR. Lung function in 
South African children with cystic fibrosis. S Afr Med J 1998;88:994-997 
259 Zar HJ, Bateman E, Ramsay M. New advances in cystic fibrosis: 
implications for developing countries. S Afr Med J 1998;88:967-8 
260 Maselli JH, Sontag MK, Norris JM, MacKenzie T, Wagener JS, Accurso 
FJ. Risk factors for initial acquisition of Pseudomonas aeruginosa in 
children with cystic fibrosis identified by newborn screening. Pediatr 
PulmonoI2003;35:257-262 
261 Nixon GM, Armstrong DS, Carzino R, et al. Clinical outcome after early 
Pseudomonas infection in cystic fibrosis. J Pediatr 2001;138:699-704 
262 Zar H, Saiman L, Quittell L, Prince A. Binding of Pseudomonas 
aeruginosa to respiratory epithelial cells from patients with various 
mutations in the cystic fibrosis transmembrane regulator. J Pediatr 
1995;126:230-233 
263 Rosenfeld M, Gibson R, McNamara, et al. Early pulmonary infection, 
inflammation and clinical outcomes in infants with cystic fibrosis. Pediatr 
Pulmonol 2000;32:356-366 
264 Kosorok MR, Zeng L, West SE, et al. Acceleration of lung disease in 
children with cystic fibrosis after Pseudomonas aeruginosa acquisition. 
Pediatr Pulmonol. 2001 Oct;32(4):277-287 
265 Henry RL, Mellis CM, Petrovic L. Mucoid Pseudomonas aeruginosa is a 
marker of poor survival in cystic fibrosis. Pediatr PulmonoI1992;12:158-
161 
266 Pedersen SS, Hoiby N, Esperen F, Koch C. Role of alginate in infection 
with mucoid Pseudomonas aeruginosa in cystic fibrosis. Thorax 
1992;47:4-13 
References 306 
267 Li Z, Kosorok MR, Farrell PM, et al. Longitudinal development of mucoid 
Pseudomonas aeruginosa infection and lung disease progression in 
children with cystic fibrosis. JAMA 2005;293:581-588 
268 Saiman L, Marshall BC, Mayer-Hamblett N, et al. Azithromycin in 
patients with cystic fibrosis chronically infected with Pseudomonas 
aeruginosa. JAMA 2003;2901749-1756 
269 Lee TW, Brownlee KG, Conway SP, Denton M, Littlewood JM. 
Evaluation of a new definition for chronic Pseudomonas aeruginosa 
infection in cystic fibrosis patients. J Cyst Fibros 2003;2:29-34 
270 Burns JL, Gibson RL, McNamara S, et al. Longitudinal assessment of 
Pseudomonas aeruginosa in young children with cystic fibrosis. J Infect 
Dis 2001;183:444-452 
271 West S, Zeng L, Leng Lee B, et al. Respiratory infections with 
Pseudomonas aeruginosa in children with cystic fibrosis: Early detection 
by serology and assessment of risk factors. JAMA 2002;287:2958-2967 
272 Armstrong DS, Grimwood K, Carlin JB, Carzino R, Olinsky A, Phelan 
PD. Bronchoalveolar lavage or oropharyngeal cultures to identify lower 
respiratory pathogens in infants with cystic fibrosis. Pediatr Pulmonol 
1996;21 :267-275 
273 Demko CA, Byard PJ, Davis PB. Gender differences in cystic fibrosis: 
Pseudomonas aeruginosa infection. J Clin EpidemioI1995;48:1041-1049 
274 Festini F, Taccetti G, Campana S, Ravenni N, de Martino M. Gender 
differences in the acquisition of P. aeruginosa. Pediatr Pulmonol 
2003;36:453-454 
275 Accurso F. Gender differences in the acquisition of P. aeruginosa. Pediatr 
PulmonoI2003;36:454 
276 Kerem E, Corey M, Stein R, Gold R, Levison H. Risk factors for 
Pseudomonas aeruginosa colonization in cystic fibrosis patients. Pediatr 
InfDis J 1990;9:494-498 
References 307 
277 Farrell PM, Shen G, Splaingard M, et al. Acquisition of Pseudomonas 
aeruginosa in children with cystic fibrosis. Pediatrics 1997:100:e2 
(http://www.pediatrics.org/cgi/contentifullIl00/5/e2) 
278 Frederiksen B, Lanng S, Koch C, Hoiby N. Improved survival in the 
Danish center-treated cystic fibrosis patients: results of aggressive 
treatment. Pediatr PulmonoI1996;21: 153-158 
279 Ratjen F, Lomes G, Paul K, et al. Effect of continuous anti staphylococcal 
therapy on the rate of P. aeruginosa acquisition in patients with cystic 
fibrosis. Pediatr Pulmonol 2001 ;31 : 13-16 
280 Stutman HR, Liebennan, Nussbaum E, Marks MI. Antibiotic prophylaxis 
in infants and young children with cystic fibrosis: a randomised controlled 
trial. J Pediatr 2002;140:299-305 
281 Kosorok MR, Jalaluddin M, Farrell PM. Comprehensive analysis of risk 
factors for acquisition of Pseudomonas aeruginosa in young children with 
cystic fibrosis. PediatrPulmonoI1998;26:81-88 
282 Gibson RL, Bums JL, Ramsey BW. Pathophysiology and management of 
pulmonary infections in cystic fibrosis. Amer J Respir Crit Care Med 
2003;168:918-951 
283 Talmaciu I, Vanlotta L, Mortensen J, Schidlow DV. Risk factors for 
emergence of Stenotrophomonas maltophilia in cystic fibrosis. Pediatr 
Pulmonol 2000;30: 1 0-15 
284 Kubesch P, Dork T, Wulbrandt U, et al. Genetic detenninants of airways' 
colonization with Pseudomonas aeruginosa in cystic fibrosis. Lancet 
1993;341: 189-193 
285 Johansen HK, Kovesi TA, Koch C, Corey M, Hoiby N, Levison H. 
Pseudomonas aeruginosa and Burkholderia cepacia infection in cystic 
fibrosis patients treated in Toronto and Copenhagen. Pediatr Pulmonol 
1998;26:89-96 
286 Speert D. A cautious approach to early intervention? in New perspectives 
in early intervention in Pseudomonas aeruginosa infection. Chiron 
Symposium. Belfast 2004 
References 308 
287 Frederiksen B, Koch C, Heiby N. Changing epidemiology of 
Pseudomonas infection in Danish cystic fibrosis patients (1974-1995). 
Pediatr Pulmonol 1999;28: 159-166 
288 De Braekeleer M, Allard C, Leblanc J-P, Aubin G, Simard F. Genetic 
determinants of Pseudomonas aeruginosa colonization in cystic fibrosis 
patients in Canada. Eur J Clin Microbiol Dis 1998;17:269-271 
289 Geddes D. Of isolates and isolation: Pseudomonas aeruginosa in adults 
with cystic fibrosis. Lancet 2001 ;358:522 
290 Hoiby N, Frederiksen B, Pressler T. Eradication of early Pseudomonas 
aeruginosa infection. J Cyst Fibros 2005;4:49-54 
291 Corey M, Levison H, Crozier D. Five- to seven-year course of pulmonary 
function in cystic fibrosis. Amer Rev Resp Dis 1976;114:1085-1092 
292 Davis PB. The decline and fall of pulmonary function in cystic fibrosis: 
New models, new lessons. J Pediatr 1997;131 :789-790 
293 Gortmaker SL, Sappenfield W. Chronic childhood disorders: prevalence 
and impact. Pediatr Clin N Amer 1984;31 :3-18 
294 Matthews LW, Drotar D. Cystic fibrosis - a challenging long-term chronic 
disease. Pediatr Clin N Amer 1984;31:133-152 
295 Stein REK, Bauman U, Westbrook LE, Coupey SM, Ireys HT. 
Framework for identifying children who have chronic conditions: the case 
for a new definition. J Pediatr 1993;122:342-347 
296 Westwood ATR. Limitation of free treatment at state hospitals. S Afr Med 
J 1992;82:207 
297 Shwachman H, Kulczycki LL, Khaw K. Studies in cystic fibrosis: a report 
on sixty-five patients over 17 years of age. Pediatrics 1965;36:689-703 
298 Rosenlund ML, Lustig HS. Young adults with cystic fibrosis. The 




Rosen DS. Transition to adult health care for adolescents and young adults 
with cancer. Cancer 1993;71:3411-3413 
Court JM. Outpatient-based transition services for youth. Pediatrician 
1991; 18: 150-156 
309 
301 Cameron JS. The continued care of pediatric patients with renal disease 
into adult life. Amer J Kidney Dis 1985;6:91-95 
302 Blum RW. Overview of transition issues for youth with disabilities 
Pediatrician 1991; 18: 101-104 
303 Blum RWM, Garell D, Hodgman CH, et al. Transition from child-centered 
to adult health-care systems for adolescents with chronic conditions. J 
Adolesc Health 1993;14:570-576 
304 Landau LI. Cystic fibrosis: transition from paediatric to adult physician's 
care. Thorax 1995;50:1031-1032 
305 Schidlow DV, Feil SB. Life beyond pediatrics. Med Clin North Amer 
1990;74:1113-1120 
306 Rosen D. Between two worlds: bridging the cultures of child health and 
adult medicine. J Adolesc Health 1995; 17: 1 0-16 
307 Sawyer SM, Phelan PD, Bowes G. Reproductive health in young women 
with cystic fibrosis: knowledge, behavior and attitudes. J Adolesc Health 
1995;17:46-50 
308 Committee on children with disabilities and committee on adolescence of 
American Academy of Pediatrics. Transition of care provided for 







Dobbin CJ, Bye PTP. Adults with cystic fibrosis: meeting the challenge! 
Internal Med J 2003;33:593-597 
Conway S. Transition programs in cystic fibrosis centers. Pediatr 
PulmonoI2004;37:1-3 
Viner R. Transition from paediatric to adult care. Bridging the gaps or 
passing the buck? Arch Dis Child 1999;81:271-275 
Viner R. Barriers to good practice in transition from paediatric to adult 
care. J Royal Soc Med 2001 S40:2-4 
Bryon M, Madge S. Transition from paediatric to adult care: psychological 
principles. J Royal Soc Med 2001 S40:5-7 
310 
314 Webb AK, Jones AW, Dodd ME. Transition from paediatric to adult care: 
problems that arise in the adult cystic fibrosis clinic. J Royal Soc Med 
2001 S40:8-11 
315 Scal P, Evans T, Blozis S, Okinow N, Blum R. Trends in transition from 
pediatric to adult health care services for young adults with chronic 
conditions. J Adolesc Health 1999;24:259-264 
316 Boyle PB, Farikhi Z, Nosky ML. Strategies for improving transition to 
adult cystic fibrosis care, based on patient and parent views. Pediatr 
PulmonoI2001;32:428-436 
317 Zack J, Jacobs CP, Keenan PM, et al. Perspectives of patients with cystic 
fibrosis on preventive counseling and transition to adult care. Pediatr 
PulmonoI2003;36:376-383 
318 Flume P A, Anderson DL, Hardy KK, Gray S. Transition programs in 
cystic fibrosis centers: perceptions of pediatric and adult program 
directors. Pediatr Pulmonol 2001;31 :443-450 
319 Anderson DL, Flume PA, Hardy KK, Gray S. Transition programs in 
cystic fibrosis centers: perceptions of patients. Pediatr Pulmonol 
2002;33:327-331 
320 Flume PA, Taylor LA, Anderson DL, Gray S, Turner D. Transition 
programs in cystic fibrosis centers: perceptions of team members. Pediatr 
Pulmonol 2004;37:4-7 
321 American Academy of Pediatrics, American Academy of Family 
Physicians, American College of Physicians-American Society of internal 
Medicine. A consensus statement on health care transitions for young 





Society for Adolescent Medicine. Transition to adult health care for 
adolescents and young adults with chronic conditions. J Adolesc Health 
2003;33:309-311 
Bridging the Gaps: Health Care for Adolescents. Royal College of 
Paediatrics and Child Health. London June 2003 
311 
324 Mitchell I, Nakielna E, Tullis E, Adair C. Cystic fibrosis. End-stage care 
in Canada. Chest 2000;118:80-84 
325 UK Cystic Fibrosis Nurse Specialist Group. National standards for the 
nursing management of cystic fibrosis. Cystic Fibrosis Trust, Bromley, 
Kent. 2001 
326 Corey M. Survival estimates in cystic fibrosis: snapshots of a moving 
target. Pediatr Pulmonol 1997;21: 149-150 
327 Kapranov N, Ginter E, Kashirskaya N, Hill CM, Ilangovan P, RoUes Cl 
Cystic fibrosis in Russia: background and a model for future collaboration 
with the West. J Royal Soc Med 1996;89(Suppl 27):44-47 
328 Macri CN, de Gentile AS, Manteola A, et al. Epidemiology of cystic 
fibrosis in Latin America: preliminary communication. Pediatr Pulmonol 
1991; 1 0:249-253 
329 Reis FJC, Camargos PAM, Rocha S deF. Survival analysis from cystic 
fibrosis in Minas Gerais state, Brazil. J Trop Pediatr 1998;44:329-331 
330 Camargos PAM, Guimaraes MDC. Prognostic aspects of cystic fibrosis in 
Brazil. Ann Trop Paediatr 2000;20:287-291 
331 Malan AF, van der Elst CW, Corazza PM, Isaacs S. Standardisation of 
perinatal mortality rates. S Afr Med J 1990;77:516-518 
332 Oliveira MCLA, Reis FJ, Monteiro APAF, Penna FJ. Effect of meconium 
ileus on the clinical prognosis of patients with cystic fibrosis. Braz J Med 
Bioi Res 2002;35:31-38 
333 Schechter MS, Shelton BJ, Margolis PA, FitzSimmons SC. Association of 
socioeconomic status with outcomes for cystic fibrosis patients in the 
United States. Amer J Respir Crit Care Med 2001 ;163:1331-1337 
334 Bowler 1M, Estlin EJ, Littlewood JM. Cystic fibrosis in Asians. Arch Dis 
Child 1993;68:120-122 
335 Britton JR. Effects of social class, sex and region of residence on age at 
death from cystic fibrosis. BMJ 1989;298:483-487 
336 Penketh ARL, Wise A, Mearns MB, Hodson ME, Batten JC. Cystic 
fibrosis in adolescents and adults. Thorax 1987;42:526-532 
References 312 
337 Lewis PA. Age at death from cystic fibrosis. BMJ 1989;298:960 
338 Curtis JR, Burke W, Kassner A W, Aitken ML. Absence of health 
insurance is associated with decreased life expectancy in patients with 
cystic fibrosis. Amer J Respir Crit Care Med 1997;155:1921-1924 
339 Harris C. Cystic fibrosis outcomes: cultures matter. J Pediatr 
1998; 132 :202-203 
340 Schechter MS, Margolis P A. Relationship between socioeconomic status 
and disease severity in cystic fibrosis. J Pediatr 1998;132:260-264 
341 Hudson I, Phelan PD. Are sex, age at diagnosis, or mode of presentation 
prognostic factors for cystic fibrosis? Pediatr PulmonoI1987;3:288-297 
342 Sharma R, Florea VO, Bolger AP, et al. Wasting as an independent 
predictor of mortality in patients with cystic fibrosis. Thorax 2001 ;56:746-
750 
343 Hayllar KM, Williams SOJ, Wise AE, et a1. A prognostic model for the 
prediction of survival in cystic fibrosis. Thorax 1997;52:313-317 
344 Beker LT, Russek-Cohen E, Fink RJ. Stature as a prognostic factor in 
cystic fibrosis survival. J Amer Diet Assoc 2001; 101 :438-442 
345 Liou TO, Adler FR, Fitzsimmons SC, Cahill BC, Hibbs JR. Predictive 5-
year survivorship model in cystic fibrosis. Amer J Epidemiol 
2001;153:345-352 
346 Kraemer R, Rudeberg A, Hadom B, Rossi E. Relative underweight in 







Kerem E, Reisman J, Canny OJ, Levison H. Prediction of mortality in 
patients with cystic fibrosis. N Engl J Med 1992;326:1187-1191 
Reisman J, Corey M, Canny 0, Levison H. Diabetes mellitus in patients 
with cystic fibrosis: effect on survival. Pediatrics 1990;86:374-377 
Lannefors L, Lindgren A. Demographic transition of the Swedish cystic 
fibrosis community - results of modem care. Resp Med 2002;96:681-685 
Kulich M, Rosenfeld M, Ooss CH, Wilmott R. Improved survival among 
young patients with cystic fibrosis. J Pediatr 2003;142:631-636 
313 
351 Dodge JA, Morrison S, Lewis PA et al. Incidence, population and survival 
of cystic fibrosis in the UK, 1968-95. Arch Dis Child 1997;77:493-496 
352 Doull UM, Ryley HC, Weller P, Goodchild MC. Cystic fibrosis-related 
deaths in infancy and the effect of newborn screening. Pediatr Pulmonol 
2001 ;31 :363-366 
353 Dodge JA, Lewis PA. Cystic fibrosis is no longer an important cause of 
childhood death in the UK. Arch Dis Child 2005;90:547 
354 Rawashdeh M, Manal H. Cystic fibrosis in Arabs: a prototype from 
Jordan. Ann Trop Paediatr 2000;20:283-285 
355 Goddard EA, Beatty DW, Hoffman EB. Immunoglobulin allotypes and 
genetic susceptibility to invasive Haemophilus injluenzae type b and 
Staphylococcus aureus infections in South African children. Pediatr Infect 
Dis J 1996;15:419-424 
356 Allen JR, McCauley JC, Selby AM, et al. Differences in resting energy 
expenditure between male and female children with cystic fibrosis. J 
Pediatr 2003;142:15-19 
357 Willis E, Miller R, Wyn J. Gendered embodiment and survival for young 
people with cystic fibrosis. Soc Sci Med 2001 ;53:1163-1174 
358 Truby H, Paxton AS. Body image and dieting behavior in cystic fibrosis. 
Pediatrics 2001 ;107:E92 
359 Medical and Scientific Advisory Committee on Cystic Fibrosis in South 
Africa. The South African Consensus Document (2nd edition). South 





Key: YEAR Year of diagnosis 
SEX: M = male; F = female 
ETHNIC: C coloured; W = white; B = black; A = Asian 
NA: sweat sodium in mmolll 
CL: sweat chloride in mmol!1 
Genotype: CFTR allelel! CFTR allele2; ~ = no mutation found after testing for SA mutations; blank = 
no testing or only tested for DF508 
HISTO = diagnosis supported by histology or post mortem findings 
StudyNumber YEAR SEX ETHNIC NA CL Genotype HISTO 
1978 M C 107 125 DF5081 
2 1975 F W DF508/DF508 
3 1985 M W 92 93 DF508/DF508 
4 1975 M W + + DF508IDF508 
5 1978 F W DF508IDF508 
6 1976 M W DF508/DF508 
7 1976 M W 100 119 
8 1982 F C 123 129 DF5081 
9 1976 M W 99 134 
10 1976 M W 78 103 DF5081 
II 1978 F W 86 101 DF508/DF508 
12 1977 F W 91 116 
13 1983 M C 73 80 
14 1979 M W 107 125 
15 1977 F W 80 135 DF508IDF508 
16 1977 M C 75 102 DF508/DF508 
17 1980 M W III 117 N1303Kf'l Yes 
18 1980 M C 88 82 
19 1979 M W 125 131 DF5081 
20 1981 M C 102 \08 
21 1980 F W 62 83 DF508/G551D 
22 1981 F C Yes 
23 1987 M W 117 120 DF508/DF508 
24 1982 F W 86 150 
25 1980 F W 83 99 DF508IDF508 
26 1980 F C 90 105 DF508/DF508 
27 1981 M C 80 115 DFS08/3120G>A 
28 1985 F W 121 130 DF508IDF508 
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StudyNumbe,' YEAR SEX ETHNIC NA CL Genotype HISTO 
~9 1982 M W 105 117 DF5081 
30 1980 M W 78 91 DF508/DFS08 
31 1981 M W 128 1:;4 
32 1995 M C 106 96 
33 1989 M W 87 101 DF50S/DF50S 
34 1986 M C 147 143 
35 1981 M W 66 82 
36 19S1 F W 85 101 DF50S/DF50S 
37 1981 F C Yes 
38 1981 M C Yes 
39 1981 F C 99 98 3272-26->Gf? 
40 1981 M C 66 86 
41 1981 F W 56 75 DF5081DF508 
42 1982 M W 90 103 
43 1982 M W 159 182 
44 1986 M W 85 118 DF50SIDF508 
45 1984 F W 84 116 DF508/DF508 
46 1983 F C DF508iDF508 
47 1982 F W + + DF5081 
48 1982 F C 72 87 DF50S/ 
49 1993 M W DF508/DF508 
50 1983 F W 102 126 
51 1983 F W 77 89 DF50S1 
52 1983 F W JOO 
53 1984 M W 92 97 
54 1986 M W 112 J 12 DFS081 
55 1987 M W 113 126 DFS081DF50S 
56 1983 F W DF508/DF508 
57 1983 F C 121 138 Yes 
58 1984 F C 82 119 DF50Sf? 
59 1984 M W 76 103 DF50S/G55 1 D 
60 1986 F W 91 95 DF508/DF50S 
61 1989 F C + + 
62 1984 F C 64 86 DF50S1 
63 1994 M C 110 114 DF508/? 
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StudyNumber YEAR SEX ETHNIC NA CL Genotype HISTO 
64 1990 F W 101 101 DF508/DF508 
65 1987 M W 99 113 DF508/DF508 
66 1986 F C 110 125 DFS081 
67 1985 F C 84 104 DFSOHI 
68 1985 F C 84 93 
69 1985 M W 96 109 DFS081 
70 1989 M C 101 116 DF508IDF508 
71 1985 F W 88 110 DF508IDF508 
72 1988 M w + + 
73 1986 M W 78 104 DF508/DF508 
74 1997 M W 123 116 DF5081 
75 1987 F W 94 123 DF508IDF508 
76 1986 F W 75 106 
77 1987 F W 67 89 DF50S/DF508 
78 1987 F W 100 121 DF508/DF508 
79 1989 M C 86 91 
SO 1993 M C 102 108 DF508fl 
SI 1988 F w + + DF50S1 
82 1988 M C 114 146 DF50S/DF50S 
83 1991 F W 91 92 DF508/DF508 
84 1991 M W 102 125 DFS08/DF508 
85 1987 F C 106 123 DFS081 
86 1996 M w 92 97 DFS081 
87 1994 F W lOS lIS DF50S/DF508 
88 1989 M C 95 109 DF508/G542X 
89 1988 M C 82 106 DFSOS/3120G>A 
90 1988 F w 98 118 DFS081 
91 1988 F w 70 110 DF508/DF508 
92 1988 M C 105 110 DFS081 
93 1992 F W DF508/DF508 
94 1994 F W 75 73 
9S 1990 M C 78 80 DF508/G55 I D 
96 1990 F C + + 
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StudyNumber YEAR SEX ETHNIC NA CL Genotype HISTO 
97 1999 M W 115 122 DFS081 
98 1989 F w + + 
99 1989 F C 81 96 DFS08/DF508 
100 1990 F C 78 102 DF508/3120+IG>A 
101 1994 M C 71 75 DFS081 
102 1996 F W 97 103 DF5081 
103 1991 M C 0 0 DF508/DF508 
104 1991 F C DFS08/DF508 
105 1994 F W 96 108 DF50S/DF508 
106 1992 F W 0 0 DF508/DF50S 
107 1993 M W 94 97 DF508/DF50S 
lOS 1991 F W 135 DF50SIDF50S 
109 1992 M C DF50S! Yes 
110 1999 F W + + 
III 1993 M C 92 105 3120+IG>N3120+IG>A 
112 1994 M C 97 104 3120+IG>Aj? 
113 1992 F C 72 104 DF50S/ 
114 1992 F C 110 96 
115 1994 M C 81 74 
116 1992 F W 73 75 DF50S/DF50S 
117 1993 F C 67 SS DF50SI? 
118 1993 M B 94 104 3120+1G>N3196de154 
1.19 1996 M W 107 126 
120 1993 M C DF50S1 
121 2002 M W 53 DF50S/A455E 
122 1995 F A + + 
123 1996 M W 119 113 DF50S/DF50S 
124 1994 F C SO 94 DF50S/DFS08 
125 1994 M W DF508IDF508 
126 1994 F W DF50SIDF508 
127 1994 F C 93 104 DF50S1 
128 1995 M C 62 98 DF508IDFS08 
129 1995 M W 77 101 DFS08/G551D 
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StudyNumber YEAR SEX ETHNIC NA CL Genotype HISTO 
130 1996 M W 81 93 DF5081 
131 1998 M C 96 102 DF50SIDF508 
132 1995 F W DF50S/DF508 
133 1997 F C 92 105 DF50S1 
134 1995 M w 68 90 DF508/DF508 
135 1995 M C 86 88 
136 1995 M W + + 
137 1995 M W 76 84 DF5081 
138 1996 M C 108 108 DFS081 
139 1998 F W 72 71 DF508/A455E 
140 2003 M C 75 67 
141 1996 M C + + DF508/3120+ I G>A 
142 1996 M C 92 105 
143 1997 M W 99 105 DF50S1 
144 1999 M C 74 73 ?n 
145 1998 M w DF508/DF508 
146 1997 F C DF508/DF508 
147 1998 F C 114 121 DF508/DF508 
148 1998 M w 90 DF508/DF508 
149 1998 M C 60 82 DF508/DF508 
150 2002 M C 108 III 
151 1998 F C 57 68 DF5081 
152 1998 M C 91 94 DF508/3120+ I G>A 
153 1998 M C 97 122 DF5081? 
154 1998 F W 81 83 DF5081394deiTT 
155 1998 M C 85 89 DF508/DF508 
156 1998 F W 79 105 DF508/DF508 
157 2002 M W 115 115 DF508/DF50S 
158 1999 F C 83 102 DF508/DF508 
159 2001 M B 101 94 ?J? 
160 1999 F C + + DF5081 
161 2000 M C 80 116 3120+IG>NG55ID 
162 2001 M W 122 120 DF508/DF508 
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StudyNumber YEAR SEX ETHNIC NA CL Genotype HISTO 
163 1999 M C 98 104 3120+IG>Af3120+IG>A 
164 2000 F W DF508IDF508 
165 2002 F C 110 DF508/3120+1G>A 
166 2001 M W 94 110 DF508/DF508 
167 2003 F W 95 109 DF508/DF508 
168 2000 F C 73 113 DF50813120+IG>A 
169 2001 F W 78 94 DF508/DF508 
170 2001 M W 103 115 DF5081 
171 2001 F C 82 109 DF5081 
172 2002 M W 100 105 ?I? 
173 2002 M W 76 88 DF508IDF508 
174 2002 M C 88 109 DF50813120+IG>A 
175 2002 M W 74 88 ?I? 
176 2002 M W DF5081W1282X 
177 2002 M W DF508IDF508 
178 2003 F B 101 97 3 I 20+ IG>Af? 
179 2003 F W 81 112 DF508/DF508 
180 2003 M W 100 115 DF508/DF508 
181 1986 F B 95 133 Yes 
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